PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
2773511-6	1989	The pathways of metabolism of ethacizin include N-de-ethylation, sulphoxidation, N-10 amide hydrolysis, aromatic hydroxylation and conjugation.	diethylamino-ethmozine	30-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-85
2656675-8	1989	The remainder of the radioactivity from papain or Pronase digests of TR-1 eluted, like the TR-3 fractions, in the salt fraction on Sepharose CL-4B.	Salts	114-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-95
2656675-8	1989	The remainder of the radioactivity from papain or Pronase digests of TR-1 eluted, like the TR-3 fractions, in the salt fraction on Sepharose CL-4B.	Sepharose CL 4B	131-146	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-95
2656675-9	1989	Peptide mapping of the nonglycosylated TR-3 fraction by TLC and high voltage electrophoresis yielded six principal and several less intensely stained ninhydrin reactive components, with the radiolabel concentrated in one of the latter peptides.	Ninhydrin	150-159	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-43
3271463-2	1987	Both are in the free base form and have an intramolecular-hydrogen bond between N10 of the acridine and the nitrogen atom of the carboxamide substituent.	Hydrogen	58-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-83
3240918-3	1988	In the first group (N = 10), a single 20-mg dose of the slow-release formulation caused an increase in 8-h sodium excretion (P less than 0.025) and urine volume (P less than 0.005).	Sodium	107-113	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-26
2626032-1	1989	Complementary DNAs (cDNAs) encoding a member of steroid receptor super-family, named TR3 receptor, were isolated from a human prostate lambda gt11 cDNA library on the basis of homology of oligonucleotide probes to the DNA-binding domain common to members of the steroid receptor super-family.	Oligonucleotides	188-203	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-88
3271463-2	1987	Both are in the free base form and have an intramolecular-hydrogen bond between N10 of the acridine and the nitrogen atom of the carboxamide substituent.	Acridines	91-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-83
3271463-2	1987	Both are in the free base form and have an intramolecular-hydrogen bond between N10 of the acridine and the nitrogen atom of the carboxamide substituent.	Nitrogen	108-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-83
3271463-2	1987	Both are in the free base form and have an intramolecular-hydrogen bond between N10 of the acridine and the nitrogen atom of the carboxamide substituent.	carboxamide	129-140	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-83
3561925-0	1987	Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance.	Androstenedione	17-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
3652558-3	1987	Although the pathophysiology of this disorder remains to be demonstrated, a defect may be present, linking hormone-receptor cyclic AMP-mediated processes with abnormalities in parasympathetic and voluntary neuronal innervation or transmission.	Cyclic AMP	124-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-123
3001307-1	1986	The relative binding affinities of 48 steroids for four classes of hormone receptor (progestin, PR; androgen, AR; glucocorticoid, GR; mineralocorticoid, MR) have been analyzed by correspondence analysis.	Steroids	38-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-83
3792219-3	1986	The hormone receptor status was determined with the dextran-coated charcoal method.	Dextrans	52-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-20
3789431-5	1986	Thiopental increased the latency of N10, N14, and N20.	Thiopental	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-39
2431651-7	1986	Muscle ribonucleic acid content rose significantly in response to testosterone administration, suggesting that testosterone initiated its effect by hormone receptor interaction with muscle nuclei.	Testosterone	66-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	148-164
2431651-7	1986	Muscle ribonucleic acid content rose significantly in response to testosterone administration, suggesting that testosterone initiated its effect by hormone receptor interaction with muscle nuclei.	Testosterone	111-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	148-164
3018913-4	1986	Treatment with methimazol however increased the nuclear T4 binding, suggesting either a direct effect of methimazol on the hormone-receptor interaction or that the patients had become slightly hypothyroid during the treatment.	Methimazole	15-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-139
3018913-4	1986	Treatment with methimazol however increased the nuclear T4 binding, suggesting either a direct effect of methimazol on the hormone-receptor interaction or that the patients had become slightly hypothyroid during the treatment.	Methimazole	105-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-139
2423167-8	1985	Serosal La3+ apparently inactivates the hormone-receptor interaction and/or the link between the ADH-receptor complex and the activation of adenylate cyclase, but does not interfere with the operation of the Na+ "pump", the basal activity of adenylate cyclase or any of the intracellular events that mediate the effect of ADH on Na+ transport.	lanthanum(3+)	8-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-56
2932536-3	1985	Magnesium is proposed to stabilize the hormone-receptor-guanine nucleotide regulatory protein complex, whereas sodium appears to destabilize this ternary complex.	Magnesium	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
3971985-5	1985	The chromophoric N10 is efficiently solvent-protected, the solvent-dependence of its 15N resonance resulting from solvent interactions at other positions of the molecule and from solvent-dependent changes in the twisting of the chromophoric system.	15n	85-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
2999175-0	1986	Receptor-positive hereditary resistance to 1,25-dihydroxyvitamin D: chromatography of hormone-receptor complexes on deoxyribonucleic acid-cellulose shows two classes of mutation.	1,25-dihydroxyvitamin D	43-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-102
2999175-0	1986	Receptor-positive hereditary resistance to 1,25-dihydroxyvitamin D: chromatography of hormone-receptor complexes on deoxyribonucleic acid-cellulose shows two classes of mutation.	deoxyribonucleic acid-cellulose	116-147	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-102
2999175-4	1986	With cells from two kindreds in whom there was mildly decreased localization of the hormone-receptor complex to the nucleus in vitro, occupied receptor interacted abnormally with DNA-cellulose (elution at 0.09-0.13 M KCl vs. normal at 0.20-0.26 M KCl); this suggested mutation(s) that affected a DNA-binding domain of the receptor in these two kindreds.	Cellulose	183-192	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
2999175-4	1986	With cells from two kindreds in whom there was mildly decreased localization of the hormone-receptor complex to the nucleus in vitro, occupied receptor interacted abnormally with DNA-cellulose (elution at 0.09-0.13 M KCl vs. normal at 0.20-0.26 M KCl); this suggested mutation(s) that affected a DNA-binding domain of the receptor in these two kindreds.	Potassium Chloride	217-220	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
2999175-4	1986	With cells from two kindreds in whom there was mildly decreased localization of the hormone-receptor complex to the nucleus in vitro, occupied receptor interacted abnormally with DNA-cellulose (elution at 0.09-0.13 M KCl vs. normal at 0.20-0.26 M KCl); this suggested mutation(s) that affected a DNA-binding domain of the receptor in these two kindreds.	Potassium Chloride	247-250	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
2413033-7	1985	Formation of the disulfide-linked complexes requires 125I-FSH, specifically bound to the hormone receptor and cross-linking, and can be prevented with an excess of native FSH but not human choriogonadotropin.	Disulfides	17-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-105
6848976-2	1983	Infants receiving the dorsal penile nerve block with lidocaine (1% Xylocaine) (N = 20) experienced significantly less stress, as evidenced by smaller decreases in transcutaneous oxygen pressure levels, less time spent crying, and smaller increases in heart rate, than infants circumcised in an identical manner without anesthetic (N = 10).	Lidocaine	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	331-337
6721511-3	1984	At dichophase , prior to the onset of the S-stage in cell division cycle, under conjugation of progesterone with a certain specific type of protein (hormone receptor) the cells are induced toward the development of secretory function, i.e. toward differentiation, resulting in no synthesis of DNA.	Progesterone	95-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-165
6500843-0	1984	Quantitative and qualitative effects of N10-methylfolate on high-affinity folate binding in human leukocytes.	Folic Acid	50-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-43
6500843-1	1984	N10-methylfolate acted as a potent competitive inhibitor of high-affinity [3H] folate binding in human leukocytes, while methotrexate had no effect.	[3h] folate	74-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-3
6500843-2	1984	Furthermore, folate binding changed into a non-cooperative type in the presence of N10-methylfolate.	Folic Acid	13-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-86
6310288-8	1983	The results indicate that GDP is not released prior to but rather coincident with formation of the complex of the hormone receptor with the regulatory protein and that enzyme activation proceeds with the same time course as agonist binds to the receptor.	Guanosine Diphosphate	26-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-130
6361354-1	1983	In this study involving 45 patients with the normal function of the sinus node and 10 patients showing signs of its damage (n-10), intravenous administration of ethmozine in a dose of 150 mg (1.5-2 mg/kg) exerted atropine like action.	Moricizine	161-170	nuclear receptor subfamily 4 group A member 1	Homo sapiens	124-128
86543-0	1979	Reduction of GTP activation of adenylate cyclase system by its coupling to hormone receptor.	Guanosine Triphosphate	13-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
6293818-9	1982	Based on the similarities between the data from these three systems and published data from other systems, we now propose that dithiol-disulfide interchange may play a general role in membrane-related processes such as transport, energy transduction and hormone-receptor interactions.	dithiol	127-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	254-270
6293818-9	1982	Based on the similarities between the data from these three systems and published data from other systems, we now propose that dithiol-disulfide interchange may play a general role in membrane-related processes such as transport, energy transduction and hormone-receptor interactions.	Disulfides	135-144	nuclear receptor subfamily 4 group A member 1	Homo sapiens	254-270
7451368-1	1980	Using 13C-NMR and mass spectral analysis we have demonstrated that the N-10 nitrogen of anthramycin is biosynthetically derived from the indole-nitrogen of tryptophan.	13c	6-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-75
7451368-1	1980	Using 13C-NMR and mass spectral analysis we have demonstrated that the N-10 nitrogen of anthramycin is biosynthetically derived from the indole-nitrogen of tryptophan.	Anthramycin	88-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-75
7451368-1	1980	Using 13C-NMR and mass spectral analysis we have demonstrated that the N-10 nitrogen of anthramycin is biosynthetically derived from the indole-nitrogen of tryptophan.	indole nitrogen	137-152	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-75
7451368-1	1980	Using 13C-NMR and mass spectral analysis we have demonstrated that the N-10 nitrogen of anthramycin is biosynthetically derived from the indole-nitrogen of tryptophan.	Tryptophan	156-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-75
7451368-3	1980	From resonance intensities and 13C-15N spin-spin coupling in the 13C-NMR spectrum of didehydroanhydroanthramycin, a derivative of anthramycin, we could then determine the 13C enrichment at C-11 and the proportion of 13C bonded to 15N at N-10.	13c	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-241
7451368-3	1980	From resonance intensities and 13C-15N spin-spin coupling in the 13C-NMR spectrum of didehydroanhydroanthramycin, a derivative of anthramycin, we could then determine the 13C enrichment at C-11 and the proportion of 13C bonded to 15N at N-10.	didehydroanhydroanthramycin	85-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-241
7451368-3	1980	From resonance intensities and 13C-15N spin-spin coupling in the 13C-NMR spectrum of didehydroanhydroanthramycin, a derivative of anthramycin, we could then determine the 13C enrichment at C-11 and the proportion of 13C bonded to 15N at N-10.	Anthramycin	101-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-241
7451368-3	1980	From resonance intensities and 13C-15N spin-spin coupling in the 13C-NMR spectrum of didehydroanhydroanthramycin, a derivative of anthramycin, we could then determine the 13C enrichment at C-11 and the proportion of 13C bonded to 15N at N-10.	13c	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-241
7451368-3	1980	From resonance intensities and 13C-15N spin-spin coupling in the 13C-NMR spectrum of didehydroanhydroanthramycin, a derivative of anthramycin, we could then determine the 13C enrichment at C-11 and the proportion of 13C bonded to 15N at N-10.	13c	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-241
7451368-4	1980	These results when combined with mass spectral analysis and isotopic dilution measurements proved that the indole nitrogen of tryptophan was completely retained at N-10 of anthramycin.	indole	107-113	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-168
7451368-4	1980	These results when combined with mass spectral analysis and isotopic dilution measurements proved that the indole nitrogen of tryptophan was completely retained at N-10 of anthramycin.	Nitrogen	114-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-168
7451368-4	1980	These results when combined with mass spectral analysis and isotopic dilution measurements proved that the indole nitrogen of tryptophan was completely retained at N-10 of anthramycin.	Tryptophan	126-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-168
7451368-4	1980	These results when combined with mass spectral analysis and isotopic dilution measurements proved that the indole nitrogen of tryptophan was completely retained at N-10 of anthramycin.	Anthramycin	172-183	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-168
222810-6	1979	The relase of the BK-A is calcium and temperature dependent, requires metabolic energy, and is controlled by hormone-receptor interactions that influence the cellular level of cyclic AMP, as has been described for other mediators of immediate hypersensitivity reactions.	Calcium	26-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-125
222810-6	1979	The relase of the BK-A is calcium and temperature dependent, requires metabolic energy, and is controlled by hormone-receptor interactions that influence the cellular level of cyclic AMP, as has been described for other mediators of immediate hypersensitivity reactions.	Cyclic AMP	176-186	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-125
6243863-6	1980	These results suggest that in intact luteal cells danazol inhibits steroidogenesis at a point distal to hormone-receptor interaction and cAMP formation.	Danazol	50-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
86543-9	1979	Furthermore, in plasma membranes isolated from butyrate-treated cells, the hormone receptor is sensitive to GTP; i.e. GTP reduces the affinity of isoproterenol for the receptor.	Butyrates	47-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
86543-9	1979	Furthermore, in plasma membranes isolated from butyrate-treated cells, the hormone receptor is sensitive to GTP; i.e. GTP reduces the affinity of isoproterenol for the receptor.	Guanosine Triphosphate	108-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
86543-9	1979	Furthermore, in plasma membranes isolated from butyrate-treated cells, the hormone receptor is sensitive to GTP; i.e. GTP reduces the affinity of isoproterenol for the receptor.	Guanosine Triphosphate	118-121	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
86543-9	1979	Furthermore, in plasma membranes isolated from butyrate-treated cells, the hormone receptor is sensitive to GTP; i.e. GTP reduces the affinity of isoproterenol for the receptor.	Isoproterenol	146-159	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
220946-0	1978	Hormone receptor levels and metabolic activity in the uterus of the ewe: regulation by oestradiol and progesterone.	Estradiol	87-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
717283-1	1978	Use of a liquid nitrogen container for convenient transport of frozen mammary carcinoma tissue for hormone-receptor assays is described.	Nitrogen	16-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-115
675244-2	1978	The highest quantum yield of solvated electrons (about 0.03) was obtained for flavins containing tyrosine on a side chain in the isoalloxazine N-3 or N-10 position.	Flavins	78-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-154
675244-2	1978	The highest quantum yield of solvated electrons (about 0.03) was obtained for flavins containing tyrosine on a side chain in the isoalloxazine N-3 or N-10 position.	Tyrosine	97-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-154
510217-4	1979	The hydrogen bond directionality observed in T4 and other thyroid structures offers an insight into the molecular details of the hormone-receptor site.	Hydrogen	4-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	129-145
220946-0	1978	Hormone receptor levels and metabolic activity in the uterus of the ewe: regulation by oestradiol and progesterone.	Progesterone	102-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
720288-1	1978	A reliable procedure is described for isolating 3H-triamcinolone acetonide (3H-TA) receptor complexes from purified chronic lymphatic leukemia (CLL) lymphocyte nuclei, based on the use of carbobenzoxy-L-phenylalanine (CBZ-L-phe) to prevent breakdown of hormone-receptor complexes during extraction of nuclei with 0.6M KCl.	Tritium	48-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	253-269
206276-5	1978	The inhibition is dependent on the photogeneration of the aryl nitrene intermediate and is relieved by protecting the hormone receptor with excess oxytocin (10(-6)M) during the photolysis.	aryl nitrene	58-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-134
199464-0	1977	Hormone--receptor interactions: [4-carboranylalanine, 5-leucine]-enkephalin as a structural probe for the opiate receptor.	[4-carboranylalanine	32-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-17
196828-0	1977	Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin.	anthracene	69-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-27
196828-0	1977	Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin.	Progesterone	117-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-27
190053-9	1976	Thus in PHP Type I, the lack of c-AMP response to PTH, coupled with the ability of infused DBc-AMP to evoke a normal renal response suggests that the metabolic defect in this disorder may exist in hormone receptor-adenyl cyclase complex.	Bucladesine	91-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	197-213
190192-0	1976	[Synthesis of [D-alanine, 4"-azido-3",5"-ditritio-L-phenylalanine, norvaline4[alpha-melanotropin as a "photoaffinity probe" for hormone-receptor interactions (author"s transl)].	dalbergioidin	15-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-144
190192-0	1976	[Synthesis of [D-alanine, 4"-azido-3",5"-ditritio-L-phenylalanine, norvaline4[alpha-melanotropin as a "photoaffinity probe" for hormone-receptor interactions (author"s transl)].	4"-azido-3",5"-ditritio-l-phenylalanine	26-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-144
190192-0	1976	[Synthesis of [D-alanine, 4"-azido-3",5"-ditritio-L-phenylalanine, norvaline4[alpha-melanotropin as a "photoaffinity probe" for hormone-receptor interactions (author"s transl)].	norvaline4	67-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-144
869360-3	1977	The development of hormone receptor analysis permits us to better understand the mechanisms of action of steroid and peptide hormones and increases the likelihood of using there hormonal agents effectively.	Steroids	105-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-35
170999-3	1975	However, hormone-receptor interaction in the human cell does not lead to an increase in intracellular cyclic AMP concentration, but in the rat cell, hormone-receptor interaction does lead to a significant increase in cyclic AMP content.	Cyclic AMP	217-227	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-165
1812-6	1975	The role of lipid mobility in modulating hormone-receptor interaction is discussed with reference to the binding of thyroid stimulating hormone.	Thyrotropin	116-143	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-57
34051231-7	2021	Acan1 and Nak1 displayed anticolitic properties via significantly reducing weight loss and colon atrophy, oedema, ulceration, and necrosis in 2,4,6-trinitrobenzene sulfonic acid exposed mice.	Trinitrobenzenesulfonic Acid	142-177	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-14
14042998-5	1963	On the basis of the results it was postulated that hormone-receptor interaction can be considered a two-step process: (a) The binding or attachment of hormone to receptor site through ionic, hydrogen, and hydrophobic bonds and (b) a disulfide interchange reaction between hormonal disulfide and receptor sulfhydryl.	Hydrogen	191-199	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
14042998-5	1963	On the basis of the results it was postulated that hormone-receptor interaction can be considered a two-step process: (a) The binding or attachment of hormone to receptor site through ionic, hydrogen, and hydrophobic bonds and (b) a disulfide interchange reaction between hormonal disulfide and receptor sulfhydryl.	Disulfides	233-242	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
14042998-5	1963	On the basis of the results it was postulated that hormone-receptor interaction can be considered a two-step process: (a) The binding or attachment of hormone to receptor site through ionic, hydrogen, and hydrophobic bonds and (b) a disulfide interchange reaction between hormonal disulfide and receptor sulfhydryl.	Disulfides	281-290	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
14042998-5	1963	On the basis of the results it was postulated that hormone-receptor interaction can be considered a two-step process: (a) The binding or attachment of hormone to receptor site through ionic, hydrogen, and hydrophobic bonds and (b) a disulfide interchange reaction between hormonal disulfide and receptor sulfhydryl.	Sulfhydryl Compounds	304-314	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
33684224-4	2021	RESULTS: Subtype shift (SS) of pBT in syLNs was observed in 28% cases for HR(+), in 6% cases for the HER2(+), and in 16% cases for the TN.	(E)-2-(pent-3-en-1-yn-1-yl)thiophene	31-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-76
34037241-15	2021	This was largely accounted for by a moderate improvement in PFS for inclusion of capecitabine in hormone receptor-positive cancers (HR 0.82, 95% CI 0.73 to 0.91; 7 studies, 1594 participants; moderate-certainty evidence) compared to no difference in PFS for hormone receptor-negative cancers (HR 0.96, 95% CI 0.83 to 1.10; 7 studies, 1122 participants; moderate-certainty evidence).	Capecitabine	81-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	258-274
34037241-27	2021	AUTHORS" CONCLUSIONS: In summary, a moderate PFS benefit by including capecitabine was seen only in hormone receptor-positive cancers in metastatic studies.	Capecitabine	70-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-116
172127-2	1975	It is demonstrated that because of limitations in the magnitude of the specific activity of radiolabeled hormone derivatives, direct binding studies of hormone-receptor interactions of high affinity (10(-9) -10(-11) M, depending on whether 3H- or 123I-labeled hormones are used) will be subject to artifactual distortions due to the need to utilize high concentrations of the receptor.	Tritium	240-242	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-168
172127-2	1975	It is demonstrated that because of limitations in the magnitude of the specific activity of radiolabeled hormone derivatives, direct binding studies of hormone-receptor interactions of high affinity (10(-9) -10(-11) M, depending on whether 3H- or 123I-labeled hormones are used) will be subject to artifactual distortions due to the need to utilize high concentrations of the receptor.	Iodine-123	247-251	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-168
14404999-0	1960	The enzymatic conversion of N5-formyl tetrahydrofolic acid (folinic acid) to N10-formyl tetrahydrofolic acid.	Leucovorin	28-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-80
14404999-0	1960	The enzymatic conversion of N5-formyl tetrahydrofolic acid (folinic acid) to N10-formyl tetrahydrofolic acid.	Leucovorin	60-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-80
13250013-0	1955	On the occurrence of N10-formyltetrahydrofolic acid by enzymic formylation of tetrahydrofolic acid and on the mechanism of this reaction.	5,6,7,8-tetrahydrofolic acid	31-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-24
33617125-1	2021	Multicolor chemiluminescent acridinium derivatives were synthesized by attaching various common fluorophores to the N10 -acridinium position through a piperazine linker.	acridinium I	28-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	116-119
33617125-1	2021	Multicolor chemiluminescent acridinium derivatives were synthesized by attaching various common fluorophores to the N10 -acridinium position through a piperazine linker.	acridinium I	121-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	116-119
33617125-1	2021	Multicolor chemiluminescent acridinium derivatives were synthesized by attaching various common fluorophores to the N10 -acridinium position through a piperazine linker.	piperazine	151-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	116-119
34037241-1	2021	BACKGROUND: Retrospective analyses suggest that capecitabine may carry superior activity in hormone receptor-positive relative to hormone receptor-negative metastatic breast cancer.	Capecitabine	48-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
34037241-12	2021	In the metastatic setting, the effect of capecitabine was heterogenous between hormone receptor-positive and -negative tumours.	Capecitabine	41-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-95
34037241-15	2021	This was largely accounted for by a moderate improvement in PFS for inclusion of capecitabine in hormone receptor-positive cancers (HR 0.82, 95% CI 0.73 to 0.91; 7 studies, 1594 participants; moderate-certainty evidence) compared to no difference in PFS for hormone receptor-negative cancers (HR 0.96, 95% CI 0.83 to 1.10; 7 studies, 1122 participants; moderate-certainty evidence).	Capecitabine	81-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
34043967-0	2021	Malayoside, a Cardenolide Glycoside Extracted from Antiaris Toxicaria Lesch, Induces Apoptosis in Human Non-small Lung Cancer Cells via MAPK-Nur77 Signaling Pathway.	Malayoside	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-146
34043967-8	2021	Meanwhile, malayoside induced Nur77 expression and mitochondrial localization, and its induction of apoptosis was Nur77-dependent.	Malayoside	11-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
34043967-8	2021	Meanwhile, malayoside induced Nur77 expression and mitochondrial localization, and its induction of apoptosis was Nur77-dependent.	Malayoside	11-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-119
34043967-9	2021	To investigate the molecular mechanism of malayoside inducing Nur77 and apoptosis, we found that malayoside activated MAPK signaling pathway, including both ERK and p38 phosphorylation.	Malayoside	42-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
34043967-9	2021	To investigate the molecular mechanism of malayoside inducing Nur77 and apoptosis, we found that malayoside activated MAPK signaling pathway, including both ERK and p38 phosphorylation.	Malayoside	97-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
34043967-10	2021	The suppression of MAPK signaling activation inhibited the expression of Nur77 and apoptosis induced by malayoside.	Malayoside	104-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-78
34043967-13	2021	Our results suggest that malayoside possesses an anti-NSCLC activity in vitro and in vivo mainly via activation of MAPK-Nur77 signaling pathway, indicating that malayoside is a promising chemotherapeutic candidate for NSCLC.	Malayoside	25-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
34043967-13	2021	Our results suggest that malayoside possesses an anti-NSCLC activity in vitro and in vivo mainly via activation of MAPK-Nur77 signaling pathway, indicating that malayoside is a promising chemotherapeutic candidate for NSCLC.	Malayoside	161-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
34046009-7	2021	This stimulation regimen helped in providing optimum levels of r-hLH supplementation to patients with impaired hormone-receptor interacting activity, to achieve higher success in pregnancy and live birth rates.	r-hlh	63-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-127
34037241-29	2021	In contrast, the addition of capecitabine in the adjuvant setting led to improved outcomes for OS and DFS in hormone receptor-negative cancer.	Capecitabine	29-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-125
34014949-7	2021	However, N addition increased BG activity in the N5 and N10 additions in the sandy grassland, and in the N5, N10, and N15 additions in the semi-fixed sandy land.	Nitrogen	9-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	56-59
34014949-7	2021	However, N addition increased BG activity in the N5 and N10 additions in the sandy grassland, and in the N5, N10, and N15 additions in the semi-fixed sandy land.	Nitrogen	9-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-112
33990575-7	2021	Thus, TGFbeta converts Nur77"s role from destabilizing ID1 protein and cancer inhibition to inducing ID1 mRNA expression and cancer promotion, which is highly relevant to colon cancer stemness, metastasis and oxaliplatin resistance.	Oxaliplatin	209-220	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
33909934-1	2021	BACKGROUND: The BYLieve trial (NCT03056755) confirmed efficacy and safety of alpelisib with fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC), after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with an aromatase inhibitor (AI) as immediate prior therapy.	Alpelisib	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-124
34006717-0	2021	[A Case of Hormone Receptor-Positive HER2-Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].	palbociclib	120-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-27
33968263-2	2021	Early results of the MonarchE trial investigating the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to standard adjuvant endocrine therapy indicated a lower recurrence rate in the combination group in a high-risk population of patients with early stage hormone receptor (HR)-positive/HER2-negative BC.	abemaciclib	114-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	279-295
33968263-2	2021	Early results of the MonarchE trial investigating the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to standard adjuvant endocrine therapy indicated a lower recurrence rate in the combination group in a high-risk population of patients with early stage hormone receptor (HR)-positive/HER2-negative BC.	abemaciclib	114-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	297-299
33657579-8	2021	Potassium stimulation caused DNA demethylation around cyclic AMP responsive element binding protein 1 (CREB1) and nuclear receptor subfamily 4 group A (NR4A) family-binding sites and a TSS; demethylation was accompanied by recruitment of CREB1 and NR4A1 and increased chromatin accessibility of the CYP11B2 promoter.	Potassium	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	248-253
33910628-0	2021	Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report.	Tamoxifen	78-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-49
33910628-3	2021	We describe the case of a patient who was treated successfully with tamoxifen for her hormone-receptor-positive breast cancer and acromegaly.	Tamoxifen	68-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-102
33910628-8	2021	CONCLUSION: This case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly.	Tamoxifen	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-107
33910628-9	2021	Unlike anastrozole, tamoxifen has the benefit of lowering insulin-like growth factor 1 levels, which underscores its advantage in reducing adverse musculoskeletal symptoms during the treatment of hormone-receptor-positive breast cancer.	Tamoxifen	20-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	196-212
33910628-10	2021	We offer the first reported use of tamoxifen monotherapy for the successful treatment of acromegaly and hormone-receptor-positive breast cancer.	Tamoxifen	35-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
33996592-0	2021	Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer.	Tamoxifen	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	143-159
33863896-1	2021	Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients.	Progesterone	59-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-30
33905134-0	2021	Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer.	Everolimus	81-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-126
33905134-1	2021	The phase 2 LEO study showed that everolimus (EVE) plus letrozole (LET) with ovarian suppression increased progression-free survival (PFS) in tamoxifen-exposed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer with visceral metastases.	Everolimus	34-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	185-201
33905134-1	2021	The phase 2 LEO study showed that everolimus (EVE) plus letrozole (LET) with ovarian suppression increased progression-free survival (PFS) in tamoxifen-exposed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer with visceral metastases.	Letrozole	56-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	185-201
33905134-1	2021	The phase 2 LEO study showed that everolimus (EVE) plus letrozole (LET) with ovarian suppression increased progression-free survival (PFS) in tamoxifen-exposed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer with visceral metastases.	Tamoxifen	142-151	nuclear receptor subfamily 4 group A member 1	Homo sapiens	185-201
33902205-4	2021	After the first cyclin-dependent kinase (CDK) 4/6 inhibitor Palbociclib entered the clinical application for HR positive and HER-2 negative advanced breast cancer patients in 2015, the clinical treatment pattern of HR positive and HER-2 negative advanced breast cancer has been changed significantly, with a consequent breakthrough improvement in patients" survival prognosis.	palbociclib	60-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-111
33902205-4	2021	After the first cyclin-dependent kinase (CDK) 4/6 inhibitor Palbociclib entered the clinical application for HR positive and HER-2 negative advanced breast cancer patients in 2015, the clinical treatment pattern of HR positive and HER-2 negative advanced breast cancer has been changed significantly, with a consequent breakthrough improvement in patients" survival prognosis.	palbociclib	60-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	215-217
33923503-0	2021	Broussochalcone A Is a Novel Inhibitor of the Orphan Nuclear Receptor NR4A1 and Induces Apoptosis in Pancreatic Cancer Cells.	broussochalcone A	0-17	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-75
33923503-2	2021	In this study, we identified broussochalcone A (BCA) as a new NR4A1 inhibitor and demonstrated that BCA inhibits cell growth partly by inducing NR4A1-mediated apoptotic pathways in human pancreatic cancer cells.	broussochalcone A	29-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
33923503-2	2021	In this study, we identified broussochalcone A (BCA) as a new NR4A1 inhibitor and demonstrated that BCA inhibits cell growth partly by inducing NR4A1-mediated apoptotic pathways in human pancreatic cancer cells.	broussochalcone A	29-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-149
33923503-2	2021	In this study, we identified broussochalcone A (BCA) as a new NR4A1 inhibitor and demonstrated that BCA inhibits cell growth partly by inducing NR4A1-mediated apoptotic pathways in human pancreatic cancer cells.	broussochalcone A	48-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
33863896-1	2021	Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients.	Progesterone	59-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-34
33258078-1	2021	PURPOSE: There are conflicting results on the potential role of HER2-status on the efficacy of aromatase inhibitors (AIs) and tamoxifen (TAM) in patients with hormone receptor (HR)-positive breast cancer (BC).	Tamoxifen	126-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-175
33924348-3	2021	We designed a cyclodextrin (CD)-based polymeric complex to deliver chemotherapeutic doxorubicin (DOX) and Nur77DeltaDBD gene for combating pumps and non-pump resistance simultaneously.	Cyclodextrins	14-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-119
33924348-3	2021	We designed a cyclodextrin (CD)-based polymeric complex to deliver chemotherapeutic doxorubicin (DOX) and Nur77DeltaDBD gene for combating pumps and non-pump resistance simultaneously.	Cyclodextrins	28-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-119
33924348-7	2021	The polymeric inclusion complex can efficiently deliver the Nur77DeltaDBD gene than polyethylenimine (PEI-25k), which is a golden standard for nonviral vector gene delivery.	Polyethyleneimine	84-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-73
33924348-7	2021	The polymeric inclusion complex can efficiently deliver the Nur77DeltaDBD gene than polyethylenimine (PEI-25k), which is a golden standard for nonviral vector gene delivery.	pei	102-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-73
33868464-0	2021	Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation.	olaparib	0-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-28
33987405-1	2021	Background: Palbociclib combined with endocrine therapy has been approved as a front-line treatment for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC).	palbociclib	12-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
33258078-1	2021	PURPOSE: There are conflicting results on the potential role of HER2-status on the efficacy of aromatase inhibitors (AIs) and tamoxifen (TAM) in patients with hormone receptor (HR)-positive breast cancer (BC).	Tamoxifen	137-140	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-175
33168657-1	2021	On May 24, 2019, the FDA granted regular approval to alpelisib in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, HER2-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.	Alpelisib	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	135-157
33138346-3	2021	We analyzed the real-world clinical practice patterns and outcome in HR-positive, MBC Asian patients treated with palbociclib.	palbociclib	114-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-71
33622114-0	2021	Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer.	Alpelisib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-63
33622114-3	2021	Alpelisib is a PI3K-alpha inhibitor and is the first PI3K inhibitor approved, in association with fulvestrant, by the FDA and EMA, based on improved progression-free survival (PFS) versus fulvestrant alone in a randomized phase III trial in HR+/HER2-, PIK3CA-mutated tumors following progression on/after HT.Areas covered: The scientific rationale, preclinical development, pharmacokinetics, and clinical efficacy/safety of alpelisib-fulvestrant are summarized.	Alpelisib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	241-243
33622114-4	2021	The role of alpelisib in the clinical setting is discussed, referencing current therapeutic options and clinical challenges associated with alpelisib"s safety profile.Expert opinion: Alpelisib is an option for patients with HR+/HER2-, PIK3CA-mutated tumors whose disease progressed during/after aromatase inhibitor treatment.	Alpelisib	183-192	nuclear receptor subfamily 4 group A member 1	Homo sapiens	224-226
33868173-1	2021	Background: Everolimus, an immunosuppressant, is approved for the treatment of advanced renal cell carcinoma, metastatic hormone receptor-positive breast cancer, and pancreatic neuroendocrine tumors (P-NETs) but has been reported to be related to hepatitis B reactivation.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-137
33683521-1	2021	PURPOSE: Treatment with Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has demonstrated significantly improved progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, when used in combination with letrozole or fulvestrant endocrine therapies.	palbociclib	24-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	161-177
33790765-0	2021	A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports.	palbociclib	35-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-109
33663585-0	2021	First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.	alrn-6924	40-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-128
33663585-12	2021	CONCLUSION: The significant synergy observed with ALRN-6924 in combination with chemotherapeutic agents supports further evaluation in patients with hormone receptor-positive breast cancer.	alrn-6924	50-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-165
33757987-0	2021	Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.	palbociclib	111-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-160
33737962-0	2021	High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study.	Tamoxifen	10-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-44
33645243-0	2021	Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.	ribociclib	22-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-99
33645243-1	2021	BACKGROUND: The 2015 American Society of Clinical Oncology guidelines recommend first-line treatment of hormone receptor (HR)-positive breast cancer with endocrine therapy plus or minus palbociclib, a selective cyclin-dependent kinase (CDK)4/6 inhibitor.	palbociclib	186-197	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
33645243-1	2021	BACKGROUND: The 2015 American Society of Clinical Oncology guidelines recommend first-line treatment of hormone receptor (HR)-positive breast cancer with endocrine therapy plus or minus palbociclib, a selective cyclin-dependent kinase (CDK)4/6 inhibitor.	palbociclib	186-197	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-124
33737962-3	2021	This study aimed to explore the efficacy of high-dose tamoxifen (TAM) treatment in patients with advanced breast cancer with highly expressed HR.	Tamoxifen	54-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	142-144
33737962-3	2021	This study aimed to explore the efficacy of high-dose tamoxifen (TAM) treatment in patients with advanced breast cancer with highly expressed HR.	Tamoxifen	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	142-144
33737962-14	2021	Conclusion: A high-dose of TAM is effective and safe for patients with advanced breast cancer with high HR expression.	Tamoxifen	27-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-106
33596096-1	2021	BACKGROUND: Tamoxifen and aromatase inhibitors (AIs) are used as adjuvant hormonal therapy (AHT) for early-stage hormone receptor-positive (HR+) breast cancer.	Tamoxifen	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-129
33527970-2	2021	Compounds Tr3, Tr7, Tr12, Tr15, and Tr16 exhibited good effect in inhibiting alpha-syn fibrillogenesis confirmed by Thioflavin-T assay and fluorescence microscopy and alpha-syn disaggregation confirmed by fluorescence microscopy.	thioflavin T	116-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-13
33527970-4	2021	Compounds Tr3, Tr7, Tr12, Tr15 and Tr16 showed good binding interactions with the essential amino acid residues of alpha-syn.	Amino Acids, Essential	82-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-13
33624592-0	2021	[Fuxinfang improves hypoxia-induced injury of human aortic endothelial cells by regulating c-Fos-NR4A1-p38 pathway].	fuxinfang	1-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-102
33460574-1	2021	BACKGROUND: Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer.	palbociclib	12-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-105
33279290-3	2021	Previously we reported that BI1071(DIM-C-pPhCF3+MeSO3-), an oxidized form and methanesulfonate salt of (4-CF3-Ph-C-DIM), can modulate Nur77"s non-genomic apoptotic pathway through that Nur77 translocated from the nucleus to mitochondria to induce cytochrome c releasing and promote apoptosis of cancer cell.	bi1071	28-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	134-139
33279290-3	2021	Previously we reported that BI1071(DIM-C-pPhCF3+MeSO3-), an oxidized form and methanesulfonate salt of (4-CF3-Ph-C-DIM), can modulate Nur77"s non-genomic apoptotic pathway through that Nur77 translocated from the nucleus to mitochondria to induce cytochrome c releasing and promote apoptosis of cancer cell.	bi1071	28-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	185-190
33279290-3	2021	Previously we reported that BI1071(DIM-C-pPhCF3+MeSO3-), an oxidized form and methanesulfonate salt of (4-CF3-Ph-C-DIM), can modulate Nur77"s non-genomic apoptotic pathway through that Nur77 translocated from the nucleus to mitochondria to induce cytochrome c releasing and promote apoptosis of cancer cell.	methanesulfonate salt	78-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	134-139
33547330-1	2021	The PvuII (rs2234693) Single Nucleotide Polymorphism (SNP) in the gene coding for the estrogen receptor-1 (ESR1), has been found associated with outcome in tamoxifen treated patients with early hormone-receptor positive breast cancer.	Tamoxifen	156-165	nuclear receptor subfamily 4 group A member 1	Homo sapiens	194-210
33676870-0	2021	First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.	ribociclib	26-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-105
33189785-6	2021	Substitution of two putative phylogenetically well-conserved small ubiquitin-like modifier (SUMO) acceptor sites, lysine 102 (K102) and 577 (K577) by arginine residues (R) modulated Nur77 transcriptional activity.	Arginine	150-158	nuclear receptor subfamily 4 group A member 1	Homo sapiens	182-187
33198527-1	2021	INTRODUCTION: Patients with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer have benefitted from treatment with palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor capable of selectively targeting mechanisms of cell cycle progression that contribute to tumor cell proliferation.	palbociclib	141-152	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-44
33634624-0	2021	Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-83
33634624-1	2021	In the PALOMA-3 trial, the median progression-free survival (PFS) was longer among patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with palbociclib plus fulvestrant than those treated with placebo plus fulvestrant.	palbociclib	229-240	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
33659039-0	2021	Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.	4-hydroxy-N-desmethyltamoxifen	17-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
33540405-2	2021	Palbociclib combined with endocrine therapy has shown promising results in hormone-receptor-positive (HR+) and human epidermal growth factor receptor-negative (HER-2-) breast cancer progression.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
33541289-9	2021	Patients treated with nab-paclitaxel had better event-free survival (EFS; HR = 0.69, 95%CI: 0.57-0.85, P < 0.001) than with sb-taxanes.	nab	22-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-76
33541289-9	2021	Patients treated with nab-paclitaxel had better event-free survival (EFS; HR = 0.69, 95%CI: 0.57-0.85, P < 0.001) than with sb-taxanes.	Paclitaxel	26-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-76
33246021-0	2021	Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.	Alpelisib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-63
33495599-0	2021	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.	Estrone	40-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-102
33495599-0	2021	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.	Progesterone	53-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-102
33183970-0	2021	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.	neratinib	26-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-69
33183970-1	2021	BACKGROUND: The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC).	neratinib	95-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	247-263
33388491-1	2021	PURPOSE: In the randomised phase II LEO trial, we investigated the effect of adding everolimus (EVE) to letrozole (LET) in ovarian-suppressed premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) recurrent/metastatic breast cancer.	Everolimus	84-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	167-183
33460574-2	2021	The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib to adjuvant endocrine therapy improves invasive disease-free survival over endocrine therapy alone in patients with hormone-receptor-positive, HER2-negative, early-stage breast cancer.	palbociclib	73-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	201-217
33421904-5	2021	Moreover, the role of Nur77 and NOR-1 in the regulation of Z-LIG-induced apoptosis and differentiation of AML cells was explored.	ligustilide	59-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-27
33230905-0	2021	Everolimus plus exemestane treatment in metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor therapy.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
33230905-0	2021	Everolimus plus exemestane treatment in metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor therapy.	exemestane	16-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
33230905-1	2021	BACKGROUND: The combination of everolimus (EVE) and exemestane (EXE) is approved for the treatment of metastatic hormone receptor-positive breast cancer (mHRBC) patients who progress on non-steroidal aromatase inhibitor (NSAI) therapy.	Everolimus	31-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-129
33230905-1	2021	BACKGROUND: The combination of everolimus (EVE) and exemestane (EXE) is approved for the treatment of metastatic hormone receptor-positive breast cancer (mHRBC) patients who progress on non-steroidal aromatase inhibitor (NSAI) therapy.	exemestane	52-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-129
33421904-0	2021	Z-Ligustilide Selectively Targets AML by Restoring Nuclear Receptors Nur77 and NOR-1-mediated Apoptosis and Differentiation.	ligustilide	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
33421904-8	2021	Importantly, Z-LIG restored Nur77 and NOR-1 expression in AML cells by increasing Ace-H3 (lys9/14) enrichment in their promoters.	ligustilide	13-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
33421904-4	2021	The anti-AML activity of Z-LIG was evaluated in vitro and in vivo, and the effect and underlying mechanisms of Z-LIG on the restoration of Nur77 and NOR-1 was determined.	ligustilide	111-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
33421904-9	2021	Meanwhile, Z-LIG enhanced the recruitment of p300 and reduced the recruitment of HDAC1, HDAC4/5/7, and MTA1 in the Nur77 promoter and enhanced the recruitment of p-CREB and reduced HDAC1 and HDAC3 in the NOR-1 promoter.	ligustilide	11-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-120
33421904-10	2021	Furthermore, Z-LIG-induced apoptosis was shown to be correlated with the mitochondria localization of Nur77/NOR-1 and subsequent Bcl-2 conformational change, converting Bcl-2 from a cyto-protective phenotype into a cyto-destructive phenotype.	ligustilide	13-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-107
33421904-11	2021	Z-LIG-promoted differentiation was found to be related to Nur77/NOR-1-mediated myeloid differentiation-associated transcription factors Jun B, c-Jun, and C/EBPbeta.	ligustilide	0-5	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-63
33514405-0	2021	Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.	everolimus exemestane	27-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-68
33504001-4	2021	Palbociclib-resistant cells were generated by exposing hormone receptor-positive breast cancer cell lines to palbociclib.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	55-71
33520003-7	2021	Results from BYLieve supports the notion that the combination of endocrine therapy with the PIK3Ca inhibitor alpelisib is a reasonable treatment approach in hormone-receptor positive/HER2-negative BC after prior CDK4/6-inhibitor therapy.	Alpelisib	109-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-173
33473115-5	2021	Moreover, natural compound, salidroside effectively abrogates nicotine-induced neutrophil polarization and consequently reduced lung metastasis of hormone receptor-negative breast cancer cells.	rhodioloside	28-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-163
33473115-5	2021	Moreover, natural compound, salidroside effectively abrogates nicotine-induced neutrophil polarization and consequently reduced lung metastasis of hormone receptor-negative breast cancer cells.	Nicotine	62-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-163
33245358-0	2020	beta-glucan from Lentinus edodes inhibits breast cancer progression via the Nur77/HIF-1alpha axis.	beta-Glucans	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-81
33552547-2	2021	Materials & methods: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor-positive and HER2-negative metastatic breast cancer.	Paclitaxel	81-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-128
32718997-1	2021	PURPOSE: This study reports the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of alpelisib or buparlisib used in combination with tamoxifen plus goserelin in premenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC).	Alpelisib	123-132	nuclear receptor subfamily 4 group A member 1	Homo sapiens	228-244
33337350-10	2021	The relationship between miR-486-5p and NEAT1 or NR4A1 was confirmed by dual-luciferase reporter assay.	mir-486-5p	25-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
33447040-1	2020	Background: Clinical studies have shown that palbociclib improves progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) patients with advanced breast cancer (ABC).	palbociclib	45-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	95-111
32328775-4	2021	METHODS: We proposed a prospective trial to measure the change in blood estradiol levels in postmenopausal women with hormone receptor-positive breast cancer undergoing treatment with aromatase inhibitors when treated with vaginal estrogen preparation, Estring, for their urogenital symptoms.	Estradiol	72-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-134
32358778-1	2021	PURPOSE: To assess the feasibility and efficacy of a non-hormonal hyaluronic acid (HLA) vaginal gel in improving vulvovaginal estrogen-deprivation symptoms in postmenopausal women with a history of hormone receptor-positive (HR+) cancer.	Hyaluronic Acid	83-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	198-214
33242757-1	2020	BACKGROUND: Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with endocrine therapy.	palbociclib	12-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-74
32926316-1	2020	The primary and secondary benefits of tamoxifen as adjuvant therapy in women with hormone-receptor-positive breast cancer are substantial: a 1% decrease in the risk of death each year for 10 years with each additional year of treatment during the first 5 years.	Tamoxifen	38-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
33336619-2	2020	We explored the conjugation of riboflavin (RF) ligand from the end of the ribityl chain (N-10) to the polymer strands as well as from the amine group on the isoalloxazine head (N-3).	Riboflavin	31-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-93
33336619-2	2020	We explored the conjugation of riboflavin (RF) ligand from the end of the ribityl chain (N-10) to the polymer strands as well as from the amine group on the isoalloxazine head (N-3).	Riboflavin	43-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-93
33336619-5	2020	The introduction of RF from the N-10 position in any composition has increased the energy level of nanocarriers.	Riboflavin	20-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-36
33336619-7	2020	Furthermore, with N-10 samples based on both polymers, non-targeted models form the stablest particles in each category.	Polymers	45-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-22
33336619-8	2020	These findings are further confirmed with molecular docking analysis which revealed affinity energy of RF toward polymer chain from N-3 and N-10 are -981.57 kJ/mole and -298.23 kJ/mole, respectively.	Polymers	113-120	nuclear receptor subfamily 4 group A member 1	Homo sapiens	140-144
33408886-0	2020	Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy.	Docetaxel	83-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-56
32946924-0	2020	Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.	govitecan	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-60
32888142-0	2020	Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients.	Phenobarbital	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-78
32881420-3	2020	With the recent FDA approval of alpelisib for the treatment of PIK3CA-mutated hormone-receptor positive metastatic breast cancer, tumor molecular profiling to identify somatic mutations and potential molecularly targeted agents is increasingly utilized in the treatment of advanced breast cancer.	Alpelisib	32-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-94
32962980-0	2020	A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer.	pam50met	58-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-99
32988969-1	2020	PURPOSE: Determine if the androgen receptor (AR) inhibitor enzalutamide improves effectiveness of endrocrine therapy (ET) in hormone receptor-positive (HR+) breast cancer.	endrocrine	98-108	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
33022852-1	2020	Fulvestrant 500 mg is standard of care for endocrine therapy-naive or pretreated women with hormone receptor-positive (HR+) metastatic breast cancer (MBC).	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
32988969-0	2020	A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer.	exemestane	57-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-130
32988969-1	2020	PURPOSE: Determine if the androgen receptor (AR) inhibitor enzalutamide improves effectiveness of endrocrine therapy (ET) in hormone receptor-positive (HR+) breast cancer.	enzalutamide	59-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
33247224-9	2020	Further study is required to clarify the molecular mechanisms of tubal metaplasia and the expression loss of hormone receptor in the endometrium as a result of MEA treatment.	Cysteamine	160-163	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-125
32459035-0	2020	A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting.	Estriol	131-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-170
33151471-1	2020	BACKGROUND: Everolimus plus exemestane is approved for the treatment of hormone receptor-positive metastatic breast cancer (MBC) after progression on nonsteroidal aromatase inhibitors.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-88
33151471-1	2020	BACKGROUND: Everolimus plus exemestane is approved for the treatment of hormone receptor-positive metastatic breast cancer (MBC) after progression on nonsteroidal aromatase inhibitors.	exemestane	28-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-88
33151471-13	2020	CONCLUSIONS: Everolimus reduces the risk of disease progression in hormone receptor (+) MBC.	Everolimus	13-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-83
33324567-1	2020	Background: Tamoxifen and fulvestrant, both approved for endocrine therapy, have remarkably increased the prognosis of hormone receptor-positive breast cancer patients.	Tamoxifen	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
33324567-1	2020	Background: Tamoxifen and fulvestrant, both approved for endocrine therapy, have remarkably increased the prognosis of hormone receptor-positive breast cancer patients.	Fulvestrant	26-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
33198673-0	2020	Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.	Fluorodeoxyglucose F18	11-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-89
32770287-0	2020	Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.	Everolimus	85-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-131
33172112-6	2020	We observed that knockdown of NR4A1 dramatically increased isoharringtonine-induced cancer cell death in A549 tumorspheroids by activating the intrinsic apoptosis pathway.	isoharringtonine	59-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
32770287-1	2020	PURPOSE: mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC).	Everolimus	24-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-63
32803637-18	2020	CONCLUSIONS: Important changes occurred in EBC treatment, particularly for hormone receptor-positive tumors, as the outbreak progressed in each region.	NSC638702	43-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
32787449-3	2020	Female and male patients in the USA and Canada diagnosed with hormone receptor-positive/HER2-negative metastatic breast cancer were enrolled in the study and treated with the cyclin-dependent kinase 4/6 inhibitor palbociclib when hormone receptor-positive/HER2-negative metastatic breast cancer was deemed to be indicated by their physician.	palbociclib	213-224	nuclear receptor subfamily 4 group A member 1	Homo sapiens	230-246
32170637-1	2020	BACKGROUND: The addition of everolimus to exemestane therapy significantly improves progression-free survival in postmenopausal patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant breast cancer.	Everolimus	28-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	142-158
33154825-0	2020	Clinical Implications of Serum 25-Hydroxyvitamin D Status after 5-Year Adjuvant Endocrine Therapy for Late Recurrence of Hormone Receptor-positive Breast Cancer.	25-hydroxyvitamin D	31-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-137
32717483-0	2020	Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators.	5-((8-methoxy-2-methylquinolin-4-yl)amino)-1h-indole-2-carbohydrazide	48-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
32717483-2	2020	Herein, we detailed the discovery of a novel series of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as potential Nur77 modulators.	5-((8-methoxy-2-methylquinolin-4-yl)amino)-1h-indole-2-carbohydrazide	55-124	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-155
32170637-1	2020	BACKGROUND: The addition of everolimus to exemestane therapy significantly improves progression-free survival in postmenopausal patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant breast cancer.	Everolimus	28-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-162
32170637-1	2020	BACKGROUND: The addition of everolimus to exemestane therapy significantly improves progression-free survival in postmenopausal patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant breast cancer.	exemestane	42-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	142-158
32170637-1	2020	BACKGROUND: The addition of everolimus to exemestane therapy significantly improves progression-free survival in postmenopausal patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant breast cancer.	exemestane	42-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-162
33046982-0	2020	Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China.	Fulvestrant	23-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-60
32831911-7	2020	The hormone receptor (HR) status and number of metastases were significant influencing factors of PFS in the BOM group.	bom	109-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-20
32831911-7	2020	The hormone receptor (HR) status and number of metastases were significant influencing factors of PFS in the BOM group.	bom	109-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-24
32831911-8	2020	Furthermore, the HR status, location of bone metastasis and number of bone metastases were significantly associated with OS of patients in the BOM group.	bom	143-146	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-19
32831911-11	2020	In the non-BOM group, patients with HR+/HER2- and HER2+ tumors had improved prognosis.	bom	11-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-38
32831911-16	2020	HR- and multiple bone metastases, as well as combined axial and appendicular bone metastases, were significantly associated with poor prognosis in the patients with BOM.	bom	165-168	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-2
32957311-11	2020	CONCLUSIONS: Our study suggested that aspirin use might be associated with a reduced risk of breast cancer, particularly for reducing the risk of hormone receptor positive tumors or in situ breast tumors, and the risk of breast cancer in postmenopausal women.	Aspirin	38-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	146-162
32951520-1	2021	PURPOSE: Exemestane, a steroidal aromatase inhibitor, is an important therapeutic option in the treatment of post-menopausal hormone receptor positive breast cancer.	exemestane	9-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
32934206-1	2020	Palbociclib, a CDK4/6 inhibitor, has been granted accelerated approval by US FDA for hormone receptor-positive HER2-negative metastatic breast cancer.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
32586939-0	2020	Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab.	Letrozole	125-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-68
32661666-0	2020	Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.	palbociclib	15-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-75
32671612-0	2020	Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.	palbociclib	44-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-110
32614992-2	2020	METHODS: Women with hormone receptor-positive BC who were taking AET completed standardized surveys about their health-related QOL, AET-related symptoms, and levels of PA using validated measures.	2-(2-Aminoethyl)isothiourea dihydrobromide	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-36
32463152-0	2020	A phase II trial of cabozantinib in hormone-receptor positive breast cancer with bone metastases.	cabozantinib	20-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-52
32868353-0	2020	Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.	Fulvestrant	10-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
32868353-0	2020	Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.	Anastrozole	27-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
32868353-1	2020	OBJECTIVE: The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC (HR+)).	Fulvestrant	74-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	255-271
32868353-1	2020	OBJECTIVE: The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC (HR+)).	Fulvestrant	87-90	nuclear receptor subfamily 4 group A member 1	Homo sapiens	255-271
32868353-1	2020	OBJECTIVE: The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC (HR+)).	Anastrozole	96-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	255-271
32868353-1	2020	OBJECTIVE: The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC (HR+)).	Anastrozole	109-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	255-271
32868353-1	2020	OBJECTIVE: The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC (HR+)).	Fluorine	87-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	255-271
33014129-0	2020	Erratum: RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.	palbociclib	103-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-134
32335491-0	2020	Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.	Sirolimus	23-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-107
32335491-1	2020	BACKGROUND: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy.	Sirolimus	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-126
32335491-1	2020	BACKGROUND: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy.	Sirolimus	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-130
32335491-2	2020	METHODS: All patients with HR-positive metastatic breast cancer treated with sirolimus plus endocrine therapy between December 2017 and July 2018 at the Cancer Hospital, Chinese Academy of Medical Sciences were consecutively and retrospectively reviewed.	Sirolimus	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-29
32335491-11	2020	CONCLUSIONS: Sirolimus is a potentially effective treatment option for patients with HR-positive advanced breast cancer.	Sirolimus	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-87
32052382-1	2020	PURPOSE: Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormone therapy (HT).	Estrogens	238-246	nuclear receptor subfamily 4 group A member 1	Homo sapiens	9-25
32052382-1	2020	PURPOSE: Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormone therapy (HT).	Estrogens	238-246	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-29
32982739-0	2020	Cantharidin Induces Apoptosis and Promotes Differentiation of AML Cells Through Nuclear Receptor Nur77-Mediated Signaling Pathway.	Cantharidin	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-102
32905449-0	2020	Bis-indole derived nuclear receptor 4A1 (NR4A1) antagonists inhibit TGFbeta-induced invasion of embryonal rhabdomyosarcoma cells.	bis-indole	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-39
32905449-0	2020	Bis-indole derived nuclear receptor 4A1 (NR4A1) antagonists inhibit TGFbeta-induced invasion of embryonal rhabdomyosarcoma cells.	bis-indole	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
32905449-2	2020	This response is inhibited by the NR4A1 antagonist 1,1-bis(3"-indoly)-1-(p-hydroxyphenyl) methane (CDIM8) and we hypothesized that similar effects would be observed in Rhabdomyosarcoma (RMS) cells.	1,1-bis(3"-indoly)-1-(p-hydroxyphenyl) methane	51-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39
32905449-2	2020	This response is inhibited by the NR4A1 antagonist 1,1-bis(3"-indoly)-1-(p-hydroxyphenyl) methane (CDIM8) and we hypothesized that similar effects would be observed in Rhabdomyosarcoma (RMS) cells.	DIM-C-pPhOH	99-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39
32905449-7	2020	The novel mechanism of CDIM8-mediated inhibition of basal and TGFbeta-induced ERMS cell invasion was due to activation of the Bcl-2-NR4A1 complex, mitochondrial disruption, induction of the tumor suppressor-like cytokine interleukin-24 (IL-24) which in turn downregulates beta-catenin expression.	DIM-C-pPhOH	23-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-137
32577940-0	2020	Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-60
32463152-1	2020	BACKGROUND: We assessed the antitumor activity of cabozantinib, a potent multi-receptor oral tyrosine kinase inhibitor, in patients with hormone-receptor positive breast cancer with bone metastases.	cabozantinib	50-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-153
32728620-3	2020	The patient is a 37-year-old woman with recurrent, hormone receptor-positive, HER2-negative MBC that had progressed despite hormonal therapy and palbociclib.	palbociclib	145-156	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
32756099-1	2020	RATIONALE: Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC).	Everolimus	84-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-173
32756099-1	2020	RATIONALE: Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC).	exemestane	106-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-173
32732875-3	2020	We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]anthracene (D) recapitulate several key features of human luminal B HR+HER2- BC, including limited immune infiltration and poor sensitivity to ICBs.	Medroxyprogesterone Acetate	45-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	169-171
32732875-3	2020	We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]anthracene (D) recapitulate several key features of human luminal B HR+HER2- BC, including limited immune infiltration and poor sensitivity to ICBs.	9,10-Dimethyl-1,2-benzanthracene	81-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	169-171
32708154-0	2020	12-Deacetyl-12-epi-Scalaradial, a Scalarane Sesterterpenoid from a Marine Sponge Hippospongia sp., Induces HeLa Cells Apoptosis via MAPK/ERK Pathway and Modulates Nuclear Receptor Nur77.	12-deacetyl-12-epi	0-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	180-185
32753876-0	2020	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib.	Everolimus	11-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
32753876-0	2020	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib.	palbociclib	120-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
32753876-1	2020	Background: Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in the management of hormone-receptor-positive HER2 non-amplified metastatic breast cancer (HR+ HER2-MBC), the optimal sequence of therapy is unclear.	Everolimus	51-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-121
32708154-7	2020	The dual-luciferase reporter assays suggested that 12-deacetyl-12-epi-scalaradial could selectively enhance the trans-activation activity of Nur77.	12-deacetyl-12-epi-scalaradial	51-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-146
32708154-8	2020	Furthermore, Western blotting analysis and fluorescence quenching showed that 12-deacetyl-12-epi-scalaradial could induce the phosphorylation of Nur77 and interact with the ligand-binding domain (LBD) of Nur77.	12-deacetyl-12-epi	78-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-150
32708154-8	2020	Furthermore, Western blotting analysis and fluorescence quenching showed that 12-deacetyl-12-epi-scalaradial could induce the phosphorylation of Nur77 and interact with the ligand-binding domain (LBD) of Nur77.	12-deacetyl-12-epi	78-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-209
32708154-9	2020	Our research confirmed 12-deacetyl-12-epi-scalaradial as a potential agent for cervical cancer therapy and provided a view that 12-deacetyl-12-epi-scalaradial may be a modulator of Nur77.	12-deacetyl-12-epi	128-146	nuclear receptor subfamily 4 group A member 1	Homo sapiens	181-186
32660609-0	2020	Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.	pyrotinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	98-114
32575989-0	2020	Bipentazole (N10): A Low-Energy Molecular Nitrogen Allotrope with High Intrinsic Stability.	bipentazole	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-17
32575989-0	2020	Bipentazole (N10): A Low-Energy Molecular Nitrogen Allotrope with High Intrinsic Stability.	Nitrogen	42-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-17
32575989-1	2020	In this letter, we report a crystal structure prediction and characterization of a molecular nitrogen allotrope N10 (bipentazole) using state-of-the-art computational methods.	Nitrogen	93-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-115
32575989-1	2020	In this letter, we report a crystal structure prediction and characterization of a molecular nitrogen allotrope N10 (bipentazole) using state-of-the-art computational methods.	bipentazole	117-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-115
32367072-13	2020	After adjustment for prognostic factors, we found that tamoxifen was found to reduce the recurrence rate by 68% (hazard ratio HR = 0.32; 95% confidence interval, CI: 0.14-0.74).	Tamoxifen	55-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-128
32760629-3	2020	Here, we present a case report of pneumonitis as a rare side effect of palbociclib in the treatment of metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (ERBB2-) breast cancer in addition to endocrine therapy.	palbociclib	71-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-130
32352244-0	2020	Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.	NVP-BKM120	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
32352244-0	2020	Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.	Tamoxifen	31-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
32385792-0	2020	Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.	Letrozole	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-165
32385792-3	2020	Therefore, we aimed to determine whether SNPs in the CYP19A1 gene are associated with adjuvant letrozole-induced "specific" AEs in postmenopausal hormone receptor-positive (HR+) breast cancer patients.	Letrozole	95-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	146-162
31773503-17	2020	CONCLUSION: The standard treatment of hormone receptor positive and HER-2 negative metastatic breast cancer is everolimus together with exemestane.	Everolimus	111-121	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-54
31773503-17	2020	CONCLUSION: The standard treatment of hormone receptor positive and HER-2 negative metastatic breast cancer is everolimus together with exemestane.	exemestane	136-146	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-54
31993850-0	2020	Lactate accelerates vascular calcification through NR4A1-regulated mitochondrial fission and BNIP3-related mitophagy.	Lactic Acid	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
32636632-1	2020	Background: Fulvestrant (FUL) and the combination of everolimus and exemestane (EVE-EXE) were the options to treat hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients who were refractory to aromatase inhibitors (AIs).	exemestane	68-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-131
32637176-2	2020	Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in PIK3CA-mutant, hormone receptor positive (HR+) BC versus ET alone; thus, better understanding the clinical and epidemiologic elements of these mutations is warranted.	Alpelisib	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-208
32570839-5	2020	In contrast, RO4929097 downregulated the NOTCH3/NR4A1 axis and counteracted the spontaneous and gliotoxin-induced apoptosis.	2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
32549380-6	2020	This lower prevalence of HER2-positive in-screen-detected breast carcinomas was observed in both hormone receptor positive (luminal HER2) and hormone-receptor-negative (HER2 enriched) tumors.	Phenobarbital	124-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
31993850-7	2020	In VSMCs, lactate increased NR4A1 expression, leading to activation of DNA-PKcs and p53.	Lactic Acid	10-17	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
31993850-8	2020	Lactate induced Drp1 migration to the mitochondria and enhanced mitochondrial fission through NR4A1.	Lactic Acid	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
31993850-11	2020	The excessive fission and deficient mitophagy damaged mitochondrial structure and impaired respiratory function, determined by mPTP opening rate, mitochondrial membrane potential, mitochondrial morphology under TEM, ATP production, and OCR, which was reversed by NR4A1 silencing.	Adenosine Triphosphate	216-219	nuclear receptor subfamily 4 group A member 1	Homo sapiens	263-268
31993850-12	2020	Mechanistically, lactate enhanced fission but halted mitophagy via activation of the NR4A1/DNA-PKcs/p53 pathway, evoking apoptosis, finally accelerating osteoblastic phenotype transition of VSMC and calcium deposition.	Lactic Acid	17-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-90
31993850-13	2020	This study suggests that the NR4A1/DNA-PKcs/p53 pathway is involved in the mechanism by which lactate accelerates vascular calcification, partly through excessive Drp-mediated mitochondrial fission and BNIP3-related mitophagy deficiency.	Lactic Acid	94-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-34
32147404-8	2020	After multivariable logistic regression analysis, variables that were associated with ALN metastasis were palpability, multifocality, location, size, histologic type, grade, lymphovascular invasion, hormone receptor expression, and Ki-67 level.	aln	86-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	199-215
32279525-5	2020	Several clinical trials are underway to develop treatment strategies based on shortterm responsiveness to NAE to improve the prognosis of hormone receptor (HR)-positive/HER2-negative breast cancer.	N-lauroylethanolamine	106-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	138-160
32541183-1	2020	An 89-year-old woman with recurrent hormone receptor-positive and HER2-negative breast cancer was treated with fulvestrant-palbociclib combination therapy.	Fulvestrant	111-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-52
32060781-1	2020	PURPOSE: To examine (1) the trend and associated factors of Oncotype DX (ODX) use among hormone receptor-positive (HR+) breast cancer (BC) patients in 2004-2015; (2) the trend of reported chemotherapy by Recurrence Score (RS); and (3) the survival differences associated with ODX use.	odx	73-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104
32458702-0	2020	Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.	neratinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-60
32257203-0	2020	Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
32257203-7	2020	The hypothesis that a selected subpopulation of patients with HR+/HER2- metastatic breast cancer may benefit from the addition of palbociclib to ongoing endocrine therapy beyond disease progression merits further investigation.	palbociclib	130-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-64
32326897-0	2020	Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.	Aspirin	84-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	124-140
31618131-1	2020	PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.	Tamoxifen	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-166
31618131-1	2020	PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.	Tamoxifen	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-170
31618131-1	2020	PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.	exemestane	27-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-166
31618131-1	2020	PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.	exemestane	27-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-170
31618131-1	2020	PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.	Tamoxifen	271-280	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-166
31618131-1	2020	PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.	Tamoxifen	271-280	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-170
31618131-1	2020	PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.	Tamoxifen	297-306	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-166
32008124-0	2020	Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.	anastrozole	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	55-71
32008124-0	2020	Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.	ici 182,780	17-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	55-71
31853795-0	2020	First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.	Anastrozole	28-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-60
31853795-1	2020	PURPOSE: In a recent randomized, open-label trial (S0226), the addition of fulvestrant to anastrozole therapy decreased the risk of progression and death in patients with hormone-receptor-positive metastatic breast cancer.	Anastrozole	90-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-187
31618131-1	2020	PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.	Tamoxifen	297-306	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-170
31618131-11	2020	CONCLUSION: Premenopausal women with HR-positive/HER2-negative breast cancer and high recurrence risk, as defined by clinicopathologic characteristics, may experience a 10% to 15% absolute improvement in 8-year freedom from distant recurrence with exemestane plus OFS versus tamoxifen plus OFS or tamoxifen alone.	exemestane	248-258	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-39
31618131-11	2020	CONCLUSION: Premenopausal women with HR-positive/HER2-negative breast cancer and high recurrence risk, as defined by clinicopathologic characteristics, may experience a 10% to 15% absolute improvement in 8-year freedom from distant recurrence with exemestane plus OFS versus tamoxifen plus OFS or tamoxifen alone.	Tamoxifen	275-284	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-39
31618131-11	2020	CONCLUSION: Premenopausal women with HR-positive/HER2-negative breast cancer and high recurrence risk, as defined by clinicopathologic characteristics, may experience a 10% to 15% absolute improvement in 8-year freedom from distant recurrence with exemestane plus OFS versus tamoxifen plus OFS or tamoxifen alone.	Tamoxifen	297-306	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-39
32183517-1	2020	We report the first time resolved resonant Raman (TR3) spectra of photo-induced charge transfer from \RuII\ to methyl viologen, with observations of vibrational structure.	Paraquat	111-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-53
32308485-2	2020	This study aims to evaluate the alternative application of Magee Equation 2 score in predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in hormone receptor (HR)-positive, HER2-negative breast cancer.	nac	165-168	nuclear receptor subfamily 4 group A member 1	Homo sapiens	173-189
32308485-2	2020	This study aims to evaluate the alternative application of Magee Equation 2 score in predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in hormone receptor (HR)-positive, HER2-negative breast cancer.	nac	165-168	nuclear receptor subfamily 4 group A member 1	Homo sapiens	191-193
32308485-13	2020	Conclusion: Among patients with HR-positive and HER2-negative breast cancer treated with NAC, Magee Equation 2 might be used as a tool for predicting the pCR and clinical outcome.	nac	89-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-34
32675948-1	2020	The aim of this retrospective study was to assess the efficacy of topical hormonal therapy (THT) to relieve vaginal symptoms resulting from antihormonal therapy in women with hormone receptor-positive breast cancer.	tetrahydrothiophene	92-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	175-191
32398983-1	2020	Tamoxifen is frequently used as adjuvant treatment in premenopausal patients with hormone receptor-positive early breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
31932237-0	2020	A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.	everolimus	31-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-109
31932237-1	2020	BACKGROUND: Therapies targeting estrogen receptor signaling are standard for patients with hormone receptor (HR)-positive (HR+) metastatic breast cancer (MBC).	Estrogens	32-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-107
31932237-1	2020	BACKGROUND: Therapies targeting estrogen receptor signaling are standard for patients with hormone receptor (HR)-positive (HR+) metastatic breast cancer (MBC).	Estrogens	32-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-111
31932237-1	2020	BACKGROUND: Therapies targeting estrogen receptor signaling are standard for patients with hormone receptor (HR)-positive (HR+) metastatic breast cancer (MBC).	Estrogens	32-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-125
31932237-3	2020	Addition of the mTOR inhibitor, everolimus, to exemestane doubled progression-free survival (PFS) in HR+/HER2- MBC patients whose disease had previously progressed during endocrine therapy.	everolimus	32-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	101-103
31932237-3	2020	Addition of the mTOR inhibitor, everolimus, to exemestane doubled progression-free survival (PFS) in HR+/HER2- MBC patients whose disease had previously progressed during endocrine therapy.	exemestane	47-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	101-103
31932237-4	2020	In this phase II study, we used everolimus in addition to the most recent endocrine therapy during which a patient"s disease progressed, in an attempt to restore and extend the benefit of the antiestrogen therapy in patients with HR+/HER2- MBC.	everolimus	32-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	230-232
31932237-14	2020	CONCLUSION: After progression during antiestrogen therapy, the addition of everolimus, without changing the hormonal therapy, resulted in a median PFS of 6.6 months, suggesting efficacy in patients with HR+/HER2- MBC.	everolimus	75-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-205
32099996-3	2020	Moreover, the treatment of these cells with bis-indole derived NR4A1 ligands 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) and its buttressed 3-chloro-5-methoxy analog (DIM-C-pPhOH-3-Cl-5-OCH3) inhibited cell growth and induced apoptosis and related genes.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	77-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
32099996-0	2020	BIS-INDOLE DERIVED NUCLEAR RECEPTOR 4A1 (NR4A1, Nur77) LIGANDS AS INHIBITORS OF ENDOMETRIOSIS.	bis-indole	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-39
32099996-3	2020	Moreover, the treatment of these cells with bis-indole derived NR4A1 ligands 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) and its buttressed 3-chloro-5-methoxy analog (DIM-C-pPhOH-3-Cl-5-OCH3) inhibited cell growth and induced apoptosis and related genes.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	125-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
32099996-0	2020	BIS-INDOLE DERIVED NUCLEAR RECEPTOR 4A1 (NR4A1, Nur77) LIGANDS AS INHIBITORS OF ENDOMETRIOSIS.	bis-indole	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
32099996-3	2020	Moreover, the treatment of these cells with bis-indole derived NR4A1 ligands 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) and its buttressed 3-chloro-5-methoxy analog (DIM-C-pPhOH-3-Cl-5-OCH3) inhibited cell growth and induced apoptosis and related genes.	3-chloro-5-methoxy	157-175	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
32099996-0	2020	BIS-INDOLE DERIVED NUCLEAR RECEPTOR 4A1 (NR4A1, Nur77) LIGANDS AS INHIBITORS OF ENDOMETRIOSIS.	bis-indole	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
32099996-3	2020	Moreover, the treatment of these cells with bis-indole derived NR4A1 ligands 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) and its buttressed 3-chloro-5-methoxy analog (DIM-C-pPhOH-3-Cl-5-OCH3) inhibited cell growth and induced apoptosis and related genes.	bis-indole	44-54	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
32099996-3	2020	Moreover, the treatment of these cells with bis-indole derived NR4A1 ligands 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) and its buttressed 3-chloro-5-methoxy analog (DIM-C-pPhOH-3-Cl-5-OCH3) inhibited cell growth and induced apoptosis and related genes.	dim-c-pphoh-3-cl-5-och3	184-207	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
32099996-7	2020	Thus, bis-indole derived NR4A1 ligands represent a novel class of drugs as non-hormonal therapy for endometriosis.	bis-indole	6-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-30
32031889-0	2020	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.	MK 2206	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	138-154
32031889-10	2020	RESULTS: MK-2206 graduated with 94 patients and 57 concurrently randomly assigned controls in 3 graduation signatures: HR-negative/HER2-positive, HR-negative, and HER2-positive.	MK 2206	9-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-121
32031889-14	2020	CONCLUSION: The Akt inhibitor MK-2206 combined with standard neoadjuvant therapy resulted in higher estimated pCR rates in HR-negative and HER2-positive breast cancer.	MK 2206	30-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-125
30941738-10	2020	In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate.	Fluorodeoxyglucose F18	290-293	nuclear receptor subfamily 4 group A member 1	Homo sapiens	191-207
32864625-1	2020	Alpelisib is a selective inhibitor of PI3Kalpha, shown to improve outcomes for PIK3CA mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy.	Alpelisib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-110
32183020-4	2020	In breast cancer (BC), dual CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, combined with other agents, were approved by the Food and Drug Administration (FDA) recently for the treatment of hormone receptor positive (HR+) advanced or metastatic breast cancer (A/MBC), as well as other sub-types of breast cancer.	palbociclib	47-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-219
32230859-7	2020	Our results suggest that hyperglycemia leads to: 1) A reduction in PI3P and PIP3, with increased PI4P that is later converted to PI(3,4)P2 at the cell surface in hormone receptor positive breast cancer; 2) a reduction in PI3P and PI4P with increased PIP3 surface expression in human epidermal growth factor receptor 2-positive (HER2+) breast cancer; and 3) an increase in di- and tri-phosphorylated PIs due to turnover of PI3P in triple negative breast cancer.	phosphoinositide-3,4-bisphosphate	129-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	162-178
32230859-7	2020	Our results suggest that hyperglycemia leads to: 1) A reduction in PI3P and PIP3, with increased PI4P that is later converted to PI(3,4)P2 at the cell surface in hormone receptor positive breast cancer; 2) a reduction in PI3P and PI4P with increased PIP3 surface expression in human epidermal growth factor receptor 2-positive (HER2+) breast cancer; and 3) an increase in di- and tri-phosphorylated PIs due to turnover of PI3P in triple negative breast cancer.	Phosphatidylinositols	399-402	nuclear receptor subfamily 4 group A member 1	Homo sapiens	162-178
32258036-8	2020	The phosphorylation of NR4A1 was increased in human osteoarthritis cartilage, and p38 inhibitor SB203580, JNK inhibitor SP600125 and ERK inhibitor FR180204 could significantly inhibited IL-1beta induced NR4A1 phosphorylation.	SB 203580	96-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
32258036-8	2020	The phosphorylation of NR4A1 was increased in human osteoarthritis cartilage, and p38 inhibitor SB203580, JNK inhibitor SP600125 and ERK inhibitor FR180204 could significantly inhibited IL-1beta induced NR4A1 phosphorylation.	pyrazolanthrone	120-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
32258036-8	2020	The phosphorylation of NR4A1 was increased in human osteoarthritis cartilage, and p38 inhibitor SB203580, JNK inhibitor SP600125 and ERK inhibitor FR180204 could significantly inhibited IL-1beta induced NR4A1 phosphorylation.	FR 180204	147-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
32258036-8	2020	The phosphorylation of NR4A1 was increased in human osteoarthritis cartilage, and p38 inhibitor SB203580, JNK inhibitor SP600125 and ERK inhibitor FR180204 could significantly inhibited IL-1beta induced NR4A1 phosphorylation.	FR 180204	147-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-208
32258036-9	2020	Reactivation of NR4A1 by its agonist cytosporone B could inhibit IL-1beta induced chondrocyte inflammation and expression of COX-2, iNOS, MMP3, MMP9, and MMP13.	cytosporone B	37-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	16-21
32440468-3	2020	Herein, a new form of stable all-nitrogen molecular crystals consisting of only bispentazole N10 molecules with exceedingly high energy density is predicted.	Nitrogen	33-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-96
32440468-3	2020	Herein, a new form of stable all-nitrogen molecular crystals consisting of only bispentazole N10 molecules with exceedingly high energy density is predicted.	bispentazole	80-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-96
31930333-5	2020	Interestingly, we found that a small molecule inhibitor of the arginine methyltransferases CARM1 and PRMT6 was able to increase, in a gene specific manner, the number of active alleles/cell before and after hormonal stimulation, suggesting that mechanisms do indeed exist to modulate hormone receptor responses at the single cell and allele level.	Arginine Vasopressin	63-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	284-300
31959898-4	2020	Here, we demonstrate that Nur77 could inhibit HCC development via transcriptional activation of the lncRNA WAP four-disulfide core domain 21 pseudogene (WFDC21P).	Disulfides	116-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-31
31959898-9	2020	Cytosporone-B (Csn-B), an agonist for Nur77, could stimulate WFDC21P expression and suppress HCC in a WFDC21P-dependent manner.	cytosporone B	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
31959898-9	2020	Cytosporone-B (Csn-B), an agonist for Nur77, could stimulate WFDC21P expression and suppress HCC in a WFDC21P-dependent manner.	cytosporone B	15-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
31746366-3	2020	The results demonstrated that NR4A1 was significantly upregulated in TNF-alpha and CHX exposed chondrocytes.	Cycloheximide	83-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
31574241-8	2020	Nur77 and 6-MP may provide a basis to develop a new treatment for patients who suffer from embryo adhesion dysfunction.Abbreviations: HB-EGF: heparin-binding epidermal growth factor-like growth factor; HOXA10: homeobox A10; NGFI-B: nerve growth factor-induced gene B; RIF: recurrent implantation failure; RPL: recurrent pregnancy loss; 6-MP: 6-mercaptopurine; IGFBP-1: insulin-like growth factor binding protein-1; LIF: leukemia inhibitory factor; IL-1beta: Interleukin - 1beta; CRISPR/Cas9: Clustered Regularly Interspaced Short Palindromic Repeats; AF-1: activation function-1 domain; HIF-1alpha: hypoxia-inducible factor 1alpha; CREB: cAMP response element binding.	Heparin	142-149	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
31574241-8	2020	Nur77 and 6-MP may provide a basis to develop a new treatment for patients who suffer from embryo adhesion dysfunction.Abbreviations: HB-EGF: heparin-binding epidermal growth factor-like growth factor; HOXA10: homeobox A10; NGFI-B: nerve growth factor-induced gene B; RIF: recurrent implantation failure; RPL: recurrent pregnancy loss; 6-MP: 6-mercaptopurine; IGFBP-1: insulin-like growth factor binding protein-1; LIF: leukemia inhibitory factor; IL-1beta: Interleukin - 1beta; CRISPR/Cas9: Clustered Regularly Interspaced Short Palindromic Repeats; AF-1: activation function-1 domain; HIF-1alpha: hypoxia-inducible factor 1alpha; CREB: cAMP response element binding.	Heparin	142-149	nuclear receptor subfamily 4 group A member 1	Homo sapiens	224-230
31706684-5	2020	These s-triazine compounds were generally more selective towards hormone receptor-positive breast cancer cell line MCF-7 than the triple negative MDA-MB-231 cell line.	Triazines	6-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	65-81
31746366-2	2020	The present study aimed to investigate the role of NR4A1 in regulating chondrocyte death in response to tumor necrosis factor-alpha (TNF-alpha) and cycloheximide (CHX) treatment, with a focus on mitochondrial fission and the AMP-activated protein kinase (AMPK) signaling pathway.	Cycloheximide	148-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
31746366-2	2020	The present study aimed to investigate the role of NR4A1 in regulating chondrocyte death in response to tumor necrosis factor-alpha (TNF-alpha) and cycloheximide (CHX) treatment, with a focus on mitochondrial fission and the AMP-activated protein kinase (AMPK) signaling pathway.	Cycloheximide	163-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
31669267-4	2020	RESULTS: The assessment of HR status showed that the overall positive estrogen receptor (ER) and progesterone receptor (PR) rates were 71.7% and 63.7% (range, 60.9%-87.9% and 43.9%-84.8%), respectively.	Estrogens	70-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-29
32060053-0	2020	Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.	Capecitabine	36-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-89
31746366-2	2020	The present study aimed to investigate the role of NR4A1 in regulating chondrocyte death in response to tumor necrosis factor-alpha (TNF-alpha) and cycloheximide (CHX) treatment, with a focus on mitochondrial fission and the AMP-activated protein kinase (AMPK) signaling pathway.	Adenosine Monophosphate	225-228	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
31746366-6	2020	Inhibiting NR4A1 attenuated TNF-alpha and CHX-induced mitochondrial fission and, thus, reduced mitochondrial dysfunction in chondrocytes, mPTP opening-related cell death and migration injury.	Cycloheximide	42-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-16
31828441-4	2019	Alpelisib in combination with fulvestrant is now available in the clinic for postmenopausal women with advanced or metastatic hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated breast cancer.	Alpelisib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-148
31563959-1	2020	Importance: Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (ET) has not yet been demonstrated.	ici 182,780	117-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-149
31769341-6	2020	Conclusion: CYP2D6*10 pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer.	Estrogens	55-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-161
31794572-11	2019	Also, L-octanoylcarnitine levels differed according to tumor size and hormone receptor expression.	octanoylcarnitine	6-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-86
31859349-5	2019	A recent large randomized trial in patients with endocrine-resistant PIK3CA-mutant hormone receptor (HR)-positive tumors led to the approval of the first PI3K inhibitor, alpelisib, in combination with fulvestrant.	Alpelisib	170-179	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-99
31859349-5	2019	A recent large randomized trial in patients with endocrine-resistant PIK3CA-mutant hormone receptor (HR)-positive tumors led to the approval of the first PI3K inhibitor, alpelisib, in combination with fulvestrant.	Alpelisib	170-179	nuclear receptor subfamily 4 group A member 1	Homo sapiens	101-103
31727981-1	2019	We previously reported the identification of a novel antimitotic agent with carbazole and benzohydrazide structures: N"-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-iodobenzohydrazide (code number NP-10).	carbazole	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-197
31025302-0	2019	Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naive Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.	Fulvestrant	31-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-119
31771627-11	2019	Our organoid model system revealed important insights into the role of PR in BRCA1-mutated benign breast cells and the critical paracrine actions that modify hormone receptor (HR)-negative cells.	organoid	4-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	158-174
31771627-11	2019	Our organoid model system revealed important insights into the role of PR in BRCA1-mutated benign breast cells and the critical paracrine actions that modify hormone receptor (HR)-negative cells.	organoid	4-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	176-178
31727981-1	2019	We previously reported the identification of a novel antimitotic agent with carbazole and benzohydrazide structures: N"-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-iodobenzohydrazide (code number NP-10).	benzoylhydrazine	90-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-197
31727981-1	2019	We previously reported the identification of a novel antimitotic agent with carbazole and benzohydrazide structures: N"-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-iodobenzohydrazide (code number NP-10).	n"-[(9-ethyl-9h-carbazol-3-yl)methylene]-2-iodobenzohydrazide	117-178	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-197
31839811-0	2019	Fenretinide-induced Apoptosis of Acute Myeloid Leukemia Cells via NR4A1 Translocation into Mitochondria and Bcl-2 Transformation.	Fenretinide	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-71
31079343-2	2019	METHODS: Meta-analysis of randomized controlled trials (RCTs) evaluating fulvestrant 500 mg in postmenopausal hormone receptor-positive ABC, to evaluate differences in clinical benefit rate (CBR; proportion of patients experiencing best overall response of complete response, partial response, or stable disease for >= 24 weeks) between fulvestrant 500 mg and comparator endocrine therapies.	Fulvestrant	73-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-126
31079343-10	2019	CONCLUSIONS: In postmenopausal patients with hormone receptor-positive ABC, fulvestrant 500 mg first-line was associated with significantly greater CBR (more patients benefiting from treatment) vs. comparator endocrine therapy.	Fulvestrant	76-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-61
31839811-1	2019	OBJECTIVE: Fenretinide is reported to induce NR4A1-associated apoptosis in several types of cancer cells.	Fenretinide	11-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
31839811-7	2019	In addition, the expression levels of NR4A1 in the nuclei and mitochondria of fenretinide-treated AML cells were also measured.	Fenretinide	78-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
31839811-11	2019	Fenretinide induced the expression of NR4A1 and mitochondria-mediated apoptotic pathway-associated proteins in a time- and concentration-dependent manner.	Fenretinide	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
31839811-13	2019	Under the action of fenretinide, the NR4A1 protein expression was down-regulated in nuclear extracts whereas up-regulated in mitochondrial extracts.	Fenretinide	20-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-42
31839811-14	2019	At the same time, fenretinide promoted NR4A1 translocation from nuclei into mitochondria, and enhanced the interaction between NR4A1 and Bcl-2, thereby exposing the BH3 domain of Bcl-2 to exert the anti-apoptotic effect.	Fenretinide	18-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
31839811-14	2019	At the same time, fenretinide promoted NR4A1 translocation from nuclei into mitochondria, and enhanced the interaction between NR4A1 and Bcl-2, thereby exposing the BH3 domain of Bcl-2 to exert the anti-apoptotic effect.	Fenretinide	18-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	127-132
31839811-17	2019	Besides, the NR4A1-mediated signaling pathway is highly involved in the fenretinide-induced apoptosis of AML cells.	Fenretinide	72-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
31638935-10	2019	A subgroup analysis revealed that the HER2+/HR- patients who received H + P showed the highest increase in the pCR.	Phlorhizin	74-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-46
31462501-0	2019	Inhibition of NR4A1 Promotes Ros Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.	Reactive Oxygen Species	29-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19
31462501-1	2019	Nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in rhabdomyosarcoma (RMS), and inactivation of NR4A1 (siNR4A1) or treatment with the NR4A1 antagonist 1,1-bis(3"-indoly)-1-(p-hydroxy-phenyl)methane (DIM-C-pPhOH) has antiproliferative and proapoptotic effects on RMS cells.	1,1-bis(3"-indoly)-1-(p-hydroxy-phenyl)methane	155-201	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-20
31462501-1	2019	Nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in rhabdomyosarcoma (RMS), and inactivation of NR4A1 (siNR4A1) or treatment with the NR4A1 antagonist 1,1-bis(3"-indoly)-1-(p-hydroxy-phenyl)methane (DIM-C-pPhOH) has antiproliferative and proapoptotic effects on RMS cells.	1,1-bis(3"-indoly)-1-(p-hydroxy-phenyl)methane	155-201	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-27
31462501-1	2019	Nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in rhabdomyosarcoma (RMS), and inactivation of NR4A1 (siNR4A1) or treatment with the NR4A1 antagonist 1,1-bis(3"-indoly)-1-(p-hydroxy-phenyl)methane (DIM-C-pPhOH) has antiproliferative and proapoptotic effects on RMS cells.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	203-214	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-20
31462501-1	2019	Nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in rhabdomyosarcoma (RMS), and inactivation of NR4A1 (siNR4A1) or treatment with the NR4A1 antagonist 1,1-bis(3"-indoly)-1-(p-hydroxy-phenyl)methane (DIM-C-pPhOH) has antiproliferative and proapoptotic effects on RMS cells.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	203-214	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-27
31462501-3	2019	Here, we report that NR4A1 silencing or inhibition resulted in accumulation of reactive oxygen species (ROS) and ROS-dependent induction of the tumor suppressor-like cytokine IL24 in RMS cells.	Reactive Oxygen Species	79-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-26
31462501-3	2019	Here, we report that NR4A1 silencing or inhibition resulted in accumulation of reactive oxygen species (ROS) and ROS-dependent induction of the tumor suppressor-like cytokine IL24 in RMS cells.	Reactive Oxygen Species	104-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-26
31462501-3	2019	Here, we report that NR4A1 silencing or inhibition resulted in accumulation of reactive oxygen species (ROS) and ROS-dependent induction of the tumor suppressor-like cytokine IL24 in RMS cells.	Reactive Oxygen Species	113-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-26
31462501-5	2019	Silencing TXNDC5 and IDH1 also induced ROS accumulation and IL24 expression in RMS cells, suggesting that NR4A1 antagonists mediate their antiproliferative and apoptotic effects through modulation of proreductant gene expression.	Reactive Oxygen Species	39-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-111
31462501-6	2019	Finally, cotreatment with the antioxidant glutathione or IL24-blocking antibody reversed the effects of NR4A1 inhibition, demonstrating the importance of both ROS and IL24 in mediating the cellular responses.Implications: Overall, these data elucidate the mechanism by which NR4A1 inhibition functions to inhibit the proliferation, survival, and migration of RMS cells.	Glutathione	42-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-109
31462501-6	2019	Finally, cotreatment with the antioxidant glutathione or IL24-blocking antibody reversed the effects of NR4A1 inhibition, demonstrating the importance of both ROS and IL24 in mediating the cellular responses.Implications: Overall, these data elucidate the mechanism by which NR4A1 inhibition functions to inhibit the proliferation, survival, and migration of RMS cells.	Glutathione	42-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	275-280
31462501-6	2019	Finally, cotreatment with the antioxidant glutathione or IL24-blocking antibody reversed the effects of NR4A1 inhibition, demonstrating the importance of both ROS and IL24 in mediating the cellular responses.Implications: Overall, these data elucidate the mechanism by which NR4A1 inhibition functions to inhibit the proliferation, survival, and migration of RMS cells.	Reactive Oxygen Species	159-162	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-109
31486299-5	2019	Fluoride release (N = 10) was evaluated in CG, SG and UG after cariogenic challenge for 11 days.	Fluorides	0-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-24
31486299-5	2019	Fluoride release (N = 10) was evaluated in CG, SG and UG after cariogenic challenge for 11 days.	cysteinylglycine	43-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-24
31498970-2	2019	With increasing the oligofluorene arm length, absorption spectra were red-shifted progressively, whereas an increase in photoluminescence quantum yields (PLQYs) and optical gain coefficients, and a corresponding reduction in amplified spontaneous emission (ASE) thresholds and loss coefficients were observed for Tr1-Tr3 except for Tr4.	oligofluorene	20-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	317-320
31788435-3	2019	Research showed the potential of depsidones as a treatment option for hormone receptor-positive breast cancer treatment, yet its effects on hormone receptor-negative breast cancer are still unkown.	depsidone	33-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-86
31492735-0	2019	Molecular, Chemical, and Structural Characterization of Prostaglandin A2 as a Novel Agonist for Nur77.	prostaglandin A2	56-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-101
31492735-4	2019	However, several more recent studies indicate that small synthetic molecules and unsaturated fatty acids can bind to Nur77.	Fatty Acids, Unsaturated	81-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	117-122
31492735-8	2019	Our data show that PGA2 induces Nur77 transcriptional activity by forming a covalent adduct between its endocyclic beta-carbon, C9, and Cys566 in the receptor"s ligand-binding domain.	prostaglandin A2	19-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-37
31492735-8	2019	Our data show that PGA2 induces Nur77 transcriptional activity by forming a covalent adduct between its endocyclic beta-carbon, C9, and Cys566 in the receptor"s ligand-binding domain.	beta-carbon	115-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-37
31492735-9	2019	The importance of this endocyclic beta-carbon was substantiated by the failure of prostaglandins without such electrophilic properties to react with Nur77.	Prostaglandins	82-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-154
31492735-10	2019	Calculated chemical properties and data from reactive molecular dynamic simulations, intrinsic reaction coordinate modeling, and covalent molecular docking also corroborate the selectivity of PGA2"s C9 beta-carbon towards Nur77"s Cys.	prostaglandin A2	192-196	nuclear receptor subfamily 4 group A member 1	Homo sapiens	222-227
31492735-10	2019	Calculated chemical properties and data from reactive molecular dynamic simulations, intrinsic reaction coordinate modeling, and covalent molecular docking also corroborate the selectivity of PGA2"s C9 beta-carbon towards Nur77"s Cys.	beta-carbon	202-213	nuclear receptor subfamily 4 group A member 1	Homo sapiens	222-227
31492735-10	2019	Calculated chemical properties and data from reactive molecular dynamic simulations, intrinsic reaction coordinate modeling, and covalent molecular docking also corroborate the selectivity of PGA2"s C9 beta-carbon towards Nur77"s Cys.	Cysteine	230-233	nuclear receptor subfamily 4 group A member 1	Homo sapiens	222-227
31492735-11	2019	In summary, our molecular, chemical, and structural characterization of the PGA2-Nur77 interaction provides the first evidence that PGA2 is an endogenous Nur77 agonist.	prostaglandin A2	76-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-86
31492735-11	2019	In summary, our molecular, chemical, and structural characterization of the PGA2-Nur77 interaction provides the first evidence that PGA2 is an endogenous Nur77 agonist.	prostaglandin A2	76-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-159
31492735-11	2019	In summary, our molecular, chemical, and structural characterization of the PGA2-Nur77 interaction provides the first evidence that PGA2 is an endogenous Nur77 agonist.	prostaglandin A2	132-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-86
31492735-11	2019	In summary, our molecular, chemical, and structural characterization of the PGA2-Nur77 interaction provides the first evidence that PGA2 is an endogenous Nur77 agonist.	prostaglandin A2	132-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-159
31551757-6	2019	Peri-menopause is marked by widely fluctuating estrogen levels resulting in periods of irregular hormone-receptor interactions.	Estrogens	47-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
31533777-1	2019	BACKGROUND: The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed.	Vinorelbine	53-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	136-152
31533777-1	2019	BACKGROUND: The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed.	mvnb	66-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	136-152
31339827-12	2019	With longer follow-up, standard chemotherapy remains superior to capecitabine among hormone receptor-negative patients (HR, 0.66; P = .02), but not among hormone receptor-positive patients (HR, 0.89; P = .43).	Capecitabine	65-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
31339827-15	2019	CONCLUSION: With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone receptor-negative disease.	Capecitabine	98-110	nuclear receptor subfamily 4 group A member 1	Homo sapiens	140-156
31273046-0	2019	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling.	Mercaptopurine	73-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	229-245	nuclear receptor subfamily 4 group A member 1	Homo sapiens	24-29
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	229-245	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-225
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	229-245	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-225
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	247-251	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-225
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	247-251	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-225
31127979-0	2019	N10 -carbonyl-substituted phenothiazines inhibiting lipid peroxidation and associated nitric oxide consumption powerfully protect brain tissue against oxidative stress.	Nitric Oxide	86-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-3
31153828-1	2019	Tamoxifen is the most commonly used endocrine therapy for patients with hormone receptor (HR)-positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-88
31153828-1	2019	Tamoxifen is the most commonly used endocrine therapy for patients with hormone receptor (HR)-positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-92
31119568-0	2019	Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.	bis-indole	38-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-77
31132532-0	2019	SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.	celastrol	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
31132532-2	2019	Our previous work found that celastrol, a pentacyclic triterpene, bound to Nur77 to inhibit inflammation in a Nur77-dependent manner.	celastrol	29-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-80
31132532-2	2019	Our previous work found that celastrol, a pentacyclic triterpene, bound to Nur77 to inhibit inflammation in a Nur77-dependent manner.	celastrol	29-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-115
31132532-2	2019	Our previous work found that celastrol, a pentacyclic triterpene, bound to Nur77 to inhibit inflammation in a Nur77-dependent manner.	Triterpenes	54-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-80
31132532-2	2019	Our previous work found that celastrol, a pentacyclic triterpene, bound to Nur77 to inhibit inflammation in a Nur77-dependent manner.	Triterpenes	54-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-115
31132532-3	2019	Celastrol binding to Nur77 promotes Nur77 translocation from nucleus to cytoplasm, resulting in clearance of inflamed mitochondria and then alleviation of inflammation.	celastrol	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-26
31132532-3	2019	Celastrol binding to Nur77 promotes Nur77 translocation from nucleus to cytoplasm, resulting in clearance of inflamed mitochondria and then alleviation of inflammation.	celastrol	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-41
31312859-5	2019	Western blotting data further confirmed that NUR77 was highly expressed in primary human term placental STB and the FSK-induced BeWo cell line.	fsk	116-119	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
31298848-3	2019	On a longer (hundreds of ns) timescale, this species rearranges to a ring-opened diazo compound, which we have also detected by time-resolved infrared and TR3 spectroscopy.	diazo compound	81-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	155-158
31051411-1	2019	BACKGROUND: Endocrine treatment with Tamoxifen and aromatase inhibitors (AIs) is a staple in the management of hormone receptor positive breast cancer (HR + BC).	Tamoxifen	37-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-127
31119568-0	2019	Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.	bis-indole	38-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-84
31119568-1	2019	BACKGROUND: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in breast and other cancer cells.	methylene-substituted bis-indole	85-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39
31119568-1	2019	BACKGROUND: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in breast and other cancer cells.	methylene-substituted bis-indole	85-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	201-206
31119568-1	2019	BACKGROUND: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in breast and other cancer cells.	methylene-substituted bis-indole	85-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	201-206
31119568-1	2019	BACKGROUND: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in breast and other cancer cells.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	129-175	nuclear receptor subfamily 4 group A member 1	Homo sapiens	201-206
31119568-1	2019	BACKGROUND: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in breast and other cancer cells.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	129-175	nuclear receptor subfamily 4 group A member 1	Homo sapiens	201-206
31119568-1	2019	BACKGROUND: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in breast and other cancer cells.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	177-188	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-32
31119568-1	2019	BACKGROUND: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in breast and other cancer cells.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	177-188	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39
31119568-7	2019	DIM-C-pPhOH is rapidly metabolized and the effects and potencies of buttressed analogs of DIM-C-pPhOH which contain one or two substituents ortho to the hydroxyl groups were investigated using NR4A1-regulated gene/gene products as endpoints.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	193-198
31053403-0	2019	Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.	ros	48-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-20
31146160-1	2019	Tamoxifen (TAM) is a first generation-SERM administered for hormone receptor-positive (HER+) breast cancer in both pre- and post-menopausal patients and may undergo metabolic activation in organisms that share similar receptors and thus face comparable mechanisms of response.	Tamoxifen	11-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-77
30980508-0	2019	Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor-positive breast and prostate cancer cells.	usnic acid	49-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-79
30980508-1	2019	The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively.	usnic acid	65-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
30980508-1	2019	The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively.	usnic acid	77-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
30980508-1	2019	The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively.	Tamoxifen	85-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
30980508-1	2019	The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively.	Tamoxifen	85-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
30980508-1	2019	The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively.	enzalutamide	104-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
30980508-1	2019	The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively.	enzalutamide	104-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
31413807-0	2019	Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs).	indolinobenzodiazepine	60-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-31
31413807-3	2019	Here, we present an alternative strategy for the IGNs, linking through a carbamate at the readily available N-10 amine present in the monoimine containing dimer.	Carbamates	73-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-112
31413807-3	2019	Here, we present an alternative strategy for the IGNs, linking through a carbamate at the readily available N-10 amine present in the monoimine containing dimer.	monoimine	134-143	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-112
31331091-0	2019	Autoantibodies Specific to ERalpha are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer.	Tamoxifen	51-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
30895534-12	2019	CONCLUSIONS: Among patients with HR-positive advanced breast cancer, the estimated PFS in patients treated with fulvestrant and palbociclib was comparable to a previously reported phase 3 trial.	Fulvestrant	112-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-35
30895534-12	2019	CONCLUSIONS: Among patients with HR-positive advanced breast cancer, the estimated PFS in patients treated with fulvestrant and palbociclib was comparable to a previously reported phase 3 trial.	palbociclib	128-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-35
31146160-1	2019	Tamoxifen (TAM) is a first generation-SERM administered for hormone receptor-positive (HER+) breast cancer in both pre- and post-menopausal patients and may undergo metabolic activation in organisms that share similar receptors and thus face comparable mechanisms of response.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-77
31340867-1	2019	BACKGROUND: Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer.	Tamoxifen	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-82
31337401-10	2019	We observed a lower plasmatic tryptophan and a higher kynurenine/tryptophan ratio in hormone receptor-negative patients compared to hormone receptor-positive cancers.	Tryptophan	30-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
31337401-10	2019	We observed a lower plasmatic tryptophan and a higher kynurenine/tryptophan ratio in hormone receptor-negative patients compared to hormone receptor-positive cancers.	Kynurenine	54-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
31337401-10	2019	We observed a lower plasmatic tryptophan and a higher kynurenine/tryptophan ratio in hormone receptor-negative patients compared to hormone receptor-positive cancers.	Tryptophan	65-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
31337401-16	2019	The Kyn/Trp ratio and Trp also showed different values according to hormone receptor status, TNM stage, T grade and histology.	Kynurenine	4-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
31337401-16	2019	The Kyn/Trp ratio and Trp also showed different values according to hormone receptor status, TNM stage, T grade and histology.	Tryptophan	8-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
31337401-16	2019	The Kyn/Trp ratio and Trp also showed different values according to hormone receptor status, TNM stage, T grade and histology.	Tryptophan	22-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
31053403-0	2019	Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.	ros	48-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-27
31053403-6	2019	CONCLUSIONS: NR4A1 exhibited pro-oncogenic activity in endometrial cells due, in part, to regulation of cell growth, survival and mTOR signaling, and all of these pathways and their associated gene products were inhibited after treatment with bis-indole-derived NR4A1 antagonists.	bis-indole	243-253	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
31053403-6	2019	CONCLUSIONS: NR4A1 exhibited pro-oncogenic activity in endometrial cells due, in part, to regulation of cell growth, survival and mTOR signaling, and all of these pathways and their associated gene products were inhibited after treatment with bis-indole-derived NR4A1 antagonists.	bis-indole	243-253	nuclear receptor subfamily 4 group A member 1	Homo sapiens	262-267
30679318-0	2019	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.	exemestane	16-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-47
31115481-4	2019	We report that CS promotes Nur77 expression and nuclear export in vivo and in vitro, which increases cigarette smoke extract (CSE)-induced autophagy.	Cesium	15-17	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
31115481-5	2019	In addition, we found that lung tissues, human bronchial epithelial (HBE) cells and A549 cells exposed to CS or CSE expressed lower levels of LC3 and Beclin-1 and contained fewer autophagosomes following Nur77 knockdown with siRNA-Nur77.	Cesium	106-108	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-209
31115481-5	2019	In addition, we found that lung tissues, human bronchial epithelial (HBE) cells and A549 cells exposed to CS or CSE expressed lower levels of LC3 and Beclin-1 and contained fewer autophagosomes following Nur77 knockdown with siRNA-Nur77.	Cesium	106-108	nuclear receptor subfamily 4 group A member 1	Homo sapiens	231-236
31115481-8	2019	This study illustrates the role of Nur77 in bronchial and alveolar destruction following exposure to CS.	Cesium	101-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-40
30679318-0	2019	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-47
30981499-9	2019	Meanwhile, in quiescent satellite cells, Nr4a1 expressed is not detected, while its protein level is highly induced in both BaCl2-induced muscle regeneration followed with satellite cells activation and satellite cells of cultured single myofiber.	barium chloride	124-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
32851295-12	2019	Vancomycin minimal inhibitory concentration (MIC) creep was found in the study period in all MRSA and ST59-SCC mec IV isolates.	Vancomycin	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-106
31289516-6	2019	Hormone receptor (HR)-negative BC is associated with a higher TMB and immune gene expression compared with HR-positive BC [TMB, estrogen receptor (ER)-negative vs. ER-negative, 55 vs. 32, respectively; P=4.1x10-13; progesterone receptor (PR)-negative vs. PR-positive, 53 vs. 31, respectively; P&lt;2.2x10-16].	1,2,4,5-tetramethoxybenzene	62-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
31289516-6	2019	Hormone receptor (HR)-negative BC is associated with a higher TMB and immune gene expression compared with HR-positive BC [TMB, estrogen receptor (ER)-negative vs. ER-negative, 55 vs. 32, respectively; P=4.1x10-13; progesterone receptor (PR)-negative vs. PR-positive, 53 vs. 31, respectively; P&lt;2.2x10-16].	1,2,4,5-tetramethoxybenzene	62-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-20
31289516-10	2019	The findings of the present study suggest that HR-negative or HER2-positive BC exhibits elevated TMB and immunogenic activity, and immunotherapeutic options are recommended.	1,2,4,5-tetramethoxybenzene	97-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-49
30957282-9	2019	Compared with the Raman bands of AH+ (N1+H+ ), the TR3 bands of AH.2+ (N1+H+ ) are significantly down-shifted, indicating a decrease in the bond order of the pyrimidine and imidazole rings due to the resonance structure of AH.2+ (N1+H+ ).	pyrimidine	158-168	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-54
30957282-9	2019	Compared with the Raman bands of AH+ (N1+H+ ), the TR3 bands of AH.2+ (N1+H+ ) are significantly down-shifted, indicating a decrease in the bond order of the pyrimidine and imidazole rings due to the resonance structure of AH.2+ (N1+H+ ).	imidazole	173-182	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-54
30868391-0	2019	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.	ki-67	21-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104
30778520-0	2019	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study.	Letrozole	91-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-27
31036468-22	2019	INTERPRETATION: Tucidinostat plus exemestane improved progression-free survival compared with placebo plus exemestane in patients with advanced, hormone receptor-positive, HER2-negative breast cancer that progressed after previous endocrine therapy.	exemestane	34-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-161
31217631-9	2019	After treatment with captopril or AT 1 R-inhibitor candesartan, VEGF-expression decreased significantly in HR-positive and HR-negative cell lines.	Captopril	21-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-109
31217631-9	2019	After treatment with captopril or AT 1 R-inhibitor candesartan, VEGF-expression decreased significantly in HR-positive and HR-negative cell lines.	Captopril	21-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-125
31217631-9	2019	After treatment with captopril or AT 1 R-inhibitor candesartan, VEGF-expression decreased significantly in HR-positive and HR-negative cell lines.	candesartan	51-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-109
31217631-9	2019	After treatment with captopril or AT 1 R-inhibitor candesartan, VEGF-expression decreased significantly in HR-positive and HR-negative cell lines.	candesartan	51-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-125
30801912-4	2019	At 6 hours, dexamethasone treatment decreased levels of NR0B2, NR4A1, NR5A1, and NR5A2 messenger RNAs (mRNAs) and NR5A2 mRNA levels remained depressed at 12 hours.	Dexamethasone	12-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
30801912-7	2019	In primary cultures of Leydig cells, 10 -9 and 10 -7 M dexamethasone decreased levels of NR4A1 and NR5A1 mRNAs and increased those of NFKBIA mRNA.	Dexamethasone	55-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
30801912-8	2019	Our discovery that dexamethasone downregulates NR4A1, NR5A1, and NR5A2 genes, known to be important for testicular functions, may be part of the mechanism by which glucocorticoids acutely decreases testosterone.	Dexamethasone	19-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-52
30801912-8	2019	Our discovery that dexamethasone downregulates NR4A1, NR5A1, and NR5A2 genes, known to be important for testicular functions, may be part of the mechanism by which glucocorticoids acutely decreases testosterone.	Testosterone	198-210	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-52
31036468-0	2019	Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.	N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide	0-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-88
30772912-7	2019	miR-21 effectively promoted the expression of the 8Br-cAMP plus medroxyprogesterone acetate (MPA)-induced hESC decidualization marker genes PRL and IGFBP-1 and morphological transformation through the modulation of KLF12 and NR4A1 expression; conversely, inhibition of miR-21 expression compromised hESC decidualization in vitro.	Medroxyprogesterone Acetate	64-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	225-230
31036468-2	2019	In an exploratory study, the combination of tucidinostat with exemestane showed preliminary signs of encouraging anti-tumour activity in patients with advanced hormone receptor-positive breast cancer.	N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide	44-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-176
31036468-2	2019	In an exploratory study, the combination of tucidinostat with exemestane showed preliminary signs of encouraging anti-tumour activity in patients with advanced hormone receptor-positive breast cancer.	exemestane	62-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-176
31036468-22	2019	INTERPRETATION: Tucidinostat plus exemestane improved progression-free survival compared with placebo plus exemestane in patients with advanced, hormone receptor-positive, HER2-negative breast cancer that progressed after previous endocrine therapy.	N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide	16-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-161
31091374-13	2019	CONCLUSIONS: Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.	alpelisib-fulvestrant	28-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-124
31088410-0	2019	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-30
31088410-1	2019	BACKGROUND: Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-160
31088410-1	2019	BACKGROUND: Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	162-164
30772912-7	2019	miR-21 effectively promoted the expression of the 8Br-cAMP plus medroxyprogesterone acetate (MPA)-induced hESC decidualization marker genes PRL and IGFBP-1 and morphological transformation through the modulation of KLF12 and NR4A1 expression; conversely, inhibition of miR-21 expression compromised hESC decidualization in vitro.	8br-camp	50-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	225-230
30723140-1	2019	PURPOSE: Addition of alpelisib to fulvestrant significantly extended progression-free survival in PIK3CA-mutant, hormone receptor-positive (HR+) advanced/metastatic breast cancer in the phase III SOLAR-1 study.	Alpelisib	21-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-129
30772912-7	2019	miR-21 effectively promoted the expression of the 8Br-cAMP plus medroxyprogesterone acetate (MPA)-induced hESC decidualization marker genes PRL and IGFBP-1 and morphological transformation through the modulation of KLF12 and NR4A1 expression; conversely, inhibition of miR-21 expression compromised hESC decidualization in vitro.	Medroxyprogesterone Acetate	93-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	225-230
30973961-4	2019	We aimed to elucidate the regulation of NR4A1 and its significance in Hcy-induced NAFLD.	Homocysteine	70-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-45
30515770-0	2019	Dietary cadmium and risk of breast cancer subtypes defined by hormone receptor status: A prospective cohort study.	Cadmium	8-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-78
30973961-6	2019	Furthermore, Hcy enhanced p300 and decreased HDAC7 recruitment to the NR4A1 promoter, resulting in histone H3K27 hyperacetylation and NR4A1 upregulation.	Homocysteine	13-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-75
30973961-6	2019	Furthermore, Hcy enhanced p300 and decreased HDAC7 recruitment to the NR4A1 promoter, resulting in histone H3K27 hyperacetylation and NR4A1 upregulation.	Homocysteine	13-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	134-139
30973961-7	2019	Moreover, NR4A1 depletion not only mimicked but also exaggerated the effects of Hcy on steatosis, whereas NR4A1 agonist Cytosporone B (CsnB) blocked Hcy-induced steatosis.	Homocysteine	80-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-15
30973961-7	2019	Moreover, NR4A1 depletion not only mimicked but also exaggerated the effects of Hcy on steatosis, whereas NR4A1 agonist Cytosporone B (CsnB) blocked Hcy-induced steatosis.	cytosporone B	120-133	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-111
30973961-7	2019	Moreover, NR4A1 depletion not only mimicked but also exaggerated the effects of Hcy on steatosis, whereas NR4A1 agonist Cytosporone B (CsnB) blocked Hcy-induced steatosis.	cytosporone B	135-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-111
30973961-7	2019	Moreover, NR4A1 depletion not only mimicked but also exaggerated the effects of Hcy on steatosis, whereas NR4A1 agonist Cytosporone B (CsnB) blocked Hcy-induced steatosis.	Homocysteine	149-152	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-111
30973961-9	2019	Thus, Hcy transiently and rapidly induces NR4A1 expression to reduce Hcy-induced steatosis.	Homocysteine	6-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-47
30973961-9	2019	Thus, Hcy transiently and rapidly induces NR4A1 expression to reduce Hcy-induced steatosis.	Homocysteine	69-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-47
30610588-0	2019	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.	Metformin	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-160
30926635-4	2019	Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway.	1,1-bis(3'-indolyl)-1-(4-trifluoromethylphenyl)methane	59-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	176-181
30926635-4	2019	Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway.	meso3 -	73-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	176-181
30926635-4	2019	Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway.	bi1071	82-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	176-181
30926635-4	2019	Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway.	indole-3-carbinol	124-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	176-181
30610588-0	2019	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.	exemestane	68-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-160
30610588-2	2019	Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer.	Metformin	43-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	163-179
30610588-2	2019	Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer.	Everolimus	56-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	163-179
30610588-2	2019	Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer.	exemestane	71-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	163-179
30610588-3	2019	We conducted a phase II trial to evaluate the efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal women with metastatic, hormone receptor-positive, HER2-negative breast cancer.	Metformin	88-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	187-203
30610588-3	2019	We conducted a phase II trial to evaluate the efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal women with metastatic, hormone receptor-positive, HER2-negative breast cancer.	Everolimus	99-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	187-203
30610588-3	2019	We conducted a phase II trial to evaluate the efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal women with metastatic, hormone receptor-positive, HER2-negative breast cancer.	exemestane	114-124	nuclear receptor subfamily 4 group A member 1	Homo sapiens	187-203
30610588-11	2019	Conclusion The combination of metformin, everolimus and exemestane was safe and had moderate clinical benefit in overweight and obese with patients metastatic, hormone receptor-positive, HER2-negative breast cancer.	Metformin	30-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-176
30610588-11	2019	Conclusion The combination of metformin, everolimus and exemestane was safe and had moderate clinical benefit in overweight and obese with patients metastatic, hormone receptor-positive, HER2-negative breast cancer.	Everolimus	41-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-176
30610588-11	2019	Conclusion The combination of metformin, everolimus and exemestane was safe and had moderate clinical benefit in overweight and obese with patients metastatic, hormone receptor-positive, HER2-negative breast cancer.	exemestane	56-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-176
30798641-0	2019	Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.	Everolimus	23-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-95
30806032-6	2019	To accelerate the drug development for non-smoking female NSCLC patients, we identified nilotinib as a potential agonist targeting NR4A1 encoded protein by molecular docking and molecular dynamic stimulation.	nilotinib	88-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	131-136
30872732-0	2019	Pro-angiogenic Ginsenosides F1 and Rh1 Inhibit Vascular Leakage by Modulating NR4A1.	Ginsenosides	15-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-83
30872732-0	2019	Pro-angiogenic Ginsenosides F1 and Rh1 Inhibit Vascular Leakage by Modulating NR4A1.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	35-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-83
30798641-0	2019	Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.	exemestane	39-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-95
30079740-7	2019	In combination with fulvestrant, CDK 4/6 inhibitors used for the treatment of hormone receptor-positive ABC resulted in a 43% to 58% improvement in median PFS versus fulvestrant alone.	Fulvestrant	20-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-94
30912283-8	2019	Clamp-derived glucose disposal rates correlated with Nur77 (r2  = 0.14) and NOR1 (r2  = 0.12) protein expression responses to insulin, whereas age (Nur77: r2  = 0.22; NOR1: r2  = 0.25) and BMI (Nur77: r2  = 0.22; NOR1: r2  = 0.42) showed inverse correlations, corroborating preclinical data.	Glucose	14-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-58
31011314-7	2019	We believe that anastrozole induced a change in the local estrogen level, which affected the hormone receptor-positive endothelial cells in the dermis near the primary lesion of the breast cancer and caused a cutaneous adverse event only in the aforementioned area.	Anastrozole	16-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-109
30079740-7	2019	In combination with fulvestrant, CDK 4/6 inhibitors used for the treatment of hormone receptor-positive ABC resulted in a 43% to 58% improvement in median PFS versus fulvestrant alone.	Fulvestrant	166-177	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-94
30478785-0	2019	G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.	Tamoxifen	132-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-73
30607817-4	2019	This led to the approval of neratinib in the EU as extended adjuvant therapy for patients with early-stage HRc-positive, HER2-positive breast cancer and who are less than 1 year from completion of prior adjuvant trastuzumab-based therapy.	neratinib	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-110
30252536-6	2019	Thus, HDAC inhibitors and RA-induced miR-22 resulted in simultaneous induction of cytoplasmic RARbeta and NUR77, leading to apoptosis of colon cancer cells.	Tretinoin	26-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-111
30700929-0	2018	Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.	N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide	30-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-148
30535552-0	2019	Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.	Fulvestrant	15-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
30535552-1	2019	The article Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer, written by Sarah Sammons, Noah S. Kornblum and Kimberly L. Blackwell, was originally published electronically on the publisher"s internet portal (currently SpringerLink).	Fulvestrant	12-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-95
30605443-10	2019	CONCLUSIONS These findings provide a rationale for future clinical trials of palbociclib and everolimus combination-based therapy in hormone receptor-positive breast cancer.	Everolimus	93-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-149
29687661-12	2019	Hormone-receptor-positive breast cancer patients who receive adjuvant endocrine therapy with tamoxifen alone might be candidates for extended endocrine therapy.	Tamoxifen	93-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
30588017-4	2018	Pooled pathological complete response (pCR) and 5-year disease-free survival (DFS) rates were higher for the neoadjuvant BEV + CT group (OR =1.37 [1.19, 1.58]; P&lt;0.001 and HR =0.84 [0.72, 0.98]; P=0.020, respectively), but 5-year overall survival (OS) rate showed no significant difference (HR =0.79 [0.55, 1.11]; P=0.180).	N-[(2z)-1,3-Thiazolidin-2-Ylidene]sulfamide	121-124	nuclear receptor subfamily 4 group A member 1	Homo sapiens	175-177
30588017-4	2018	Pooled pathological complete response (pCR) and 5-year disease-free survival (DFS) rates were higher for the neoadjuvant BEV + CT group (OR =1.37 [1.19, 1.58]; P&lt;0.001 and HR =0.84 [0.72, 0.98]; P=0.020, respectively), but 5-year overall survival (OS) rate showed no significant difference (HR =0.79 [0.55, 1.11]; P=0.180).	N-[(2z)-1,3-Thiazolidin-2-Ylidene]sulfamide	121-124	nuclear receptor subfamily 4 group A member 1	Homo sapiens	294-296
30588017-5	2018	Subgroup analysis showed that the pCR rate was significantly higher in both patients with hormone receptor (HR)-positive breast cancer (OR =1.30 [1.01, 1.66]; P=0.040) and those with HR-negative breast cancer (OR =1.52 [1.25, 1.83]; P&lt;0.001) in BEV + CT group.	bev + ct	248-256	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-106
30588017-5	2018	Subgroup analysis showed that the pCR rate was significantly higher in both patients with hormone receptor (HR)-positive breast cancer (OR =1.30 [1.01, 1.66]; P=0.040) and those with HR-negative breast cancer (OR =1.52 [1.25, 1.83]; P&lt;0.001) in BEV + CT group.	bev + ct	248-256	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-110
30588017-5	2018	Subgroup analysis showed that the pCR rate was significantly higher in both patients with hormone receptor (HR)-positive breast cancer (OR =1.30 [1.01, 1.66]; P=0.040) and those with HR-negative breast cancer (OR =1.52 [1.25, 1.83]; P&lt;0.001) in BEV + CT group.	bev + ct	248-256	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-185
30136059-0	2019	Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-83
30136059-1	2019	Fulvestrant is recommended for patients with hormone receptor-positive (HR+) advanced breast cancer (ABC) who progress after aromatase inhibitor therapy.	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-61
30605443-9	2019	Importantly, everolimus enhanced the antitumor effect of palbociclib in palbociclib-sensitive hormone receptor-positive cells (MCF-7 cells).	Everolimus	13-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-110
30361875-9	2019	CONCLUSIONS: Metronomic oral capecitabine combined with AIs showed good efficacy, minimal toxicities, and good tolerance in HR-positive patients with ABC.	Capecitabine	29-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	124-126
30700929-0	2018	Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.	exemestane	118-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-148
30536272-1	2018	Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	101-117
30032697-1	2018	OBJECTIVES: The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.	Letrozole	114-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	200-216
30035646-1	2018	Letrozole (LTZ) is effective for the treatment of hormone-receptor-positive breast cancer in postmenopausal women.	Letrozole	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
30035646-1	2018	Letrozole (LTZ) is effective for the treatment of hormone-receptor-positive breast cancer in postmenopausal women.	Letrozole	11-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
30325029-3	2018	Based on these findings, we hypothesized that cytosporone-B (Csn-B), an NR4A1 agonist, may hold significant therapeutic potential.	cytosporone B	46-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-77
30325029-3	2018	Based on these findings, we hypothesized that cytosporone-B (Csn-B), an NR4A1 agonist, may hold significant therapeutic potential.	cytosporone B	61-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-77
30072581-2	2018	Moreover, TGFbeta-induced migration of the cells is also blocked by the nuclear export inhibitor leptomycin B (LMB) and the orphan nuclear receptor 4A1 (NR4A1) ligand 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (CDIM8), which retains NR4A1 in the nucleus.	leptomycin B	97-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-242
30072581-2	2018	Moreover, TGFbeta-induced migration of the cells is also blocked by the nuclear export inhibitor leptomycin B (LMB) and the orphan nuclear receptor 4A1 (NR4A1) ligand 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (CDIM8), which retains NR4A1 in the nucleus.	leptomycin B	111-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-242
30072581-2	2018	Moreover, TGFbeta-induced migration of the cells is also blocked by the nuclear export inhibitor leptomycin B (LMB) and the orphan nuclear receptor 4A1 (NR4A1) ligand 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (CDIM8), which retains NR4A1 in the nucleus.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	167-213	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
30072581-2	2018	Moreover, TGFbeta-induced migration of the cells is also blocked by the nuclear export inhibitor leptomycin B (LMB) and the orphan nuclear receptor 4A1 (NR4A1) ligand 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (CDIM8), which retains NR4A1 in the nucleus.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	167-213	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-242
30072581-2	2018	Moreover, TGFbeta-induced migration of the cells is also blocked by the nuclear export inhibitor leptomycin B (LMB) and the orphan nuclear receptor 4A1 (NR4A1) ligand 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (CDIM8), which retains NR4A1 in the nucleus.	DIM-C-pPhOH	215-220	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
30072581-4	2018	Thus, NR4A1 also plays an integral role in mediating TGFbeta-induced lung cancer invasion, and the NR4A1 ligand CDIM8, which binds nuclear NR4A1, represents a novel therapeutic approach for TGFbeta-induced blocking of lung cancer migration/invasion.	DIM-C-pPhOH	112-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-104
30072581-4	2018	Thus, NR4A1 also plays an integral role in mediating TGFbeta-induced lung cancer invasion, and the NR4A1 ligand CDIM8, which binds nuclear NR4A1, represents a novel therapeutic approach for TGFbeta-induced blocking of lung cancer migration/invasion.	DIM-C-pPhOH	112-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-104
30536272-1	2018	Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer.	Tamoxifen	11-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	101-117
30568462-0	2018	A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis.	Fulvestrant	16-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-92
30568462-1	2018	Fulvestrant is recommended for the hormone receptor-positive metastatic breast cancer (MBC) patients progressed during or after prior endocrine therapy.	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-51
30568462-12	2018	Taken together, combination of fulvestrant with a targeted agent, especially inhibitors targeting CDK4/6 or PI3K/mTOR pathway, may open a new avenue for more effective therapies in relapse or metastatic hormone receptor-positive breast cancer after prior aromatase inhibitors or tamoxifen treatment.	Fulvestrant	31-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-219
29974356-0	2018	Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.	Fulvestrant	23-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-83
30555632-0	2018	Antitumor properties of Salvianolic acid B against triple-negative and hormone receptor-positive breast cancer cells via ceramide-mediated apoptosis.	salvianolic acid B	24-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-87
29982165-0	2018	Molecular dynamics study of TMPA mediated dissociation of Nur77-LKB1 complex.	trimethyl phosphate	28-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-63
29594945-3	2018	In the current study, we explored the effects of Nur77, an orphan nuclear receptor, on prostate cancer cell invasion following ADT.	adt	127-130	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
30412117-11	2018	Women with hormone receptor (HR)-negative tumors were more likely to exhibit pCR than those with HR-positive tumors (P = .007).Decreased BPE of patients with HER2-positive breast cancer may serve as an indicator of NAC effectiveness.	nac	215-218	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-27
29594945-6	2018	The effects of Nur77 over-expression and knockdown on ADT-induced prostate cancer cell invasion were characterized.	adt	54-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-20
29594945-10	2018	Nur77 over-expression blocked invasion-promoting effect of ADT, which is consistent with the down-regulation of MMP9 and Snail protein expression.	adt	59-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
29594945-13	2018	CONCLUSION: Considering the limited success of management of prostate cancer metastasis following ADT, our data strongly suggest that Nur77 regulation could be a promising direction for search of complementary therapeutic strategy on top of classic ADT therapy.	adt	98-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	134-139
29594945-13	2018	CONCLUSION: Considering the limited success of management of prostate cancer metastasis following ADT, our data strongly suggest that Nur77 regulation could be a promising direction for search of complementary therapeutic strategy on top of classic ADT therapy.	adt	249-252	nuclear receptor subfamily 4 group A member 1	Homo sapiens	134-139
30382056-0	2018	[Indoleamine 2,3-Dioxygenase Activity during Long-Term Letrozole Therapy for Hormone Receptor-Positive Breast Cancer].	Letrozole	55-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-93
29982165-4	2018	It is reported that the interaction of LKB1 with Nur77 is disrupted by the small molecular ligand TMPA (ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate), such that the LKB1 is enabled to play its role in cytoplasm and further to regulate/reduce the blood glucose level.	trimethyl phosphate	98-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
29982165-4	2018	It is reported that the interaction of LKB1 with Nur77 is disrupted by the small molecular ligand TMPA (ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate), such that the LKB1 is enabled to play its role in cytoplasm and further to regulate/reduce the blood glucose level.	ethyl 2-(2,3,4-trimethoxy-6-(1-octanoyl)phenyl)acetate	104-158	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
29982165-4	2018	It is reported that the interaction of LKB1 with Nur77 is disrupted by the small molecular ligand TMPA (ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate), such that the LKB1 is enabled to play its role in cytoplasm and further to regulate/reduce the blood glucose level.	Glucose	262-269	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
29982165-6	2018	The present study reveals that TMPAs induce an open-close motion of Nur77 which further decrease the stability of Nur77-LKB1 complex.	trimethyl phosphate	31-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-73
29982165-6	2018	The present study reveals that TMPAs induce an open-close motion of Nur77 which further decrease the stability of Nur77-LKB1 complex.	trimethyl phosphate	31-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-119
30312983-7	2018	The nodules corresponding to NIFTP were classified according to ACR as TR3 in 28.5% of cases, TR4 in 67.8%, and TR5 in only 3.5%.	niftp	29-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-74
30412117-11	2018	Women with hormone receptor (HR)-negative tumors were more likely to exhibit pCR than those with HR-positive tumors (P = .007).Decreased BPE of patients with HER2-positive breast cancer may serve as an indicator of NAC effectiveness.	nac	215-218	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-31
30111648-7	2018	C-DIM5 prevented nuclear export of Nur77 in astrocytes induced by MPTP treatment and simultaneously recruited Nurr1 to the nucleus, consistent with known transrepressive properties of this receptor.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	66-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-40
30235292-7	2018	In previously endocrine therapy-treated postmenopausal patients with hormone-receptor positive advanced breast cancer, the PFS (HR = 0.77, 95%CI: 0.66-0.91) and ORR (RR = 1.78, 95%CI: 1.35-2.34) of combination therapy group were significantly higher than that from fulvestrant monotherapy group.	Fulvestrant	265-276	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
29789969-0	2018	Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.	Letrozole	140-149	nuclear receptor subfamily 4 group A member 1	Homo sapiens	61-77
29793946-0	2018	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.	2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide	18-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-119
30075223-8	2018	In particular, we will focus our discussion on the FDA approved HDAC inhibitor valproic acid (VPA) which has been shown to alter proliferation, survival, cell migration, and hormone receptor expression of breast cancer cells in both the pre-clinical and clinical settings.	Valproic Acid	79-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	174-190
30075223-8	2018	In particular, we will focus our discussion on the FDA approved HDAC inhibitor valproic acid (VPA) which has been shown to alter proliferation, survival, cell migration, and hormone receptor expression of breast cancer cells in both the pre-clinical and clinical settings.	Valproic Acid	94-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	174-190
30233207-0	2018	Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.	Fulvestrant	20-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
30202448-4	2018	Results: Palbociclib is indicated in combination with an aromatase inhibitor as initial endocrine therapy (ET) or with fulvestrant for patients with disease progression following ET for hormone receptor positive, human epidermal growth factor receptor 2 negative ABC or metastatic breast cancer.	palbociclib	9-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	186-202
29789969-1	2018	BACKGROUND: In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole.	Letrozole	157-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-31
30130984-2	2018	The CDK4/6 inhibitor palbociclib in combination with endocrine therapy has been approved for treatment of HR-positive/HER2-negative breast cancer patients.	palbociclib	21-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-108
29564714-2	2018	Palbociclib, a specific inhibitor of CDK4/6 with outstanding clinical efficacy data and limited toxicity, has been recently approved for the treatment of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor or in combination with fulvestrant in women who have received prior endocrine therapy.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-170
29564714-2	2018	Palbociclib, a specific inhibitor of CDK4/6 with outstanding clinical efficacy data and limited toxicity, has been recently approved for the treatment of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor or in combination with fulvestrant in women who have received prior endocrine therapy.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	172-174
30134173-4	2018	Nur77-deficient macrophages fail to downregulate IDH expression and accumulate higher levels of succinate and other TCA cycle-derived metabolites in response to inflammatory stimulation in a glutamine-independent manner.	Succinic Acid	96-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
30134173-4	2018	Nur77-deficient macrophages fail to downregulate IDH expression and accumulate higher levels of succinate and other TCA cycle-derived metabolites in response to inflammatory stimulation in a glutamine-independent manner.	Trichloroacetic Acid	116-119	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
30134173-4	2018	Nur77-deficient macrophages fail to downregulate IDH expression and accumulate higher levels of succinate and other TCA cycle-derived metabolites in response to inflammatory stimulation in a glutamine-independent manner.	Glutamine	191-200	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
30123220-7	2018	Treatment of human moDCs with 6-mercaptopurine, an activator of Nur77, leads to diminished DC activation resulting in an impaired capacity to induce IFNgamma production by allogeneic T cells.	Mercaptopurine	30-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
32914002-1	2018	Purpose: In the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2), the pan-erythroblastic oncogene B inhibitor neratinib was available to all hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) subtypes and graduated in the HR-negative/HER2-positive signature.	neratinib	184-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	215-231
32914002-1	2018	Purpose: In the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2), the pan-erythroblastic oncogene B inhibitor neratinib was available to all hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) subtypes and graduated in the HR-negative/HER2-positive signature.	neratinib	184-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	233-235
32914002-1	2018	Purpose: In the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2), the pan-erythroblastic oncogene B inhibitor neratinib was available to all hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) subtypes and graduated in the HR-negative/HER2-positive signature.	neratinib	184-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	315-317
29893769-1	2018	Background: The cyclin-dependent kinase 4 (CDK4)/6 inhibitor Palbociclib is a new standard treatment in hormone-receptor positive breast cancer patients.	palbociclib	61-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
29731395-2	2018	Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases.	Letrozole	111-120	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-99
29786125-7	2018	The highest proportions and greatest increases in proportions of NAC were seen among triple-negative breast cancers (TNBC; 19.5-33.7%) and HER2+ (HR-/HER2+, 21.5-39.8%; HR+/HER2+, 17.0-33.7%) tumors.	nac	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	146-148
29786125-10	2018	The highest use of NAC is in TNBC and HER2+ disease, with use in these subgroups being twice as frequent as in HR+/HER2- disease.	nac	19-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-113
30111977-1	2018	Background: Oncotype dx [odx (Genomic Health, Redwood City, CA, U.S.A.)] is an approved prognostic tool for women with node-negative, hormone receptor-positive, her2-negative breast cancer.	odx	25-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	134-150
29783894-0	2018	Fulvestrant in management of hormone receptor-positive metastatic breast cancer.	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-45
30140215-1	2018	Everolimus is an effective treatment for advanced and/or metastatic breast cancer, especially in hormone receptor-positive cases.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
29437768-4	2018	An improvement in progression-free survival (PFS) was observed in patients receiving ribociclib plus letrozole compared with patients receiving placebo plus letrozole [HR = 0.556; 95% confidence interval (CI), 0.429-0.720].	Letrozole	101-110	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-170
29770955-0	2018	LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.	Anthracyclines	70-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-122
29437768-4	2018	An improvement in progression-free survival (PFS) was observed in patients receiving ribociclib plus letrozole compared with patients receiving placebo plus letrozole [HR = 0.556; 95% confidence interval (CI), 0.429-0.720].	Letrozole	157-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-170
30358233-0	2018	Should addition of five years of ovarian suppression to tamoxifen be "must" for hormone receptor positive and HER-2 positive breast cancer under the age of 35?	Tamoxifen	56-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-96
30197363-1	2018	Tamoxifen plays a critical role in the treatment of hormone receptor-positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-68
29804902-1	2018	BACKGROUND: In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer.	Letrozole	44-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-199
29804902-1	2018	BACKGROUND: In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer.	Letrozole	44-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	201-203
30026420-1	2018	Several cases of hormone receptor-positive HER2-negative advanced and recurrent breast cancer treated with fulvestrant (FUL)were retrospectively investigated to assess the efficacy and safety of the treatment.	Fulvestrant	107-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-33
29396664-9	2018	CONCLUSIONS: Eighty percent of HR-negative, HER2-positive breast cancers achieve pCR with paclitaxel/FEC neoadjuvant chemotherapy administered concomitantly with pertuzumab and trastuzumab.	Paclitaxel	90-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-33
30013988-3	2018	Hyperfunction or dysfunction of NR4A1 is implicated in various metabolic processes, including carbohydrate metabolism, lipid metabolism, and energy balance, in major metabolic tissues, such as liver, skeletal muscle, pancreatic tissues, and adipose tissues.	Carbohydrates	94-106	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-37
30013988-6	2018	And we focus on the physiological functions of NR4A1 receptor to the development of the metabolic diseases, with a special focus on the impact on carbohydrate and lipid metabolism in skeletal muscle, liver, adipose tissue, and islet.	Carbohydrates	146-158	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-52
29963233-5	2018	Furthermore, we performed single cell analysis of cells from an estrogen dependent/hormone receptor-positive patient derived xenograft (PDX) tumor model treated with palbociclib.	palbociclib	166-177	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-99
29116433-1	2018	BACKGROUND: Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
29116433-1	2018	BACKGROUND: Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-105
29116433-1	2018	BACKGROUND: Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer.	exemestane	28-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
29116433-1	2018	BACKGROUND: Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer.	exemestane	28-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-105
29397517-3	2018	We aimed to investigate metformin"s effects on proliferation, metastasis, and hormone receptor expressions in breast cancer cell line MCF-7 incubated in two different glucose conditions.	Metformin	24-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-94
29861853-0	2018	Oxidized analogs of Di(1H-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activity.	di(1h-indol-3-yl)methyl-4-substituted benzenes	20-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-76
29899843-6	2018	The Nur77 derived peptide preferentially induced apoptosis in paclitaxel-resistant cancer cells with high expression of Bcl-2.	Paclitaxel	62-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-9
29861853-1	2018	Di(1H-indol-3-yl)(4-trifluoromethylphenyl)methane (DIM-Ph-4-CF3) is an analog of orphan nuclear receptor 4A1 (NR4A1) ligand cytosporone B.	di(1h-indol-3-yl)(4-trifluoromethylphenyl)methane	0-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-115
29861853-1	2018	Di(1H-indol-3-yl)(4-trifluoromethylphenyl)methane (DIM-Ph-4-CF3) is an analog of orphan nuclear receptor 4A1 (NR4A1) ligand cytosporone B.	dim-ph-4-cf3	51-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-115
29861853-1	2018	Di(1H-indol-3-yl)(4-trifluoromethylphenyl)methane (DIM-Ph-4-CF3) is an analog of orphan nuclear receptor 4A1 (NR4A1) ligand cytosporone B.	cytosporone B	124-137	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-115
29861853-7	2018	Independently of DIM-Ph-4-CF3+ OMs-, the bulk of NR4A1 localized to the cytoplasm in various cancer cell lines, suggesting a cytoplasmic mechanism-of-action of DIM-Ph-4-CF3+ OMs- in UPR induction and cell death.	dim-ph-4-cf3+ oms	160-177	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
29500843-0	2018	Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.	2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide	17-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-94
29700504-1	2018	Through the coupling of central and terminal naphthalene diimide functionalities, a unique non-fullerene electron acceptor, coded as N10, was designed, synthesized, characterized and applied in solution-processable bulk-heterojunction devices.	naphthalenediimide	45-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-136
29700504-1	2018	Through the coupling of central and terminal naphthalene diimide functionalities, a unique non-fullerene electron acceptor, coded as N10, was designed, synthesized, characterized and applied in solution-processable bulk-heterojunction devices.	Fullerenes	95-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-136
29700504-2	2018	The target N10 displayed good solubility, excellent thermal stability and energy levels complementing those of the conventional donor polymer poly(3-hexyl thiophene) (P3HT).	polymer poly(3-hexyl thiophene)	134-165	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-14
29700504-2	2018	The target N10 displayed good solubility, excellent thermal stability and energy levels complementing those of the conventional donor polymer poly(3-hexyl thiophene) (P3HT).	poly(3-hexylthiophene)	167-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-14
29700504-3	2018	An excellent power conversion efficiency of 7.65% was obtained in simple BHJ devices (P3HT : N10 1 : 1.2), which is the highest observed so far for NDI core-based non-fullerene acceptors.	{(3S)-7-[(2-chloro-5-{5-(methylsulfonyl)-1-[3-(morpholin-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}(piperidin-1-yl)methanone	73-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-96
29728098-0	2018	The 21-gene Recurrence Score  assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).	Epirubicin	171-181	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104
29728098-0	2018	The 21-gene Recurrence Score  assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).	Docetaxel	187-196	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104
29728098-0	2018	The 21-gene Recurrence Score  assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).	Epirubicin	206-216	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104
29414782-9	2018	Although an initial report has suggested that an unstructured loop region between the Bcl-2 BH4 and BH3 domains is required for Bcl-2"s interaction with Nur77/Nor-1, we found that it is dispensable for this interaction.	sapropterin	92-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
29324303-1	2018	OBJECTIVES: The double-blind, phase III CONFIRM study (NCT00099437) evaluated fulvestrant 500 mg vs fulvestrant 250 mg in postmenopausal women with hormone receptor-positive locally advanced/metastatic breast cancer (LA/MBC).	Fulvestrant	78-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	148-164
29247442-1	2018	BACKGROUND: Palbociclib, a CDK4-6 inhibitor, combined with endocrine therapy (ET) is a new standard of treatment for Hormone Receptor-positive Metastatic Breast Cancer.	palbociclib	12-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	117-133
29138067-5	2018	RESULTS: In patients with HR-positive (HR+)/HER2-/NG-low tumors, regardless of change in tumor size, the loss of node positivity after NAC significantly improved disease-free survival (DFS).	nac	135-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-28
29138067-5	2018	RESULTS: In patients with HR-positive (HR+)/HER2-/NG-low tumors, regardless of change in tumor size, the loss of node positivity after NAC significantly improved disease-free survival (DFS).	nac	135-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-41
29138067-9	2018	CONCLUSION: Our results revealed that changes in tumor stage and nodal status after NAC might be prognostic markers in patients with HR+/HER2-/NG-high tumors or HR-/HER2- tumors, even if there are residual tumors in the breast.	nac	84-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-135
29414782-11	2018	Bcl-2 alanine mutants at this region could no longer interact with Nur77/Nor-1 and could not initiate Nur77/Bcl-2-mediated cell death.	Alanine	6-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-72
29501489-7	2018	Together, our results are the first to demonstrate that rApoptin was able to effectively induce breast cancer cell apoptosis both in vitro and in vivo and that this activity could be regulated by the phosphorylation of Nur77 and Akt and the mitochondrial pathway.	rapoptin	56-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	219-224
29501489-0	2018	rApoptin induces apoptosis in human breast cancer cells via phosphorylation of Nur77 and Akt.	rapoptin	0-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-84
29501489-5	2018	Furthermore, we found via western blot that rApoptin-induced apoptosis in MCF-7 and MDA-MB-231 cells was associated with the phosphorylation of Nur77 (p-Nur77) and Akt (p-Akt).	rapoptin	44-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-149
29501489-5	2018	Furthermore, we found via western blot that rApoptin-induced apoptosis in MCF-7 and MDA-MB-231 cells was associated with the phosphorylation of Nur77 (p-Nur77) and Akt (p-Akt).	rapoptin	44-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	151-158
29329000-4	2018	The SAR analysis revealed that C3-O-neoglycosides of digoxigenin exhibited stronger cytotoxicity and induction of Nur77 expression of tumor cells than C3-MeON-neoglycosides.	c3-o-neoglycosides	31-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-119
29399694-4	2018	Inhibitors of CDK4/6 are presently the subjects of numerous studies, and PD 0332991, an inhibitor of CDK4/6, has been used to treat hormone receptor (HR)-positive, advanced-stage breast cancer.	palbociclib	73-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-148
29399694-4	2018	Inhibitors of CDK4/6 are presently the subjects of numerous studies, and PD 0332991, an inhibitor of CDK4/6, has been used to treat hormone receptor (HR)-positive, advanced-stage breast cancer.	palbociclib	73-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-152
29556076-0	2018	The Nuclear Orphan Receptor Nur77 Alleviates Palmitate-induced Fat Accumulation by Down-regulating G0S2 in HepG2 Cells.	Palmitates	45-54	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
29556076-4	2018	Using human HepG2 hepatoma cells, this study aimed to investigate the functional role of Nur77 in palmitate-induced hepatic steatosis.	Palmitates	98-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
29556076-6	2018	In addition, palmitate significantly suppressed Nur77 expression and stimulated the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and its target genes.	Palmitates	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
29556076-7	2018	Nur77 overexpression significantly reduced palmitate-induced expression of PPARgamma and its target genes.	Palmitates	43-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
29556076-8	2018	Moreover, Nur77 overexpression attenuated lipid accumulation and augmented lipolysis in palmitate-treated hepatocytes.	Palmitates	88-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-15
29556076-10	2018	In summary, palmitate suppresses Nur77 expression in HepG2 cells, and Nur77 overexpression alleviates palmitate-induced hepatic fat accumulation by down-regulating G0S2.	Palmitates	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-38
29556076-10	2018	In summary, palmitate suppresses Nur77 expression in HepG2 cells, and Nur77 overexpression alleviates palmitate-induced hepatic fat accumulation by down-regulating G0S2.	Palmitates	102-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-75
29556076-11	2018	These results display a novel molecular mechanism linking Nur77-regulated G0S2 expression to palmitate-induced hepatic steatosis.	Palmitates	93-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-63
29498706-4	2018	Based on the NR4A1 protein structure, 2-imino-6-methoxy-2H-chromene-3-carbothioamide (IMCA) was identified from the Specs compounds database using the protein structure-guided virtual screening approach.	2-Imino-6-methoxy-2H-chromene-3-carbothioamide	38-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
29329000-4	2018	The SAR analysis revealed that C3-O-neoglycosides of digoxigenin exhibited stronger cytotoxicity and induction of Nur77 expression of tumor cells than C3-MeON-neoglycosides.	Digoxigenin	53-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-119
29329000-6	2018	Among them, 3beta-O-(beta-l-fucopyranosyl)-digoxigenin (3i) showed the highest activity on induction of Nur77 expression and translocation from the nucleus to cytoplasm, leading to cancer cell apoptosis.	3beta-o-(beta-l-fucopyranosyl)-digoxigenin	12-54	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-109
29207128-8	2018	Mechanistically, the overexpression of NR4A1 augmented caspase-9-dependent mitochondrial apoptosis, as evidenced by reduced mitochondrial membrane potential, reactive oxygen species (ROS) overproduction, mitochondrial permeability transition pore (mPTP) opening and the leakage of cytochrome c (Cyt-c) leakage.	Reactive Oxygen Species	158-181	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
29124456-0	2018	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.	exemestane	55-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-129
29124456-0	2018	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.	Cyclophosphamide	84-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-129
29124456-4	2018	METHODS: This was a single-arm phase II trial of exemestane with cyclophosphamide in patients with metastatic HR-positive/HER2-negative breast cancer who had progressed on prior endocrine therapy (ClinicalTrials.gov: NCT01963481).	exemestane	49-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-112
29177689-1	2018	PURPOSE: Hormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT).	nact	110-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	9-25
29177689-1	2018	PURPOSE: Hormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT).	nact	110-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-29
29207128-8	2018	Mechanistically, the overexpression of NR4A1 augmented caspase-9-dependent mitochondrial apoptosis, as evidenced by reduced mitochondrial membrane potential, reactive oxygen species (ROS) overproduction, mitochondrial permeability transition pore (mPTP) opening and the leakage of cytochrome c (Cyt-c) leakage.	Reactive Oxygen Species	183-186	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
29423003-5	2018	We found that GATA4 and SF-1 were particularly critical for Leydig-specific markers expression and that GATA4, SF-1, and NGFI-B were necessary to generate functional iLCs that secreted testosterone.	Testosterone	185-197	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-127
30415262-0	2018	Triclosan Suppresses Testicular Steroidogenesis via the miR-6321/JNK/ Nur77 Cascade.	Triclosan	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-75
30147088-6	2018	The factors adversely affecting DFS in EBC were node metastasis (P &lt; 0.001), higher metastatic nodes (P &lt; 0.001), hormone receptor negativity (P = 0.001), and human epidermal growth factor receptor 2 (Her2neu) positivity (P = 0.033).	NSC638702	39-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-136
30415262-10	2018	CONCLUSION: Taken together, the miR-6321/Map3k1-regulated JNK/c-Jun/ Nur77 cascade contributes to TCS-caused suppression of testicular steroidogenesis, and the decrease in 5alpha-Reductase expressions may be the compensatory mechanism.	Triclosan	98-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
29270913-1	2018	Fulvestrant (Faslodex ), a selective estrogen receptor (ER) degrader, is now indicated for the treatment of ER+ or hormone-receptor positive (HR+)/HER2- advanced breast cancer in postmenopausal women previously untreated with endocrine therapy.	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-131
29270913-1	2018	Fulvestrant (Faslodex ), a selective estrogen receptor (ER) degrader, is now indicated for the treatment of ER+ or hormone-receptor positive (HR+)/HER2- advanced breast cancer in postmenopausal women previously untreated with endocrine therapy.	Fulvestrant	13-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-131
29371962-8	2017	Consistently, Oncomine analysis showed that NR4A1 was overexpressed in NSCLC tissues compared with normal tissues in published datasets (P &lt; 0.001).	oncomine	14-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-49
28981157-10	2018	Mechanistically, melatonin halted fission but recovered mitophagy via blockade of NR4A1/DNA-PKcs/p53 pathway, finally improving mitochondrial and liver function in the setting of NAFLD.	Melatonin	17-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-87
28981157-12	2018	Meanwhile, we also confirm that melatonin has the ability to cut off the NR4A1/DNA-PKcs/p53 pathway, which confers a protective advantage to hepatocytes and mitochondria.	Melatonin	32-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-78
28981157-13	2018	The manipulation of NR4A1/DNA-PKcs/p53 pathway by melatonin highlights a new entry point for treating NAFLD.	Melatonin	50-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-25
30220928-0	2018	SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.	sabcs	0-5	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-47
29353824-0	2018	Alcohol Consumption and Breast Cancer Risk According to Hormone Receptor Status in Japanese Women: A Case-Control Study.	Alcohols	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	56-72
29269871-5	2017	Depolarization and cAMP signals induce preferential transcription of activity-dependent genes containing promoters with proximal CRE/TATA sequences, such as c-fos, Dusp1, Nr4a1, Nr4a2 and Ptgs2, but not genes with proximal CRE/TATA-less promoters (e.g. Nr4a3, Presenilin-1 and Presenilin-2).	Cyclic AMP	19-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-176
29285035-3	2017	Clinical studies have suggested that everolimus combined with endocrine therapy prolongs progression-free survival in hormone receptor-positive breast cancer patients.	Everolimus	37-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-134
29199269-4	2017	DDA is a partial agonist on liver-X-receptor (LXR) increasing Nur77, Nor1, and LC3 expression leading to autolysosome formation.	5-hydroxy-6-(2-(1H-imidazol-4-yl)ethylamino)cholestan-3-ol	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
28942098-8	2017	Age &lt;50 years, breast MRI, large tumour size, advanced nodal disease, negative hormone receptor status and hospital participation in neoadjuvant clinical studies were significant independent predictors of NAC use (all P &lt; 0.001).	nac	208-211	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
29178841-9	2017	ST59-SCCmec IV-t437 (61.7%) was the most prevalent genotype of MRSA, and ST22-t309 (18.2%), ST5-t002 (9.1%), ST6-t701 (9.1%), ST188-t189 (9.1%) were the top four genotypes of methicillin-sensitive SA (MSSA).	Methicillin	175-186	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-4
28778424-4	2017	Polyethylene oxide N10, a semicrystalline thermoplastic polymer (polyethylene oxide N10; Mol.	Polyethylene Glycols	0-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-22
28778424-4	2017	Polyethylene oxide N10, a semicrystalline thermoplastic polymer (polyethylene oxide N10; Mol.	Polyethylene Glycols	0-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-87
28778424-4	2017	Polyethylene oxide N10, a semicrystalline thermoplastic polymer (polyethylene oxide N10; Mol.	Polyethylene Glycols	65-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-22
29178841-15	2017	The prevalence of the biofilm associated genes among ST59-SCCmec IV-t437 clone was: icaA (100.0%), icaD (97.3%), fnbpA (100.0%), fnbpB (0), clfA (100%), clfB (100%), cna (2.7%), bbp (0), ebpS (88.5%), sdrC (78.4%), sdrD (5.4%), and sdrE (94.5%).	icaa	84-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-57
29178841-15	2017	The prevalence of the biofilm associated genes among ST59-SCCmec IV-t437 clone was: icaA (100.0%), icaD (97.3%), fnbpA (100.0%), fnbpB (0), clfA (100%), clfB (100%), cna (2.7%), bbp (0), ebpS (88.5%), sdrC (78.4%), sdrD (5.4%), and sdrE (94.5%).	fnbpa	113-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-57
29178841-15	2017	The prevalence of the biofilm associated genes among ST59-SCCmec IV-t437 clone was: icaA (100.0%), icaD (97.3%), fnbpA (100.0%), fnbpB (0), clfA (100%), clfB (100%), cna (2.7%), bbp (0), ebpS (88.5%), sdrC (78.4%), sdrD (5.4%), and sdrE (94.5%).	fnbpb	129-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-57
29178841-15	2017	The prevalence of the biofilm associated genes among ST59-SCCmec IV-t437 clone was: icaA (100.0%), icaD (97.3%), fnbpA (100.0%), fnbpB (0), clfA (100%), clfB (100%), cna (2.7%), bbp (0), ebpS (88.5%), sdrC (78.4%), sdrD (5.4%), and sdrE (94.5%).	clfa	140-144	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-57
29178841-15	2017	The prevalence of the biofilm associated genes among ST59-SCCmec IV-t437 clone was: icaA (100.0%), icaD (97.3%), fnbpA (100.0%), fnbpB (0), clfA (100%), clfB (100%), cna (2.7%), bbp (0), ebpS (88.5%), sdrC (78.4%), sdrD (5.4%), and sdrE (94.5%).	clfb	153-157	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-57
29178841-15	2017	The prevalence of the biofilm associated genes among ST59-SCCmec IV-t437 clone was: icaA (100.0%), icaD (97.3%), fnbpA (100.0%), fnbpB (0), clfA (100%), clfB (100%), cna (2.7%), bbp (0), ebpS (88.5%), sdrC (78.4%), sdrD (5.4%), and sdrE (94.5%).	4-boronic acid benzophenone	178-181	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-57
29178841-15	2017	The prevalence of the biofilm associated genes among ST59-SCCmec IV-t437 clone was: icaA (100.0%), icaD (97.3%), fnbpA (100.0%), fnbpB (0), clfA (100%), clfB (100%), cna (2.7%), bbp (0), ebpS (88.5%), sdrC (78.4%), sdrD (5.4%), and sdrE (94.5%).	ebps	187-191	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-57
28885430-4	2017	Given the hormone receptor status and size of the tumor, the patient was initially treated with fulvestrant and goserelin acetate in an attempt to reduce the size of the mass.	Fulvestrant	96-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-26
28872880-8	2017	Furthermore, the study also permitted the identification of ten novel prospective allosteric sites named NP1 to NP10, involving in most of the cases protein structural elements that control kinase activation including the activation loop, the catalytic loop, the alphaC helix, the L16 loop, and the glycine-rich loop.	Glycine	299-306	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-116
28904441-1	2017	Recently, everolimus (Evl) has been introduced in the management of hormone receptor-positive metastatic breast cancer, in combination with aromatase inhibitors.	Everolimus	10-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
28754437-2	2017	In the present study, we identified fangchinoline, a bisbenzyltetrahydroisoquinoline alkaloid from Stephania tetrandra, as a new inactivator of nuclear NR4A1 and demonstrated that fangchinoline inhibits cell proliferation and induces apoptosis, in part, via the NR4A1-dependent pro-apoptotic pathways in human pancreatic cancer cells.	fangchinoline	180-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	262-267
28754437-4	2017	These results suggest that inhibition of NR4A1-mediated transcriptional activity was involved in the anticancer effects of fangchinoline, and fangchinoline represents a novel class of mechanism-based anticancer agents targeting NR4A1 that is overexpressed in pancreatic cancer.	fangchinoline	123-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
28754437-4	2017	These results suggest that inhibition of NR4A1-mediated transcriptional activity was involved in the anticancer effects of fangchinoline, and fangchinoline represents a novel class of mechanism-based anticancer agents targeting NR4A1 that is overexpressed in pancreatic cancer.	fangchinoline	123-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	228-233
28754437-4	2017	These results suggest that inhibition of NR4A1-mediated transcriptional activity was involved in the anticancer effects of fangchinoline, and fangchinoline represents a novel class of mechanism-based anticancer agents targeting NR4A1 that is overexpressed in pancreatic cancer.	fangchinoline	142-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	228-233
28793767-0	2017	Ginsenoside 20(S)-Rh2 Induces Apoptosis and Differentiation of Acute Myeloid Leukemia Cells: Role of Orphan Nuclear Receptor Nur77.	ginsenoside 20(s)-rh2	0-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-130
28793767-3	2017	In our study, 20(S)-Rh2 induced the expression of orphan nuclear receptor Nur77 and death receptor proteins Fas, FasL, DR5, and TRAIL, as well as the cleavage of caspase 8 and caspase 3 in HL-60 cells.	rh2	20-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-79
28793767-5	2017	Meanwhile, 20(S)-Rh2 promoted Nur77 translocation from the nucleus to mitochondria and enhanced the interaction between Nur77 and Bcl-2, resulting in the exposure of the BH3 domain of Bcl-2 and activation of Bax.	(s)-rh2	13-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
28793767-5	2017	Meanwhile, 20(S)-Rh2 promoted Nur77 translocation from the nucleus to mitochondria and enhanced the interaction between Nur77 and Bcl-2, resulting in the exposure of the BH3 domain of Bcl-2 and activation of Bax.	(s)-rh2	13-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
28754437-0	2017	Inactivation of the orphan nuclear receptor NR4A1 contributes to apoptosis induction by fangchinoline in pancreatic cancer cells.	fangchinoline	88-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-49
28754437-2	2017	In the present study, we identified fangchinoline, a bisbenzyltetrahydroisoquinoline alkaloid from Stephania tetrandra, as a new inactivator of nuclear NR4A1 and demonstrated that fangchinoline inhibits cell proliferation and induces apoptosis, in part, via the NR4A1-dependent pro-apoptotic pathways in human pancreatic cancer cells.	fangchinoline	36-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-157
28754437-2	2017	In the present study, we identified fangchinoline, a bisbenzyltetrahydroisoquinoline alkaloid from Stephania tetrandra, as a new inactivator of nuclear NR4A1 and demonstrated that fangchinoline inhibits cell proliferation and induces apoptosis, in part, via the NR4A1-dependent pro-apoptotic pathways in human pancreatic cancer cells.	fangchinoline	36-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	262-267
28754437-2	2017	In the present study, we identified fangchinoline, a bisbenzyltetrahydroisoquinoline alkaloid from Stephania tetrandra, as a new inactivator of nuclear NR4A1 and demonstrated that fangchinoline inhibits cell proliferation and induces apoptosis, in part, via the NR4A1-dependent pro-apoptotic pathways in human pancreatic cancer cells.	bisbenzyltetrahydroisoquinoline alkaloid	53-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-157
28601930-8	2017	Within the HR-positive/Her2-negative subtype, more women received gonadotropin-releasing hormone agonist and tamoxifen treatment from 2003 to 2008 compared with 1989 to 2002 (p = 0.001 and p = 0.075, respectively).	Tamoxifen	109-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-13
28601930-9	2017	CONCLUSIONS: HR-positive young breast cancer patients have a poorer survival compared with older patients, even with more frequent chemotherapy, but more recent use of tamoxifen and ovarian suppression might improve this outcome in these patients.	Tamoxifen	168-177	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-15
28904441-1	2017	Recently, everolimus (Evl) has been introduced in the management of hormone receptor-positive metastatic breast cancer, in combination with aromatase inhibitors.	Everolimus	22-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
28851309-0	2017	Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer.	long	16-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-127
28838387-7	2017	RESULTS AND CONCLUSION: The TR3 activator cytosporone B was used to investigate TR3-mediated apoptosis in NSCLC cells under normoxic and hypoxic conditions.	cytosporone B	42-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-31
28838387-7	2017	RESULTS AND CONCLUSION: The TR3 activator cytosporone B was used to investigate TR3-mediated apoptosis in NSCLC cells under normoxic and hypoxic conditions.	cytosporone B	42-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-83
28418095-4	2017	1,1-Bis(3"-indolyl)-1-(p-substituted phenyl)methane (C-DIM) compounds containing p-hydroxy (DIM-C-pPhOH) and p-carbomethoxy (DIM-C-pPhCO2 Me) groups are NR4A1 ligands that act as antagonists for this receptor.	1,1-bis(3"-indolyl)-1-(p-substituted phenyl)methane	0-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
28418095-4	2017	1,1-Bis(3"-indolyl)-1-(p-substituted phenyl)methane (C-DIM) compounds containing p-hydroxy (DIM-C-pPhOH) and p-carbomethoxy (DIM-C-pPhCO2 Me) groups are NR4A1 ligands that act as antagonists for this receptor.	c-dim	53-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
28418095-5	2017	Treatment of pancreatic and colon cancer cells with DIM-C-pPhOH or DIM-C-pPhCO2 Me mimics the effects of NR4A1 knockdown and decreases beta1-integrin expression, beta1-integrin regulated genes and responses including migration and adhesion.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	52-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-110
28418095-5	2017	Treatment of pancreatic and colon cancer cells with DIM-C-pPhOH or DIM-C-pPhCO2 Me mimics the effects of NR4A1 knockdown and decreases beta1-integrin expression, beta1-integrin regulated genes and responses including migration and adhesion.	p-carboxymethylphenyl 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane	67-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-110
28789401-0	2017	Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.	Everolimus	119-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-39
28816294-1	2017	OBJECTIVE: To optimize and establish the best hydrolysis method of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate through the optimization of simple compound of diethyl N-(4-aminobenzoyl)-L-glutamate.	N-(4-aminobenzoyl)-L-glutamate	186-216	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-106
28816294-2	2017	METHODS: To increase the low yield of hydrolysis reaction of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate due to the by-products and difficult purification, we studied the effect of NaOH and KOH, two kinds of alkalis, three concentrations between 0.175-1 mol/L and five types of reaction time involved in 20, 30, 60, 120 and 180 min on the common side chain diethyl N-(4-aminobenzoyl)-L-glutamate.	Ether	61-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-100
28816294-2	2017	METHODS: To increase the low yield of hydrolysis reaction of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate due to the by-products and difficult purification, we studied the effect of NaOH and KOH, two kinds of alkalis, three concentrations between 0.175-1 mol/L and five types of reaction time involved in 20, 30, 60, 120 and 180 min on the common side chain diethyl N-(4-aminobenzoyl)-L-glutamate.	Sodium Hydroxide	201-205	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-100
28816294-2	2017	METHODS: To increase the low yield of hydrolysis reaction of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate due to the by-products and difficult purification, we studied the effect of NaOH and KOH, two kinds of alkalis, three concentrations between 0.175-1 mol/L and five types of reaction time involved in 20, 30, 60, 120 and 180 min on the common side chain diethyl N-(4-aminobenzoyl)-L-glutamate.	potassium hydroxide	210-213	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-100
28816294-2	2017	METHODS: To increase the low yield of hydrolysis reaction of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate due to the by-products and difficult purification, we studied the effect of NaOH and KOH, two kinds of alkalis, three concentrations between 0.175-1 mol/L and five types of reaction time involved in 20, 30, 60, 120 and 180 min on the common side chain diethyl N-(4-aminobenzoyl)-L-glutamate.	N-(4-Aminobenzoyl)-L-glutamic acid diethyl ester	377-415	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-100
28816294-4	2017	Finally, on the basis of the best hydrolysis method of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate, we completed the optimization of the hydrolysis reaction conditions of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate.	Ether	55-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-94
28816294-4	2017	Finally, on the basis of the best hydrolysis method of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate, we completed the optimization of the hydrolysis reaction conditions of diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate.	Ether	55-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	227-230
28816294-6	2017	The results indicated that treated with the optimized condition of 0.3 mol/L KOH in 60 min at the room temperature, diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate was converted into its diacid derivative in 95.6 % yield, which turned to be a better reaction condition compared with the previous reaction condition.	potassium hydroxide	77-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-155
28816294-6	2017	The results indicated that treated with the optimized condition of 0.3 mol/L KOH in 60 min at the room temperature, diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate was converted into its diacid derivative in 95.6 % yield, which turned to be a better reaction condition compared with the previous reaction condition.	diethyl ester 4-amino-n5-formyl-n8	116-150	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-155
28816294-6	2017	The results indicated that treated with the optimized condition of 0.3 mol/L KOH in 60 min at the room temperature, diethyl ester 4-amino-N5-formyl-N8, N10-dideazatetrahydrofolate was converted into its diacid derivative in 95.6 % yield, which turned to be a better reaction condition compared with the previous reaction condition.	CARBROMAL	203-209	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-155
28818208-8	2017	RESULTS: Enhanced beta-adrenergic signaling in TTS-iPSC-CMs under catecholamine-induced stress increased expression of the cardiac stress marker NR4A1; cyclic adenosine monophosphate levels; and cyclic adenosine monophosphate-dependent protein kinase A-mediated hyperphosphorylation of RYR2-S2808, PLN-S16, TNI-S23/24, and Cav1.2-S1928, and leads to a reduced calcium time to transient 50% decay.	Catecholamines	66-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-150
28633895-8	2017	Moreover, some MeON-neoglycosides (2b and 8b) could significant induce the expression of Nur77 and its translocation from the nucleus to cytoplasm.	meon-neoglycosides	15-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
28515111-4	2017	Among those with hormone receptor-positive cancer, 74.8% initiated AET compared with 5.6% of women with negative and 54.0% with unknown-receptor status.	2-(2-Aminoethyl)isothiourea dihydrobromide	67-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-33
28515111-9	2017	Discontinuing treatment was associated with higher risk of all-cause and cancer-specific mortality regardless of hormone receptor status.Impact: This study underscores the need to study factors that influence discontinuation and the survival benefits of receiving AET for hormone receptor-negative breast cancer.	2-(2-Aminoethyl)isothiourea dihydrobromide	264-267	nuclear receptor subfamily 4 group A member 1	Homo sapiens	272-288
28789401-0	2017	Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.	exemestane	142-152	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-39
28025696-0	2017	Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer.	Vitamin D	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-52
28770167-1	2017	A 60- to 65-year-old female on prior statin therapy was initiated on palbociclib and fulvestrant for the treatment of metastatic, hormone-receptor positive breast cancer.	Fulvestrant	85-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	130-146
28785180-2	2017	5 years of tamoxifen or an aromatase inhibitor for all patients with HR-positive early breast cancer is considered standard; however, there are now data to support an extended approach using up to 10 years of treatment.	Tamoxifen	11-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-71
29050237-3	2017	In this study, we examined the regulation of the Nur77-Bcl-2 pathway by CCE9, a xanthone compound.	cce9	72-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
29050237-3	2017	In this study, we examined the regulation of the Nur77-Bcl-2 pathway by CCE9, a xanthone compound.	xanthone	80-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
29050237-6	2017	Inhibition of p38alpha MAPK activation by knocking down or knocking out p38alpha MAPK impaired the effect of CCE9 on inducing apoptosis and the expression and cytoplasmic localization of Nur77.	cce9	109-113	nuclear receptor subfamily 4 group A member 1	Homo sapiens	187-192
28195993-1	2017	OBJECTIVE: Hormone receptor-positive breast cancers respond favorably to subcutaneous testosterone combined with an aromatase inhibitor.	Testosterone	86-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-27
28576675-0	2017	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.	NVP-BKM120	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-95
28195993-4	2017	METHODS: A 51-year-old woman on testosterone replacement therapy was diagnosed with hormone receptor-positive invasive breast cancer.	Testosterone	32-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
27627986-3	2017	METHODS: The EvAluate-TM study is a prospective, multicenter noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive primary breast cancer.	Letrozole	133-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	186-202
28978063-2	2017	Hormone receptor expression can also be found in MIBC, reflecting luminal and basal subtypes of breast cancer.	4-METHYL-2-PENTANOL	49-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
28324247-0	2017	Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
28422735-9	2017	Particularly, Oct4 expression was associated with poor clinical outcome in patients with hormone receptor-positive breast cancer treated with tamoxifen.	Tamoxifen	142-151	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-105
28281345-1	2017	Photoinduced dehalogenation of the antifungal drug itraconazole (ITR) in acetonitrile (ACN) and ACN/water mixed solutions was investigated using femtosecond and nanosecond time-resolved transient absorption (fs-TA and ns-TA, respectively) and nanosecond time-resolved resonance Raman spectroscopy (ns-TR3) experiments.	Itraconazole	51-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	301-304
28431397-6	2017	Importantly, Z-ligustilide-mediated autophagy inhibition restored Nur77 expression in MCF-7TR5 cells.	ligustilide	13-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-71
28431397-7	2017	Furthermore, Z-ligustilide promoted the interaction of Nur77 with Ku80 and thereby abolished the association of DNA-PKcs with DNA ends.	ligustilide	13-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	55-60
28281345-1	2017	Photoinduced dehalogenation of the antifungal drug itraconazole (ITR) in acetonitrile (ACN) and ACN/water mixed solutions was investigated using femtosecond and nanosecond time-resolved transient absorption (fs-TA and ns-TA, respectively) and nanosecond time-resolved resonance Raman spectroscopy (ns-TR3) experiments.	Itraconazole	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	301-304
28281345-6	2017	The ns-TA and ns-TR3 results also provide some evidence that radical intermediates are generated through a homolytic carbon-halogen bond cleavage via predominantly the singlet excited state pathway in ACN but via mainly the triplet state pathway in the aqueous solutions.	Carbon	117-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
28281345-6	2017	The ns-TA and ns-TR3 results also provide some evidence that radical intermediates are generated through a homolytic carbon-halogen bond cleavage via predominantly the singlet excited state pathway in ACN but via mainly the triplet state pathway in the aqueous solutions.	Halogens	124-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
28281345-6	2017	The ns-TA and ns-TR3 results also provide some evidence that radical intermediates are generated through a homolytic carbon-halogen bond cleavage via predominantly the singlet excited state pathway in ACN but via mainly the triplet state pathway in the aqueous solutions.	acetonitrile	201-204	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
28337303-11	2017	Inhibiting p38 by SB203580 could decrease TNF-induced NR4A1 to some extent, while inhibiting JNK could not.	SB 203580	18-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-59
28388439-0	2017	Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy.	celastrol	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-23
28388439-3	2017	Here, we report that celastrol, a potent anti-inflammatory pentacyclic triterpene, binds Nur77 to inhibit inflammation and induce autophagy in a Nur77-dependent manner.	celastrol	21-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
28388439-3	2017	Here, we report that celastrol, a potent anti-inflammatory pentacyclic triterpene, binds Nur77 to inhibit inflammation and induce autophagy in a Nur77-dependent manner.	celastrol	21-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-150
28388439-3	2017	Here, we report that celastrol, a potent anti-inflammatory pentacyclic triterpene, binds Nur77 to inhibit inflammation and induce autophagy in a Nur77-dependent manner.	Triterpenes	71-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
28388439-4	2017	Celastrol promotes Nur77 translocation from the nucleus to mitochondria, where it interacts with tumor necrosis factor receptor-associated factor 2 (TRAF2), a scaffold protein and E3 ubiquitin ligase important for inflammatory signaling.	celastrol	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-24
28388439-7	2017	Together, our results identify Nur77 as a critical intracellular target for celastrol and unravel a mechanism of Nur77-dependent clearance of inflamed mitochondria to alleviate inflammation.	celastrol	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
28049055-5	2017	In this work, a dual-inhibitor system containing EGCG and negatively charged polymeric nanoparticles (NP10), which was also demonstrated effective on the inhibition of Abeta aggregation, was developed and comprehensively studied by extensive biophysical and biological assays.	epigallocatechin gallate	49-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-106
28049055-10	2017	NP10 might also help EGCG binding to Abeta, leading to its enhanced inhibitory effects on fibril elongation and secondary nucleation.	epigallocatechin gallate	21-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-4
28293118-1	2017	INTRODUCTION AND AIMS: Tamoxifen is an adjuvant drug effective in treating hormone receptor - positive breast cancer.	Tamoxifen	23-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
27554482-0	2017	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.	Letrozole	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
27554482-4	2017	MATERIALS AND METHODS: This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012.	Letrozole	113-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-64
27864345-4	2017	Similarly, cell treatment with the NR4A1 small-molecule antagonists 1,1-bis(3-indolyl)-1-(p-hydroxy or p-carbomethoxyphenyl)methane (C-DIM) decreased PAX3-FOXO1A.	1,1-bis(3-indolyl)-1-(p-hydroxy or p-carbomethoxyphenyl)methane	68-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-40
27864345-4	2017	Similarly, cell treatment with the NR4A1 small-molecule antagonists 1,1-bis(3-indolyl)-1-(p-hydroxy or p-carbomethoxyphenyl)methane (C-DIM) decreased PAX3-FOXO1A.	Carbon	133-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-40
28203301-6	2017	Based on results of randomized clinical trials, palbociclib was granted accelerated approval by the US Food and Drug Administration (FDA) for use in combination with letrozole as initial endocrine-based therapy for metastatic disease in postmenopausal women with HR-positive, HER2-negative breast cancer, and was approved for use in combination with fulvestrant in women with HR-positive, HER2-negative advanced breast cancer with disease progression following endocrine therapy.	palbociclib	48-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	263-265
28007942-1	2017	In a phase II trial, the mTOR inhibitor everolimus, combined with the endocrine therapy fulvestrant, improved progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who had become resistant to aromatase inhibitors.	Everolimus	40-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	165-181
27826831-0	2017	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.	orteronel	18-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-73
27826831-3	2017	Thus, we conducted a phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.	orteronel	39-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-94
28203301-6	2017	Based on results of randomized clinical trials, palbociclib was granted accelerated approval by the US Food and Drug Administration (FDA) for use in combination with letrozole as initial endocrine-based therapy for metastatic disease in postmenopausal women with HR-positive, HER2-negative breast cancer, and was approved for use in combination with fulvestrant in women with HR-positive, HER2-negative advanced breast cancer with disease progression following endocrine therapy.	palbociclib	48-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	376-378
27815995-0	2017	Impairment of the executive attention network in premenopausal women with hormone receptor-positive breast cancer treated with tamoxifen.	Tamoxifen	127-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-90
28072715-8	2017	Three-year CDFS increased continuously each year after 1 year of DFS in hormone receptor (HR)-negative patients but decreased each year in HR-positive patients.In HR-positive patients who are disease free after 3 years, continuous care including surveillance and metastases workup should be considered, although this is not recommended in the current guidelines.	cdfs	11-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-88
28072715-8	2017	Three-year CDFS increased continuously each year after 1 year of DFS in hormone receptor (HR)-negative patients but decreased each year in HR-positive patients.In HR-positive patients who are disease free after 3 years, continuous care including surveillance and metastases workup should be considered, although this is not recommended in the current guidelines.	cdfs	11-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-92
27811009-5	2017	alpha6- and beta4-integrins as well as alpha5- and beta1-integrins are Sp-regulated genes that are also coregulated by the orphan nuclear receptor NR4A1 and these integrins can be targeted by agents such as penfluridol that suppress Sp1, Sp3, and Sp4 and also by NR4A1 antagonists.	Penfluridol	207-218	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-152
27746162-0	2017	Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.	Everolimus	71-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-44
27746162-1	2017	Mammalian target of rapamycin (mTOR) inhibitor, everolimus, provides benefit for metastatic hormone receptor positive breast cancer after failure of the endocrine therapy.	Everolimus	48-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
27908454-15	2016	INTERPRETATION: Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients.	Fulvestrant	16-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
27573562-0	2016	Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
27388585-10	2016	PIK3CA, PTEN, and AKT1 mutations occurred more frequently in the presence of hormone receptor overexpression (androgen, progesterone, or estrogen receptor).	Progesterone	120-132	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-93
27876882-3	2016	Here, we showed that NR4A1 protein was predominantly expressed in neurons and up-regulated in patients with epilepsy as well as pilocarpine-induced mouse epileptic models.	Pilocarpine	128-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-26
27717303-13	2016	CONCLUSIONS: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the ribociclib group.	Letrozole	225-234	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-71
27723330-6	2016	The ns-TR3 and density functional theory (DFT) computational results were compared, and this indicates the binol moiety and water molecules both have important roles in the characteristics and structure of the key reactive BQM intermediate produced from BQMP-b.	BINOL, naphthol	107-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	7-10
27723330-6	2016	The ns-TR3 and density functional theory (DFT) computational results were compared, and this indicates the binol moiety and water molecules both have important roles in the characteristics and structure of the key reactive BQM intermediate produced from BQMP-b.	Water	124-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	7-10
27819368-1	2016	A tumor active targeting beta-cyclodextrin based nanocarrier beta-NC-OEI-SS-FA was designed by the modification of star shaped cationic derivatives beta-NC-OEI with folic acid through a disulfide bond, to co-deliver chemotherapeutic paclitaxel and the Nur77 gene for overcoming Bcl-2 mediated non-pump resistance by an "enemy to friend" strategy for potential drug resistant cancer therapy.	betadex	25-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	252-257
27435628-5	2016	For example, in 2013 the European Medicines Agency approved the combination of lapatinib and trastuzumab in HER-2+/HR- patients.	Lapatinib	79-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-117
27644246-8	2016	Furthermore, RNA sequencing analysis revealed GABA-induced changes in the mRNA expression of 30 genes, including EGR1, MAPK4, NR4A1, Fos, and FosB, in all the three types of CCC.	gamma-Aminobutyric Acid	46-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-131
27663436-1	2016	PURPOSE: The purpose of this study is to evaluate survival outcome in patients with hormone receptor (HR)-positive (+) metastatic breast cancer (MBC) who received fluoxymesterone after disease progression while receiving contemporary hormonal therapy, as well as the association between estrogen receptor (ER)/androgen receptor (AR) status and survival outcome in these patients.	Fluoxymesterone	163-178	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
27663436-1	2016	PURPOSE: The purpose of this study is to evaluate survival outcome in patients with hormone receptor (HR)-positive (+) metastatic breast cancer (MBC) who received fluoxymesterone after disease progression while receiving contemporary hormonal therapy, as well as the association between estrogen receptor (ER)/androgen receptor (AR) status and survival outcome in these patients.	Fluoxymesterone	163-178	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-104
27663436-2	2016	METHODS: We retrospectively identified 103 patients treated with fluoxymesterone for HR + MBC from 2000 to 2014 and with at least one previous hormonal therapy in a metastatic setting.	Fluoxymesterone	65-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-87
27644246-10	2016	The data suggest that GABA inhibits colon cancer cell proliferation perhaps by attenuating EGR1-NR4A1 axis, EGR1-Fos axis, and by disrupting MEK-EGR1 signaling pathway.	gamma-Aminobutyric Acid	22-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-101
27281556-0	2016	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.	Letrozole	106-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-58
27407089-0	2016	FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.	palbociclib	16-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
27407089-1	2016	On February 19, 2016, the FDA approved palbociclib (Ibrance, Pfizer) for use in combination with fulvestrant (Faslodex, AstraZeneca) for the treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (MBC) with disease progression following endocrine therapy.	palbociclib	39-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	165-181
27407089-1	2016	On February 19, 2016, the FDA approved palbociclib (Ibrance, Pfizer) for use in combination with fulvestrant (Faslodex, AstraZeneca) for the treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (MBC) with disease progression following endocrine therapy.	palbociclib	39-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-185
27407089-5	2016	A statistically significant and clinically meaningful improvement in PFS (9.5 months vs. 4.6 months) was observed in patients receiving palbociclib plus fulvestrant [HR 0.46; 95% confidence interval (CI), 0.36-0.59; P &lt; 0.0001].	palbociclib	136-147	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-168
27407089-5	2016	A statistically significant and clinically meaningful improvement in PFS (9.5 months vs. 4.6 months) was observed in patients receiving palbociclib plus fulvestrant [HR 0.46; 95% confidence interval (CI), 0.36-0.59; P &lt; 0.0001].	Fulvestrant	153-164	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-168
27325862-0	2016	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.	Methotrexate	35-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-80
27281556-0	2016	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.	Lapatinib	132-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-58
27281556-15	2016	Patients with HR-positive/HER2-negative disease with a HER2-enriched profile may benefit from lapatinib in combination with endocrine therapy.	Lapatinib	94-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-16
27368881-0	2016	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-74
27368881-15	2016	IMPLICATIONS FOR PRACTICE: Treatment with palbociclib in combination with fulvestrant was generally safe and well-tolerated in patients with hormone receptor (HR)-positive metastatic breast cancer.	palbociclib	42-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-157
27368881-15	2016	IMPLICATIONS FOR PRACTICE: Treatment with palbociclib in combination with fulvestrant was generally safe and well-tolerated in patients with hormone receptor (HR)-positive metastatic breast cancer.	palbociclib	42-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-161
27506945-8	2016	Compared with HR-negative tumor, HR-positive tumor had significantly better response to sunitinib (p = 0.035).	Sunitinib	88-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-35
27651692-3	2016	A change in hormone receptor status after neoadjuvant chemotherapy (NACT) has important therapeutic and prognostic consequences.	nact	68-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-28
27117241-0	2016	Adjuvant Surgical Oophorectomy Plus Tamoxifen in Premenopausal Women With Operable Hormone Receptor-Positive Breast Cancer: A Global Treatment Option.	Tamoxifen	36-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-99
27518192-6	2016	In comparison, TR3 (Rubescin D), a limonoid isolated in parallel and structurally highly similar to TR4 and TR9, did not interfere with hepatoma cell viability.	rubescin d	20-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-18
28244487-10	2016	CONCLUSIONS: Everolimus based treatment has meaningful activity in heavily pretreated patients with HR-positive MBC but is associated with considerable toxicity and requirement for dose adjustment.	Everolimus	13-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-102
27210004-4	2016	Everolimus has been approved in combination with exemestane for the treatment of hormone-receptor-positive advanced breast cancer after failure of nonsteroidal aromatase inhibitor therapy.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
27210004-4	2016	Everolimus has been approved in combination with exemestane for the treatment of hormone-receptor-positive advanced breast cancer after failure of nonsteroidal aromatase inhibitor therapy.	exemestane	49-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
27150036-1	2016	Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel.	Paclitaxel	24-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
27150036-1	2016	Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel.	Paclitaxel	174-184	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
27150036-1	2016	Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel.	Paclitaxel	174-184	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
27430727-8	2016	Importantly, we found that either knockdown of Nr4a1 or 3, 3"- Diindolylmethane (DIM), an Nr4a1 antagonist, were able to rescue the effects of SNRPN knockdown on neurite outgrowth of embryonic cortical neurons, providing the potential therapeutic methods for SNRPN deletion disorders.	3,3'-diindolylmethane	56-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-95
27406346-11	2016	RESULTS: Neratinib reached the prespecified efficacy threshold with regard to the HER2-positive, hormone-receptor-negative signature.	neratinib	9-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
27406346-12	2016	Among patients with HER2-positive, hormone-receptor-negative cancer, the mean estimated rate of pathological complete response was 56% (95% Bayesian probability interval [PI], 37 to 73%) among 115 patients in the neratinib group, as compared with 33% among 78 controls (95% PI, 11 to 54%).	neratinib	213-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-51
27406346-14	2016	CONCLUSIONS: Neratinib added to standard therapy was highly likely to result in higher rates of pathological complete response than standard chemotherapy with trastuzumab among patients with HER2-positive, hormone-receptor-negative breast cancer.	neratinib	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	206-222
27012810-1	2016	Tamoxifen may require metabolic activation to endoxifen for efficacy in treating hormone receptor-positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
27012810-1	2016	Tamoxifen may require metabolic activation to endoxifen for efficacy in treating hormone receptor-positive breast cancer.	4-hydroxy-N-desmethyltamoxifen	46-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
27264120-1	2016	BACKGROUND: Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor-positive early breast cancer in postmenopausal women.	Tamoxifen	95-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-160
27128111-2	2016	A recent metabolomics study identified unsaturated fatty acids, including arachidonic acid and docosahexaenoic acid (DHA), that interact with the ligand-binding domain (LBD) of a related orphan receptor, Nur77/NR4A1.	Fatty Acids, Unsaturated	39-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-209
27128111-2	2016	A recent metabolomics study identified unsaturated fatty acids, including arachidonic acid and docosahexaenoic acid (DHA), that interact with the ligand-binding domain (LBD) of a related orphan receptor, Nur77/NR4A1.	Fatty Acids, Unsaturated	39-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	210-215
27128111-2	2016	A recent metabolomics study identified unsaturated fatty acids, including arachidonic acid and docosahexaenoic acid (DHA), that interact with the ligand-binding domain (LBD) of a related orphan receptor, Nur77/NR4A1.	Arachidonic Acid	74-90	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-209
27128111-2	2016	A recent metabolomics study identified unsaturated fatty acids, including arachidonic acid and docosahexaenoic acid (DHA), that interact with the ligand-binding domain (LBD) of a related orphan receptor, Nur77/NR4A1.	Arachidonic Acid	74-90	nuclear receptor subfamily 4 group A member 1	Homo sapiens	210-215
27128111-2	2016	A recent metabolomics study identified unsaturated fatty acids, including arachidonic acid and docosahexaenoic acid (DHA), that interact with the ligand-binding domain (LBD) of a related orphan receptor, Nur77/NR4A1.	Docosahexaenoic Acids	95-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-209
27128111-2	2016	A recent metabolomics study identified unsaturated fatty acids, including arachidonic acid and docosahexaenoic acid (DHA), that interact with the ligand-binding domain (LBD) of a related orphan receptor, Nur77/NR4A1.	Docosahexaenoic Acids	95-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	210-215
27128111-2	2016	A recent metabolomics study identified unsaturated fatty acids, including arachidonic acid and docosahexaenoic acid (DHA), that interact with the ligand-binding domain (LBD) of a related orphan receptor, Nur77/NR4A1.	Docosahexaenoic Acids	117-120	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-209
27128111-2	2016	A recent metabolomics study identified unsaturated fatty acids, including arachidonic acid and docosahexaenoic acid (DHA), that interact with the ligand-binding domain (LBD) of a related orphan receptor, Nur77/NR4A1.	Docosahexaenoic Acids	117-120	nuclear receptor subfamily 4 group A member 1	Homo sapiens	210-215
27129202-5	2016	Nur77 binds adjacent to the BH3 peptide-binding crevice, suggesting the possibility of cross-talk between these discrete binding sites.	BH 3	28-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
27322146-9	2016	Importantly, ATA therapy may be useful for decreasing blood glucose levels by reversing NR4A1-dependent insulin signaling.	Glucose	60-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-93
27445490-1	2016	BACKGROUND: Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising antitumor activity when combined with trastuzumab and chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine agents for hormone receptor (HR)-positive tumors.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	276-292
27445490-1	2016	BACKGROUND: Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising antitumor activity when combined with trastuzumab and chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine agents for hormone receptor (HR)-positive tumors.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	294-296
27029704-1	2016	BACKGROUND: In the PALOMA-3 study, palbociclib plus fulvestrant demonstrated improved progression-free survival compared with fulvestrant plus placebo in hormone receptor-positive, HER2- endocrine-resistant metastatic breast cancer (MBC).	Fulvestrant	52-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-170
27243969-2	2016	The studied flavin compounds were disubstituted with polar substituents at the N1 and N3 positions (alloxazine) or at the N3 and N10 positions (isoalloxazines).	4,6-dinitro-o-cresol	12-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	129-132
28247605-10	2016	Conclusion: Patients with HR altered from positive to negative after NAC may still gain benefit from AET.	nac	69-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-28
27228187-0	2016	Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.	estrone sulfate	16-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-110
26859101-1	2016	AIMS: In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer.	Anastrozole	49-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	135-151
26859101-1	2016	AIMS: In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer.	Anastrozole	49-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-155
26859101-1	2016	AIMS: In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer.	Fulvestrant	66-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	135-151
26859101-1	2016	AIMS: In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer.	Fulvestrant	66-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-155
26482374-7	2016	RESULTS: We found a positive correlation between the variant GG genotype of CTSO rs10030044 and shorter disease-free survival, or overall survival in hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.	Tamoxifen	218-227	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-166
26482374-9	2016	Multivariate Cox regression analysis revealed that this genotype was an independent factor indicating a poor prognosis in hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.	Tamoxifen	190-199	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-138
28247605-9	2016	Cox regression analysis showed that AET-administered or not was the independent predictor for 5-year DFS (HR=2.096, 95% CI:1.081-4.065, P&lt;0.05).	2-(2-Aminoethyl)isothiourea dihydrobromide	36-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-108
28247605-10	2016	Conclusion: Patients with HR altered from positive to negative after NAC may still gain benefit from AET.	2-(2-Aminoethyl)isothiourea dihydrobromide	101-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-28
27313785-0	2016	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.	Paclitaxel	156-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-48
27144436-5	2016	1,1-Bis(3-indolyl)-1-(p-substituted phenyl)methane (C-DIM) analogs containing p-hydroxyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) substituents are NR4A1 ligands that decreased NR4A1-dependent transactivation in RMS cells and inhibited RMS cell and tumor growth and induced apoptosis.	1,1-bis(3-indolyl)-1-(p-substituted phenyl)methane	0-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-162
27144436-5	2016	1,1-Bis(3-indolyl)-1-(p-substituted phenyl)methane (C-DIM) analogs containing p-hydroxyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) substituents are NR4A1 ligands that decreased NR4A1-dependent transactivation in RMS cells and inhibited RMS cell and tumor growth and induced apoptosis.	1,1-bis(3-indolyl)-1-(p-substituted phenyl)methane	0-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	186-191
27144436-5	2016	1,1-Bis(3-indolyl)-1-(p-substituted phenyl)methane (C-DIM) analogs containing p-hydroxyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) substituents are NR4A1 ligands that decreased NR4A1-dependent transactivation in RMS cells and inhibited RMS cell and tumor growth and induced apoptosis.	c-dim	52-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-162
27144436-5	2016	1,1-Bis(3-indolyl)-1-(p-substituted phenyl)methane (C-DIM) analogs containing p-hydroxyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) substituents are NR4A1 ligands that decreased NR4A1-dependent transactivation in RMS cells and inhibited RMS cell and tumor growth and induced apoptosis.	c-dim	52-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	186-191
27144436-7	2016	Both NR4A1 knockdown and treatment with DIM-C-pPhOH and DIM-C-pPhCO2Me also induced ROS which activated stress genes and induced sestrin 2 which activated AMPK and inhibited mTOR in the mutant p53 RMS cells.	p-carboxymethylphenyl 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane	56-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	5-10
27144436-7	2016	Both NR4A1 knockdown and treatment with DIM-C-pPhOH and DIM-C-pPhCO2Me also induced ROS which activated stress genes and induced sestrin 2 which activated AMPK and inhibited mTOR in the mutant p53 RMS cells.	ros	84-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	5-10
27313785-3	2016	Although CDK4/6 inhibition by palbociclib in combination with endocrine therapy has shown potent antiproliferative effects in HR-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the potential role of palbociclib in re-sensitizing chemotherapy-resistant HR-positive breast cancer is not well defined.	palbociclib	30-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-128
27313785-4	2016	We hypothesized that CDK4/6 inhibition by palbociclib re-sensitizes HR-positive/HER2-negative residual breast cancer to taxane-based adjuvant therapy.	palbociclib	42-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-70
27313785-4	2016	We hypothesized that CDK4/6 inhibition by palbociclib re-sensitizes HR-positive/HER2-negative residual breast cancer to taxane-based adjuvant therapy.	taxane	120-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-70
27313785-9	2016	Nevertheless, the fact that CDK4/6 activation remained intact in paclitaxel-resistant cells indicates that patients who have HR-positive/HER2-negative residual disease after taxane-based neoadjuvant chemotherapy may still benefit from palbociclib in combination with other regimens, such as endocrine therapies, for adjuvant therapy.	Paclitaxel	65-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-127
27182557-7	2016	Tumor uptake of the radiotracer 18F-fluorodeoxyglucose was associated with protein expression clusters characterized by hormone receptor loss, PTEN alteration, and HER2 gene amplification.	Fluorodeoxyglucose F18	32-54	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-136
27123064-12	2016	The present study demonstrated that neoadjuvant FEC followed by weekly administration of paclitaxel and/or trastuzumab induces a high pathological response and a high pCR rate in patients with hormone receptor-negative breast cancer.	Paclitaxel	89-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	193-209
27123064-0	2016	Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature.	Paclitaxel	128-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
26947331-0	2016	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-94
25900861-0	2016	Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.	Tamoxifen	90-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-48
25900861-1	2016	BACKGROUND/PURPOSE: Extended hormonal therapy with tamoxifen for &gt; 5 years has improved disease-free survival (DFS) and overall survival (OS) in hormone receptor (HR)-positive breast cancer patients.	Tamoxifen	51-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	148-164
25900861-1	2016	BACKGROUND/PURPOSE: Extended hormonal therapy with tamoxifen for &gt; 5 years has improved disease-free survival (DFS) and overall survival (OS) in hormone receptor (HR)-positive breast cancer patients.	Tamoxifen	51-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-168
25900861-10	2016	CONCLUSION: Our findings suggest that HR-positive breast cancer women either aged &lt; 40 years or with positive lymph node status were justified in continuing with tamoxifen therapy for &gt; 5 years.	Tamoxifen	165-174	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-40
26947172-1	2016	PURPOSE: This review compared the real-world effectiveness of everolimus-based therapy versus endocrine monotherapy or chemotherapy in postmenopausal hormone receptor positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) patients with multiple metastatic sites.	Everolimus	62-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-166
26152740-1	2016	PURPOSE: Most hormone receptor (HR)(+)/HER2(-) breast cancer patients respond unfavorably to neoadjuvant chemotherapy (NAC); however, genomic tests may identify those patients who are likely to benefit.	nac	119-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-30
26984766-1	2016	BACKGROUND: Neoadjuvant endocrine therapy (NAE) has been employed to improve surgical outcomes for hormone receptor-positive breast cancers in postmenopausal women.	N-lauroylethanolamine	43-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-115
26311476-5	2016	DISCUSSION: In light of the potential for environmental release of oil and gas chemicals that can disrupt hormone receptor systems, we recommend methods for assessing complex hormonally active environmental mixtures.	Oils	67-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-122
26829011-5	2016	Hormone receptor negative (HR-) patients on lapatinib had a significantly prolonged disease-free survival (DFS) compared to HR- patients on placebo (hazard ratio 0.64, P=0.003).	Lapatinib	44-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
26440050-5	2016	Here, we clone and express the novel TR3-iso2 protein and find that expression of TR3-iso2, in contrast to TR3-iso1, inhibits endothelial cell proliferation induced by VEGF-A, histamine, and phorbol-12-myristate-13-acetate (PMA).	Histamine	176-185	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-40
26440050-5	2016	Here, we clone and express the novel TR3-iso2 protein and find that expression of TR3-iso2, in contrast to TR3-iso1, inhibits endothelial cell proliferation induced by VEGF-A, histamine, and phorbol-12-myristate-13-acetate (PMA).	Histamine	176-185	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-85
26440050-5	2016	Here, we clone and express the novel TR3-iso2 protein and find that expression of TR3-iso2, in contrast to TR3-iso1, inhibits endothelial cell proliferation induced by VEGF-A, histamine, and phorbol-12-myristate-13-acetate (PMA).	Histamine	176-185	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-85
26440050-5	2016	Here, we clone and express the novel TR3-iso2 protein and find that expression of TR3-iso2, in contrast to TR3-iso1, inhibits endothelial cell proliferation induced by VEGF-A, histamine, and phorbol-12-myristate-13-acetate (PMA).	Tetradecanoylphorbol Acetate	191-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-40
26440050-5	2016	Here, we clone and express the novel TR3-iso2 protein and find that expression of TR3-iso2, in contrast to TR3-iso1, inhibits endothelial cell proliferation induced by VEGF-A, histamine, and phorbol-12-myristate-13-acetate (PMA).	Tetradecanoylphorbol Acetate	191-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-85
26440050-5	2016	Here, we clone and express the novel TR3-iso2 protein and find that expression of TR3-iso2, in contrast to TR3-iso1, inhibits endothelial cell proliferation induced by VEGF-A, histamine, and phorbol-12-myristate-13-acetate (PMA).	Tetradecanoylphorbol Acetate	191-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-85
26440050-8	2016	We further demonstrate that several intracellular signaling pathways are involved in histamine-induced TR3 transcript variants, including histamine receptor H1-mediated phospholipase C (PLC)/calcium /calcineurin/protein kinase C (PKC)/protein kinase D (PKD) pathway and ERK pathway, as well as histamine receptor H3-mediated PKC-ERK pathway.	Histamine	85-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-106
26440050-9	2016	Further, expressions of TR3-TV1, TR3-TV2, and TR3-TV3 by VEGF and histamine are regulated by different promoters, but not by their mRNA stability.	Histamine	66-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	24-27
26440050-9	2016	Further, expressions of TR3-TV1, TR3-TV2, and TR3-TV3 by VEGF and histamine are regulated by different promoters, but not by their mRNA stability.	Histamine	66-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-36
26440050-9	2016	Further, expressions of TR3-TV1, TR3-TV2, and TR3-TV3 by VEGF and histamine are regulated by different promoters, but not by their mRNA stability.	Histamine	66-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-36
26354331-5	2016	In DETECT IVa, postmenopausal patients with hormone-receptor positive primary cancer and HER2-negative CTC receive everolimus and standard endocrine therapy.	Everolimus	115-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-60
26507507-0	2016	Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.	Everolimus	66-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-110
26507507-2	2016	Because of the significant improvement in progression-free survival for everolimus plus exemestane compared with exemestane plus placebo, everolimus, an mTOR inhibitor, was approved in the United States for the treatment of patients with hormone receptor-positive (HR+), HER-negative, advanced breast cancer whose disease had progressed while receiving letrozole or anastrozole.	Everolimus	138-148	nuclear receptor subfamily 4 group A member 1	Homo sapiens	238-254
26786154-3	2016	Of the 12,198 women with hormone receptor-positive breast cancer, 74.8 % received AET within 12 months of diagnosis, of which 17.3 % received tamoxifen and 82.8 % received AIs.	2-(2-Aminoethyl)isothiourea dihydrobromide	82-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-41
26505879-0	2016	Honokiol sensitizes breast cancer cells to TNF-alpha induction of apoptosis by inhibiting Nur77 expression.	honokiol	0-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-95
26876074-7	2016	CONCLUSION: Tumor-infiltrating lymphocytes-positive and HR-negative were independent predictive factors of pCR in primary HER2-positive breast cancer treated with trastuzumab-based NAC.	nac	181-184	nuclear receptor subfamily 4 group A member 1	Homo sapiens	56-58
26505879-9	2016	Our in vitro and animal studies also identified honokiol as an effective sensitizer of TNF-alpha-induced apoptosis by inhibiting TNF-alpha-induced Nur77 mRNA expression, which could be attributed to its interference of TNFR1"s interaction with receptor-interacting protein 1 (RIPK1).	honokiol	48-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-152
26707825-6	2016	The treated keratinocytes show a dose-dependent growth reduction to DHT and T. DHT increases the expression of TR3 in keratinocytes, associated with a concomitant increase of BAD and decrease of Bcl-2 expression.	Dihydrotestosterone	79-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-114
26613834-4	2016	The administration of an aromatase inhibitor plus OFS represents an additional therapeutic option for hormone-receptor positive premenopausal breast cancer patients, according to the combined analysis of the SOFT and TEXT trials.	ofs	50-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-118
26707825-7	2016	Knockdown TR3 expression by siRNA blocks the inhibitory effect of DHT on keratinocyte proliferation.	Dihydrotestosterone	66-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-13
26779371-3	2015	Everolimus, an mTOR inhibitor, is currently approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-90
26779371-3	2015	Everolimus, an mTOR inhibitor, is currently approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-94
26315555-9	2015	Further subgroup analyses showed that aspirin use could decrease risk of in situ breast tumors or hormone receptor-positive tumors and reduce risk of breast cancer in postmenopausal women.	Aspirin	38-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	98-114
26396259-7	2015	Both total cholesterol and low-density lipoprotein cholesterol levels in plasma were positively correlated with NR4A1 mRNA level.	Cholesterol	11-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-117
26396259-10	2015	Supporting our clinical observations, cholesterol enhanced p300 acetyltransferase and decreased HDAC7 (histone deacetylase 7) recruitment to the NR4A1 promoter region, resulting in histone H3 hyperacetylation and further contributing to NR4A1 up-regulation in monocytes.	Cholesterol	38-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-150
26396259-10	2015	Supporting our clinical observations, cholesterol enhanced p300 acetyltransferase and decreased HDAC7 (histone deacetylase 7) recruitment to the NR4A1 promoter region, resulting in histone H3 hyperacetylation and further contributing to NR4A1 up-regulation in monocytes.	Cholesterol	38-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-242
26396259-11	2015	Moreover, cytosporone B, an NR4A1 agonist, completely reversed cholesterol-induced IL-6 (interleukin 6) and MCP-1 (monocyte chemoattractant protein 1) expression to below basal levels, and knockdown of NR4A1 expression by siRNA not only mimicked, but also exaggerated the effects of cholesterol on inflammatory biomarker up-regulation.	cytosporone B	10-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
26396259-11	2015	Moreover, cytosporone B, an NR4A1 agonist, completely reversed cholesterol-induced IL-6 (interleukin 6) and MCP-1 (monocyte chemoattractant protein 1) expression to below basal levels, and knockdown of NR4A1 expression by siRNA not only mimicked, but also exaggerated the effects of cholesterol on inflammatory biomarker up-regulation.	cytosporone B	10-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	202-207
26396259-11	2015	Moreover, cytosporone B, an NR4A1 agonist, completely reversed cholesterol-induced IL-6 (interleukin 6) and MCP-1 (monocyte chemoattractant protein 1) expression to below basal levels, and knockdown of NR4A1 expression by siRNA not only mimicked, but also exaggerated the effects of cholesterol on inflammatory biomarker up-regulation.	Cholesterol	63-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
26396259-11	2015	Moreover, cytosporone B, an NR4A1 agonist, completely reversed cholesterol-induced IL-6 (interleukin 6) and MCP-1 (monocyte chemoattractant protein 1) expression to below basal levels, and knockdown of NR4A1 expression by siRNA not only mimicked, but also exaggerated the effects of cholesterol on inflammatory biomarker up-regulation.	Cholesterol	63-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	202-207
26556724-8	2015	Our findings showed that ApoA-IV colocalizes with NR4A1, which suppresses G6Pase and PEPCK gene expression at the transcriptional level, reducing hepatic glucose output and lowering blood glucose.	Glucose	154-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-55
26324355-1	2015	OBJECTIVE: To review palbociclib, a novel small-molecule inhibitor of cyclin-dependent kinases 4 and 6, and its current place in therapy for the treatment of hormone receptor (HMR)-positive, human epidermal growth factor receptor 2 (Her2)-negative advanced breast cancer.	palbociclib	21-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	158-174
26324355-1	2015	OBJECTIVE: To review palbociclib, a novel small-molecule inhibitor of cyclin-dependent kinases 4 and 6, and its current place in therapy for the treatment of hormone receptor (HMR)-positive, human epidermal growth factor receptor 2 (Her2)-negative advanced breast cancer.	palbociclib	21-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	176-179
26315555-10	2015	Aspirin use may not affect overall risk of breast cancer, but decrease risk of in situ breast tumors or hormone receptor-positive tumors and reduce risk of breast cancer in postmenopausal women.	Aspirin	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
26229035-7	2015	1,1-Bis(3"-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) are NR4A1 ligands that act as NR4A1 antagonists.	c-dims	54-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
26491966-2	2015	In this study, we investigated the anti-proliferative effect of quercetin in two breast cancer cell lines (MCF-7 and MDA-MB-231), which differed in hormone receptor.	Quercetin	64-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	148-164
25677034-11	2015	Overall, our results confirm the association between alcohol intake and both hormone receptor positive and hormone receptor negative breast tumors, suggesting that timing of exposure to alcohol drinking may affect the risk.	Alcohols	53-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-93
25677034-11	2015	Overall, our results confirm the association between alcohol intake and both hormone receptor positive and hormone receptor negative breast tumors, suggesting that timing of exposure to alcohol drinking may affect the risk.	Alcohols	53-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-123
25677034-11	2015	Overall, our results confirm the association between alcohol intake and both hormone receptor positive and hormone receptor negative breast tumors, suggesting that timing of exposure to alcohol drinking may affect the risk.	Alcohols	186-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-93
25677034-11	2015	Overall, our results confirm the association between alcohol intake and both hormone receptor positive and hormone receptor negative breast tumors, suggesting that timing of exposure to alcohol drinking may affect the risk.	Alcohols	186-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-123
26362840-0	2015	Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.	Letrozole	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	98-114
26446233-7	2015	Subgroup analysis revealed that metformin improved the overall survival by 65% after adjusting for hormone receptor expression (HR: 0.35; 95% CI: 0.15-0.84).	Metformin	32-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-115
26446233-12	2015	Subgroup analysis revealed that metformin improved the overall survival by 65% after adjusting for hormone receptor expression.	Metformin	32-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-115
26392314-9	2015	These results suggest that HCV core protein decreases the sensitivity of hepatocytes to cisplatin by inhibiting the expression of NR4A1 and promoting the expression of smad7, which negatively regulates the TGF-beta pathway.	Cisplatin	88-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	130-135
26229035-7	2015	1,1-Bis(3"-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) are NR4A1 ligands that act as NR4A1 antagonists.	1,1-bis(3"-indolyl)-1-(p-substituted phenyl)methanes	0-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-71
26229035-7	2015	1,1-Bis(3"-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) are NR4A1 ligands that act as NR4A1 antagonists.	1,1-bis(3"-indolyl)-1-(p-substituted phenyl)methanes	0-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
26417203-2	2015	Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor-positive, human epidermal growth factor receptor-negative metastatic disease that has progressed after prior endocrine therapy.	Everolimus	59-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-165
26229035-7	2015	1,1-Bis(3"-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) are NR4A1 ligands that act as NR4A1 antagonists.	c-dims	54-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-71
26148973-8	2015	In particular, SR11237 (BMS649) has stronger potency for recruitment of CoA motif and transcriptional activity with the heterodimer Nur77/RXR than other complexes.	SR 11237	15-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-137
26148973-8	2015	In particular, SR11237 (BMS649) has stronger potency for recruitment of CoA motif and transcriptional activity with the heterodimer Nur77/RXR than other complexes.	BMS 649	24-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-137
26417636-1	2015	Two randomised trials have compared 5 years versus 10 years of tamoxifen therapy following surgery for hormone receptor-positive early breast cancer.	Tamoxifen	63-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-119
26264704-1	2015	Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy.	palbociclib	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-137
26235054-3	2015	We previously reported that autophagic cell death mediated by nuclear receptor TR3 and driven by a chemical agonist, 1-(3,4,5-trihydroxyphenyl)nonan-1-one (THPN), is highly effective in the therapy of melanoma but not any other cancer types.	1-(3,4,5-trihydroxyphenyl)nonan-1-one	156-160	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-82
25703176-0	2015	Mixture effects of levonorgestrel and ethinylestradiol: estrogenic biomarkers and hormone receptor mRNA expression during sexual programming.	Levonorgestrel	19-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
25624176-3	2015	In the last years many targeted agents have been investigated to prevent or overcome endocrine resistance; only a few of them have been found effective in HR positive MBC, such as everolimus, CK4/6 inhibitors and HDAC inhibitors.	Everolimus	180-190	nuclear receptor subfamily 4 group A member 1	Homo sapiens	155-157
26270486-2	2015	A NR4A1/bis-indole ligand complex at this novel site has been found to be stable over 1 mus of simulation and to result in an interesting conformational transmission to a remote loop that has the capacity to communicate with a NBRE within a RXR-alpha/NR4A1 heterodimer.	Bismuth	8-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	2-7
26270486-2	2015	A NR4A1/bis-indole ligand complex at this novel site has been found to be stable over 1 mus of simulation and to result in an interesting conformational transmission to a remote loop that has the capacity to communicate with a NBRE within a RXR-alpha/NR4A1 heterodimer.	Bismuth	8-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	251-256
26270486-2	2015	A NR4A1/bis-indole ligand complex at this novel site has been found to be stable over 1 mus of simulation and to result in an interesting conformational transmission to a remote loop that has the capacity to communicate with a NBRE within a RXR-alpha/NR4A1 heterodimer.	indole	12-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	2-7
26270486-2	2015	A NR4A1/bis-indole ligand complex at this novel site has been found to be stable over 1 mus of simulation and to result in an interesting conformational transmission to a remote loop that has the capacity to communicate with a NBRE within a RXR-alpha/NR4A1 heterodimer.	indole	12-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	251-256
26035713-5	2015	We have recently demonstrated that selected 1,1-bis(3"-indolyl)-1-(p-substituted phenyl)methane (C-DIM) compounds including the p-hydroxyphenyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) analogs bind NR4A1 and act as antagonists.	1,1-bis(3"-indolyl)-1-(p-substituted phenyl)methane	44-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
26035713-5	2015	We have recently demonstrated that selected 1,1-bis(3"-indolyl)-1-(p-substituted phenyl)methane (C-DIM) compounds including the p-hydroxyphenyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) analogs bind NR4A1 and act as antagonists.	c-dim	97-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
26035713-5	2015	We have recently demonstrated that selected 1,1-bis(3"-indolyl)-1-(p-substituted phenyl)methane (C-DIM) compounds including the p-hydroxyphenyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) analogs bind NR4A1 and act as antagonists.	p-hydroxyphenyl	128-143	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
25792492-1	2015	UNLABELLED: In postmenopausal women with low bone mass and hormone-receptor-positive breast cancer on an aromatase inhibitor, risedronate maintained skeletal health assessed by bone density and turnover markers.	Risedronic Acid	126-137	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-75
26102468-3	2015	In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer.	Lapatinib	15-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	279-295
25760782-9	2015	However, elevated risks for hormone receptor-negative tumors were observed for higher exposure to cadmium compounds and possibly inorganic arsenic among never-smoking non-movers.	Cadmium	98-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-44
25760782-9	2015	However, elevated risks for hormone receptor-negative tumors were observed for higher exposure to cadmium compounds and possibly inorganic arsenic among never-smoking non-movers.	Arsenic	139-146	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-44
25703176-0	2015	Mixture effects of levonorgestrel and ethinylestradiol: estrogenic biomarkers and hormone receptor mRNA expression during sexual programming.	Ethinyl Estradiol	38-54	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
25663912-6	2015	Compared with the patients who did not receive lapatinib, the pCR rate was higher in the hormone receptor (HR)-positive [risk ratio (RR), 1.39; 95% confidence interval (CI), 1.12-1.72; P=0.002) and HR-negative (RR, 1.38; 95% CI, 1.14-1.68; P=0.0009) patients that received lapatinib.	Lapatinib	47-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-105
25931227-2	2015	METHODS: The fusion protein PET28a-NR4A1-DBD was constructed and purified with the nickel affinity chromatography, cation-exchange chromatography and gel filtration chromatography.	Nickel	83-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-40
25931227-3	2015	RESULTS: The protein PET28a-NR4A1-DBD was mostly soluable at 24  C. A total of 2-3 mg/L pure NR4A1 proteins were yielded in bacterial culture and the purity for final fractions of NR4A1-DBD protein were great than 95% by SDS-PAGE analysis.	Sodium Dodecyl Sulfate	221-224	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
25931227-3	2015	RESULTS: The protein PET28a-NR4A1-DBD was mostly soluable at 24  C. A total of 2-3 mg/L pure NR4A1 proteins were yielded in bacterial culture and the purity for final fractions of NR4A1-DBD protein were great than 95% by SDS-PAGE analysis.	Sodium Dodecyl Sulfate	221-224	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-98
25931227-3	2015	RESULTS: The protein PET28a-NR4A1-DBD was mostly soluable at 24  C. A total of 2-3 mg/L pure NR4A1 proteins were yielded in bacterial culture and the purity for final fractions of NR4A1-DBD protein were great than 95% by SDS-PAGE analysis.	Sodium Dodecyl Sulfate	221-224	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-98
25663912-6	2015	Compared with the patients who did not receive lapatinib, the pCR rate was higher in the hormone receptor (HR)-positive [risk ratio (RR), 1.39; 95% confidence interval (CI), 1.12-1.72; P=0.002) and HR-negative (RR, 1.38; 95% CI, 1.14-1.68; P=0.0009) patients that received lapatinib.	Lapatinib	47-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-109
25663912-6	2015	Compared with the patients who did not receive lapatinib, the pCR rate was higher in the hormone receptor (HR)-positive [risk ratio (RR), 1.39; 95% confidence interval (CI), 1.12-1.72; P=0.002) and HR-negative (RR, 1.38; 95% CI, 1.14-1.68; P=0.0009) patients that received lapatinib.	Lapatinib	273-282	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-105
25663912-6	2015	Compared with the patients who did not receive lapatinib, the pCR rate was higher in the hormone receptor (HR)-positive [risk ratio (RR), 1.39; 95% confidence interval (CI), 1.12-1.72; P=0.002) and HR-negative (RR, 1.38; 95% CI, 1.14-1.68; P=0.0009) patients that received lapatinib.	Lapatinib	273-282	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-109
26075448-5	2015	Temsirolimus is approved for advanced RCC; everolimus is registered for the treatment of advanced RCC, pancreatic neuroendocrine tumors and postmenopausal, hormone receptor-positive/HER2-negative, advanced breast cancer.	Everolimus	43-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	156-172
25232032-0	2015	Bile acids regulate nuclear receptor (Nur77) expression and intracellular location to control proliferation and apoptosis.	Bile Acids and Salts	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
25232032-4	2015	The intracellular location of BA-induced Nur77 was time dependent; short-term (1-3 hours) exposure induced nuclear Nur77, whereas longer (1-2 days) exposure also increased cytosolic Nur77 expression and apoptosis.	Bile Acids and Salts	30-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
25232032-4	2015	The intracellular location of BA-induced Nur77 was time dependent; short-term (1-3 hours) exposure induced nuclear Nur77, whereas longer (1-2 days) exposure also increased cytosolic Nur77 expression and apoptosis.	Bile Acids and Salts	30-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-120
25232032-4	2015	The intracellular location of BA-induced Nur77 was time dependent; short-term (1-3 hours) exposure induced nuclear Nur77, whereas longer (1-2 days) exposure also increased cytosolic Nur77 expression and apoptosis.	Bile Acids and Salts	30-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-120
25232032-5	2015	Inhibiting Nur77 nuclear export with leptomycin B decreased lithocholic acid (LCA)-induced apoptosis.	leptomycin B	37-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-16
25232032-5	2015	Inhibiting Nur77 nuclear export with leptomycin B decreased lithocholic acid (LCA)-induced apoptosis.	Lithocholic Acid	60-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-16
25232032-5	2015	Inhibiting Nur77 nuclear export with leptomycin B decreased lithocholic acid (LCA)-induced apoptosis.	Lithocholic Acid	78-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-16
25232032-6	2015	Extended (7 days) treatment with BA generated resistance to BA with increased nuclear Nur77, viability, and mobility.	Bile Acids and Salts	33-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-91
25232032-7	2015	While, knockdown of Nur77 in BA-resistant cells increased cellular susceptibility to LCA-induced apoptosis.	Lithocholic Acid	85-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-25
25232032-10	2015	Consistently, BA-induced upregulation of the aforementioned genes was abrogated by a lack of Nur77.	Bile Acids and Salts	14-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-98
25232032-11	2015	Importantly, Nur77 was overexpressed in high percentage of human colon and liver cancer specimens, and the intracellular location of Nur77 correlated with elevated serum total BA levels in patients with colon cancer.	Bile Acids and Salts	176-178	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
25232032-11	2015	Importantly, Nur77 was overexpressed in high percentage of human colon and liver cancer specimens, and the intracellular location of Nur77 correlated with elevated serum total BA levels in patients with colon cancer.	Bile Acids and Salts	176-178	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-138
25330024-0	2015	Nuclear receptor subfamily 4, group A, member 1 inhibits extrinsic apoptosis and reduces caspase-8 activity in H2O2-induced human HUC-F2 fibroblasts.	Hydrogen Peroxide	111-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-47
25330024-4	2015	In the current study, we focused on the potential role of NR4A1 in hydrogen peroxide (H2O2)-induced apoptosis of normal human umbilical cord fibroblast (HUC-F2) cells.	Hydrogen Peroxide	67-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-63
25330024-4	2015	In the current study, we focused on the potential role of NR4A1 in hydrogen peroxide (H2O2)-induced apoptosis of normal human umbilical cord fibroblast (HUC-F2) cells.	Hydrogen Peroxide	86-90	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-63
25330024-10	2015	RESULTS: H2O2 treatment led to enhanced NR4A1 expression.	Hydrogen Peroxide	9-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-45
25488719-6	2015	An interaction between HER2 and HR was observed, with a HER2-positive status significantly associated with ALN involvement at the time of diagnosis only in HR-negative patients (P &lt; 0.0001).	aln	107-110	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-34
25488719-8	2015	The HR and HER2 statuses are significantly associated with ALN involvement at the time of diagnosis.	aln	59-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-6
26273337-8	2015	NAC can alter HR and Ki-67 status in breast adenocarcinoma patients.	nac	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-16
26457979-1	2015	BACKGROUND: Everolimus (Afinitor ) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal women without symptomatic visceral disease after recurrence or progression following aromatase inhibitors.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
26457979-1	2015	BACKGROUND: Everolimus (Afinitor ) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal women without symptomatic visceral disease after recurrence or progression following aromatase inhibitors.	Everolimus	24-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
26457979-1	2015	BACKGROUND: Everolimus (Afinitor ) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal women without symptomatic visceral disease after recurrence or progression following aromatase inhibitors.	exemestane	40-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
25385240-5	2014	RESULTS: The administration of ET was significantly associated with improved disease-free survival (p=0.018) in patients with a positive-to-negative switch of HR status.	et	31-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-161
25505228-1	2015	BACKGROUND: There is limited evidence on the association between dietary folate intake and the risk of breast cancer (BC) by hormone receptor expression in the tumors.	Folic Acid	73-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
25505228-15	2015	CONCLUSIONS: Higher dietary folate intake may be associated with a lower risk of sex hormone receptor-negative BC in premenopausal women.	Folic Acid	28-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
25385240-8	2014	CONCLUSIONS: This study revealed that patients with HR altered from positive to negative after NAC still benefit from ET.	nac	95-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-54
25385240-9	2014	The HR status should be evaluated not only in specimens obtained during post-NAC surgery but also in specimens biopsied before NAC.	nac	77-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-6
25385240-9	2014	The HR status should be evaluated not only in specimens obtained during post-NAC surgery but also in specimens biopsied before NAC.	nac	127-130	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-6
25284689-3	2014	By using quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), we show that either ectopic expression of orphan nuclear receptor Nur77 or pharmacological activation of Nur77 by 6-mercaptopurine (6-MP) substantially inhibits ET-1 expression in human umbilical vein endothelial cells (HUVECs), under both basal and thrombin-stimulated conditions.	Mercaptopurine	207-223	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-164
25451590-6	2014	Global gene expression analysis confirmed by real-time PCR revealed that shikonin drastically inhibited the IgE/antigen-induced and calcium ionophore-induced upregulation of mRNA expression of the nuclear orphan receptor 4a family (Nr4a1, Nr4a2 and Nr4a3) in mBMMCs, and knockdown of Nr4a1 or Nr4a2 suppressed the IgE/antigen-induced upregulation of TNF-alpha mRNA expression.	Calcium	132-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	232-237
25451590-6	2014	Global gene expression analysis confirmed by real-time PCR revealed that shikonin drastically inhibited the IgE/antigen-induced and calcium ionophore-induced upregulation of mRNA expression of the nuclear orphan receptor 4a family (Nr4a1, Nr4a2 and Nr4a3) in mBMMCs, and knockdown of Nr4a1 or Nr4a2 suppressed the IgE/antigen-induced upregulation of TNF-alpha mRNA expression.	Calcium	132-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	284-289
25187486-0	2014	Induction of Nur77-dependent apoptotic pathway by a coumarin derivative through activation of JNK and p38 MAPK.	coumarin	52-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
25284689-3	2014	By using quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), we show that either ectopic expression of orphan nuclear receptor Nur77 or pharmacological activation of Nur77 by 6-mercaptopurine (6-MP) substantially inhibits ET-1 expression in human umbilical vein endothelial cells (HUVECs), under both basal and thrombin-stimulated conditions.	Mercaptopurine	207-223	nuclear receptor subfamily 4 group A member 1	Homo sapiens	198-203
25239681-0	2014	Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.	Anthracyclines	53-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	151-167
23404211-1	2014	BACKGROUND: The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR(+)) breast cancer refractory to letrozole or anastrozole.	Everolimus	43-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-173
25239681-0	2014	Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.	taxane	67-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	151-167
25471040-3	2014	The development of drugs to target these hormone receptors, such as tamoxifen, has brought about significant improvement in survival for women with hormone receptor-positive breast cancers.	Tamoxifen	68-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-57
25289075-10	2014	Furthermore, 250 muM PA stimulation was shown to increase NR4A1 expression and the secretion of inflammatory cytokines in the cultured PBMCs.	Palmitic Acid	21-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-63
25279188-1	2014	The aim of the present study was to investigate whether breast cancer patients with changes from positive to negative in the hormone receptor following neoadjuvant chemotherapy (NAC) could benefit from adjuvant endocrine therapy (ET).	nac	178-181	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
25279188-2	2014	Between December 2000 and November 2010, 97 eligible patients with a positive-to-negative switch of the hormone receptor status following NAC were identified.	nac	138-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
25279188-5	2014	The administration of ET was associated with a significantly improved disease-free survival (DFS) (P=0.018) in patients with a positive-to-negative switch of the hormone receptor status.	et	22-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	162-178
25279188-8	2014	The present study revealed that patients with the hormone receptor that was altered from positive to negative following NAC benefit from ET, and the hormone receptor status should be evaluated not only in specimens obtained during post-NAC surgery, but also in specimens biopsied prior to NAC.	nac	120-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
25279188-8	2014	The present study revealed that patients with the hormone receptor that was altered from positive to negative following NAC benefit from ET, and the hormone receptor status should be evaluated not only in specimens obtained during post-NAC surgery, but also in specimens biopsied prior to NAC.	nac	236-239	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
25279188-8	2014	The present study revealed that patients with the hormone receptor that was altered from positive to negative following NAC benefit from ET, and the hormone receptor status should be evaluated not only in specimens obtained during post-NAC surgery, but also in specimens biopsied prior to NAC.	nac	236-239	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-165
25279188-8	2014	The present study revealed that patients with the hormone receptor that was altered from positive to negative following NAC benefit from ET, and the hormone receptor status should be evaluated not only in specimens obtained during post-NAC surgery, but also in specimens biopsied prior to NAC.	nac	236-239	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
25279188-8	2014	The present study revealed that patients with the hormone receptor that was altered from positive to negative following NAC benefit from ET, and the hormone receptor status should be evaluated not only in specimens obtained during post-NAC surgery, but also in specimens biopsied prior to NAC.	nac	236-239	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-165
25090634-6	2014	The results of the in vitro study also indicated that the expression levels of 3beta-HSD1, CYP11A1, StAR, 5alpha-red1 and NGFI-B were elevated by forskolin.	Colforsin	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-128
25275504-8	2014	The expression of HDAC1,2,3,4,7 and Nur77 increased in PA samples at levels significantly higher than those observed in the CP group (p = 0.0160; 0.0114; 0.0227; 0.0440; 0.0136; 0.0004, respectively).	Protactinium	55-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-41
25302045-3	2014	Everolimus is an inhibitor of mtor (the mammalian target of rapamycin) that is used as targeted therapy for advanced, hormone receptor-positive, her2-negative breast cancer in postmenopausal women in combination with exemestane, after treatment failure with letrozole or anastrozole.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-134
25153259-4	2014	Testosterone-reduced expression of some steroidogenic enzymes/proteins (Tspo,StAR,Hsd3b1/2) and transcription factors (Nur77,Gata4,Dax1) was completely abrogated, while decreased expression of Star,Cyp11a1,Cyp17a1,Hsd17b4,Creb1a was partially prevented.	Testosterone	0-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-124
24885573-5	2014	Glucagon and forskolin increased Nur77 and FGF21 expression in vivo and in vitro, respectively, and adenovirus-mediated overexpression of Nur77 (Ad-Nur77) increased FGF21 expression in vitro and in vivo.	Glucagon	0-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-38
24840230-4	2014	METHODS: The Tamoxifen Exemestane Adjuvant Multinational Lifestyle study was a side study of the Tamoxifen Exemestane Adjuvant Multinational trial and prospectively investigated lifestyle habits of postmenopausal, hormone receptor-positive breast cancer patients.	tamoxifen exemestane	13-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	214-230
25400769-13	2014	CONCLUSIONS: Our results suggest that Ki67 expression in HR-negative breast cancer may improve the assessment of pathological response after NAC, and Ki67 score in residual tumor was an independent prognosticator for DFS in the HR-negative breast cancer patients.	nac	141-144	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-59
23184499-0	2014	Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.	Tamoxifen	58-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-87
25139196-6	2014	Among the four chemotherapy regimens, only CAX regimen had a predictive value for cOR (HR 2.30, 95 % CI 1.16-4.58, P = 0.009).	CAX	43-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-89
25099012-4	2014	Moreover, we also show that knockdown of NR4A1 by RNA interference (small interfering NR4A1) or treatment with DIM-C-pPhOH and related compounds decreased colon cancer cell growth, induced apoptosis, decreased expression of survivin and other Sp-regulated genes, and inhibited mammalian target of rapamycin signaling.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	111-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
25063800-4	2014	We hypothesize that acute ozone (AO) exposure during postnatal airway development disrupts SP/NK-1R/Nur77 pathway expression and that these changes correlate with increased ozone-induced cell death.	Acridine Orange	33-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-105
25063800-4	2014	We hypothesize that acute ozone (AO) exposure during postnatal airway development disrupts SP/NK-1R/Nur77 pathway expression and that these changes correlate with increased ozone-induced cell death.	Ozone	26-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-105
25063800-8	2014	We found that 1) ozone increases SP/NK-1R/Nur77 pathway expression in conducting airways, 2) an ozone exposure cycle (5 days/cycle) delivered early at age 2 mo resulted in an airway that was hypersensitive to AO exposure at the end of 2 mo, and 3) continued episodic exposure (11 cycles) resulted in an airway that was hyposensitive to AO exposure at 6 mo.	Ozone	17-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-47
25199766-9	2014	Tamoxifen is indicated for premenopausal hormone receptor (HR) positive tumors in 86.5% of cases and aromatase inhibitors (AI"s) for postmenopausal in 86%.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-57
25199766-9	2014	Tamoxifen is indicated for premenopausal hormone receptor (HR) positive tumors in 86.5% of cases and aromatase inhibitors (AI"s) for postmenopausal in 86%.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-61
24975596-10	2014	Postmenopausal women with hormone receptor-positive breast cancer receiving adjuvant anastrozole displayed less fatty liver disease, suggesting that this drug had a more favorable hepatic safety profile than tamoxifen and may be preferred for patients with potential hepatic dysfunction.	Anastrozole	85-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-42
23837522-4	2014	The optimized formulation, NP10 was dispersed in carbopol 934 P to form nanoparticulate in situ gels (NP-ISG1--NP-ISG5).	carboxypolymethylene	49-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-31
24885573-5	2014	Glucagon and forskolin increased Nur77 and FGF21 expression in vivo and in vitro, respectively, and adenovirus-mediated overexpression of Nur77 (Ad-Nur77) increased FGF21 expression in vitro and in vivo.	Colforsin	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-38
24885573-6	2014	Moreover, knockdown of endogenous Nur77 expression by siRNA-Nur77 abolished the effect of forskolin on FGF21 expression.	Colforsin	90-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39
24885573-6	2014	Moreover, knockdown of endogenous Nur77 expression by siRNA-Nur77 abolished the effect of forskolin on FGF21 expression.	Colforsin	90-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-65
24769509-8	2014	Moreover, we showed using salubrinal, an ER stress inhibitor that reactive oxygen species production, JNK activation, and Nur77 upregulation and its translocation to cytoplasm are necessary for ER-induced stress.	salubrinal	26-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-127
25120787-1	2014	BACKGROUND: To investigate the prognostic value of hormone receptor (HR) status conversion after neoadjuvant chemotherapy (NAC) in patients with primary breast cancer.	nac	123-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
24924416-0	2014	Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.	vandetanib	68-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-155
25120787-5	2014	RESULTS: In total, 15.7% of patients had HR status change after NAC.	nac	64-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-43
25120787-8	2014	CONCLUSIONS: The switch of HR status after NAC is remarkable for breast cancer.	nac	43-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-29
24922658-6	2014	In particular, the prognostic impact of rs11614913 was limited to the hormone receptor-expressing subtype, where the patients bearing the CC genotype showed worse survival in terms of DFS and DDFS compared with the patients with the TT or TC genotype as a recessive model (hazard ratio=2.610, p=0.003 for DFS; hazard ratio=2.730, p=0.013 for DDFS).	Technetium	239-241	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-86
24625784-10	2014	CONCLUSIONS: Ly-6C(high) monocytes orchestrate both inflammatory and reparative phases during myocardial infarction and depend on Nr4a1 to limit their influx and inflammatory cytokine expression.	ly-6c	13-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	130-135
24751388-4	2014	Comparable visual analog scale scores for rest pain at each measured time interval among the three groups demonstrated that adequate pain relief was offered; however, the cumulative dose of nalbuphine administered to the patients in Group N10 attenuated the analgesic effect of epidural morphine in moving pain at POh24 only.	Nalbuphine	190-200	nuclear receptor subfamily 4 group A member 1	Homo sapiens	239-242
24657612-1	2014	Amoitone B, a natural agonist to Nur77, is a promising anticancer drug.	n-amyl 2-(3,5-dihydroxy-2-(1-nonanoyl)phenyl)acetate	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-38
24751388-4	2014	Comparable visual analog scale scores for rest pain at each measured time interval among the three groups demonstrated that adequate pain relief was offered; however, the cumulative dose of nalbuphine administered to the patients in Group N10 attenuated the analgesic effect of epidural morphine in moving pain at POh24 only.	Morphine	287-295	nuclear receptor subfamily 4 group A member 1	Homo sapiens	239-242
24464780-0	2014	A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.	Capecitabine	33-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
24680679-0	2014	Mitochondrial translocation of Nur77 induced by ROS contributed to cardiomyocyte apoptosis in metabolic syndrome.	ros	48-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
24680679-2	2014	Nur77, a nuclear orphan receptor, is involved in such various cellular events as apoptosis, proliferation, and glucose and lipid metabolism in several cell types.	Glucose	111-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
24680679-7	2014	In this report, we observed that, accompanied by the substantial decline in apoptosis inducer Nur77, MI/R induced cardiac dysfunction was manifested as cardiomyopathy and increased ROS.	r	104-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
24680679-7	2014	In this report, we observed that, accompanied by the substantial decline in apoptosis inducer Nur77, MI/R induced cardiac dysfunction was manifested as cardiomyopathy and increased ROS.	ros	181-184	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
24680679-9	2014	However, inhibition of the relocation of Nur77 to mitochondria via Cyclosporin A reversed the changes in membrane potential mediated by H2O2 and reduced myocardial cell injury.	Cyclosporine	67-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
24680679-9	2014	However, inhibition of the relocation of Nur77 to mitochondria via Cyclosporin A reversed the changes in membrane potential mediated by H2O2 and reduced myocardial cell injury.	Hydrogen Peroxide	136-140	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
24615500-0	2014	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.	Everolimus	29-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
24615500-1	2014	BACKGROUND: In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer.	Everolimus	35-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	245-261
24562770-4	2014	We show that the investigational drug MLN0128, which inhibits both complexes of mTOR (mTORC1 and mTORC2), and the hydroxamic acid pan-HDAC inhibitor TSA synergistically inhibit the viability of a phenotypically diverse panel of five breast cancer cell lines (HR-/+, HER2-/+).	INK128	38-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	259-261
24562770-4	2014	We show that the investigational drug MLN0128, which inhibits both complexes of mTOR (mTORC1 and mTORC2), and the hydroxamic acid pan-HDAC inhibitor TSA synergistically inhibit the viability of a phenotypically diverse panel of five breast cancer cell lines (HR-/+, HER2-/+).	Hydroxamic Acids	114-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	259-261
24562770-4	2014	We show that the investigational drug MLN0128, which inhibits both complexes of mTOR (mTORC1 and mTORC2), and the hydroxamic acid pan-HDAC inhibitor TSA synergistically inhibit the viability of a phenotypically diverse panel of five breast cancer cell lines (HR-/+, HER2-/+).	trichostatin A	149-152	nuclear receptor subfamily 4 group A member 1	Homo sapiens	259-261
24743359-1	2014	Japanese clinical trials of a tegafur/uracil(UFT)-based postoperative chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil(CMF)treatment have shown that UFT is not inferior to CMF for the treatment of hormone receptor-positive breast cancer patients.	Tegafur	45-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	232-248
24743359-1	2014	Japanese clinical trials of a tegafur/uracil(UFT)-based postoperative chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil(CMF)treatment have shown that UFT is not inferior to CMF for the treatment of hormone receptor-positive breast cancer patients.	CMF regimen	154-157	nuclear receptor subfamily 4 group A member 1	Homo sapiens	232-248
23584473-0	2014	PKA/Smurf1 signaling-mediated stabilization of Nur77 is required for anticancer drug cisplatin-induced apoptosis.	Cisplatin	85-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-52
24515801-3	2014	Treatment of pancreatic cancer cells with the NR4A1 antagonist 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) gave similar results.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	63-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-51
24515801-3	2014	Treatment of pancreatic cancer cells with the NR4A1 antagonist 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) gave similar results.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	111-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-51
24515801-4	2014	Moreover, both NR4A1 knockdown and DIM-C-pPhOH induced reactive oxygen species (ROS), and induction of ROS and endoplasmic reticulum stress by these agents was attenuated after cotreatment with antioxidants.	Reactive Oxygen Species	55-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-20
24515801-4	2014	Moreover, both NR4A1 knockdown and DIM-C-pPhOH induced reactive oxygen species (ROS), and induction of ROS and endoplasmic reticulum stress by these agents was attenuated after cotreatment with antioxidants.	Reactive Oxygen Species	80-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-20
24515801-5	2014	Manipulation of NR4A1 expression coupled with gene expression profiling identified a number of ROS metabolism transcripts regulated by NR4A1.	Reactive Oxygen Species	95-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	16-21
24515801-5	2014	Manipulation of NR4A1 expression coupled with gene expression profiling identified a number of ROS metabolism transcripts regulated by NR4A1.	Reactive Oxygen Species	95-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	135-140
24515801-6	2014	Knockdown of one of these transcripts, thioredoxin domain containing 5 (TXNDC5), recapitulated the elevated ROS and endoplasmic reticulum stress; thus, demonstrating that NR4A1 regulates levels of endoplasmic reticulum stress and ROS in pancreatic cancer cells to facilitate cell proliferation and survival.	Reactive Oxygen Species	108-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-176
24515801-6	2014	Knockdown of one of these transcripts, thioredoxin domain containing 5 (TXNDC5), recapitulated the elevated ROS and endoplasmic reticulum stress; thus, demonstrating that NR4A1 regulates levels of endoplasmic reticulum stress and ROS in pancreatic cancer cells to facilitate cell proliferation and survival.	Reactive Oxygen Species	230-233	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-176
24515801-7	2014	Finally, inactivation of NR4A1 by knockdown or DIM-C-pPhOH decreased TXNDC5, resulting in activation of the ROS/endoplasmic reticulum stress and proapoptotic pathways.	Reactive Oxygen Species	108-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-30
24515801-8	2014	IMPLICATIONS: The NR4A1 receptor is pro-oncogenic, regulates the ROS/endoplasmic reticulum stress pathways, and inactivation of the receptor represents a novel pathway for inducing cell death in pancreatic cancer.	Reactive Oxygen Species	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-23
23584473-7	2014	Accordingly, cyclic AMP/PKA signaling switches the fate of Nur77 from degradation to triggering apoptosis in chemotherapy drug cisplatin-treated cells.	Cyclic AMP	13-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
23584473-7	2014	Accordingly, cyclic AMP/PKA signaling switches the fate of Nur77 from degradation to triggering apoptosis in chemotherapy drug cisplatin-treated cells.	Cisplatin	127-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
23584473-8	2014	Hence, our study revealed a novel mechanism, by which PKA/Smurf1 antagonizes the downregulating effect of JNK on Nur77, leading to the accumulation of Nur77 for apoptosis induction triggered by cisplatin.	Cisplatin	194-203	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-118
23584473-8	2014	Hence, our study revealed a novel mechanism, by which PKA/Smurf1 antagonizes the downregulating effect of JNK on Nur77, leading to the accumulation of Nur77 for apoptosis induction triggered by cisplatin.	Cisplatin	194-203	nuclear receptor subfamily 4 group A member 1	Homo sapiens	151-156
24333837-9	2014	Taken together, telmisartan may stimulate CYP11B2 transcription via NGFIB and the CaMK-mediated induction of NURR1 that activates the Ad5 element, independent of AII type 1 receptor.	Telmisartan	16-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-73
24586619-7	2014	The genome of SA268 was almost identical to that of the Taiwanese ST59 CA-MRSA strains M013 and SA957.	sa268	14-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-70
24355487-1	2014	BACKGROUND: This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer.	Anastrozole	130-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	179-195
24316735-3	2014	A sequence of molecular events leading to cellular demise is launched by a specific chemical compound, 1-(3,4,5-trihydroxyphenyl)nonan-1-one, newly acquired from screening a library of TR3-targeting compounds.	1-(3,4,5-trihydroxyphenyl)nonan-1-one	103-140	nuclear receptor subfamily 4 group A member 1	Homo sapiens	185-188
24463450-4	2014	We then applied information from this analysis to classify human breast tumors based on normal cell types into 4 major subtypes, HR0-HR3, which were differentiated by vitamin D, androgen, and estrogen hormone receptor (HR) expression.	Vitamin D	167-176	nuclear receptor subfamily 4 group A member 1	Homo sapiens	129-131
24498071-4	2014	METHODS AND RESULTS: The Nur77 gene, a nuclear hormone receptor, was highly induced by treatment with Cytosporone B (Csn-B, specific Nur77 agonist), recombinant plasmid over-expressing Nur77 (pcDNA-Nur77), while inhibited by treatment with siRNAs against Nur77 (si-Nur77) in THP-1 macrophage-derived foam cells, HepG2 cells and Caco-2 cells, respectively.	cytosporone B	102-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-30
24485460-4	2014	Integration of an endothelial genome-wide transcriptional profile with chromatin immunoprecipitation sequencing revealed that PR induces an NR4A1 (Nur77/TR3)-dependent transcriptional program that broadly regulates vascular permeability in response to progesterone.	Progesterone	252-264	nuclear receptor subfamily 4 group A member 1	Homo sapiens	140-145
24498071-4	2014	METHODS AND RESULTS: The Nur77 gene, a nuclear hormone receptor, was highly induced by treatment with Cytosporone B (Csn-B, specific Nur77 agonist), recombinant plasmid over-expressing Nur77 (pcDNA-Nur77), while inhibited by treatment with siRNAs against Nur77 (si-Nur77) in THP-1 macrophage-derived foam cells, HepG2 cells and Caco-2 cells, respectively.	cytosporone B	102-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-138
24498071-4	2014	METHODS AND RESULTS: The Nur77 gene, a nuclear hormone receptor, was highly induced by treatment with Cytosporone B (Csn-B, specific Nur77 agonist), recombinant plasmid over-expressing Nur77 (pcDNA-Nur77), while inhibited by treatment with siRNAs against Nur77 (si-Nur77) in THP-1 macrophage-derived foam cells, HepG2 cells and Caco-2 cells, respectively.	cytosporone B	102-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-138
24498071-4	2014	METHODS AND RESULTS: The Nur77 gene, a nuclear hormone receptor, was highly induced by treatment with Cytosporone B (Csn-B, specific Nur77 agonist), recombinant plasmid over-expressing Nur77 (pcDNA-Nur77), while inhibited by treatment with siRNAs against Nur77 (si-Nur77) in THP-1 macrophage-derived foam cells, HepG2 cells and Caco-2 cells, respectively.	cytosporone B	102-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-138
24498071-4	2014	METHODS AND RESULTS: The Nur77 gene, a nuclear hormone receptor, was highly induced by treatment with Cytosporone B (Csn-B, specific Nur77 agonist), recombinant plasmid over-expressing Nur77 (pcDNA-Nur77), while inhibited by treatment with siRNAs against Nur77 (si-Nur77) in THP-1 macrophage-derived foam cells, HepG2 cells and Caco-2 cells, respectively.	cytosporone B	102-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	262-270
24485460-4	2014	Integration of an endothelial genome-wide transcriptional profile with chromatin immunoprecipitation sequencing revealed that PR induces an NR4A1 (Nur77/TR3)-dependent transcriptional program that broadly regulates vascular permeability in response to progesterone.	Progesterone	252-264	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-152
24485460-4	2014	Integration of an endothelial genome-wide transcriptional profile with chromatin immunoprecipitation sequencing revealed that PR induces an NR4A1 (Nur77/TR3)-dependent transcriptional program that broadly regulates vascular permeability in response to progesterone.	Progesterone	252-264	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-156
24272078-0	2014	Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.	Fulvestrant	58-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-90
24360559-4	2014	We define the unique molecular profile of a compound (SM145) that regulates hormone receptor protein levels through hsp90 inhibition without inducing the heat shock response.	sm145	54-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-92
24857109-1	2014	Treatment with adjuvant endocrine therapy, including tamoxifen and the aromatase inhibitors, has resulted in notable improvements in disease-free and overall survival for patients with hormone receptor-positive breast cancer.	Tamoxifen	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	185-201
24434530-1	2014	The selective estrogen receptor modulator, tamoxifen, is extensively used for the endocrine treatment of all stages of hormone receptor-positive breast cancer.	Tamoxifen	43-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
24531914-7	2014	However, the levels of NGFIB expression were significantly higher in RSZ of IHA than in RSZ of adjacent adrenals of APA and the ZG of NA (P&lt;0.05), which may partly account for the expression levels of 3beta-HSD among the three groups of adrenals.	3r0y	69-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
24531914-7	2014	However, the levels of NGFIB expression were significantly higher in RSZ of IHA than in RSZ of adjacent adrenals of APA and the ZG of NA (P&lt;0.05), which may partly account for the expression levels of 3beta-HSD among the three groups of adrenals.	3r0y	88-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
24903080-0	2014	Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.	Cesium	29-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
24531914-8	2014	These results may imply NGFIB plays important roles in the marked differences in steroidogenic functions in the two distinct types of RSZ of PA cases.	3r0y	134-137	nuclear receptor subfamily 4 group A member 1	Homo sapiens	24-29
24927845-3	2014	Genome-wide analysis of hormone receptor-related networks will provide new insights into the understanding of the molecular mechanism orchestrated by estrogen and androgen receptors, and will enable the development of new methods for the diagnosis and treatment of steroid hormone-related cancers.	Steroids	265-280	nuclear receptor subfamily 4 group A member 1	Homo sapiens	24-40
24550751-0	2013	Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.	Lapatinib	22-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-93
24756805-3	2014	Everolimus has been approved by the FDA and the EMA for the treatment of advanced renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TSC), pancreatic neuroendocrine tumors (PNET), in combination with exemestane in advanced hormone-receptor (HR)-positive, HER2-negative breast cancer.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	279-295
24756805-3	2014	Everolimus has been approved by the FDA and the EMA for the treatment of advanced renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TSC), pancreatic neuroendocrine tumors (PNET), in combination with exemestane in advanced hormone-receptor (HR)-positive, HER2-negative breast cancer.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	297-299
24185007-7	2013	Expression of transcription factors activated downstream of MAP kinase and cAMP pathways also conferred resistance, including c-FOS, NR4A1, NR4A2 and MITF.	Cyclic AMP	75-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-138
24550751-0	2013	Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.	Letrozole	37-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-93
24299210-5	2013	In our cell culture model, we also demonstrated that Nur77 competitively inhibits androgen-dependent transcription activity and more specifically, Nur77 competes with androgen receptor for binding to src-1, a well-known coactivator for steroids.	Steroids	236-244	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-58
24299210-5	2013	In our cell culture model, we also demonstrated that Nur77 competitively inhibits androgen-dependent transcription activity and more specifically, Nur77 competes with androgen receptor for binding to src-1, a well-known coactivator for steroids.	Steroids	236-244	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-152
24299210-6	2013	More importantly, we also showed that a small molecule agonist for Nur77, Cytosporone B, significantly inhibits androgen-dependent bladder cancer cell growth in two different cell lines.	cytosporone B	74-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-72
24267730-1	2013	BACKGROUND: Postmenopausal women with hormone receptor-positive (HR(+)) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with exemestane (EXE), but no single standard of care exists in this setting.	exemestane	216-226	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-54
23873636-9	2013	alpha,beta-methylene-ATP and beta,gamma-methylene-ATP applied for 30 min to 4 h increased the expression of NR4A1; NF449 blocked or attenuated this effect.	alpha,beta-methyleneadenosine 5'-triphosphate	0-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-113
24335365-0	2013	[Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience].	Fulvestrant	51-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-115
24335365-1	2013	Fulvestrant, a pure estrogen receptor antagonist with no known agonist effects, was approved in September 2011 for the treatment of hormone-receptor positive metastatic breast cancer(MBC)in postmenopausal women in Japan.	Fulvestrant	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-148
23873636-9	2013	alpha,beta-methylene-ATP and beta,gamma-methylene-ATP applied for 30 min to 4 h increased the expression of NR4A1; NF449 blocked or attenuated this effect.	5'-adenylyl (beta,gamma-methylene)diphosphonate	29-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-113
23873636-10	2013	Small interfering RNA directed against NR4A1 diminished the antiproliferative effects of alpha,beta-methylene-ATP and beta,gamma-methylene-ATP.	alpha,beta-methyleneadenosine 5'-triphosphate	89-113	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
23873636-10	2013	Small interfering RNA directed against NR4A1 diminished the antiproliferative effects of alpha,beta-methylene-ATP and beta,gamma-methylene-ATP.	5'-adenylyl (beta,gamma-methylene)diphosphonate	118-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
23873636-12	2013	In conclusion, our results demonstrate for the first time that adenine nucleotides acting at P2X1 receptors inhibit the proliferation of human coronary smooth muscle cells via the induction of the early gene NR4A1.	Adenine Nucleotides	63-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
24371718-1	2013	Low-grade papillary serous ovarian carcinoma has unique epidemiologic and disease-specific characteristics Cyberknife radiotherapy is a unique treatment that may successfully be used to treat unresectable disease Anastrozole is an effective treatment for hormone receptor-positive low-grade papillary serous ovarian carcinoma.	Anastrozole	213-224	nuclear receptor subfamily 4 group A member 1	Homo sapiens	255-271
24534345-5	2013	RESULTS: The 3-year recurrence free survival for HR+/HER2-, HER2+ and HR-/HER2- were 94.9%, 89.5% ane 92.3% respectively.	camphene	98-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-51
24534345-5	2013	RESULTS: The 3-year recurrence free survival for HR+/HER2-, HER2+ and HR-/HER2- were 94.9%, 89.5% ane 92.3% respectively.	camphene	98-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-72
24396871-0	2013	Palmitate increases Nur77 expression by modulating ZBP89 and Sp1 binding to the Nur77 proximal promoter in pancreatic beta-cells.	Palmitates	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-25
24396871-0	2013	Palmitate increases Nur77 expression by modulating ZBP89 and Sp1 binding to the Nur77 proximal promoter in pancreatic beta-cells.	Palmitates	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-85
24396871-1	2013	Nur77 is a stress sensor in pancreatic beta-cells, which negatively regulates glucose-stimulated insulin secretion.	Glucose	78-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
24396871-2	2013	We recently showed that a lipotoxic shock caused by exposure of beta-cells to the saturated fatty acid palmitate strongly increases Nur77 expression.	saturated fatty acid palmitate	82-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-137
24396871-4	2013	Chromatin immunoprecipitation, transient transfection and siRNA-mediated knockdown assays revealed that palmitate induced Nur77 promoter activation involves Sp1 recruitment and ZBP89 release from the gene promoter.	Palmitates	104-113	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-127
24032657-1	2013	Amoitone B, a novel compound chemically synthesized as the analogue of cytosporone B, has been proved to own superior affinity with Nur77 than its parent compound and exhibit notable anticancer activity.	n-amyl 2-(3,5-dihydroxy-2-(1-nonanoyl)phenyl)acetate	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-137
24032657-1	2013	Amoitone B, a novel compound chemically synthesized as the analogue of cytosporone B, has been proved to own superior affinity with Nur77 than its parent compound and exhibit notable anticancer activity.	cytosporone B	71-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-137
24155635-0	2013	Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.	Lapatinib	22-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	65-81
24155635-1	2013	BACKGROUND: The cost-effectiveness of first-line treatment with lapatinib plus letrozole for postmenopausal women with hormone receptor-positive (hr+), human epidermal growth factor receptor 2-positive (her2+) metastatic breast cancer (mbc) has not been assessed from the Canadian health care system and societal perspectives.	Lapatinib	64-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
24155635-1	2013	BACKGROUND: The cost-effectiveness of first-line treatment with lapatinib plus letrozole for postmenopausal women with hormone receptor-positive (hr+), human epidermal growth factor receptor 2-positive (her2+) metastatic breast cancer (mbc) has not been assessed from the Canadian health care system and societal perspectives.	Letrozole	79-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
24033101-3	2013	Several of the cardiac glycosides induced apoptosis in lung cancer cells, which was accompanied by induction of Nur77 protein expression.	Glycosides	23-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-117
24033101-4	2013	Treatment of cancer cells with the cardiac glycosides resulted in translocation of the Nur77 protein from the nucleus to the cytoplasm and subsequent targeting to mitochondria.	Glycosides	43-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-92
24033101-5	2013	The results show that the cardiac glycosides exert their apoptotic effect through the Nur77-dependent apoptotic pathway.	Glycosides	34-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-91
24512852-0	2013	Palmitate increases Nur77 expression by modulating ZBP89 and Sp1 binding to the Nur77 proximal promoter in pancreatic beta-cells.	Palmitates	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-25
24512852-0	2013	Palmitate increases Nur77 expression by modulating ZBP89 and Sp1 binding to the Nur77 proximal promoter in pancreatic beta-cells.	Palmitates	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-85
24512852-1	2013	Nur77 is a stress sensor in pancreatic beta-cells, which negatively regulates glucose-stimulated insulin secretion.	Glucose	78-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
24512852-2	2013	We recently showed that a lipotoxic shock caused by exposure of beta-cells to the saturated fatty acid palmitate strongly increases Nur77 expression.	saturated fatty acid palmitate	82-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-137
24512852-4	2013	Chromatin immunoprecipitation, transient transfection and siRNA-mediated knockdown assays revealed that palmitate induced Nur77 promoter activation involves Sp1 recruitment and ZBP89 release from the gene promoter.	Palmitates	104-113	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-127
23903894-7	2013	RESULTS: In peripheral blood mononuclear cells, Nur77 was significantly and consistently decreased 2 h after vorinostat administration on both days 1 and 9, median ratio of gene expression relative to baseline of 0.69 with interquartile range 0.49-1.04 (p &lt; 0.001); 0.28 (0.15-0.7) (p &lt; 0.001), respectively, with more pronounced decrease on day 9, when patients received both vorinostat and bortezomib.	Vorinostat	109-119	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
23903894-7	2013	RESULTS: In peripheral blood mononuclear cells, Nur77 was significantly and consistently decreased 2 h after vorinostat administration on both days 1 and 9, median ratio of gene expression relative to baseline of 0.69 with interquartile range 0.49-1.04 (p &lt; 0.001); 0.28 (0.15-0.7) (p &lt; 0.001), respectively, with more pronounced decrease on day 9, when patients received both vorinostat and bortezomib.	Vorinostat	383-393	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
23903894-7	2013	RESULTS: In peripheral blood mononuclear cells, Nur77 was significantly and consistently decreased 2 h after vorinostat administration on both days 1 and 9, median ratio of gene expression relative to baseline of 0.69 with interquartile range 0.49-1.04 (p &lt; 0.001); 0.28 (0.15-0.7) (p &lt; 0.001), respectively, with more pronounced decrease on day 9, when patients received both vorinostat and bortezomib.	Bortezomib	398-408	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
23903894-8	2013	p21, a downstream target of Nur77, was significantly decreased on day 9, 2 and 6 h after administration of vorinostat and bortezomib, 0.67 (0.41-1.03) (p &lt; 0.01); 0.44 (0.25-1.3) (p &lt; 0.01), respectively.	Vorinostat	107-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
23903894-8	2013	p21, a downstream target of Nur77, was significantly decreased on day 9, 2 and 6 h after administration of vorinostat and bortezomib, 0.67 (0.41-1.03) (p &lt; 0.01); 0.44 (0.25-1.3) (p &lt; 0.01), respectively.	Bortezomib	122-132	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
23903894-9	2013	The ChIP assay demonstrated a protein-DNA interaction, in this case interaction of Nur77, HSP70 and p21 with acetylated histone H3, at baseline and at day 9 after treatment with vorinostat in tissue biopsies in most patients.	Vorinostat	178-188	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-88
23903894-10	2013	CONCLUSION: Vorinostat inhibits Nur77 expression, which in turn may decrease p21 and AKT expression in PBMCs.	Vorinostat	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-37
23831020-0	2013	Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells.	Docetaxel	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19
23836374-5	2013	In addition, chromatin immunoprecipitation-PCR, avidin-biotin-conjugated DNA precipitation, and luciferase reporter assays confirmed that NUR77 directly regulated the transcription of the inhibin-alpha gene through the specific NGFI-B response element located within its promoter.	avidin-biotin	48-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	138-143
23982884-9	2013	The combination of letrozole and gonadotropin-releasing hormone analog is effective and safe in hormone-receptor positive, metastatic male breast cancer patients.	Letrozole	19-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-112
23860520-11	2013	CONCLUSION: The data from the current study demonstrated that the addition of goserelin to TAM results in downregulation of estradiol level, followed by significant reduction in BD and ET in premenopausal and perimenopausal women with hormone receptor-positive breast cancer, which may eventually lead to better outcome in these patients.	tam	91-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	235-251
23720056-0	2013	TR3 modulates platinum resistance in ovarian cancer.	Platinum	14-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-3
23720056-4	2013	Moreover, TR3 expression was significantly lower in platinum-resistant tumors in patients with metastatic disease, and low TR3 staining was associated with poorer overall and progression-free survival.	Platinum	52-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-13
23720056-5	2013	We have identified a direct role for TR3 in cisplatin-induced apoptosis in ovarian cancer cells.	Cisplatin	44-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-40
23720056-6	2013	Nucleus-to-cytoplasm translocation of TR3 was observed in cisplatin-sensitive (OVCAR8, OVCAR3, and A2780PAR) but not cisplatin-resistant (NCI/ADR-RES and A2780CP20) ovarian cancer cells.	Cisplatin	58-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-41
23720056-6	2013	Nucleus-to-cytoplasm translocation of TR3 was observed in cisplatin-sensitive (OVCAR8, OVCAR3, and A2780PAR) but not cisplatin-resistant (NCI/ADR-RES and A2780CP20) ovarian cancer cells.	Cisplatin	117-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-41
23720056-7	2013	Immunofluorescent analyses showed clear overlap between TR3 and mitochondrial Hsp60 in cisplatin-treated cells, which was associated with cytochrome c release.	Cisplatin	87-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	56-59
23720056-8	2013	Ovarian cancer cells with stable shRNA- or transient siRNA-mediated TR3 downregulation displayed substantial reduction in cisplatin effects on apoptotic markers and cell growth in vitro and in vivo.	Cisplatin	122-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-71
23720056-9	2013	Mechanistic studies showed that the cisplatin-induced cytoplasmic TR3 translocation required for apoptosis induction was regulated by JNK activation and inhibition of Akt.	Cisplatin	36-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-69
23720056-10	2013	Finally, cisplatin resistance was partially overcome by ectopic TR3 overexpression and by treatment with the JNK activator anisomycin and Akt pathway inhibitor, wortmannin.	Cisplatin	9-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-67
24074783-6	2013	Recent data demonstrating that 10 years of tamoxifen improves outcomes compared to 5 may be particularly beneficial for young women with hormone receptor-positive tumors given the risk benefit profile.	Tamoxifen	43-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-153
24415983-0	2013	Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-46
23720056-11	2013	Our results suggest that disruption of TR3 activity, via downregulation or nuclear sequestration, likely contributes to platinum resistance in ovarian cancer.	Platinum	120-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-42
23720056-12	2013	Moreover, we have described a treatment strategy aimed at overcoming platinum resistance by targeting TR3.	Platinum	69-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-105
23997526-2	2013	METHODS: Consecutive 160 postmenopausal women with T1-3N0-1M0 hormone receptor (HR)-positive invasive breast cancer were treated with anastrozole for 16 weeks before surgery.	Anastrozole	134-145	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-78
23997526-2	2013	METHODS: Consecutive 160 postmenopausal women with T1-3N0-1M0 hormone receptor (HR)-positive invasive breast cancer were treated with anastrozole for 16 weeks before surgery.	Anastrozole	134-145	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-82
23663895-0	2013	NR4A1 enhances neural survival following oxygen and glucose deprivation: an in vitro study.	Oxygen	41-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
23829891-8	2013	In the multivariate analysis, patients with long-term clinical benefit had a higher likelihood of having hormone receptor-positive tumors (odds ratio [OR]positive vs. negative = 2.39 [95% confidence interval (CI), 1.08-5.31]; P = .032); and a lower likelihood of having received adjuvant trastuzumab (ORadjuvant trastuzumab vs. no adjuvant trastuzumab = 0.30 [95% CI, 0.10-0.96]; P = .043].	oradjuvant	301-311	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-121
23660295-6	2013	When stimulated with 12-O-tetradecanoylphorbol 13-acetate (TPA) or CD437, this TR3-TRAPgamma interaction not only induced Ca(2+) depletion in the endoplasmic reticulum (ER) but also promoted the expression of the proapoptotic transcriptional regulator CHOP.	Tetradecanoylphorbol Acetate	21-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-82
23660295-6	2013	When stimulated with 12-O-tetradecanoylphorbol 13-acetate (TPA) or CD437, this TR3-TRAPgamma interaction not only induced Ca(2+) depletion in the endoplasmic reticulum (ER) but also promoted the expression of the proapoptotic transcriptional regulator CHOP.	Tetradecanoylphorbol Acetate	59-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-82
23660295-6	2013	When stimulated with 12-O-tetradecanoylphorbol 13-acetate (TPA) or CD437, this TR3-TRAPgamma interaction not only induced Ca(2+) depletion in the endoplasmic reticulum (ER) but also promoted the expression of the proapoptotic transcriptional regulator CHOP.	CD 437	67-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-82
23686401-2	2013	Results from the phase III BOLERO-2 trial demonstrated that everolimus in combination with exemestane provided significant clinical benefit to patients with advanced hormone receptor-positive breast cancer.	Everolimus	60-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-182
23686401-2	2013	Results from the phase III BOLERO-2 trial demonstrated that everolimus in combination with exemestane provided significant clinical benefit to patients with advanced hormone receptor-positive breast cancer.	exemestane	91-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-182
23904760-2	2013	The present retrospective study compared the efficacy and safety of toremifene and tamoxifen in the treatment of operable hormone receptor-positive breast cancer in premenopausal women.	Toremifene	68-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-138
23904760-2	2013	The present retrospective study compared the efficacy and safety of toremifene and tamoxifen in the treatment of operable hormone receptor-positive breast cancer in premenopausal women.	Tamoxifen	83-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-138
23904760-13	2013	CONCLUSIONS: In this retrospective study, the efficacy and safety profiles of toremifene and tamoxifen for the treatment of operable hormone receptor-positive breast cancer in premenopausal women were similar.	Toremifene	78-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-149
23904760-13	2013	CONCLUSIONS: In this retrospective study, the efficacy and safety profiles of toremifene and tamoxifen for the treatment of operable hormone receptor-positive breast cancer in premenopausal women were similar.	Tamoxifen	93-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-149
23686401-0	2013	Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.	Everolimus	99-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-62
23686401-1	2013	Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive HER2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	332-348
23663895-4	2013	Our results showed that oxygen and glucose deprivation (OGD) dramatically induced primary culture neural cell apoptosis and NR4A1 expression at both protein and mRNA level.	Oxygen	24-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	124-129
23551242-10	2013	Interestingly, within the haloperidol-treated group, TD-free animals showed higher Nur77 expression in putamen subterritories compared with dyskinetic animals.	Haloperidol	26-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-88
23874725-4	2013	Our studies confirm that the HSD3B2 promoter is regulated by transcription factors GATA, Nur77 and SF1/LRH1 in concert and that the NBRE/Nur77 site is crucial for hormonal stimulation with cAMP.	Cyclic AMP	189-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-142
23715630-0	2013	A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.	exemestane	48-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-161
23755153-6	2014	Tamoxifen treatment significantly altered the hormone receptor expression levels of the tumor, while additionally upregulating Bcl-2 and Cyclin D1.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-62
23551242-0	2013	Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia.	Haloperidol	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-34
23551242-9	2013	Postmortem analysis of Nur77 expression measured by in situ hybridization revealed a stark contrast between the two drugs, as Nur77 mRNA levels in the caudate-putamen were strongly upregulated in animals exposed to haloperidol but were spared following clozapine treatment.	Haloperidol	215-226	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
23551242-9	2013	Postmortem analysis of Nur77 expression measured by in situ hybridization revealed a stark contrast between the two drugs, as Nur77 mRNA levels in the caudate-putamen were strongly upregulated in animals exposed to haloperidol but were spared following clozapine treatment.	Haloperidol	215-226	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-131
23551242-9	2013	Postmortem analysis of Nur77 expression measured by in situ hybridization revealed a stark contrast between the two drugs, as Nur77 mRNA levels in the caudate-putamen were strongly upregulated in animals exposed to haloperidol but were spared following clozapine treatment.	Clozapine	253-262	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
23715630-1	2013	The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer.	exemestane	25-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-157
23715630-1	2013	The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer.	Anastrozole	40-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-157
23819026-2	2013	In young women with hormone-receptor positive disease, 5 years of adjuvant tamoxifen, with or without ovarian suppression/ablation, is considered the standard endocrine therapy.	Tamoxifen	75-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-36
23187735-4	2013	Importantly we identify a molecular mechanism involving sitagliptin-mediated attenuation of TNFalpha-mediated induction of NFkappaB and orphan nuclear receptor NUR77 mRNA expression, also able to be reproduced, in part, independent of GLP-1.	Sitagliptin Phosphate	56-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-165
23247046-0	2013	HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.	entinostat	19-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-120
23247046-5	2013	We here report that inhibition of histone deacetylase (HDAC) using the specific class I HDAC inhibitor SNDX-275 restored the expression of Nur77/Nor1 and induced expression of activator protein 1 transcription factors c-Jun and JunB, and of death receptor TRAIL, in AML cells and in CD34(+)/38(-) AML LSCs.	entinostat	103-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
23247046-6	2013	Importantly, SNDX-275 induced extensive apoptosis in AML cells, which could be suppressed by silencing nur77 and nor1.	entinostat	13-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-108
23580071-1	2013	Tamoxifen is a widely utilized adjuvant anti-estrogen agent for hormone receptor-positive breast cancer, known to undergo CYP2D6-mediated bioactivation to endoxifen.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-80
23580071-1	2013	Tamoxifen is a widely utilized adjuvant anti-estrogen agent for hormone receptor-positive breast cancer, known to undergo CYP2D6-mediated bioactivation to endoxifen.	4-hydroxy-N-desmethyltamoxifen	155-164	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-80
23425564-11	2013	CONCLUSION: These exploratory analyses suggest that everolimus has beneficial effects on bone turnover and progressive disease in bone in patients receiving exemestane for hormone receptor-positive breast cancer progressing during/after nonsteroidal aromatase inhibitor therapy.	Everolimus	52-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	172-188
23425564-11	2013	CONCLUSION: These exploratory analyses suggest that everolimus has beneficial effects on bone turnover and progressive disease in bone in patients receiving exemestane for hormone receptor-positive breast cancer progressing during/after nonsteroidal aromatase inhibitor therapy.	exemestane	157-167	nuclear receptor subfamily 4 group A member 1	Homo sapiens	172-188
23391443-3	2013	Both salmon calcitonin (sCT) and hyaluronic acid (HA) attenuated activated mRNA expression of NR4A1, NR4A2, NR4A3, and matrix metalloproteinases (MMPs) 1, 3 and 13 in three human cell lines: SW1353 chondrocytes, U937 and THP-1 monocytes.	Hyaluronic Acid	33-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
23391443-3	2013	Both salmon calcitonin (sCT) and hyaluronic acid (HA) attenuated activated mRNA expression of NR4A1, NR4A2, NR4A3, and matrix metalloproteinases (MMPs) 1, 3 and 13 in three human cell lines: SW1353 chondrocytes, U937 and THP-1 monocytes.	Hyaluronic Acid	50-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
23315169-0	2013	The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.	Histamine	36-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-91
23315169-0	2013	The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.	Histamine	36-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
23315169-0	2013	The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.	Serotonin	50-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-91
23315169-0	2013	The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.	Serotonin	50-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
23358971-13	2013	Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor-positive breast cancer.	exemestane	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	95-111
23359049-8	2013	The DSS benefit with BCT compared with mastectomy was greater among women age &gt;= 50 with HR-positive disease (hazard ratio = 0.86, 95% CI = 0.82-0.91) than among women age &lt; 50 with HR-negative disease (hazard ratio = 0.88, 95% CI = 0.79-0.98); however, this trend was seen among all subgroups analyzed.	dss	4-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-94
23359049-8	2013	The DSS benefit with BCT compared with mastectomy was greater among women age &gt;= 50 with HR-positive disease (hazard ratio = 0.86, 95% CI = 0.82-0.91) than among women age &lt; 50 with HR-negative disease (hazard ratio = 0.88, 95% CI = 0.79-0.98); however, this trend was seen among all subgroups analyzed.	Bicarbonates	21-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-94
23538253-2	2013	Evolving understanding of the metabolism and pharmacogenomics of tamoxifen, an early example of targeted therapy for women with hormone receptor-positive breast cancer, has created decision-making challenges for healthcare providers and their patients.	Tamoxifen	65-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-144
23450278-0	2013	Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.	Epirubicin	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-69
23450278-1	2013	BACKGROUND: We report on the activity of the combination of epirubicin and docetaxel given in neoadjuvant setting for 4 and 8 cycles respectively in 2 successive series of patients with large operable or locally advanced, hormone receptor positive, HER-2 negative breast cancer.	Epirubicin	60-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	222-238
23450278-1	2013	BACKGROUND: We report on the activity of the combination of epirubicin and docetaxel given in neoadjuvant setting for 4 and 8 cycles respectively in 2 successive series of patients with large operable or locally advanced, hormone receptor positive, HER-2 negative breast cancer.	Docetaxel	75-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	222-238
23053261-0	2013	Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.	exemestane	17-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-139
23184079-9	2013	Our study supported that hormonal therapy, whether in the form of an aromatase inhibitor or tamoxifen, confers a survival benefit when added to chemotherapy and trastuzumab in patients with HR-positive/HER2-positive primary breast cancer.	Tamoxifen	92-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	190-192
23224235-8	2013	Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-78
26909267-11	2013	This large, retrospective study demonstrates a significant survival benefit with adjuvant bisphosphonates in patients with early breast cancer, particularly in patients with node-positive and hormone receptor-positive disease.	Diphosphonates	90-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-208
23053261-0	2013	Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.	Rosiglitazone	62-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-139
23053261-3	2013	We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer.	exemestane	57-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	178-194
23012478-4	2012	The overall N10 structures are similar to each other and to other known influenza NA structures, with a single highly conserved calcium binding site in each monomer.	Calcium	128-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-15
22994502-0	2012	Everolimus  in the treatment of hormone receptor-positive breast cancer.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-48
22674155-9	2012	Histamine modulated the expression of NR4A1-3 orphan receptors in primary and immortalized human chondrocyte cells in a time- and concentration-dependent manner.	Histamine	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
22553196-7	2012	CONCLUSIONS: The addition of everolimus to exemestane for women with HR-positive metastatic BC is now considered a new therapeutic strategy.	Everolimus	29-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-71
22553196-7	2012	CONCLUSIONS: The addition of everolimus to exemestane for women with HR-positive metastatic BC is now considered a new therapeutic strategy.	exemestane	43-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-71
23058912-3	2012	cAMP/dexamethasone (Dex) significantly increased BTG2 and other gluconeogenic genes such as Nur77, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) in hepatocytes.	Cyclic AMP	0-4	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
23058912-3	2012	cAMP/dexamethasone (Dex) significantly increased BTG2 and other gluconeogenic genes such as Nur77, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) in hepatocytes.	Dexamethasone	5-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
23058912-3	2012	cAMP/dexamethasone (Dex) significantly increased BTG2 and other gluconeogenic genes such as Nur77, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) in hepatocytes.	dex	20-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
22622474-3	2012	We reported that high PCNA(+) TAM counts were associated with hormone receptor (HR)-negative, high-grade tumors and early recurrence.	Tamoxifen	30-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-78
22622474-3	2012	We reported that high PCNA(+) TAM counts were associated with hormone receptor (HR)-negative, high-grade tumors and early recurrence.	Tamoxifen	30-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-82
22674155-13	2012	Stable knockdown of NR4A1-3 expression resulted in reduced endogenous OPG levels and the loss of histamine-dependent regulation of RANKL expression.	Histamine	97-106	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-25
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Serine	41-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Serine	41-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Serine	252-255	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Proline	261-264	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Proline	261-264	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Proline	261-264	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Proline	261-264	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Serine	41-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Serine	41-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Threonine	45-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Threonine	45-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Threonine	45-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Threonine	45-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Proline	49-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Proline	49-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Proline	49-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Proline	49-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Serine	252-255	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Serine	252-255	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
22789442-7	2012	A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances protein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving protein kinase CK2-mediated phosphorylation of the Ser(152)-Pro(153) motif in Nur77.	Serine	252-255	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
23997516-16	2012	The standard treatment for all HR positive patients was administration of tamoxifen.	Tamoxifen	74-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-33
22803611-2	2012	In this paper, we have employed time-resolved resonance Raman (TR3) spectroscopy to understand solvent-induced subtle structural changes in the lowest excited triplet state of thioxanthone.	thioxanthone	176-188	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-66
22912978-0	2012	Developing in vitro reporter gene assays to assess the hormone receptor activities of chemicals frequently detected in drinking water.	Drinking Water	119-133	nuclear receptor subfamily 4 group A member 1	Homo sapiens	55-71
22270929-11	2012	The improvement in DFS with docetaxel-containing regimens was observed across all subgroups (age, under or over 50; number of involved nodes; hormone receptor or HER2 status (including triple negative status), or administration schedule (sequential or concomitant).	Docetaxel	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	142-158
22579996-1	2012	Amoitone B, as a new derivative of cytosporone B, has been proved to be a natural agonist for Nur77.	n-amyl 2-(3,5-dihydroxy-2-(1-nonanoyl)phenyl)acetate	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
22579996-1	2012	Amoitone B, as a new derivative of cytosporone B, has been proved to be a natural agonist for Nur77.	cytosporone B	35-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
22002310-3	2012	There are at least three phospho-Ser-Pro motifs on TR3 that bind to Pin1.	Serine	33-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-54
22081070-6	2012	1,1-Bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) is a recently discovered inhibitor of TR3, which mimics the effects of siTR3.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	0-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-102
22081070-6	2012	1,1-Bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) is a recently discovered inhibitor of TR3, which mimics the effects of siTR3.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	48-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-102
22988612-1	2012	Four different textile preparation effluents were simulated to examine the applicability of the hydrogen peroxide/ultraviolet-C (H2O2/UV-C) advanced oxidation process for the treatment of real textile preparation (desizing, scouring and bleaching) wastewater bearing the non-ionic surfactant nonyl phenol decaethoxylate (NP-10).	Hydrogen Peroxide	96-113	nuclear receptor subfamily 4 group A member 1	Homo sapiens	321-326
22988612-2	2012	In the absence of any textile preparation chemical, NP-10 degradation was complete in 15 min (rate coefficient: 0.22 min(-1)) accompanied by 78% chemical oxygen demand (COD) (rate coefficient: 0.026 min(-1)) and 57% total organic carbon (TOC) (rate coefficient: 0.014 min(-1)) removals achieved after 60 min photochemical treatment.	Oxygen	154-160	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-57
22988612-2	2012	In the absence of any textile preparation chemical, NP-10 degradation was complete in 15 min (rate coefficient: 0.22 min(-1)) accompanied by 78% chemical oxygen demand (COD) (rate coefficient: 0.026 min(-1)) and 57% total organic carbon (TOC) (rate coefficient: 0.014 min(-1)) removals achieved after 60 min photochemical treatment.	Carbon	230-236	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-57
22988612-4	2012	The organic, phosphonate-based sequestering agents competed with NP-10 for UV-C light absorption and HO* radicals.	Organophosphonates	13-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	65-70
22988612-8	2012	For this textile preparation effluent, NP-10 degradation was complete after 50 min (rate coefficient: 0.061 min(-1)) exposure to H2O2/UV-C treatment.	Hydrogen Peroxide	129-133	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
21945605-7	2012	In both cases the hormone receptor recruits an ATP-dependent chromatin remodeler, whose binding to chromatin is stabilized by distinct histone modifications.	Adenosine Triphosphate	47-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-34
22002310-3	2012	There are at least three phospho-Ser-Pro motifs on TR3 that bind to Pin1.	Proline	37-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-54
22425607-10	2012	The meta-analysis demonstrated that DD therapy can improve DFS (3356 patients; HR=0.83; 95% CI 0.73-0.95; p=0.005), independent of hormone receptor expression status.	dd	36-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	131-147
21986938-8	2012	DLC-induced Nur77 protein was mainly found in the cytoplasm, and inhibition of Nur77 nuclear export by the CRM1-dependent nuclear export inhibitor leptomycin B or Jun N-terminal kinase inhibitor prevented the effect of DLC on inducing beta-catenin degradation.	leptomycin B	147-159	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-17
22688624-1	2012	Tamoxifen is a mainstay in the treatment of hormone-receptor sensitive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-60
22470048-0	2012	The orphan nuclear receptor Nur77 regulates hepatic cholesterol metabolism             through the suppression of LDLR and HMGCR expression.	Cholesterol	52-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
22470048-3	2012	In order to investigate whether Nur77 is capable of regulating cholesterol metabolism in HepG2 cells and to demonstrate the underlying mechanism, the downregulation and upregulation of Nur77 expression in HepG2 cells was achieved by the transfection of siRNA specific to Nur77 and the transfection of the recombinant plasmid, pcDNA3.1-Nur77, respectively.	Cholesterol	63-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-37
22470048-7	2012	As for the hepatic cholesterol metabolism genes, low-density lipoprotein receptor (LDLR) and HMGCoA reductase (HMGCR) levels increased following the downregulation of Nur77 expression and decreased following the upregulation of Nur77 expression.	Cholesterol	19-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	167-172
22470048-9	2012	According to these findings, we conclude that Nur77 is capable of reducing hepatic cholesterol based on lipid overloading, and that this may be due to the decrease in LDLR and HMGCR levels.	Cholesterol	83-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-51
21986938-8	2012	DLC-induced Nur77 protein was mainly found in the cytoplasm, and inhibition of Nur77 nuclear export by the CRM1-dependent nuclear export inhibitor leptomycin B or Jun N-terminal kinase inhibitor prevented the effect of DLC on inducing beta-catenin degradation.	leptomycin B	147-159	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-84
29702826-2	2012	For treatment of postmenopausal, hormone receptor positive early stage breast cancer, tamoxifen or aromatase inhibitors such as anastrozole are prescribed either as first-line therapy or sequentially.	Tamoxifen	86-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-49
22370313-3	2012	METHODS: We developed a Markov state transition model to simulate clinical practice and outcomes in a hypothetical cohort of women age 60 years with HR-positive EBC starting a 5-year course of AI therapy after primary surgery for breast cancer.	NSC638702	161-164	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-151
29702826-2	2012	For treatment of postmenopausal, hormone receptor positive early stage breast cancer, tamoxifen or aromatase inhibitors such as anastrozole are prescribed either as first-line therapy or sequentially.	Anastrozole	128-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-49
22306153-8	2012	CONCLUSIONS: We provide novel evidence demonstrating that the anti-inflammatory effects of minocycline in human monocytes include, in addition to decreased NF-kappaB activation, abrogation of the LPS-stimulated LOX-1, LITAF, Nur77 pathways, p38 MAPK inhibition and PI3K/Akt activation.	Minocycline	91-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	225-230
22236200-4	2012	Approximately, 90% of patients received adjuvant chemotherapy and hormonal therapy with tamoxifen for hormone-receptor (HR)-positive breast cancer.	Tamoxifen	88-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-118
22306153-6	2012	Minocycline inhibited LPS-induced activation of the lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), NF-kappaB, LPS-induced TNF-alpha factor (LITAF) and the Nur77 nuclear receptor.	Minocycline	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	173-178
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	162-189	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-69
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	71-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-69
22664513-4	2012	From these blocks hormone receptor expression was assessed by immunohistochemistry using the technique of streptoavidin-biotin-immunoperoxidase and anti-ER and anti-PR primary antibodies.	Biotin	120-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-34
22306153-0	2012	Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition.	Minocycline	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-110
22236200-4	2012	Approximately, 90% of patients received adjuvant chemotherapy and hormonal therapy with tamoxifen for hormone-receptor (HR)-positive breast cancer.	Tamoxifen	88-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-122
21862331-6	2012	The eLEcTRA trial showed that the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 positive and HR positive MBC.	Letrozole	49-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-154
21761396-8	2012	CONCLUSIONS: BRCA1-associated, HRec-negative metastatic breast cancer patients were less sensitive to taxane chemotherapy than sporadic HRec-negative patients.	taxane	102-108	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-35
21761396-9	2012	HRec-positive BRCA1- and BRCA2-associated patients had a sensitivity to taxane chemotherapy similar to that of sporadic patients.	taxane	72-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-4
20809206-0	2012	Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma.	butylidenephthalide	34-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19
22172646-3	2012	METHODS: The IDEAL trial is a prospective, open-label phase-III trial comparing 2.5 with 5 years of extended adjuvant letrozole (LET) in hormone receptor positive (HR+) postmenopausal early breast-cancer patients after 5 years of adjuvant endocrine therapy (ET).	Letrozole	118-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-153
22531359-1	2012	Tamoxifen is an effective antiestrogen used in the treatment of hormone receptor-positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-80
22610153-4	2012	Radiotherapy was mandatory after conservative surgery and tamoxifen was given for 5 years to hormone receptor (HR)-positive patients.	Tamoxifen	58-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-109
22610153-4	2012	Radiotherapy was mandatory after conservative surgery and tamoxifen was given for 5 years to hormone receptor (HR)-positive patients.	Tamoxifen	58-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-113
22396769-9	2012	Meanwhile, the subgroup analysis revealed that capecitabine improved the DFS in triple negative (HR = 0.71, 95% CI: 0.53-0.96, P = 0.028), hormone receptor negative (HR = 0.73, CI: 0.56-0.94, P = 0.017) and HER2 negative (HR = 0.81, CI: 0.67-0.98, P = 0.034) patients.	Capecitabine	47-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-155
24367183-0	2011	Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.	Lapatinib	39-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
22077320-5	2011	NR4A1 and NR4A3 expression was also induced by Cu ions released into the medium.	Copper	47-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
22068628-1	2011	Third-generation aromatase inhibitors (AIs) have proven to be superior to tamoxifen in terms of time to disease progression in patients with hormone receptor (HR) positive (HR+) status and, nowadays, are used in the adjuvant and neoadjuvant settings, and first-line therapy for advanced breast cancer.	Tamoxifen	74-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-157
22068628-12	2011	In fact, the coadministration of both agents seems to increase the efficacy of letrozole in newly-diagnosed HR+ patients.	Letrozole	79-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-110
22068628-13	2011	Once resistance to sequential trastuzumab and AI as monotherapy has been found, trastuzumab and letrozole combined in HR+ and HER2+ patients with advanced breast cancer can overcome resistance to both drugs administered as single agents, according to recently reported results.	Letrozole	96-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-120
21936511-1	2011	Using the minima hopping global geometry optimization method on density functional potential energy surface, we have studied the structural and electronic properties of magnesium clusters for a size range of Mg(N) where N = 10-56.	Magnesium	169-178	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-226
21903773-0	2011	A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.	Dasatinib	19-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-92
21903773-2	2011	A phase 2 trial of dasatinib, a potent oral tyrosine kinase inhibitor of SFKs, was carried out in patients with human epidermal growth factor receptor 2-positive (HER2+) and/or hormone receptor-positive (HR+) advanced breast cancer.	Dasatinib	19-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	177-193
24367183-0	2011	Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.	Letrozole	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
21907028-4	2011	The nitrate system featured a limit of detection of 0.04 mg N L(-1), 0.4%RSD (1 mg N L(-1) as nitrate, n=10), a coefficient of determination (R(2)) of 0.9995 over the calibration range 0.0-2.0 mg N L(-1), and a data acquisition time of 1.5s per spectrum.	Nitrates	4-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-107
21907028-5	2011	The total nitrogen system featured a limit of detection of 0.05 mg N L(-1), 1%RSD (1 mg N L(-1) as ammonium chloride, n=10), a coefficient of determination of 0.9989 over the calibration range 0.0-2.0 mg N L(-1), and a throughput of 5 sample h(-1) measured in triplicate.	Nitrogen	10-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-122
21945431-2	2011	We found that the cytosolic levels of NGFI-B and RXRalpha were increased in cultures of cerebellar granule neurons 2h after treatment with glutamate (excitatory neurotransmitter in the brain, involved in stroke).	Deuterium	115-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-44
21945431-2	2011	We found that the cytosolic levels of NGFI-B and RXRalpha were increased in cultures of cerebellar granule neurons 2h after treatment with glutamate (excitatory neurotransmitter in the brain, involved in stroke).	Glutamic Acid	139-148	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-44
21945431-0	2011	Delayed translocation of NGFI-B/RXR in glutamate stimulated neurons allows late protection by 9-cis retinoic acid.	Glutamic Acid	39-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-31
21945431-6	2011	The RXR ligand 9-cis retinoic acid was used to arrest NGFI-B and RXR in the nucleus.	Alitretinoin	15-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-60
21945431-0	2011	Delayed translocation of NGFI-B/RXR in glutamate stimulated neurons allows late protection by 9-cis retinoic acid.	Alitretinoin	94-113	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-31
21945431-7	2011	Addition of 9-cis retinoic acid 1h after treatment with glutamate reduced the cytosolic translocation of NGFI-B and RXRalpha, the cytosolic translocation of NGFI-Bgfp observed in live neurons, as well as the neuronal death.	9-cis retinoic acid 1h	12-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-111
21945431-7	2011	Addition of 9-cis retinoic acid 1h after treatment with glutamate reduced the cytosolic translocation of NGFI-B and RXRalpha, the cytosolic translocation of NGFI-Bgfp observed in live neurons, as well as the neuronal death.	Glutamic Acid	56-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-111
21813404-0	2011	Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study.	Steroids	25-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-62
21813404-2	2011	While evidence toward the existence of distinct subtypes of breast cancer accumulates, few studies have investigated the associations of sex steroid hormone levels with risk of hormone receptor [estrogen receptor (ER) and/or progesterone receptor (PR)] defined breast cancer.	Steroids	141-156	nuclear receptor subfamily 4 group A member 1	Homo sapiens	177-193
21170551-2	2011	METHODS: Patients received exemestane or tamoxifen as adjuvant therapy for hormone receptor-positive breast cancer.	exemestane	27-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
21228009-8	2011	Knockdown of Nur77 rescued hydrogen peroxide-induced cardiomyocyte apoptosis.	Hydrogen Peroxide	27-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
21665134-12	2011	CONCLUSION: Bevacizumab combined with either anastrozole or fulvestrant was feasible and active in the first-line treatment of patients who have hormone receptor-positive metastatic breast cancer.	Fulvestrant	60-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-161
21802721-1	2011	BACKGROUND: As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor measurements (and other patient characteristics) to long-term outcome can be assessed increasingly reliably.	Tamoxifen	36-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-110
20842526-5	2011	The presence of intratumoral promacs was significantly correlated with high grade, hormone receptor negative tumors, and a basal-like subtype.	promacs	29-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-99
21681327-2	2011	Herein, we report the first study for developing mesoporous silica functionalized with phosphonate (NP10) as a sorbent for U(VI) sorption from aqueous solution.	Silicon Dioxide	60-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-104
21681327-2	2011	Herein, we report the first study for developing mesoporous silica functionalized with phosphonate (NP10) as a sorbent for U(VI) sorption from aqueous solution.	Organophosphonates	87-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-104
21362629-0	2011	Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors.	3,3'-diindolylmethane	39-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-25
21362629-0	2011	Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors.	3,3'-diindolylmethane	39-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
21362629-1	2011	NR4A1 (Nur77, TR3) is overexpressed in pancreatic tumors and activation of TR3 by 1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) inhibits cell and tumor growth and induces apoptosis.	1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane	82-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
21362629-1	2011	NR4A1 (Nur77, TR3) is overexpressed in pancreatic tumors and activation of TR3 by 1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) inhibits cell and tumor growth and induces apoptosis.	1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane	82-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-78
21362629-1	2011	NR4A1 (Nur77, TR3) is overexpressed in pancreatic tumors and activation of TR3 by 1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) inhibits cell and tumor growth and induces apoptosis.	dim-c-pphoch	130-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
21362629-1	2011	NR4A1 (Nur77, TR3) is overexpressed in pancreatic tumors and activation of TR3 by 1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) inhibits cell and tumor growth and induces apoptosis.	dim-c-pphoch	130-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	7-12
21362629-1	2011	NR4A1 (Nur77, TR3) is overexpressed in pancreatic tumors and activation of TR3 by 1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) inhibits cell and tumor growth and induces apoptosis.	dim-c-pphoch	130-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-17
21362629-1	2011	NR4A1 (Nur77, TR3) is overexpressed in pancreatic tumors and activation of TR3 by 1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) inhibits cell and tumor growth and induces apoptosis.	dim-c-pphoch	130-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-78
21362629-5	2011	Results of this and previous studies demonstrate that TR3 is unique among nuclear receptors since nuclear TR3 is activated or deactivated by diindolylmethane derivatives to induce different apoptotic and growth inhibitory pathways that inhibit pancreatic cancer cell and tumor growth.	3,3'-diindolylmethane	141-157	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-57
21362629-5	2011	Results of this and previous studies demonstrate that TR3 is unique among nuclear receptors since nuclear TR3 is activated or deactivated by diindolylmethane derivatives to induce different apoptotic and growth inhibitory pathways that inhibit pancreatic cancer cell and tumor growth.	3,3'-diindolylmethane	141-157	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-109
21170551-2	2011	METHODS: Patients received exemestane or tamoxifen as adjuvant therapy for hormone receptor-positive breast cancer.	Tamoxifen	41-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
21253674-8	2011	Interestingly, MCT-3, MG and AZA alone and in combination increased expression of the novel tumour suppressor gene Nur77, important in leukemogenesis, with MG a more potent inducer as a single agent.	Azacitidine	29-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-120
20354821-6	2011	HR-negative patients and those whose PS was &gt;= 2, regardless of age, were more likely to choose BSC without chemotherapy.	bsc	99-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-2
21109603-4	2011	METHODS AND RESULTS: Whole-genome DNA array hybridization revealed that adenosine induced a set of early genes including the nuclear receptor subfamily 4, group A, member 1 (NR4A1/Nur77/TR3).	Adenosine	72-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-172
21380453-1	2011	Acridones carrying an appropriate substituent at N-10 showed significant fluorescence changes on interacting with ATP in HEPES buffer at pH 7.2.	Acridones	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-53
21380453-1	2011	Acridones carrying an appropriate substituent at N-10 showed significant fluorescence changes on interacting with ATP in HEPES buffer at pH 7.2.	Adenosine Triphosphate	114-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-53
21380453-1	2011	Acridones carrying an appropriate substituent at N-10 showed significant fluorescence changes on interacting with ATP in HEPES buffer at pH 7.2.	HEPES	121-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-53
21241664-3	2011	Previously, we have shown that fenretinide-induced apoptosis is Nur77 dependent, and the sensitivity of the cancer cells to fenretinide-induced apoptosis is positively associated with cytoplasmic enrichment of Nur77.	Fenretinide	31-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
21241664-3	2011	Previously, we have shown that fenretinide-induced apoptosis is Nur77 dependent, and the sensitivity of the cancer cells to fenretinide-induced apoptosis is positively associated with cytoplasmic enrichment of Nur77.	Fenretinide	31-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	210-215
21241664-3	2011	Previously, we have shown that fenretinide-induced apoptosis is Nur77 dependent, and the sensitivity of the cancer cells to fenretinide-induced apoptosis is positively associated with cytoplasmic enrichment of Nur77.	Fenretinide	124-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	210-215
21241664-4	2011	The goal of current study was to identify means to modulate nuclear export of Nur77 in order to improve the efficacy of fenretinide.	Fenretinide	120-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-83
21241664-9	2011	Fenretinide/PD98059-induced cell death of HepG2 cell was positively associated with induction and cytoplasmic location as well as mitochondria enrichment of Nur77.	Fenretinide	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-162
21241664-9	2011	Fenretinide/PD98059-induced cell death of HepG2 cell was positively associated with induction and cytoplasmic location as well as mitochondria enrichment of Nur77.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	12-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-162
21241664-11	2011	Taken together, the current study demonstrates that ERK1/2-modulated Nur77 intracellular location dictates the efficacy of fenretinide-induced apoptosis.	Fenretinide	123-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
21185724-1	2011	Tamoxifen has a key role in the management of women with hormone receptor (HR) positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-73
21185724-1	2011	Tamoxifen has a key role in the management of women with hormone receptor (HR) positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-77
21109603-4	2011	METHODS AND RESULTS: Whole-genome DNA array hybridization revealed that adenosine induced a set of early genes including the nuclear receptor subfamily 4, group A, member 1 (NR4A1/Nur77/TR3).	Adenosine	72-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	174-179
21109603-4	2011	METHODS AND RESULTS: Whole-genome DNA array hybridization revealed that adenosine induced a set of early genes including the nuclear receptor subfamily 4, group A, member 1 (NR4A1/Nur77/TR3).	Adenosine	72-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	180-185
21109603-4	2011	METHODS AND RESULTS: Whole-genome DNA array hybridization revealed that adenosine induced a set of early genes including the nuclear receptor subfamily 4, group A, member 1 (NR4A1/Nur77/TR3).	Adenosine	72-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	186-189
21109603-6	2011	Real-time reverse-transcriptase PCR confirmed that adenosine and its analogue N-ethyl-carboxamidoadenosine elicited a strong induction of NR4A1.	Adenosine	51-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	138-143
21109603-6	2011	Real-time reverse-transcriptase PCR confirmed that adenosine and its analogue N-ethyl-carboxamidoadenosine elicited a strong induction of NR4A1.	Adenosine-5'-(N-ethylcarboxamide)	78-106	nuclear receptor subfamily 4 group A member 1	Homo sapiens	138-143
21109603-10	2011	Treatment with small interfering RNA directed against NR4A1 attenuated the inhibitory effect of 8CPT on proliferation.	8cpt	96-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-59
21246566-13	2011	The JNK inhibitor, SP600125, inhibited Nur77 mRNA expression and reduced PCH4-induced apoptosis.	pyrazolanthrone	19-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
21246566-14	2011	CONCLUSIONS: In conclusion, PCH4, a derivative of BP, induced Nur77-mediated apoptosis via the JNK pathway and this mechanism, which is different from that of BP, may explain the increase in the anti-tumor effects on GBM.	butylidenephthalide	50-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
21319187-0	2011	Enrichment of Nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors.	Fenretinide	130-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19
20732932-10	2011	With AP-D, pCR rate was 17.8% for hormone receptor (HR)-negative patients and 15.9% for HR-positive patients.	Deuterium	8-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-50
20732932-10	2011	With AP-D, pCR rate was 17.8% for hormone receptor (HR)-negative patients and 15.9% for HR-positive patients.	Deuterium	8-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-54
20732932-10	2011	With AP-D, pCR rate was 17.8% for hormone receptor (HR)-negative patients and 15.9% for HR-positive patients.	Deuterium	8-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-90
21319187-7	2011	Upon fenretinide and HDACi treatment, the expression of RARbeta and Nur77 were induced and colocalized in the cytosol.	Fenretinide	5-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-73
21319187-10	2011	Nur77 was essential for fenretinide-induced and HDACi-induced apoptosis of Huh7 cells.	Fenretinide	24-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
21319187-11	2011	Induction of the expression, the interaction, and the nuclear export of RARbeta and Nur77 mediate fenretinide-induced and HDACi-induced apoptosis.	Fenretinide	98-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-89
21222496-0	2011	Lapatinib in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer: profile report.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
21383902-6	2011	Results revealed that the new class of 5-deazapteridine and steroid hybrid compounds VIa,b, and d, and the vertical-type bispyridodipyrimidine with n-hexyl chain junction between its N-10 and N-10 atoms Xa, exhibited non-selective PTK binding capacities, with the lowest (Gb).	Steroids	60-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-196
21383902-6	2011	Results revealed that the new class of 5-deazapteridine and steroid hybrid compounds VIa,b, and d, and the vertical-type bispyridodipyrimidine with n-hexyl chain junction between its N-10 and N-10 atoms Xa, exhibited non-selective PTK binding capacities, with the lowest (Gb).	bispyridodipyrimidine	121-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-187
21383902-6	2011	Results revealed that the new class of 5-deazapteridine and steroid hybrid compounds VIa,b, and d, and the vertical-type bispyridodipyrimidine with n-hexyl chain junction between its N-10 and N-10 atoms Xa, exhibited non-selective PTK binding capacities, with the lowest (Gb).	bispyridodipyrimidine	121-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-196
21383902-6	2011	Results revealed that the new class of 5-deazapteridine and steroid hybrid compounds VIa,b, and d, and the vertical-type bispyridodipyrimidine with n-hexyl chain junction between its N-10 and N-10 atoms Xa, exhibited non-selective PTK binding capacities, with the lowest (Gb).	Nitrogen	26-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-187
21383902-6	2011	Results revealed that the new class of 5-deazapteridine and steroid hybrid compounds VIa,b, and d, and the vertical-type bispyridodipyrimidine with n-hexyl chain junction between its N-10 and N-10 atoms Xa, exhibited non-selective PTK binding capacities, with the lowest (Gb).	Nitrogen	26-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-196
21383902-6	2011	Results revealed that the new class of 5-deazapteridine and steroid hybrid compounds VIa,b, and d, and the vertical-type bispyridodipyrimidine with n-hexyl chain junction between its N-10 and N-10 atoms Xa, exhibited non-selective PTK binding capacities, with the lowest (Gb).	dipicrylamine	150-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-187
21383902-6	2011	Results revealed that the new class of 5-deazapteridine and steroid hybrid compounds VIa,b, and d, and the vertical-type bispyridodipyrimidine with n-hexyl chain junction between its N-10 and N-10 atoms Xa, exhibited non-selective PTK binding capacities, with the lowest (Gb).	dipicrylamine	150-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	192-196
21146499-4	2011	Nur77 mRNA expression in hESCs was significantly increased after decidualization stimulated by 8-Br-cAMP and medroxyprogesterone acetate (MPA).	8-Bromo Cyclic Adenosine Monophosphate	95-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
20669045-0	2011	Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.	Aspirin	10-17	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-96
20669045-1	2011	Aspirin and other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit aromatase activity and thus could selectively lower incidence of hormone receptor positive tumors.	Aspirin	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-170
20669045-1	2011	Aspirin and other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit aromatase activity and thus could selectively lower incidence of hormone receptor positive tumors.	Aspirin	22-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-170
21146499-4	2011	Nur77 mRNA expression in hESCs was significantly increased after decidualization stimulated by 8-Br-cAMP and medroxyprogesterone acetate (MPA).	Medroxyprogesterone Acetate	109-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
21146499-4	2011	Nur77 mRNA expression in hESCs was significantly increased after decidualization stimulated by 8-Br-cAMP and medroxyprogesterone acetate (MPA).	Medroxyprogesterone Acetate	138-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
21146499-6	2011	Furthermore, knockdown of Nur77 in hESCs significantly decreased decidual PRL promoter activation and substantially attenuated PRL mRNA expression and PRL secretion (P &lt; 0.01) induced by 8-Br-cAMP and MPA.	8-Bromo Cyclic Adenosine Monophosphate	190-199	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-31
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	167-183
20978184-0	2011	PPARgamma-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells.	2,4-thiazolidinedione	22-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
20978184-3	2011	We have previously reported PPARgamma-independent modulation of NUR77 (also known as Nr4a1), an orphan nuclear receptor deemed important in the atherogenic process, in association with TZD-mediated inhibition of tumour necrosis factor alpha (TNFalpha) induction of plasminogen activator inhibitor type 1 expression.	2,4-thiazolidinedione	185-188	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
20978184-3	2011	We have previously reported PPARgamma-independent modulation of NUR77 (also known as Nr4a1), an orphan nuclear receptor deemed important in the atherogenic process, in association with TZD-mediated inhibition of tumour necrosis factor alpha (TNFalpha) induction of plasminogen activator inhibitor type 1 expression.	2,4-thiazolidinedione	185-188	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-90
20978184-4	2011	Here, we report NUR77 mRNA expression is increased in human vascular endothelial cells (HUVEC) stimulated by TNFalpha and that this effect is inhibited by a TZD in a PPARgamma-independent manner.	2,4-thiazolidinedione	157-160	nuclear receptor subfamily 4 group A member 1	Homo sapiens	16-21
20978184-6	2011	TZD treatment also attenuated the binding of nuclear proteins to the nuclear factor kappa B (NF-kappaB)-binding site of the NUR77 promoter in HUVEC in a PPARgamma-independent manner.	2,4-thiazolidinedione	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	124-129
21747904-7	2011	Thus, the presence of ESO Ab identifies a tumor subtype of HR- (HER2- or HER2+) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.	eso ab	22-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-61
21747904-7	2011	Thus, the presence of ESO Ab identifies a tumor subtype of HR- (HER2- or HER2+) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.	Epoxidized soya bean oil	22-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-61
21747904-7	2011	Thus, the presence of ESO Ab identifies a tumor subtype of HR- (HER2- or HER2+) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.	Epoxidized soya bean oil	105-108	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-61
21126059-3	2010	Mechanistic investigations have shown that, upon AKH stimulation, adipokinetic hormone receptor (AKHR) couples to a Gs protein and enhances adenylate cyclase activity, leading to intracellular cAMP accumulation.	Cyclic AMP	193-197	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-95
20847229-3	2011	We showed that levels of Nur77 were elevated in a majority of human colon tumors (9/12) compared to their nontumorous tissues and that Nur77 expression could be strongly induced by different colonic carcinogens including deoxycholic acid (DCA).	Deoxycholic Acid	221-237	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-30
20847229-3	2011	We showed that levels of Nur77 were elevated in a majority of human colon tumors (9/12) compared to their nontumorous tissues and that Nur77 expression could be strongly induced by different colonic carcinogens including deoxycholic acid (DCA).	Deoxycholic Acid	221-237	nuclear receptor subfamily 4 group A member 1	Homo sapiens	135-140
20847229-3	2011	We showed that levels of Nur77 were elevated in a majority of human colon tumors (9/12) compared to their nontumorous tissues and that Nur77 expression could be strongly induced by different colonic carcinogens including deoxycholic acid (DCA).	Deoxycholic Acid	239-242	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-30
20847229-3	2011	We showed that levels of Nur77 were elevated in a majority of human colon tumors (9/12) compared to their nontumorous tissues and that Nur77 expression could be strongly induced by different colonic carcinogens including deoxycholic acid (DCA).	Deoxycholic Acid	239-242	nuclear receptor subfamily 4 group A member 1	Homo sapiens	135-140
20847229-4	2011	DCA-induced Nur77 expression resulted in up-regulation of antiapoptotic BRE and angiogenic VEGF, and it enhanced the growth, colony formation, and migration of colon cancer cells.	Deoxycholic Acid	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-17
20049562-6	2010	Anthracycline era as an independent predictor of OS and DSS was evaluated using Cox proportional hazards models with patient age, hormone receptor status, tumor size, use of radiation therapy, and number of metastatic ALNs as covariates.	Anthracyclines	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	130-146
21058635-1	2010	In this paper, time-resolved resonance Raman (TR3) spectra of intermediates generated by proton-induced electron-transfer reaction between triplet 2-methoxynaphthalene ((3)ROMe) and decafluorobenzophenone (DFBP) are presented.	2-methoxynaphthalene	147-167	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-49
21058635-1	2010	In this paper, time-resolved resonance Raman (TR3) spectra of intermediates generated by proton-induced electron-transfer reaction between triplet 2-methoxynaphthalene ((3)ROMe) and decafluorobenzophenone (DFBP) are presented.	Decafluorobenzophenone	182-204	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-49
21058635-1	2010	In this paper, time-resolved resonance Raman (TR3) spectra of intermediates generated by proton-induced electron-transfer reaction between triplet 2-methoxynaphthalene ((3)ROMe) and decafluorobenzophenone (DFBP) are presented.	dfbp	206-210	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-49
21058635-2	2010	The TR3 vibrational spectra and structure of 2-methoxynaphthalene cation radical (ROMe( +)) have been analyzed by density functional theory (DFT) calculation.	2-methoxynaphthalene cation radical	45-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
20977404-4	2010	The results of clinical studies of adjuvant treatment on early-stage hormone-receptor-positive breast-cancer patients under hormonal treatment - especially with the bisphosphonate zoledronic acid - caused excitement because they demonstrated an additive effect on decreasing disease relapses at bone or other sites.	Diphosphonates	165-179	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
20829507-0	2010	alpha-Lipoic acid prevents neointimal hyperplasia via induction of p38 mitogen-activated protein kinase/Nur77-mediated apoptosis of vascular smooth muscle cells and accelerates postinjury reendothelialization.	Thioctic Acid	0-17	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-109
20829507-3	2010	ALA treatment strongly induced apoptosis of vascular smooth muscle cells and enhanced the expression and cytoplasmic localization of Nur77, which triggers intrinsic apoptotic events.	Thioctic Acid	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-138
20829507-4	2010	Small interfering RNA-mediated downregulation of Nur77 diminished this proapoptotic effect of ALA.	Thioctic Acid	94-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-54
20829507-5	2010	Moreover, ALA increased p38 mitogen-activated protein kinase phosphorylation, and inhibition of p38 mitogen-activated protein kinase completely blocked ALA-induced vascular smooth muscle cell apoptosis and Nur77 induction and cytoplasmic localization.	Thioctic Acid	152-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	206-211
20829507-7	2010	This preventive effect of ALA was significantly reduced by infection of an adenovirus encoding Nur77 small hairpin (sh)RNA.	Thioctic Acid	26-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	95-100
20977404-4	2010	The results of clinical studies of adjuvant treatment on early-stage hormone-receptor-positive breast-cancer patients under hormonal treatment - especially with the bisphosphonate zoledronic acid - caused excitement because they demonstrated an additive effect on decreasing disease relapses at bone or other sites.	Zoledronic Acid	180-195	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
20977404-9	2010	TAKE HOME MESSAGE: Current evidence supports zoledronic acid as an effective treatment in adjuvant breast-cancer therapy for hormone-receptor-positive breast-cancer patients when added to hormonotherapy.	Zoledronic Acid	45-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
20805064-5	2010	A large meta-analysis showed that the addition of a taxane to an anthracycline-based regimen improves outcomes in high-risk patients regardless of age, menopausal status, number of nodes involved, hormone receptor status, and type of taxane.	taxane	52-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	197-213
20731528-1	2010	BACKGROUND: The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen.	Anastrozole	58-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-180
20731528-1	2010	BACKGROUND: The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen.	Tamoxifen	68-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-180
20700120-3	2010	METHODS: We selected patients treated with tamoxifen (40 mg per day) for hormone receptor-positive MBC from whom a blood sample for pharmacogenetic analysis (CYP2D6*3, *4, *5, *6, *10 and *41) was available.	Tamoxifen	43-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-89
20660371-3	2010	Small interfering RNA-mediated knockdown of TR3 or cell treatment with the TR3 antagonist 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) decreased proliferation, induced apoptosis, and decreased expression of antiapoptotic genes including Bcl-2 and survivin in pancreatic cancer cells.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	90-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-78
20660371-3	2010	Small interfering RNA-mediated knockdown of TR3 or cell treatment with the TR3 antagonist 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) decreased proliferation, induced apoptosis, and decreased expression of antiapoptotic genes including Bcl-2 and survivin in pancreatic cancer cells.	1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane	138-149	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-78
20733117-8	2010	In multivariable adjusted analyses, alcohol consumption was positively related to risk of invasive breast cancer overall, invasive lobular carcinoma, and hormone receptor-positive tumors (all P(trend) &lt;= .022).	Alcohols	36-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-170
20438716-6	2010	Treatment with a histone deacetylase (HDAC) inhibitor, trichostatin A, also increased Nur77 acetylation.	trichostatin A	55-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-91
20438716-10	2010	Finally, the expression of Nur77 increased along with that of p300, but decreased with induction of HDAC1 after treatment with epithelial growth factor, nerve growth factor, or 6-mercaptopurine, suggesting that the self-control of the acetylation status contributes to the transient induction of Nur77 protein.	Mercaptopurine	177-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
20805064-5	2010	A large meta-analysis showed that the addition of a taxane to an anthracycline-based regimen improves outcomes in high-risk patients regardless of age, menopausal status, number of nodes involved, hormone receptor status, and type of taxane.	Anthracyclines	65-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	197-213
20682991-0	2010	Combination therapy of 5-fluorouracil with rapamycin for hormone receptor-negative human breast cancer.	Fluorouracil	23-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-73
20716898-3	2010	Furthermore, administration of aromatase inhibitor (anastrozole) and trastuzumab was started due to the postoperative pathological diagnosis of hormone receptor-positive and HER2 (score 3+).	Anastrozole	52-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-160
20614948-0	2010	Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-56
20411565-5	2010	We found that HK434, a PKC agonist, in combination with calcium ionophore, can induce Nur77 and Nor-1 phosphorylation, translocation, Bcl-2 BH3 exposure and thymocyte apoptosis.	hk434	14-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-91
20411565-5	2010	We found that HK434, a PKC agonist, in combination with calcium ionophore, can induce Nur77 and Nor-1 phosphorylation, translocation, Bcl-2 BH3 exposure and thymocyte apoptosis.	Calcium	56-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-91
20426605-2	2010	Tamoxifen has been the standard adjuvant endocrine therapy for both pre- and post-menopausal women with hormone receptor-positive early breast cancer and remains the standard of care for premenopausal women.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
20410157-0	2010	Assessing hormone receptor activities of pyrethroid insecticides and their metabolites in reporter gene assays.	Pyrethrins	41-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-26
20505214-6	2010	A combination of metabolites that increased in plasma in response to exercise (glycerol, niacinamide, glucose-6-phosphate, pantothenate, and succinate) up-regulated the expression of nur77, a transcriptional regulator of glucose utilization and lipid metabolism genes in skeletal muscle in vitro.	Glycerol	79-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-188
20505214-6	2010	A combination of metabolites that increased in plasma in response to exercise (glycerol, niacinamide, glucose-6-phosphate, pantothenate, and succinate) up-regulated the expression of nur77, a transcriptional regulator of glucose utilization and lipid metabolism genes in skeletal muscle in vitro.	Niacinamide	89-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-188
20505214-6	2010	A combination of metabolites that increased in plasma in response to exercise (glycerol, niacinamide, glucose-6-phosphate, pantothenate, and succinate) up-regulated the expression of nur77, a transcriptional regulator of glucose utilization and lipid metabolism genes in skeletal muscle in vitro.	Glucose-6-Phosphate	102-121	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-188
20505214-6	2010	A combination of metabolites that increased in plasma in response to exercise (glycerol, niacinamide, glucose-6-phosphate, pantothenate, and succinate) up-regulated the expression of nur77, a transcriptional regulator of glucose utilization and lipid metabolism genes in skeletal muscle in vitro.	Pantothenic Acid	123-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-188
20505214-6	2010	A combination of metabolites that increased in plasma in response to exercise (glycerol, niacinamide, glucose-6-phosphate, pantothenate, and succinate) up-regulated the expression of nur77, a transcriptional regulator of glucose utilization and lipid metabolism genes in skeletal muscle in vitro.	Succinic Acid	141-150	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-188
20505214-6	2010	A combination of metabolites that increased in plasma in response to exercise (glycerol, niacinamide, glucose-6-phosphate, pantothenate, and succinate) up-regulated the expression of nur77, a transcriptional regulator of glucose utilization and lipid metabolism genes in skeletal muscle in vitro.	Glucose	102-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	183-188
20209619-13	2010	Treatment of HR-positive patients with either tamoxifen or toremifene is appropriate.	Tamoxifen	46-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-15
20209619-13	2010	Treatment of HR-positive patients with either tamoxifen or toremifene is appropriate.	Toremifene	59-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-15
20388790-2	2010	We previously reported that the octaketide cytosporone B (Csn-B) is a natural agonist for Nur77.	octaketide cytosporone b	32-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-95
20388790-2	2010	We previously reported that the octaketide cytosporone B (Csn-B) is a natural agonist for Nur77.	cytosporone B	58-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-95
20388790-3	2010	In this study, we synthesized a series of Csn-B analogues and performed a structure-activity analysis that suggested criteria for the development of a unique pharmacophore to activate Nur77.	cytosporone B	42-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	184-189
20388790-4	2010	The components of the pharmacophore necessary for binding Nur77 included the benzene ring, the phenolic hydroxyl group, and the acyl chain of the Csn-B scaffold, whereas the key feature for activating the biological function of Nur77 was the ester group.	Benzene	77-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-63
20388790-4	2010	The components of the pharmacophore necessary for binding Nur77 included the benzene ring, the phenolic hydroxyl group, and the acyl chain of the Csn-B scaffold, whereas the key feature for activating the biological function of Nur77 was the ester group.	Esters	242-247	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-63
20388790-5	2010	Csn-B analogues that bound Nur77 tightly not only stimulated its transactivation activity but also initiated mitochondrial apoptosis by means of novel cross-talk between Nur77 and BRE, an antiapoptotic protein regulated at the transcriptional level.	cytosporone B	0-5	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
20388790-5	2010	Csn-B analogues that bound Nur77 tightly not only stimulated its transactivation activity but also initiated mitochondrial apoptosis by means of novel cross-talk between Nur77 and BRE, an antiapoptotic protein regulated at the transcriptional level.	cytosporone B	0-5	nuclear receptor subfamily 4 group A member 1	Homo sapiens	170-175
19912993-0	2010	Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells.	Fenretinide	58-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-49
19912993-4	2010	The induction of Nur77 and the cytoplasmic distribution of Nur77 induced by fenretinide were positively correlated with the apoptotic effect of fenretinide in HCC cells.	Fenretinide	76-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-22
19912993-4	2010	The induction of Nur77 and the cytoplasmic distribution of Nur77 induced by fenretinide were positively correlated with the apoptotic effect of fenretinide in HCC cells.	Fenretinide	76-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
19912993-4	2010	The induction of Nur77 and the cytoplasmic distribution of Nur77 induced by fenretinide were positively correlated with the apoptotic effect of fenretinide in HCC cells.	Fenretinide	144-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-22
19912993-4	2010	The induction of Nur77 and the cytoplasmic distribution of Nur77 induced by fenretinide were positively correlated with the apoptotic effect of fenretinide in HCC cells.	Fenretinide	144-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
19912993-6	2010	The intracellular location of Nur77 was also associated with the differential capability of fenretinide-induced ROS generation in these two cell lines.	Fenretinide	92-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19912993-6	2010	The intracellular location of Nur77 was also associated with the differential capability of fenretinide-induced ROS generation in these two cell lines.	ros	112-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19912993-7	2010	In addition, the knockdown of Nur77 expression by siRNA greatly reduced fenretinide-induced apoptosis and cleaved caspase 3 in Huh-7 cells.	Fenretinide	72-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19912993-8	2010	Therefore, our findings demonstrate that fenretinide-induced apoptosis of HCC cells is Nur77 dependent and that the intracellular localization of Nur77 dictates the sensitivity of the HCC cells to fenretinide-induced apoptosis.	Fenretinide	41-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-92
19912993-8	2010	Therefore, our findings demonstrate that fenretinide-induced apoptosis of HCC cells is Nur77 dependent and that the intracellular localization of Nur77 dictates the sensitivity of the HCC cells to fenretinide-induced apoptosis.	Fenretinide	197-208	nuclear receptor subfamily 4 group A member 1	Homo sapiens	146-151
20096738-0	2010	Involvement of induction and mitochondrial targeting of orphan nuclear receptor Nur77 in 6-OHDA-induced SH-SY5Y cell death.	Oxidopamine	89-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-85
20060711-8	2010	Women with hormone-receptor positive tumours, with low levels (-/+/++) of 17HSD1, had a 43% reduced risk of recurrence, when treated with tamoxifen (Hazard Ratio (HR)=0.57; 95% confidence interval (CI), 0.37-0.86; p=0.0086).	Tamoxifen	138-147	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-27
20097716-12	2010	In summary, these results suggest that ATF/CREB and NGFI-B family members play a crucial role in the transcriptional regulation of CYP11B2 and adrenal cell capacity to produce aldosterone.	Aldosterone	176-187	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-58
20023005-0	2010	Activation of nerve growth factor-induced B alpha by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth.	methylene-substituted diindolylmethanes	53-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-43
20023005-2	2010	1,1-Bis(3"-indolyl)-1-(p-methoxyphenyl)-methane (DIM-C-pPhOCH(3)) and 1,1-bis(3"-indolyl)-1-(p-phenyl)methane have previously been identified as activators of Nur77, and both compounds inhibited growth and induced apoptosis of UC-5 and KU7 bladder cancer cells.	1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)-methane	0-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-164
20023005-2	2010	1,1-Bis(3"-indolyl)-1-(p-methoxyphenyl)-methane (DIM-C-pPhOCH(3)) and 1,1-bis(3"-indolyl)-1-(p-phenyl)methane have previously been identified as activators of Nur77, and both compounds inhibited growth and induced apoptosis of UC-5 and KU7 bladder cancer cells.	1,1-bis(3"-indolyl)-1-(p-phenyl)methane	70-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-164
20023005-3	2010	The proapoptotic effects of methylene-substituted diindolylmethanes (C-DIMs) were unaffected by cotreatment with leptomycin B and were dependent on nuclear Nur77, and RNA interference with a small inhibitory RNA for Nur77 (iNur77) demonstrated that C-DIM-induced activation of apoptosis was Nur77-dependent.	methylene-substituted diindolylmethanes	28-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	156-161
20023005-3	2010	The proapoptotic effects of methylene-substituted diindolylmethanes (C-DIMs) were unaffected by cotreatment with leptomycin B and were dependent on nuclear Nur77, and RNA interference with a small inhibitory RNA for Nur77 (iNur77) demonstrated that C-DIM-induced activation of apoptosis was Nur77-dependent.	methylene-substituted diindolylmethanes	28-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	216-221
20023005-3	2010	The proapoptotic effects of methylene-substituted diindolylmethanes (C-DIMs) were unaffected by cotreatment with leptomycin B and were dependent on nuclear Nur77, and RNA interference with a small inhibitory RNA for Nur77 (iNur77) demonstrated that C-DIM-induced activation of apoptosis was Nur77-dependent.	methylene-substituted diindolylmethanes	28-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	216-221
20023005-5	2010	DIM-C-pPhOCH(3) (25 mg/kg/d) also induced apoptosis and inhibited tumor growth in athymic nude mice bearing KU7 cells as xenografts, demonstrating that Nur77-active C-DIMs exhibit potential for bladder cancer chemotherapy by targeting Nur77, which is overexpressed in this tumor type.	dim-c-pphoch(3)	0-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	152-157
20023005-5	2010	DIM-C-pPhOCH(3) (25 mg/kg/d) also induced apoptosis and inhibited tumor growth in athymic nude mice bearing KU7 cells as xenografts, demonstrating that Nur77-active C-DIMs exhibit potential for bladder cancer chemotherapy by targeting Nur77, which is overexpressed in this tumor type.	dim-c-pphoch(3)	0-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	235-240
20059973-2	2010	Here, we reported the identification of human apolipoprotein A5 (ApoA5), which implicated in lowering plasma triglyceride levels, as a novel target gene of Nur77.	Triglycerides	109-121	nuclear receptor subfamily 4 group A member 1	Homo sapiens	156-161
20015449-10	2010	Western blotting revealed that polyethylene combustion products also upregulated several acrolein-responsive protein markers, including GADD45beta, NQO1, HMOX, Hsp70, Nur77 and Egr1.	Polyethylene	31-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	167-172
20059973-6	2010	Taken together, our results demonstrated that Nur77 is a novel regulator of human ApoA5 gene expression and provide a new insight into the role of this orphan nuclear receptor in lipoprotein metabolism and triglyceride homeostasis.	Triglycerides	206-218	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-51
20890549-0	2010	[Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer].	anastrazol	26-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-92
20890549-15	2010	Therefore, for postmenopausal, early breast cancer hormone receptor positive women in Colombia, the cost-effective alternative is tamoxifen used as adjuvant therapy for five years.	Tamoxifen	130-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
19741502-8	2009	HER2-negative, HR-positive ABC patients have a relatively good prognostic after docetaxel-containing first-line therapy.	Docetaxel	80-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-17
20847826-5	2010	Furthermore, chemotherapy-free regimens (trastuzumab or lapatinib plus aromatase inhibitors) have been identified as additional options for hormone receptor (HR)- and HER2-positive patients.	Lapatinib	56-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	140-156
20847826-5	2010	Furthermore, chemotherapy-free regimens (trastuzumab or lapatinib plus aromatase inhibitors) have been identified as additional options for hormone receptor (HR)- and HER2-positive patients.	Lapatinib	56-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	158-160
20847831-0	2010	Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-46
20798196-0	2010	Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.	Letrozole	108-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-35
20798196-0	2010	Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.	Lapatinib	147-156	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-35
19996222-8	2009	CONCLUSIONS: In patients with HR-positive, HER2-normal breast cancer, a population known to have a low incidence of TOP2A gene alterations thought to be predictive of anthracycline benefit, there is a range of TOP2A RNA expression that is strongly associated with recurrence after adjuvant anthracyclines, which provides information complementary to RS, indicating that it merits further evaluation as a prognostic and predictive marker.	Anthracyclines	167-180	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-32
19996222-8	2009	CONCLUSIONS: In patients with HR-positive, HER2-normal breast cancer, a population known to have a low incidence of TOP2A gene alterations thought to be predictive of anthracycline benefit, there is a range of TOP2A RNA expression that is strongly associated with recurrence after adjuvant anthracyclines, which provides information complementary to RS, indicating that it merits further evaluation as a prognostic and predictive marker.	Anthracyclines	290-304	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-32
19956103-2	2009	Vitamin D deficiency is likely to be one of the many environmental factors influencing T1D development and diagnosis, and, hence, the hormone receptor gene, VDR, was examined for association with T1D risk.	Vitamin D	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	134-150
19786658-0	2009	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
19786658-2	2009	This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR) -positive metastatic breast cancer (MBC).	Lapatinib	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	245-261
19553291-0	2009	Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.	Gefitinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-61
19553291-2	2009	Gefinitib is an orally active selective EGFR inhibitor which might benefit advanced breast cancer (ABC) patients either with acquired hormone resistance or with hormone receptor (HR)-negative tumors.	gefinitib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	161-177
19553291-2	2009	Gefinitib is an orally active selective EGFR inhibitor which might benefit advanced breast cancer (ABC) patients either with acquired hormone resistance or with hormone receptor (HR)-negative tumors.	gefinitib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	179-181
19731013-0	2010	A randomized trial exploring the biomarker effects  of neoadjuvant sequential treatment with exemestane  and anastrozole in post-menopausal women with hormone  receptor-positive breast cancer.	exemestane	93-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	151-168
19731013-0	2010	A randomized trial exploring the biomarker effects  of neoadjuvant sequential treatment with exemestane  and anastrozole in post-menopausal women with hormone  receptor-positive breast cancer.	Anastrozole	109-120	nuclear receptor subfamily 4 group A member 1	Homo sapiens	151-168
20043345-0	2010	Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy.	Tamoxifen	145-154	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-63
20156908-0	2010	Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-74
20156908-1	2010	OBJECTIVE: To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC).	Letrozole	56-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
20156908-1	2010	OBJECTIVE: To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC).	Lapatinib	71-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
20389141-1	2010	BACKGROUND: In the "Arimidex", Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients.	Anastrozole	108-119	nuclear receptor subfamily 4 group A member 1	Homo sapiens	222-239
19751824-0	2009	ROS inhibit the expression of testicular steroidogenic enzyme genes via the suppression of Nur77 transactivation.	Reactive Oxygen Species	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-96
19751824-3	2009	Here, we investigated the effects of ROS on the transcriptional activity of Nur77, one of the major transcription factors that regulate the expression of steroidogenic enzyme genes.	Reactive Oxygen Species	37-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-81
19751824-4	2009	ROS signaling inhibited Nur77 transactivation, which was diminished by either treatment with c-Jun N-terminal kinase (JNK) inhibitor or the expression of a dominant negative form of JNK.	Reactive Oxygen Species	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	24-29
19751824-9	2009	Together, these results suggest that ROS signaling-mediated c-Jun upregulation suppresses the expression of steroidogenic enzyme genes by inhibiting Nur77 transactivation, resulting in the reduction of testicular steroidogenesis.	Reactive Oxygen Species	37-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-154
19786670-9	2009	CONCLUSION: Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor-copositive MBC compared with anastrozole alone, although adverse events and serious adverse events were more frequent with the combination.	Anastrozole	29-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
19809429-1	2009	BACKGROUND: To evaluate the impact of change in the hormone receptor (HR) status (HR status conversion) on the long-term outcomes of breast cancer patients treated with neoadjuvant chemotherapy (NAC).	nac	195-198	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-68
19809429-1	2009	BACKGROUND: To evaluate the impact of change in the hormone receptor (HR) status (HR status conversion) on the long-term outcomes of breast cancer patients treated with neoadjuvant chemotherapy (NAC).	nac	195-198	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-72
19809429-1	2009	BACKGROUND: To evaluate the impact of change in the hormone receptor (HR) status (HR status conversion) on the long-term outcomes of breast cancer patients treated with neoadjuvant chemotherapy (NAC).	nac	195-198	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-84
19619604-4	2009	In this study we report the antibacterial properties of a peptide (AVWQFRKMIK-CONH(2); N10 peptide), which corresponds to the N-terminal first ten amino acid residues of hp-sPLA(2), against E. coli.	hp-spla	170-177	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-90
19838061-1	2009	Tetraiodothyroacetic acid (tetrac) inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.	tetraiodothyroacetic acid	0-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	101-117
19838061-1	2009	Tetraiodothyroacetic acid (tetrac) inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.	tetraiodothyroacetic acid	27-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	101-117
19809024-1	2009	CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.	Tamoxifen	41-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-103
19897535-10	2009	Patients with HR(-) tumors had significantly lower 10-year DFS (17.3% versus 46.4%; p = .018) and OS (17.3% versus 70.2%; p = .002) rates.	Osmium	98-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-16
19809024-1	2009	CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	160-178	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-103
19809024-1	2009	CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.	4-hydroxy-N-desmethyltamoxifen	183-192	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-103
19671798-0	2009	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.	Paclitaxel	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-76
19738041-0	2009	Structural basis for the inhibition of human 5,10-methenyltetrahydrofolate synthetase by N10-substituted folate analogues.	Folic Acid	68-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-92
19738041-6	2009	Binding of N10-substituted folate analogues places Y152 in the middle of the channel connecting ATP binding site with the substrate binding pocket, precluding the positioning of gamma-phosphate for a nucleophilic attack.	Folic Acid	27-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-14
19738041-6	2009	Binding of N10-substituted folate analogues places Y152 in the middle of the channel connecting ATP binding site with the substrate binding pocket, precluding the positioning of gamma-phosphate for a nucleophilic attack.	Adenosine Triphosphate	96-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-14
19738041-6	2009	Binding of N10-substituted folate analogues places Y152 in the middle of the channel connecting ATP binding site with the substrate binding pocket, precluding the positioning of gamma-phosphate for a nucleophilic attack.	gamma-phosphate	178-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-14
19635563-0	2009	Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	52-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
19635563-0	2009	Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.	Docosahexaenoic Acids	78-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
19635563-6	2009	On the other hand, denervation reduced Nur77 mRNA levels, whereas chronic L-Dopa treatment strongly induced Nur77 transcripts.	Levodopa	74-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-113
19635563-8	2009	Interestingly, combination of L-Dopa with DHA further increases Nur77 mRNA levels in the anterior caudate-putamen, and mainly in striosomes.	Levodopa	30-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
19635563-8	2009	Interestingly, combination of L-Dopa with DHA further increases Nur77 mRNA levels in the anterior caudate-putamen, and mainly in striosomes.	Docosahexaenoic Acids	42-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
19635563-10	2009	Taken together, our results show that Nur77 expression is modulated following dopamine denervation and chronic L-Dopa therapy in a non-human primate model of Parkinson"s disease, and suggest that strong modulation of Nur77 expression might be linked to a reduced risk to develop LIDs.	Dopamine	78-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
19635563-10	2009	Taken together, our results show that Nur77 expression is modulated following dopamine denervation and chronic L-Dopa therapy in a non-human primate model of Parkinson"s disease, and suggest that strong modulation of Nur77 expression might be linked to a reduced risk to develop LIDs.	Levodopa	111-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
19671798-4	2009	We tested the hypothesis that paclitaxel mimics Nur77, which, like paclitaxel, changes the function of Bcl-2.	Paclitaxel	30-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
19671798-4	2009	We tested the hypothesis that paclitaxel mimics Nur77, which, like paclitaxel, changes the function of Bcl-2.	Paclitaxel	67-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
19671798-5	2009	This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria.	Paclitaxel	58-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19671798-5	2009	This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria.	Paclitaxel	185-195	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19671798-5	2009	This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria.	Paclitaxel	185-195	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
19682370-1	2009	BACKGROUND: Neuron-derived orphan receptor (Nor) 1, nuclear receptor (Nur) 77, and nuclear receptor-related protein (Nurr) 1 constitute the NR4A family of orphan nuclear receptors which were recently found to modulate hepatic glucose production, insulin signalling in adipocytes, and oxidative metabolism in skeletal muscle.	Glucose	226-233	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-77
19675165-5	2009	Specifically, we demonstrate that RSK phosphorylates Nur77 at serine 354 and this modulates Nur77 nuclear export and intracellular translocation during T cell death.	Serine	62-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-58
19675165-5	2009	Specifically, we demonstrate that RSK phosphorylates Nur77 at serine 354 and this modulates Nur77 nuclear export and intracellular translocation during T cell death.	Serine	62-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
19690310-2	2009	OBJECTIVE: To determine whether 6 mg of estradiol (daily) is a viable therapy for postmenopausal women with advanced aromatase inhibitor-resistant hormone receptor-positive breast cancer.	Estradiol	40-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-163
19378296-1	2009	PPARgamma agonist DIM-Ph-4-CF(3), a template for RXRalpha agonist (E)-3-[5-di(1-methyl-1H-indol-3-yl)methyl-2-thienyl] acrylic acid: DIM-Ph-CF(3) is reported to inhibit cancer growth independent of PPARgamma and to interact with NR4A1.	dim-ph-4-cf	18-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	229-234
19541862-0	2009	Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.	Tamoxifen	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-57
19121891-5	2009	In this work, five surfactants, namely Brij 35, Tergitol NP10, Tween 20, Tween 80 and Tyloxapol, are evaluated on the desorption of PAHs [benzanthracene (BzA), fluoranthene (FLU), and pyrene (PYR), single and in mixture] from a model sample such as kaolin.	Polycyclic Aromatic Hydrocarbons	132-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-61
19378296-1	2009	PPARgamma agonist DIM-Ph-4-CF(3), a template for RXRalpha agonist (E)-3-[5-di(1-methyl-1H-indol-3-yl)methyl-2-thienyl] acrylic acid: DIM-Ph-CF(3) is reported to inhibit cancer growth independent of PPARgamma and to interact with NR4A1.	(e)-3-[5-di(1-methyl-1h-indol-3-yl)methyl-2-thienyl] acrylic acid	66-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	229-234
19378296-1	2009	PPARgamma agonist DIM-Ph-4-CF(3), a template for RXRalpha agonist (E)-3-[5-di(1-methyl-1H-indol-3-yl)methyl-2-thienyl] acrylic acid: DIM-Ph-CF(3) is reported to inhibit cancer growth independent of PPARgamma and to interact with NR4A1.	dim-ph	18-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	229-234
19378296-4	2009	Structure-based direct design led to an RXRalpha agonist.1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene (DIM-Ph-4-CF(3)) is reported to inhibit cancer cell growth and to act as a transcriptional agonist of peroxisome proliferator-activated receptor gamma (PPARgamma) and nuclear receptor 4A subfamily member 1 (NR4A1).	1-di(1h-indol-3-yl)methyl-4-trifluoromethylbenzene	57-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	275-313
19378296-4	2009	Structure-based direct design led to an RXRalpha agonist.1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene (DIM-Ph-4-CF(3)) is reported to inhibit cancer cell growth and to act as a transcriptional agonist of peroxisome proliferator-activated receptor gamma (PPARgamma) and nuclear receptor 4A subfamily member 1 (NR4A1).	1-di(1h-indol-3-yl)methyl-4-trifluoromethylbenzene	57-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	315-320
21783983-8	2009	Of these, rapid and transient induction of the TR3 gene was noted as a possible key process in Cd-induced apoptosis.	Cadmium	95-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-50
19451417-0	2009	Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.	Paclitaxel	23-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
19473021-1	2009	Time-resolved resonance Raman spectroscopy (TR3) has been used to study the effect of solvent polarity on the mechanism and nature of intermediates formed in photoinduced electron-transfer reaction between triplet flouranil ((3)FL) and tetramethylbenzene (TMB).	triplet flouranil	206-223	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-47
19473021-1	2009	Time-resolved resonance Raman spectroscopy (TR3) has been used to study the effect of solvent polarity on the mechanism and nature of intermediates formed in photoinduced electron-transfer reaction between triplet flouranil ((3)FL) and tetramethylbenzene (TMB).	1,2,3,4-TETRAMETHYLBENZENE	236-254	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-47
19473021-1	2009	Time-resolved resonance Raman spectroscopy (TR3) has been used to study the effect of solvent polarity on the mechanism and nature of intermediates formed in photoinduced electron-transfer reaction between triplet flouranil ((3)FL) and tetramethylbenzene (TMB).	1,2,4,5-tetramethoxybenzene	256-259	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-47
19473021-2	2009	Comparison of the TR3 spectra in polar, nonpolar, and medium polar media suggests that formation of radical anion due to electron-transfer reaction between (3)FL and TMB is favored in more polar solvents, whereas ketyl radical formation is more favored in less polar media.	(3)fl	156-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-21
19473021-2	2009	Comparison of the TR3 spectra in polar, nonpolar, and medium polar media suggests that formation of radical anion due to electron-transfer reaction between (3)FL and TMB is favored in more polar solvents, whereas ketyl radical formation is more favored in less polar media.	1,2,4,5-tetramethoxybenzene	166-169	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-21
19473021-2	2009	Comparison of the TR3 spectra in polar, nonpolar, and medium polar media suggests that formation of radical anion due to electron-transfer reaction between (3)FL and TMB is favored in more polar solvents, whereas ketyl radical formation is more favored in less polar media.	ketyl radical	213-226	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-21
19584258-1	2009	1,1-Bis(3"-indolyl)-1-(p-anisyl)methane (DIM-C-pPhOCH3) activates the orphan receptor nerve growth factor-induced Balpha (Nur77) in cancer cells, and in this study, DIM-C-pPhOCH3 decreased Panc1 pancreatic cancer cell survival and arrested cells in G0-G1.	1,1-bis(3'-indolyl)-1-(p-anisyl)methane	0-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-127
19584258-1	2009	1,1-Bis(3"-indolyl)-1-(p-anisyl)methane (DIM-C-pPhOCH3) activates the orphan receptor nerve growth factor-induced Balpha (Nur77) in cancer cells, and in this study, DIM-C-pPhOCH3 decreased Panc1 pancreatic cancer cell survival and arrested cells in G0-G1.	DIM-C-pPhOCH3	41-54	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-127
19584258-5	2009	Interactions of Nur77 with the p21 promoter in Panc1 cells treated with DIM-C-pPhOCH3 were also confirmed in chromatin immunoprecipitation assays.	DIM-C-pPhOCH3	72-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	16-21
19451417-0	2009	Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.	Paclitaxel	23-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-96
19074726-4	2009	Here, we demonstrate that treatment with panobinostat rapidly inhibits the in vitro and intracellular activity, as well as the mRNA and protein levels of HDAC7, and induces expression and translocation of Nur77 to the mitochondria.	Panobinostat	41-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	205-210
19436228-2	2009	Treatment with thapsigargin in the presence of blockers of NMDA (N-methyl-D-aspartic acid) receptors upregulates some activity-dependent genes (Egr2 and Nr4a1), leaving unaltered the expression level of other activity-dependent genes (Bdnf and Arc).	Thapsigargin	15-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
19454038-0	2009	Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases.	Nitrogen	31-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
19454038-1	2009	BACKGROUND: This retrospective study evaluated, according to hormone receptor status, the antitumor effects of bisphosphonate especially on survival and disease progression in breast cancer patients with metastatic bone disease.	Diphosphonates	111-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	61-77
19454038-4	2009	RESULTS: 87.8% of HR positive and 69.0% of HR negative patients received BPs with a median number of 17.7 cycles.	Diphosphonates	73-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-45
19454038-5	2009	Although BPs treatment made no survival benefit in HR positive group, HR negative patients showed a significant prolonged survival when they received BPs treatment (hazard ratio = 0.56 [95% CI 0.34 to 0.91], P = 0.019).	Diphosphonates	150-153	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-72
19454038-7	2009	CONCLUSION: Bisphosphonate treatment can result in a survival benefit in metastatic breast cancer patients with HR negative tumors.	Diphosphonates	12-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-114
19153124-1	2009	BACKGROUND: Fulvestrant produces a clinical benefit rate (CBR) of approximately 45% in tamoxifen-resistant, hormone receptor (HR)-positive metastatic breast cancer (MBC) and 32% in aromatase inhibitor (AI)-resistant disease.	Fulvestrant	12-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-124
19153124-1	2009	BACKGROUND: Fulvestrant produces a clinical benefit rate (CBR) of approximately 45% in tamoxifen-resistant, hormone receptor (HR)-positive metastatic breast cancer (MBC) and 32% in aromatase inhibitor (AI)-resistant disease.	Fulvestrant	12-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-128
19416189-8	2009	Testosterone responsiveness was found to be mediated through an element located in the proximal INSL3 promoter, which also contains a NUR77-SF1-binding site.	Testosterone	0-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	134-139
19153124-3	2009	The objective of this study was to determine the efficacy and safety of tipifarnib-fulvestrant combination in HR-positive MBC.	tipifarnib-fulvestrant	72-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-112
19136619-6	2009	Taken together, these observations indicate that liraglutide inhibits TNF- or glucose-mediated induction of PAI-1 and vascular adhesion molecule expression, and this effect may involve the modulation of NUR77.	Glucose	78-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-208
19153124-10	2009	CONCLUSIONS: The target CBR of 70% for the tipifarnib-fulvestrant combination in HR-positive MBC was set too high and was not achieved.	tipifarnib-fulvestrant	43-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-83
18954499-2	2008	For over 20 years, tamoxifen was the standard adjuvant (postoperative) endocrine treatment for hormone receptor-positive (i.e., endocrine-responsive) early breast cancer.	Tamoxifen	19-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	95-111
19243953-1	2009	By combining the structural features of acridone based anti-cancer drugs (like amsacrine) and MDR modulator propafenone, acridones with hydroxyl amine chain at N-10 have been designed and synthesized.	Propafenone	108-119	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-164
19243953-1	2009	By combining the structural features of acridone based anti-cancer drugs (like amsacrine) and MDR modulator propafenone, acridones with hydroxyl amine chain at N-10 have been designed and synthesized.	Acridones	121-130	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-164
19243953-1	2009	By combining the structural features of acridone based anti-cancer drugs (like amsacrine) and MDR modulator propafenone, acridones with hydroxyl amine chain at N-10 have been designed and synthesized.	Hydroxylamine	136-150	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-164
18727708-0	2009	Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment.	Lithium	80-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-24
18727708-4	2009	NR4A1 can be transiently increased by a variety of stimuli, including lithium, which is used as adjuvant therapy of thyroid carcinoma with (131)I.	Lithium	70-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
18727708-5	2009	We tested if lithium could restore NR4A1 expression.	Lithium	13-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-40
18727708-11	2009	Lithium induced NR4A1 and FOSB expression, reduced CCDN1 expression, inhibited cell growth and triggered apoptosis in a FTC cell line.	Lithium	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	16-21
18727708-15	2009	Lithium restores NR4A1 expression, induces apoptosis and reduces cell growth.	Lithium	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-22
20198292-7	2009	In fact, retrospective analyses of clinical trials suggest that anthracyclines may be less active in hormone-receptor positive HER2-negative patients, while several other trials and meta-analyses involving taxanes, showed a benefit in terms of risk of relapse and death reduction.	Anthracyclines	64-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	101-117
20198292-11	2009	Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.	Taxoids	30-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
20198292-11	2009	Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.	Docetaxel	46-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
20198292-11	2009	Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.	Anthracyclines	60-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
19148494-0	2009	The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression.	Azacitidine	76-90	nuclear receptor subfamily 4 group A member 1	Homo sapiens	116-121
19148494-4	2009	Interestingly, MCT-1 in combination with AZA significantly induced the recently identified suppressor of leukemogenesis Nur77 and attenuated AZA-induced MMP-9 expression.	Azacitidine	41-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
18501502-7	2008	For example, p-trifluoromethylphenyl, p-t-butylphenyl and p-biphenyl analogs activate peroxisome proliferator-activated receptor gamma (PPARgamma), and p-methoxyphenyl and p-phenyl compounds activate nerve growth factor-induced-Balpha (NGFI-Balpha, Nur77) orphan nuclear receptor.	phenyl compounds	174-190	nuclear receptor subfamily 4 group A member 1	Homo sapiens	249-254
18158620-0	2008	Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).	exemestane	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-61
18158620-9	2008	CONCLUSION: This study shows that exemestane is effective and safe as a preoperative therapy in post-menopausal patients with strongly hormone receptor-positive breast cancer.	exemestane	34-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	135-151
19046107-1	2008	A 5-year regimen of tamoxifen hormone therapy has historically been the recommendation for hormone receptor-positive, postmenopausal women with early-stage breast cancer.	Tamoxifen	20-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-107
18756015-0	2008	Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer.	vitamin d	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
18756015-1	2008	Evidence has emerged for a role of vitamin D in the development of breast cancer, and there is some suggestion that its antiproliferative effect is greater in hormone-receptor-positive cells.	vitamin d	35-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-175
18501502-8	2008	The effects of C-DIMs on PPARgamma and Nur77 coupled with their receptor-independent activities has resulted in the development of a novel group of multi-targeted anticancer drugs with excellent potential for clinical treatment of cancer.	c-dims	15-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
18490163-3	2008	The aromatase inhibitors (anastrozole, letrozole, and exemestane) have been shown to be superior to tamoxifen in improving disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.	Anastrozole	26-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	174-190
18676081-5	2008	Our results show that NGFI-B LBD undergoes a two-state guanidine hydrochloride (GndHCl) induced denaturation, as judged by changes in the alpha-helical content of the protein monitored by circular dichroism spectroscopy (CD).	Guanidine	55-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-28
18676081-5	2008	Our results show that NGFI-B LBD undergoes a two-state guanidine hydrochloride (GndHCl) induced denaturation, as judged by changes in the alpha-helical content of the protein monitored by circular dichroism spectroscopy (CD).	Guanidine	80-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-28
18852139-1	2008	1,1-Bis(3"-indoly)-1-(p-substituted phenyl)methanes (C-DIM) exhibit structure-dependent activation of peroxisome proliferator-activated receptor gamma and nerve growth factor-induced Balpha (Nur77) and induce receptor-dependent and receptor-independent apoptosis in cancer cells and tumors.	1,1-bis(3"-indoly)-1-(p-substituted phenyl)methanes	0-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	191-196
18599618-5	2008	We have now established that StAR transcription in cAMP-stimulated Leydig cells requires de novo protein synthesis and involves NUR77.	Cyclic AMP	51-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-133
18599618-6	2008	We found that cAMP-induced NUR77 expression precedes that of StAR both at the mRNA and protein levels in Leydig cells.	Cyclic AMP	14-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
18599618-7	2008	In these cells, small interfering RNA-mediated NUR77 knockdown reduces cAMP-induced StAR expression.	Cyclic AMP	71-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-52
18599618-12	2008	All together, our results implicate NUR77 as a mediator of cAMP action on StAR transcription in steroidogenic Leydig cells and identify a role for CaMKI in this process.	Cyclic AMP	59-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-41
18490163-3	2008	The aromatase inhibitors (anastrozole, letrozole, and exemestane) have been shown to be superior to tamoxifen in improving disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.	Letrozole	39-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	174-190
18490163-3	2008	The aromatase inhibitors (anastrozole, letrozole, and exemestane) have been shown to be superior to tamoxifen in improving disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.	exemestane	54-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	174-190
18075758-0	2008	Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.	Anastrozole	32-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	136-152
18626112-1	2008	Nuclear receptor TR3/Nur77/NR4A1 binds several antiapoptotic Bcl-2-family proteins (Bcl-B, Bcl-2, Bfl-1) in a non-BH3-dependent manner.	BH 3	114-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
18626112-1	2008	Nuclear receptor TR3/Nur77/NR4A1 binds several antiapoptotic Bcl-2-family proteins (Bcl-B, Bcl-2, Bfl-1) in a non-BH3-dependent manner.	BH 3	114-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-26
18626112-1	2008	Nuclear receptor TR3/Nur77/NR4A1 binds several antiapoptotic Bcl-2-family proteins (Bcl-B, Bcl-2, Bfl-1) in a non-BH3-dependent manner.	BH 3	114-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
18626112-2	2008	A 9-amino-acid peptide derived from full-length TR3 with polyarginine tail (TR3-r8) recapitulates TR3"s binding specificity, displaying high affinity for Bcl-B.	polyarginine	57-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-51
18626112-2	2008	A 9-amino-acid peptide derived from full-length TR3 with polyarginine tail (TR3-r8) recapitulates TR3"s binding specificity, displaying high affinity for Bcl-B.	polyarginine	57-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-79
18626112-2	2008	A 9-amino-acid peptide derived from full-length TR3 with polyarginine tail (TR3-r8) recapitulates TR3"s binding specificity, displaying high affinity for Bcl-B.	polyarginine	57-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-79
18626112-4	2008	A fluorescence polarization assay (FPA) employing fluorescein isothiocyanate (FITC)-labeled TR3-r8 peptide (FITC-TR3-r8) and Bcl-B protein was optimized, with nonfluorescent TR3-r8 serving to demonstrate reversible, competitive binding.	Fluorescein-5-isothiocyanate	50-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-95
18626112-4	2008	A fluorescence polarization assay (FPA) employing fluorescein isothiocyanate (FITC)-labeled TR3-r8 peptide (FITC-TR3-r8) and Bcl-B protein was optimized, with nonfluorescent TR3-r8 serving to demonstrate reversible, competitive binding.	Fluorescein-5-isothiocyanate	50-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-116
18626112-4	2008	A fluorescence polarization assay (FPA) employing fluorescein isothiocyanate (FITC)-labeled TR3-r8 peptide (FITC-TR3-r8) and Bcl-B protein was optimized, with nonfluorescent TR3-r8 serving to demonstrate reversible, competitive binding.	Fluorescein-5-isothiocyanate	50-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-116
18626112-4	2008	A fluorescence polarization assay (FPA) employing fluorescein isothiocyanate (FITC)-labeled TR3-r8 peptide (FITC-TR3-r8) and Bcl-B protein was optimized, with nonfluorescent TR3-r8 serving to demonstrate reversible, competitive binding.	Fluorescein-5-isothiocyanate	78-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-95
18626112-5	2008	Approximately 50,000 compounds were screened at 3.75 mg/L, yielding 145 reproducible hits with &gt; or =50% FITC-TR3-r8 displacement (a confirmed hit rate of 0.29%).	Fluorescein-5-isothiocyanate	108-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-116
18419761-6	2008	After BP treatment in GBM 8401 cells, Nur77 translocated from the nucleus to the cytoplasm, the cytochrome c was released from the mitochondria, and caspase 3 became activated.	butylidenephthalide	6-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
18419761-8	2008	Inhibition of BP-induced Nur77 expression by Nur77 short interfering RNA blocked BP-induced apoptosis in GBM 8401 cells, suggesting that the induction of Nur77 negatively affected GBM 8401 cell survival.	butylidenephthalide	14-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-30
18419761-8	2008	Inhibition of BP-induced Nur77 expression by Nur77 short interfering RNA blocked BP-induced apoptosis in GBM 8401 cells, suggesting that the induction of Nur77 negatively affected GBM 8401 cell survival.	butylidenephthalide	14-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
18419761-8	2008	Inhibition of BP-induced Nur77 expression by Nur77 short interfering RNA blocked BP-induced apoptosis in GBM 8401 cells, suggesting that the induction of Nur77 negatively affected GBM 8401 cell survival.	butylidenephthalide	14-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
18419761-8	2008	Inhibition of BP-induced Nur77 expression by Nur77 short interfering RNA blocked BP-induced apoptosis in GBM 8401 cells, suggesting that the induction of Nur77 negatively affected GBM 8401 cell survival.	butylidenephthalide	81-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-30
18419761-8	2008	Inhibition of BP-induced Nur77 expression by Nur77 short interfering RNA blocked BP-induced apoptosis in GBM 8401 cells, suggesting that the induction of Nur77 negatively affected GBM 8401 cell survival.	butylidenephthalide	81-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
18419761-8	2008	Inhibition of BP-induced Nur77 expression by Nur77 short interfering RNA blocked BP-induced apoptosis in GBM 8401 cells, suggesting that the induction of Nur77 negatively affected GBM 8401 cell survival.	butylidenephthalide	81-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
18419761-9	2008	In summary, our results suggest that up-regulation of Nur77 may explain the antitumoral activity of BP in brain tumor cells.	butylidenephthalide	100-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-59
18424253-3	2008	Glucocorticoid hormone receptor (GR) was translocated from the cytoplasm to the nucleus and de-phosphorylated at serine residue 203 in the nucleus, by combined treatment with dexamethasone and PD98059.	Serine	113-119	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-31
18424253-3	2008	Glucocorticoid hormone receptor (GR) was translocated from the cytoplasm to the nucleus and de-phosphorylated at serine residue 203 in the nucleus, by combined treatment with dexamethasone and PD98059.	Dexamethasone	175-188	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-31
18424253-3	2008	Glucocorticoid hormone receptor (GR) was translocated from the cytoplasm to the nucleus and de-phosphorylated at serine residue 203 in the nucleus, by combined treatment with dexamethasone and PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	193-200	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-31
18459800-0	2008	Mapping peptide hormone-receptor interactions using a disulfide-trapping approach.	Disulfides	54-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	16-32
18460448-1	2008	1,1-Bis(3"-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) activate the orphan receptors peroxisome proliferator-activated receptor gamma (PPARgamma) and Nur77 and induce receptor-dependent and -independent apoptotic pathways in colon and other cancer cells.	1,1-bis(3"-indolyl)-1-(p-substituted phenyl)methanes	0-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-162
18460448-1	2008	1,1-Bis(3"-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) activate the orphan receptors peroxisome proliferator-activated receptor gamma (PPARgamma) and Nur77 and induce receptor-dependent and -independent apoptotic pathways in colon and other cancer cells.	c-dims	54-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-162
18202854-0	2008	Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei.	Vitamin K 2	55-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-116
18202854-0	2008	Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei.	Vitamin K 2	55-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	117-122
18202854-9	2008	Treatment of PA-1 cells with small interfering RNA (siRNA) directed against TR3, and with cycloheximide or SP600125 (an inhibitor of c-jun N-terminal kinase; JNK), separately, inhibited the VK(2)-induced synthesis of TR3 and apoptosis.	Cycloheximide	90-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	217-220
18202854-9	2008	Treatment of PA-1 cells with small interfering RNA (siRNA) directed against TR3, and with cycloheximide or SP600125 (an inhibitor of c-jun N-terminal kinase; JNK), separately, inhibited the VK(2)-induced synthesis of TR3 and apoptosis.	pyrazolanthrone	107-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	217-220
18466322-3	2008	Another class of transcription factors, namely, the nuclear receptor subgroup called Nurs (Nur77, Nurr1 and Nor-1), has recently been associated with behavioral and biochemical effects mediated by dopamine.	Dopamine	197-205	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-96
18466322-8	2008	Interestingly, modulation of dopamine drug-induced locomotor activities by kinase inhibitors is in accordance with the effects on Nur77, but not Nor-1, expression.	Dopamine	29-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	130-135
18075758-10	2008	CONCLUSIONS: These data support the findings of the main PROACT trial, which confirmed that anastrozole, as compared with tamoxifen, is an effective neoadjuvant endocrine treatment in objective response rates for postmenopausal women with large operable hormone-receptor positive breast cancer.	Anastrozole	92-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	254-270
18163434-5	2008	The transcriptional regulation of NGFI-B/Nur77 by LH/human chorionic gonadotropin (hCG) or 8-bromoadenosine 3"-5"-cyclic monophosphate (8 Br-cAMP) was examined in mouse Leydig tumor cells MA-10.	8-Bromo Cyclic Adenosine Monophosphate	91-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-40
18048288-7	2008	Steroid hormone target sensitivity can be affected by variables such as metabolizing enzyme activity, hormone receptor expression as well as receptor cofactor expression.	Steroids	0-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-118
18163434-5	2008	The transcriptional regulation of NGFI-B/Nur77 by LH/human chorionic gonadotropin (hCG) or 8-bromoadenosine 3"-5"-cyclic monophosphate (8 Br-cAMP) was examined in mouse Leydig tumor cells MA-10.	8-Bromo Cyclic Adenosine Monophosphate	91-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
18163434-5	2008	The transcriptional regulation of NGFI-B/Nur77 by LH/human chorionic gonadotropin (hCG) or 8-bromoadenosine 3"-5"-cyclic monophosphate (8 Br-cAMP) was examined in mouse Leydig tumor cells MA-10.	8-Bromo Cyclic Adenosine Monophosphate	138-145	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-40
18163434-5	2008	The transcriptional regulation of NGFI-B/Nur77 by LH/human chorionic gonadotropin (hCG) or 8-bromoadenosine 3"-5"-cyclic monophosphate (8 Br-cAMP) was examined in mouse Leydig tumor cells MA-10.	8-Bromo Cyclic Adenosine Monophosphate	138-145	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
17957723-0	2008	1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells.	1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane	0-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-62
18454044-2	2008	For more than 2 decades, tamoxifen has been the standard endocrine agent for hormone receptor-positive tumors.	Tamoxifen	25-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-93
18037293-0	2008	Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer.	Vitamin D	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
18316794-0	2008	Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.	Fulvestrant	53-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	172-188
17653859-0	2008	Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.	Letrozole	22-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-122
17957723-1	2008	1,1-Bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) is a methylene-substituted diindolylmethane (C-DIM) analog that activates the orphan receptor nerve growth factor-induced-Balpha (NGFI-Balpha, Nur77).	1,1-bis(3"-indolyl)-1-(p-methoxyphenyl)methane	0-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
17957723-1	2008	1,1-Bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) is a methylene-substituted diindolylmethane (C-DIM) analog that activates the orphan receptor nerve growth factor-induced-Balpha (NGFI-Balpha, Nur77).	dim-c-pphoch	48-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
17957723-1	2008	1,1-Bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) is a methylene-substituted diindolylmethane (C-DIM) analog that activates the orphan receptor nerve growth factor-induced-Balpha (NGFI-Balpha, Nur77).	methylene-substituted diindolylmethane	70-108	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
17957723-1	2008	1,1-Bis(3"-indolyl)-1-(p-methoxyphenyl)methane (DIM-C-pPhOCH(3)) is a methylene-substituted diindolylmethane (C-DIM) analog that activates the orphan receptor nerve growth factor-induced-Balpha (NGFI-Balpha, Nur77).	c-dim	110-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
17957723-7	2008	Thus, the effectiveness of DIM-C-pPhOCH(3) as a tumor growth inhibitor is through activation of Nur77-dependent and -independent pathways.	dim-c-pphoch	27-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-101
18288313-0	2008	Arsenic as an endocrine disruptor: arsenic disrupts retinoic acid receptor-and thyroid hormone receptor-mediated gene regulation and thyroid hormone-mediated amphibian tail metamorphosis.	Arsenic	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-103
18248459-2	2008	As a transcription factor, Nur77 participates in a variety of biological processes, including T cell development, inflammatory responses, steroid hormone synthesis, and hepatic glucose metabolism.	Steroids	138-153	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
18622910-1	2008	Tamoxifen is the standard treatment in premenopausal hormone-receptor positive breast cancer patients with additional benefit in some of these women by adding ovarian ablation or suppression.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-69
18622910-9	2008	In selected postmenopausal patients with hormone-receptor positive disease the use of five years of tamoxifen can still be a viable option.	Tamoxifen	100-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-57
18225870-1	2008	Time-resolved resonance Raman (TR3) studies of the photochemistry of phenyl azide, 3-hyroxyphenyl azide, 3-methoxyphenyl azide and 3-nitrophenyl azide in acetonitrile:water solutions is reported.	phenylazide	69-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-34
18225870-1	2008	Time-resolved resonance Raman (TR3) studies of the photochemistry of phenyl azide, 3-hyroxyphenyl azide, 3-methoxyphenyl azide and 3-nitrophenyl azide in acetonitrile:water solutions is reported.	3-hyroxyphenyl azide	83-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-34
18225870-1	2008	Time-resolved resonance Raman (TR3) studies of the photochemistry of phenyl azide, 3-hyroxyphenyl azide, 3-methoxyphenyl azide and 3-nitrophenyl azide in acetonitrile:water solutions is reported.	3-methoxyphenyl azide	105-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-34
18225870-1	2008	Time-resolved resonance Raman (TR3) studies of the photochemistry of phenyl azide, 3-hyroxyphenyl azide, 3-methoxyphenyl azide and 3-nitrophenyl azide in acetonitrile:water solutions is reported.	3-nitrophenyl azide	131-150	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-34
18225870-2	2008	After photolysis of these four aryl azides in room temperature solutions, only one species was observed in the TR3 spectra for each azide, respectively at the probe wavelengths employed in the TR3 experiments.	aryl azides	31-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-114
18225870-2	2008	After photolysis of these four aryl azides in room temperature solutions, only one species was observed in the TR3 spectra for each azide, respectively at the probe wavelengths employed in the TR3 experiments.	aryl azides	31-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	193-196
18225870-2	2008	After photolysis of these four aryl azides in room temperature solutions, only one species was observed in the TR3 spectra for each azide, respectively at the probe wavelengths employed in the TR3 experiments.	Azides	36-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-114
18225870-2	2008	After photolysis of these four aryl azides in room temperature solutions, only one species was observed in the TR3 spectra for each azide, respectively at the probe wavelengths employed in the TR3 experiments.	Azides	36-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	193-196
18288313-0	2008	Arsenic as an endocrine disruptor: arsenic disrupts retinoic acid receptor-and thyroid hormone receptor-mediated gene regulation and thyroid hormone-mediated amphibian tail metamorphosis.	Arsenic	35-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-103
17939708-1	2007	A nanosecond time-resolved resonance Raman (ns-TR3) spectroscopic study of the reactions of the 2-fluorenylnitrenium ion with several C8-substituted guanosine derivatives is reported.	2-fluorenylnitrenium	96-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-50
17693420-6	2008	Compared with tamoxifen, anastrozole and letrozole significantly improved disease-free survival as early adjuvant treatment for hormone-receptor-positive disease.	Anastrozole	25-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-144
17693420-6	2008	Compared with tamoxifen, anastrozole and letrozole significantly improved disease-free survival as early adjuvant treatment for hormone-receptor-positive disease.	Letrozole	41-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-144
18282367-1	2007	Third-generation aromatase inhibitors (AIs; anastrozole, letrozole, exemestane) have replaced tamoxifen as the adjuvant treatment of choice for postmenopausal women with hormone receptor-positive early-stage breast cancer.	Letrozole	57-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	170-186
18282367-1	2007	Third-generation aromatase inhibitors (AIs; anastrozole, letrozole, exemestane) have replaced tamoxifen as the adjuvant treatment of choice for postmenopausal women with hormone receptor-positive early-stage breast cancer.	exemestane	68-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	170-186
17892469-1	2007	The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - positive breast cancer in postmenopausal women.	Letrozole	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-165
17761950-8	2007	9-cis retinoic acid, a ligand for RXRalpha, enhanced the association of RXRalpha with TR3, rather than acetylation of RXRalpha by p300.	Alitretinoin	0-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-89
17761950-10	2007	Upon the treatment of 9-cis retinoic acid, RXRalpha was translocated with TR3 from the nucleus to the mitochondria, and apoptosis was induced.	Alitretinoin	22-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-77
18547136-1	2008	Anastrozole (Arimidex) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer.	Anastrozole	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	184-200
18547136-1	2008	Anastrozole (Arimidex) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer.	Anastrozole	13-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	184-200
18547136-4	2008	In patients with hormone receptor-positive tumours, 5 years of anastrozole treatment was more efficacious in reducing breast cancer recurrence than 5 years of tamoxifen, both in a head-to-head comparison and in switching trials when given after 2-3 years of tamoxifen treatment.	Anastrozole	63-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-33
18547136-13	2008	However, the evidence to date establishes anastrozole as a valuable adjuvant and extended adjuvant treatment for postmenopausal women with hormone receptor-positive, early-stage breast cancer.	Anastrozole	42-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-155
18073527-0	2007	Staurosporine sensitizes T lymphoma cells to glucocorticoid-induced apoptosis: role of Nur77 and Bcl-2.	Staurosporine	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-92
17923408-7	2007	Hormone receptor (HR) status, one of the critical determinants of BC biology, had been suggested to be a factor modulating response to adjuvant chemotherapy in general and taxanes in particular.	Taxoids	172-179	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
17923408-7	2007	Hormone receptor (HR) status, one of the critical determinants of BC biology, had been suggested to be a factor modulating response to adjuvant chemotherapy in general and taxanes in particular.	Taxoids	172-179	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-20
17923408-9	2007	Indirect (retrospective, unplanned) analysis suggest that the magnitude of benefit from taxanes is somewhat more in the HR negative subset, but the benefit also exists, and is clinically relevant, in patients with HR positive cancers.	Taxoids	88-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-122
17939708-1	2007	A nanosecond time-resolved resonance Raman (ns-TR3) spectroscopic study of the reactions of the 2-fluorenylnitrenium ion with several C8-substituted guanosine derivatives is reported.	Guanosine	149-158	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-50
17939708-2	2007	The TR3 spectra show that the 2-fluorenylnitrenium ion reacts with the C8-substituted guanosine derivatives (C8-methylguanosine and C8-bromoguanosine) to produce C8 intermediates with the methyl and bromine moieties still attached to the intermediate species at the C8 position.	2-fluorenylnitrenium	30-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17939708-2	2007	The TR3 spectra show that the 2-fluorenylnitrenium ion reacts with the C8-substituted guanosine derivatives (C8-methylguanosine and C8-bromoguanosine) to produce C8 intermediates with the methyl and bromine moieties still attached to the intermediate species at the C8 position.	Guanosine	86-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17939708-2	2007	The TR3 spectra show that the 2-fluorenylnitrenium ion reacts with the C8-substituted guanosine derivatives (C8-methylguanosine and C8-bromoguanosine) to produce C8 intermediates with the methyl and bromine moieties still attached to the intermediate species at the C8 position.	c8-methylguanosine	109-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17939708-2	2007	The TR3 spectra show that the 2-fluorenylnitrenium ion reacts with the C8-substituted guanosine derivatives (C8-methylguanosine and C8-bromoguanosine) to produce C8 intermediates with the methyl and bromine moieties still attached to the intermediate species at the C8 position.	c8-bromoguanosine	132-149	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17939708-2	2007	The TR3 spectra show that the 2-fluorenylnitrenium ion reacts with the C8-substituted guanosine derivatives (C8-methylguanosine and C8-bromoguanosine) to produce C8 intermediates with the methyl and bromine moieties still attached to the intermediate species at the C8 position.	Bromine	199-206	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17701362-3	2007	Here it is shown that in thymic lymphoma cells resistant to calcium-mediated apoptosis, cytochrome c release is abolished despite of Nur77 mitochondrial targeting.	Calcium	60-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-138
17785466-2	2007	We found that both NR4A3 and NR4A1 were induced by insulin and by thiazolidinedione drugs (pioglitazone and troglitazone) in 3T3-L1 adipocytes.	2,4-thiazolidinedione	66-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-34
17785466-2	2007	We found that both NR4A3 and NR4A1 were induced by insulin and by thiazolidinedione drugs (pioglitazone and troglitazone) in 3T3-L1 adipocytes.	Pioglitazone	91-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-34
17785466-2	2007	We found that both NR4A3 and NR4A1 were induced by insulin and by thiazolidinedione drugs (pioglitazone and troglitazone) in 3T3-L1 adipocytes.	Troglitazone	108-120	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-34
17675581-3	2007	To explore the functional importance of MR in mammalian skin, we have generated a conditional doxycycline-inducible model of MR overexpression, resulting in double-transgenic (DT) mice [keratin 5-tTa/tetO-human MR (hMR)], targeting the human MR specifically to keratinocytes of the epidermis and hair follicle (HF).	Doxycycline	94-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-127
17715970-1	2007	A nanosecond time-resolved resonance Raman (ns-TR3) spectroscopic study of the triplet state benzophenone reaction with the 2-propanol hydrogen-donor solvent and subsequent reactions is presented.	benzophenone	93-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-50
17715970-1	2007	A nanosecond time-resolved resonance Raman (ns-TR3) spectroscopic study of the triplet state benzophenone reaction with the 2-propanol hydrogen-donor solvent and subsequent reactions is presented.	2-Propanol	124-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-50
17715970-1	2007	A nanosecond time-resolved resonance Raman (ns-TR3) spectroscopic study of the triplet state benzophenone reaction with the 2-propanol hydrogen-donor solvent and subsequent reactions is presented.	Hydrogen	135-143	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-50
17715970-2	2007	The TR3 spectra show that the benzophenone triplet state (npi*) hydrogen-abstraction reaction with 2-propanol is very fast (about 10 to 20 ns) and forms a diphenylketyl radical and an associated 2-propanol radical partner.	benzophenone	30-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17715970-2	2007	The TR3 spectra show that the benzophenone triplet state (npi*) hydrogen-abstraction reaction with 2-propanol is very fast (about 10 to 20 ns) and forms a diphenylketyl radical and an associated 2-propanol radical partner.	Hydrogen	64-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17715970-2	2007	The TR3 spectra show that the benzophenone triplet state (npi*) hydrogen-abstraction reaction with 2-propanol is very fast (about 10 to 20 ns) and forms a diphenylketyl radical and an associated 2-propanol radical partner.	2-Propanol	99-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17715970-2	2007	The TR3 spectra show that the benzophenone triplet state (npi*) hydrogen-abstraction reaction with 2-propanol is very fast (about 10 to 20 ns) and forms a diphenylketyl radical and an associated 2-propanol radical partner.	diphenylketyl radical	155-176	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17715970-2	2007	The TR3 spectra show that the benzophenone triplet state (npi*) hydrogen-abstraction reaction with 2-propanol is very fast (about 10 to 20 ns) and forms a diphenylketyl radical and an associated 2-propanol radical partner.	2-propanol radical	195-213	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
17715970-3	2007	The temporal evolution of the TR3 spectra also indicates that recombination of these two radical species occurs with a time constant of about 1170 ns to produce a LAT (light absorbing transient) intermediate that is identified as the 2-[4-(hydroxylphenylmethylene)cyclohexa-2,5-dienyl]propan-2-ol (p-LAT) species.	Lactose	163-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-33
17715970-3	2007	The temporal evolution of the TR3 spectra also indicates that recombination of these two radical species occurs with a time constant of about 1170 ns to produce a LAT (light absorbing transient) intermediate that is identified as the 2-[4-(hydroxylphenylmethylene)cyclohexa-2,5-dienyl]propan-2-ol (p-LAT) species.	2-[4-(hydroxylphenylmethylene)cyclohexa-2,5-dienyl]propan-2-ol	234-296	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-33
17715970-3	2007	The temporal evolution of the TR3 spectra also indicates that recombination of these two radical species occurs with a time constant of about 1170 ns to produce a LAT (light absorbing transient) intermediate that is identified as the 2-[4-(hydroxylphenylmethylene)cyclohexa-2,5-dienyl]propan-2-ol (p-LAT) species.	p-lat	298-303	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-33
17890213-7	2007	Tamoxifen has been the gold standard endocrine therapy for hormone-receptor-positive early breast cancer for many years, and the long-term side effects of this agent are well documented.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-75
17675581-3	2007	To explore the functional importance of MR in mammalian skin, we have generated a conditional doxycycline-inducible model of MR overexpression, resulting in double-transgenic (DT) mice [keratin 5-tTa/tetO-human MR (hMR)], targeting the human MR specifically to keratinocytes of the epidermis and hair follicle (HF).	Doxycycline	94-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-127
17675581-3	2007	To explore the functional importance of MR in mammalian skin, we have generated a conditional doxycycline-inducible model of MR overexpression, resulting in double-transgenic (DT) mice [keratin 5-tTa/tetO-human MR (hMR)], targeting the human MR specifically to keratinocytes of the epidermis and hair follicle (HF).	Doxycycline	94-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-127
17574328-6	2007	MEHP-induced Nur77 transcription was inhibited by bisindolylmaleimide I (protein kinase C inhibitor) and wortmannin (phosphoinositide 3-kinase inhibitor).	mono-(2-ethylhexyl)phthalate	0-4	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
17588685-0	2007	Ionomycin-induced apoptosis of thymocytes is independent of Nur77 NBRE or NurRE binding, but is accompanied by Nur77 mitochondrial targeting.	Ionomycin	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-65
17588685-0	2007	Ionomycin-induced apoptosis of thymocytes is independent of Nur77 NBRE or NurRE binding, but is accompanied by Nur77 mitochondrial targeting.	Ionomycin	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-116
17588685-2	2007	Ionomycin treatment induces endogenous Nur77 expression as well as apoptosis and cytochrome c release in thymocytes.	Ionomycin	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
17588685-3	2007	Here it is shown for the first time that in normal thymocytes undergoing apoptosis, ionomycin induces translocation of endogenous Nur77 not only to the nucleus, but also to mitochondria.	Ionomycin	84-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	130-135
17588685-4	2007	Immunosuppressant FK506 inhibits Nur77 NBRE and NurRE binding activity but has no effect on thymocytes apoptosis, the subcellular localization of Nur77, or cytochrome c release.	Tacrolimus	18-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-38
17574328-6	2007	MEHP-induced Nur77 transcription was inhibited by bisindolylmaleimide I (protein kinase C inhibitor) and wortmannin (phosphoinositide 3-kinase inhibitor).	bisindolylmaleimide I	50-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
17574328-6	2007	MEHP-induced Nur77 transcription was inhibited by bisindolylmaleimide I (protein kinase C inhibitor) and wortmannin (phosphoinositide 3-kinase inhibitor).	Wortmannin	105-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
17574328-7	2007	Finally, ectopic expression of Nur77 markedly suppressed forskolin-induced transcriptional activation of promoters I.3 and II of the CYP19 gene.	Colforsin	57-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
17690028-6	2007	RESULTS: We propose some new strategies to achieve transplant tolerance in rodent animals via manipulating Treg function, including using histone deacetylase (HDAC) inhibitor to regulate Foxp3 transcription and enhance Treg suppression, induction of Treg-sparing apoptosis via Nur77, and identification of the co-inhibitory molecule herpes virus entry mediator (HVEM) as an effector molecule for Treg function.	treg	107-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	277-282
17543302-3	2007	The present study was designed to determine the intracellular localization of TR3 following CD437-induced nucleocytoplasmic translocation and the mechanisms involved in TR3-induced apoptosis.	CD 437	92-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-81
17601725-2	2007	Using a methylation microarray, we analysed 117 candidate genes in hormone receptor-positive tumours from 109 breast cancer patients treated by adjuvant tamoxifen.	Tamoxifen	153-162	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-83
17600153-3	2007	To unveil the structural organization of NGFI-B in solution, we determined the quaternary structure of the NGFI-B LBD by a combination of ab initio procedures from small-angle X-ray scattering (SAXS) data and hydrogen-deuterium exchange followed by mass spectrometry.	Deuterium	218-227	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-113
17601725-10	2007	Based on PITX2 methylation, about half of hormone receptor-positive, node-negative breast cancer patients receiving adjuvant tamoxifen monotherapy can be considered low-risk regarding development of distant recurrences and may thus be spared adjuvant chemotherapy.	Tamoxifen	125-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-58
17146432-0	2007	6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1alpha resulting in new vessel formation.	Mercaptopurine	0-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39
17515570-0	2007	Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.	Tamoxifen	84-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	16-32
17450590-0	2007	Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.	Tamoxifen	134-143	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
17450590-3	2007	The authors conducted a retrospective analysis to identify risk factors of early recurrences in hormone receptor (HR)-positive, postmenopausal women within the first 3 years of adjuvant tamoxifen.	Tamoxifen	186-195	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-112
17450590-3	2007	The authors conducted a retrospective analysis to identify risk factors of early recurrences in hormone receptor (HR)-positive, postmenopausal women within the first 3 years of adjuvant tamoxifen.	Tamoxifen	186-195	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-116
17439837-9	2007	In LNNBCs with positive HR status, HER-2 overexpression and/or amplification confer an aggressive tumor phenotype, and this might be related to tamoxifen unresponsiveness.	Tamoxifen	144-153	nuclear receptor subfamily 4 group A member 1	Homo sapiens	24-26
17023523-4	2007	Here we showed that JNK activator anisomycin induced TR3 phosphorylation through JNK1 rather than p38 and ERK signals, which is mediated by its upstream factors MAPK kinase 4 and MAPK kinase 7.	Anisomycin	34-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-56
17690503-0	2007	Relation of serum levels of estrogen and dehydroepiandrosterone sulfate to hormone receptor status among postmenopausal women with breast cancer.	Dehydroepiandrosterone Sulfate	41-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
18062723-5	2007	In a noncomparative phase II study of trastuzumab plus letrozole in postmenopausal women with HER2 and HR co-positive metastatic breast cancer, the majority of adverse events were mild or moderate in severity.	Letrozole	55-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	103-105
17492927-5	2007	Letrozole is the only aromatase inhibitor to demonstrate a significant 27% reduction in the risk of distant metastases (p = 0.001) in the clinically relevant, hormone receptor-positive population in the initial adjuvant setting.	Letrozole	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-175
17234778-4	2007	The induction of apoptosis and TRAIL by DIM-C-pPhOCH3 was significantly inhibited by a small inhibitory RNA for Nur77 (iNur77); however, it was evident from RNA interference studies that DIM-C-pPhOCH3 also induced Nur77-independent apoptosis.	DIM-C-pPhOCH3	40-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-117
17234778-4	2007	The induction of apoptosis and TRAIL by DIM-C-pPhOCH3 was significantly inhibited by a small inhibitory RNA for Nur77 (iNur77); however, it was evident from RNA interference studies that DIM-C-pPhOCH3 also induced Nur77-independent apoptosis.	DIM-C-pPhOCH3	40-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
17234778-4	2007	The induction of apoptosis and TRAIL by DIM-C-pPhOCH3 was significantly inhibited by a small inhibitory RNA for Nur77 (iNur77); however, it was evident from RNA interference studies that DIM-C-pPhOCH3 also induced Nur77-independent apoptosis.	DIM-C-pPhOCH3	187-200	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
17234778-5	2007	Analysis of DIM-C-pPhOCH3-induced gene expression using microarrays identified several proapoptotic genes, and analysis by reverse transcription-PCR in the presence or absence of iNur77 showed that induction of programmed cell death gene 1 was Nur77 dependent, whereas induction of cystathionase and activating transcription factor 3 was Nur77 independent.	DIM-C-pPhOCH3	12-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	244-249
17023523-5	2007	We also identified the exact phosphorylation site of JNK to be serine 95 at the N terminus of TR3, around which a classical JNK phosphorylation motif exists.	Serine	63-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-97
17566296-4	2007	At present, the identity of the receptor is unknown; the hormone-receptor interactions are facilitated by albumin and disulphide bonds.	disulphide	118-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-73
17220670-6	2007	Therefore, HR and HER 2 were associated with the sensitivity to a chemotherapeutic agent, taxane.	taxane	90-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-13
17150035-6	2007	Agents, such as 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN/CD437), which induce Nur77 migration from the nucleus to mitochondria, effectively induce apoptosis of cancer cells.	CD 437	16-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-114
17220670-2	2007	Among the patients treated with taxane alone,the response rates were 37.5% (n=67) in the HR (+) patients and 14.6% (n=41) in the HR (-) patients (p=0.0131).	taxane	32-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-91
17220670-3	2007	In particular, taxane resistance was suggested in the HR (-)/HER 2 (-) patients (response rate: 4.2%, n=24).	taxane	15-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-56
17220670-4	2007	Concerning combination therapy with trastuzumab and taxane, the response rate were 52.8% in the HR (+)/HER 2 (+) patients and 60.4% in the HR (-)/HER 2 (+) patients.	taxane	52-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-98
17220670-4	2007	Concerning combination therapy with trastuzumab and taxane, the response rate were 52.8% in the HR (+)/HER 2 (+) patients and 60.4% in the HR (-)/HER 2 (+) patients.	taxane	52-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-141
17220670-5	2007	In 27 of these patients, single therapy with taxane was switched to combination therapy with taxane and trastuzumab after they became resistant to taxane, and 8.3% of the HR (+)/HER 2 (+) patients and 53.3% of the HR (-)/HER 2 (+) patients responded to this combination therapy (p=0.0192), suggesting the synergistic effects of the two agents in HR (-)/HER 2 (+) patients.	taxane	45-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-173
16904076-2	2006	Details of interaction revealed that C-terminal ligand binding domain (LBD) of Nur77 specifically interacted with highly conserved glycine-rich loop of PKC required for catalytic activity.	Glycine	131-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-84
16574409-2	2006	Extent of primary biodegradation of a nonylphenol ethoxylates (NP-10) was excess of 92% after 1.5 days, and reached 99% after 2 days, which was similar to the results obtained using modified CTAS (thiocyanate active substances) method.	ethoxylates	50-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
16574409-2	2006	Extent of primary biodegradation of a nonylphenol ethoxylates (NP-10) was excess of 92% after 1.5 days, and reached 99% after 2 days, which was similar to the results obtained using modified CTAS (thiocyanate active substances) method.	thiocyanate	197-208	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
16574409-3	2006	Degradation of benzene ring of NP-10 was studied using UV-absorbance at 277 nm in chloroform.	Benzene	15-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
16574409-3	2006	Degradation of benzene ring of NP-10 was studied using UV-absorbance at 277 nm in chloroform.	Chloroform	82-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
17134767-0	2007	Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation.	Dopamine	51-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
16959170-26	2006	We accepted that hormone receptor status (ER) for hormonal therapy such as tamoxifen and prediction of response to trastuzumab by HER2 did not require systematic review, as the mechanism of action of these drugs requires intact receptors.	Tamoxifen	75-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-33
16940812-6	2006	We treated three premenopausal patients with hormone receptor-positive metastatic breast cancer with combined oophorectomy or ovarian irradiation and anastrozole.	Anastrozole	150-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-61
16827799-0	2006	Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1.	Tyrosine	12-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-87
16760268-1	2006	BACKGROUND: Hormone receptor (HR)-positive breast cancer cells grow through estrogen receptor (ER)-signaling pathways that mediate both genomic and nongenomic actions, which cross-talk with growth factors associated with resistance to tamoxifen.	Tamoxifen	235-244	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-28
16760268-1	2006	BACKGROUND: Hormone receptor (HR)-positive breast cancer cells grow through estrogen receptor (ER)-signaling pathways that mediate both genomic and nongenomic actions, which cross-talk with growth factors associated with resistance to tamoxifen.	Tamoxifen	235-244	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-32
16899609-1	2006	PURPOSE: Tamoxifen has long been the drug of choice in adjuvant endocrine therapy of steroid hormone receptor-positive breast cancer, and it still remains important due to its well-documented beneficial effect.	Tamoxifen	9-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-109
16413707-0	2006	Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps?	Tamoxifen	5-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-50
16413707-8	2006	CONCLUSIONS: Tamoxifen has a significant affect on hormone receptor expression and markers of apoptosis in endometrial polyps.	Tamoxifen	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-67
16434970-2	2006	Nur77 translocation is induced by certain apoptotic stimuli, including the synthetic retinoid-related 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN)/CD437 class.	Retinoids	85-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
16723716-7	2006	Finally, stretch-mediated proliferation was inhibited by 6-mercaptopurine, an agonist of TR3.	Mercaptopurine	57-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-92
16434970-6	2006	In addition, several JNK upstream activators, including the phorbol ester TPA, anisomycin and MAPK kinase kinase-1 (MEKK1), phosphorylated Nur77 and induced its nuclear export.	Phorbol Esters	60-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
16434970-2	2006	Nur77 translocation is induced by certain apoptotic stimuli, including the synthetic retinoid-related 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN)/CD437 class.	CD 437	102-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
16434970-6	2006	In addition, several JNK upstream activators, including the phorbol ester TPA, anisomycin and MAPK kinase kinase-1 (MEKK1), phosphorylated Nur77 and induced its nuclear export.	Tetradecanoylphorbol Acetate	74-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
16434970-6	2006	In addition, several JNK upstream activators, including the phorbol ester TPA, anisomycin and MAPK kinase kinase-1 (MEKK1), phosphorylated Nur77 and induced its nuclear export.	Anisomycin	79-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
16434970-2	2006	Nur77 translocation is induced by certain apoptotic stimuli, including the synthetic retinoid-related 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN)/CD437 class.	CD 437	174-179	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
16434970-3	2006	In this study, we investigated the molecular mechanism by which AHPN/CD437 analog (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces Nur77 nuclear export.	CD 437	64-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-169
16434970-3	2006	In this study, we investigated the molecular mechanism by which AHPN/CD437 analog (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces Nur77 nuclear export.	CD 437	69-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-169
16434970-3	2006	In this study, we investigated the molecular mechanism by which AHPN/CD437 analog (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces Nur77 nuclear export.	4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid	82-143	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-169
16434970-3	2006	In this study, we investigated the molecular mechanism by which AHPN/CD437 analog (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces Nur77 nuclear export.	4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid	145-154	nuclear receptor subfamily 4 group A member 1	Homo sapiens	164-169
16434970-4	2006	Our results demonstrate that 3-Cl-AHPC effectively activated Jun N-terminal kinase (JNK), which phosphorylates Nur77.	3-cl	29-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	111-116
16434970-5	2006	Inhibition of JNK activation by a JNK inhibitor suppressed 3-Cl-AHPC-induced Nur77 nuclear export and apoptosis.	4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid	59-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-82
16631355-0	2006	Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders.	Dopamine	13-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-68
16585961-9	2006	In concert, these data promote a distinctive mechanism for normal human development whereby cortisol production, determined by transient NGFI-B and HSD3B2 expression, provides feedback at the anterior pituitary to modulate androgen biosynthesis and safeguard normal female sexual differentiation.	Hydrocortisone	92-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-143
16446340-1	2006	PURPOSE: Adjuvant chemotherapy followed by tamoxifen is a standard treatment option for women with intermediate or high-risk hormone receptor-positive breast cancer.	Tamoxifen	43-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
16493264-6	2006	In addition, some epidemiologic studies have reported that hormone-receptor-positive breast tumors are more responsive to aspirin, which is consistent with these preclinical findings.	Aspirin	122-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-75
16293862-12	2005	TAM is effective in HR-positive disease, but not in HR-negative disease.	Tamoxifen	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-22
16392918-5	2005	Despite this, the attraction basin around each GM is relatively large, since after all their atomic coordinates are randomly displaced by values as high as 2.0 bohrs, the perturbed structures, upon reoptimization, relax back to the GM in more than 50% of the cases (except for n=10 and 11).	gm	47-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	277-288
16198568-3	2005	Tamoxifen significantly decreases the risk of recurrence and improves survival in all women with hormone receptor-positive invasive breast cancer, including women 70 years and older.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
16204640-10	2005	Three of those (an orphan nuclear receptor NUR77, a guanosine 5"-diphosphate/guanosine 5"-triphosphate exchange factor RABEX5, and a PRK1-associated protein AWP1) were particularly potent inhibitors of NF-kappaB activation.	Guanosine Triphosphate	77-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-48
16288995-2	2005	Although NGFI-B also forms a heterodimer with the retinoid X receptor (RXR), a receptor for 9-cis retinoic acid (9CRA), endogenous targets of the heterodimer have not been identified.	Alitretinoin	92-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	9-15
16288995-3	2005	We investigated the role of RXR ligand binding in NGFI-B/RXR activation and found that dibenzodiazepine-derived ligands, such as the weak RXR agonist HX600, selectively activate NGFI-B/RXR heterodimers.	6-benzyl-5H-dibenzodiazepine	87-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-56
16288995-3	2005	We investigated the role of RXR ligand binding in NGFI-B/RXR activation and found that dibenzodiazepine-derived ligands, such as the weak RXR agonist HX600, selectively activate NGFI-B/RXR heterodimers.	6-benzyl-5H-dibenzodiazepine	87-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	178-184
16293862-6	2005	CAF had slightly better OS than CMF (85% v 82%, HR = 1.19 for CMF v CAF; 95% CI, 0.99 to 1.43); values were statistically significant in the planned one-sided test (P = .03).	cafestol palmitate	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-50
15896973-6	2005	In this specific territory, the number of Nur77-positive cells was decreased, in response to L-DOPA, when compared to the medial part of the lesioned striatum.	Levodopa	93-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-47
16293862-9	2005	For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05).	Tamoxifen	26-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-6
16293862-9	2005	For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05).	Tamoxifen	26-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-53
16293862-9	2005	For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05).	Tamoxifen	26-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-53
16293862-9	2005	For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05).	Tamoxifen	26-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-53
16293862-9	2005	For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05).	Tamoxifen	26-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-53
16293862-9	2005	For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05).	Tamoxifen	26-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-53
16197980-1	2005	The biotransformation and mineralization of a mixture of two polycyclic aromatic hydrocarbons (PAHs), anthracene and pyrene, which are known contaminants of soil and groundwater, by an enrichment culture in the presence or absence of 100 mg l(-1) Tergitol NP-10, a non-ionic surfactant, and at temperatures of 10 degrees C and 25 degrees C were investigated.	Polycyclic Aromatic Hydrocarbons	95-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	256-261
16197980-1	2005	The biotransformation and mineralization of a mixture of two polycyclic aromatic hydrocarbons (PAHs), anthracene and pyrene, which are known contaminants of soil and groundwater, by an enrichment culture in the presence or absence of 100 mg l(-1) Tergitol NP-10, a non-ionic surfactant, and at temperatures of 10 degrees C and 25 degrees C were investigated.	pyrene	117-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	256-261
15896973-7	2005	L-DOPA treatment increased dopamine D3 receptor and glutamate transporter 1 (GLT1) mRNA expression in the lesioned striatum and that, specifically in an area overlapping one of Nur77 decrease and of NT/DYN induction.	Levodopa	0-6	nuclear receptor subfamily 4 group A member 1	Homo sapiens	177-182
16009706-1	2005	A series of 30 N10-substituted phenoxazines were synthesized and screened as potential inhibitors of Akt.	phenoxazine	31-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-18
16264271-2	2005	It has been shown that the Nur77 promoter is activated by at least two signaling pathways, one mediated by calcium and the other by protein kinase C (PKC).	Calcium	107-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
16264271-3	2005	MEF2D has been known to regulate Nur77 expression in a calcium- dependent manner.	Calcium	55-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-38
16140267-9	2005	This finding represents a novel crosstalk between ERK2 and RXR signaling pathways, and explains how two independent inhibitors of apoptosis (EGF and 9-cis-retinoic acid) may cooperate to regulate nuclear targeting of apoptosis inducer NGFI-B.	Alitretinoin	149-168	nuclear receptor subfamily 4 group A member 1	Homo sapiens	235-241
16205597-6	2005	It is well established that tamoxifen (T), a selective estrogen receptor modulator (SERM), improves overall survival (OS) in women with hormone receptor (HR) positive breast cancer.	Tamoxifen	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	136-152
16205597-6	2005	It is well established that tamoxifen (T), a selective estrogen receptor modulator (SERM), improves overall survival (OS) in women with hormone receptor (HR) positive breast cancer.	Tamoxifen	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-156
16051191-0	2005	Nur77 nuclear import and its NBRE-binding activity in thymic lymphoma cells are regulated by different mechanisms sensitive to FK506 or HA1004.	Tacrolimus	127-132	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
16009706-3	2005	Substitutions at the 2-position (Cl or CF3) did not alter inhibitory activity, whereas N10-substitutions with derivatives having acetyl (20B) or morpholino (12B) side chain lost activity compared with propyl or butyl substituents (7B and 14B).	Cysteine	129-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-90
16051191-0	2005	Nur77 nuclear import and its NBRE-binding activity in thymic lymphoma cells are regulated by different mechanisms sensitive to FK506 or HA1004.	N-(2-guanidinoethyl)-5-isoquinolinesulfonamide	136-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
16051191-2	2005	In apoptosis-resistant cells, ionomycin-induced Nur77 strongly binds DNA during the first 2 h of response, in contrast to lymphoma cells treated with ionomycin together with FK506 or HA1004, which undergo massive apoptosis.	Ionomycin	30-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
16051191-3	2005	We show that Nur77 could discriminate between calcium signals sensitive to FK506 and those sensitive to HA1004, as the inhibitors differentially regulate the kinetics of Nur77 nuclear import, and FK506, unlike HA1004, inhibits Nur77 DNA-binding activity.	Calcium	46-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
16051191-3	2005	We show that Nur77 could discriminate between calcium signals sensitive to FK506 and those sensitive to HA1004, as the inhibitors differentially regulate the kinetics of Nur77 nuclear import, and FK506, unlike HA1004, inhibits Nur77 DNA-binding activity.	Tacrolimus	75-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
16051191-3	2005	We show that Nur77 could discriminate between calcium signals sensitive to FK506 and those sensitive to HA1004, as the inhibitors differentially regulate the kinetics of Nur77 nuclear import, and FK506, unlike HA1004, inhibits Nur77 DNA-binding activity.	N-(2-guanidinoethyl)-5-isoquinolinesulfonamide	104-110	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
16009706-3	2005	Substitutions at the 2-position (Cl or CF3) did not alter inhibitory activity, whereas N10-substitutions with derivatives having acetyl (20B) or morpholino (12B) side chain lost activity compared with propyl or butyl substituents (7B and 14B).	Morpholinos	145-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-90
16051191-3	2005	We show that Nur77 could discriminate between calcium signals sensitive to FK506 and those sensitive to HA1004, as the inhibitors differentially regulate the kinetics of Nur77 nuclear import, and FK506, unlike HA1004, inhibits Nur77 DNA-binding activity.	Tacrolimus	196-201	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
16013898-5	2005	In the modafinil (N = 10) and placebo (N = 10) groups, fatigue improved significantly over time (p &lt; .01), but there were no differences between groups on changes in fatigue, positive and negative symptoms, or cognition.	Modafinil	7-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-24
15956351-3	2005	Recently, we found that the purine antimetabolite 6-Mercaptopurine (6-MP), which is widely used as an anti-neoplastic and anti-inflammatory drug, modulated the NR4A1-3 subfamily.	purine	28-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-165
16002533-9	2005	The corepressor SMRT interacted with SF-1 in the presence of AII and with nur77 in cells treated with forskolin.	Colforsin	102-111	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-79
16002533-6	2005	In the H295R adrenal tumour cell line, SF-1 and nur77 transcripts were increased in cells in the presence of forskolin, whereas nur77 mRNA was also induced with angiotensin II (AII).	Colforsin	109-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
15956351-3	2005	Recently, we found that the purine antimetabolite 6-Mercaptopurine (6-MP), which is widely used as an anti-neoplastic and anti-inflammatory drug, modulated the NR4A1-3 subfamily.	Mercaptopurine	50-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-165
15956351-3	2005	Recently, we found that the purine antimetabolite 6-Mercaptopurine (6-MP), which is widely used as an anti-neoplastic and anti-inflammatory drug, modulated the NR4A1-3 subfamily.	Mercaptopurine	68-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-165
15896025-3	2005	In the mixed system, DM is identified to be the "active" component and NP-10 is the "passive" one for the process of adsorption on alumina, while their roles are reversed for silica.	Aluminum Oxide	131-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-76
15984106-1	2005	(1) After surgical excision of hormone-receptor-positive non metastatic breast cancer in postmenopausal women, a meta-analysis of 55 trials has shown that adjuvant tamoxifen, 20 mg/day for 5 years, reduces the risk of relapse by 8% and the risk of death by 5% (absolute values).	Tamoxifen	164-173	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-47
15984106-11	2005	(5) Pending results of further clinical trials, tamoxifen remains the first-line adjuvant hormone therapy for most postmenopausal women with hormone-receptor-positive non metastatic breast cancer.	Tamoxifen	48-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-157
15865850-0	2005	Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.	Fulvestrant	34-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-91
16833683-7	2005	This provides a framework to interpret the differences observed in the TR3 spectral and triplet lifetime obtained in the neat MeCN solvent (attributed to the free MAP triplet state) and the 50% H2O/50% MeCN solvent (due to the triplet of the hydrogen-bond complex).	acetonitrile	126-130	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-74
16833683-7	2005	This provides a framework to interpret the differences observed in the TR3 spectral and triplet lifetime obtained in the neat MeCN solvent (attributed to the free MAP triplet state) and the 50% H2O/50% MeCN solvent (due to the triplet of the hydrogen-bond complex).	Water	194-197	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-74
16833683-7	2005	This provides a framework to interpret the differences observed in the TR3 spectral and triplet lifetime obtained in the neat MeCN solvent (attributed to the free MAP triplet state) and the 50% H2O/50% MeCN solvent (due to the triplet of the hydrogen-bond complex).	acetonitrile	202-206	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-74
16833683-7	2005	This provides a framework to interpret the differences observed in the TR3 spectral and triplet lifetime obtained in the neat MeCN solvent (attributed to the free MAP triplet state) and the 50% H2O/50% MeCN solvent (due to the triplet of the hydrogen-bond complex).	Hydrogen	242-250	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-74
15767262-3	2005	We show that Rb and the related proteins p107 and p130 enhance the activity of NRs related to NGFI-B (Nur factors) through direct interactions with NGFI-B and SRC-2.	Rubidium	13-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-100
15767262-3	2005	We show that Rb and the related proteins p107 and p130 enhance the activity of NRs related to NGFI-B (Nur factors) through direct interactions with NGFI-B and SRC-2.	Rubidium	13-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	148-154
15716272-6	2005	Similarly, mutation of Met414 in helix 3 to leucine or of Leu591 in helix 12 to isoleucine (the corresponding residues found in NGFI-B) significantly affects Nurr1 transactivation.	Isoleucine	80-90	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-134
15865850-7	2005	In light of the results of comparative phase III trials, fulvestrant is effective and well tolerated in the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer.	Fulvestrant	57-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-163
15615861-11	2005	Therefore, our data suggest that the NGFI-B may play a significant role in up-regulation of HSD3B2 that leads to the increase in progesterone production that is seen in granulosa cells at ovulation.	Progesterone	129-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-43
15625237-7	2005	Nur77 and SHP competitively bound to cAMP response element-binding protein-binding protein and the expression of coactivators, such as cAMP response element-binding protein-binding protein and activating signal cointegrator-2, recovered the decreased function of Nur77 caused by SHP.	Cyclic AMP	37-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
15625237-7	2005	Nur77 and SHP competitively bound to cAMP response element-binding protein-binding protein and the expression of coactivators, such as cAMP response element-binding protein-binding protein and activating signal cointegrator-2, recovered the decreased function of Nur77 caused by SHP.	Cyclic AMP	37-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	263-268
15625237-7	2005	Nur77 and SHP competitively bound to cAMP response element-binding protein-binding protein and the expression of coactivators, such as cAMP response element-binding protein-binding protein and activating signal cointegrator-2, recovered the decreased function of Nur77 caused by SHP.	Cyclic AMP	135-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
15625237-7	2005	Nur77 and SHP competitively bound to cAMP response element-binding protein-binding protein and the expression of coactivators, such as cAMP response element-binding protein-binding protein and activating signal cointegrator-2, recovered the decreased function of Nur77 caused by SHP.	Cyclic AMP	135-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	263-268
15767916-12	2005	Hormone therapy with progestogens (hormone receptor expression of the tumor is 71% for estrogens and 95% for progesterone) is widely studied in the literature with a 46% response rate and 46% rate of disease stabilization.	Progesterone	109-121	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-51
15615861-4	2005	Real-time RT-PCR was used to quantify mRNA expression levels of the NGFI-B family members in human ovarian follicles, corpora lutea and in human granulosa cells after FSH, phorbol ester (TPA) and forskolin treatment.	Phorbol Esters	172-185	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-74
15615861-4	2005	Real-time RT-PCR was used to quantify mRNA expression levels of the NGFI-B family members in human ovarian follicles, corpora lutea and in human granulosa cells after FSH, phorbol ester (TPA) and forskolin treatment.	Tetradecanoylphorbol Acetate	187-190	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-74
15615861-4	2005	Real-time RT-PCR was used to quantify mRNA expression levels of the NGFI-B family members in human ovarian follicles, corpora lutea and in human granulosa cells after FSH, phorbol ester (TPA) and forskolin treatment.	Colforsin	196-205	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-74
15615861-6	2005	In human granulosa tumour (HGT) cells, the NGFI-B expression increased after TPA, and to a lesser extent, after forskolin treatment.	Tetradecanoylphorbol Acetate	77-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-49
15615861-6	2005	In human granulosa tumour (HGT) cells, the NGFI-B expression increased after TPA, and to a lesser extent, after forskolin treatment.	Colforsin	112-121	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-49
15615861-7	2005	Treatment of primary cultures of human granulosa cells with forskolin and FSH rapidly increased the NGFI-B mRNA levels followed by an increase in 3beta-hydroxysteroid dehydrogenase type 2 (HSD3B2).	Colforsin	60-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-106
15668953-0	2005	Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.	Paraffin	127-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-102
15668953-1	2005	BACKGROUND: For 4 years we used a multiparameter DNA flow cytometric (MP-FCM) technique to assess steroid hormone receptor expression in the diagnostic workup of routinely processed formalin-fixed, paraffin-embedded breast carcinomas as an alternative to immunohistochemistry (IHC) for the quantification of hormone receptor-positive cells.	Formaldehyde	182-190	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-122
15668953-1	2005	BACKGROUND: For 4 years we used a multiparameter DNA flow cytometric (MP-FCM) technique to assess steroid hormone receptor expression in the diagnostic workup of routinely processed formalin-fixed, paraffin-embedded breast carcinomas as an alternative to immunohistochemistry (IHC) for the quantification of hormone receptor-positive cells.	Paraffin	198-206	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-122
15713533-5	2005	Deletion studies of cells stably transfected with truncated hMR indicated that the N-terminal and the DNA binding domains of hMR are essential for enhancement of the catecholamine signal transduction pathway.	Catecholamines	166-179	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-63
15713533-5	2005	Deletion studies of cells stably transfected with truncated hMR indicated that the N-terminal and the DNA binding domains of hMR are essential for enhancement of the catecholamine signal transduction pathway.	Catecholamines	166-179	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-128
15713533-6	2005	In conclusion, our findings suggest a novel interplay between cAMP and MR signaling pathways.	Cyclic AMP	62-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-73
15813510-0	2005	Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.	Fulvestrant	41-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-109
16198055-1	2005	This paper outlines the development of fulvestrant, the first in a new class of antioestrogen agents with no agonist effects, to be used for the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.	Fulvestrant	39-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	158-174
15813510-0	2005	Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.	Fulvestrant	54-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-109
15586024-9	2005	Furthermore, recent studies demonstrating the effect of isoflavones on prostate-specific antigen, testosterone, estrogen, and hormone receptor expression in human subjects will be reviewed.	Isoflavones	56-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-142
16203663-6	2005	It is well established that tamoxifen, a selective estrogen receptor modulator (SERM), improves overall survival (OS) in women with hormone receptor (HR) positive breast cancer.	Tamoxifen	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-148
16203663-6	2005	It is well established that tamoxifen, a selective estrogen receptor modulator (SERM), improves overall survival (OS) in women with hormone receptor (HR) positive breast cancer.	Tamoxifen	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-152
15632249-2	2005	Here we discuss the influence of clinical trial results from the Arimidex, Tamoxifen Alone or in Combination trial on the usage of tamoxifen and anastrozole in the treatment of postmenopausal women with hormone receptor-positive early breast cancer.	Anastrozole	65-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-219
15486232-7	2005	Interestingly, ectopic expression of NURR1 or NGFI-B severely attenuated the cAMP-responsive activation of the ovary-specific aromatase promoter.	Cyclic AMP	77-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-52
15486232-9	2005	The cis-elements responsible for NURR1/NGFI-B-mediated repression were mapped to the minimal aromatase promoter sequence that confers camp responsiveness.	Cyclic AMP	134-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-45
15632249-2	2005	Here we discuss the influence of clinical trial results from the Arimidex, Tamoxifen Alone or in Combination trial on the usage of tamoxifen and anastrozole in the treatment of postmenopausal women with hormone receptor-positive early breast cancer.	Tamoxifen	75-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-219
15632249-2	2005	Here we discuss the influence of clinical trial results from the Arimidex, Tamoxifen Alone or in Combination trial on the usage of tamoxifen and anastrozole in the treatment of postmenopausal women with hormone receptor-positive early breast cancer.	Tamoxifen	131-140	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-219
15632249-2	2005	Here we discuss the influence of clinical trial results from the Arimidex, Tamoxifen Alone or in Combination trial on the usage of tamoxifen and anastrozole in the treatment of postmenopausal women with hormone receptor-positive early breast cancer.	Anastrozole	145-156	nuclear receptor subfamily 4 group A member 1	Homo sapiens	203-219
15456750-6	2004	Intrinsic fluorescence of a tryptophan at residue 698 (Trp-698) in the most N-terminal motif was cooperatively quenched by the addition of Ca2+ to Asn-700 Tr2, Tr3, and Tr4 constructs.	Tryptophan	28-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-163
15456750-6	2004	Intrinsic fluorescence of a tryptophan at residue 698 (Trp-698) in the most N-terminal motif was cooperatively quenched by the addition of Ca2+ to Asn-700 Tr2, Tr3, and Tr4 constructs.	Tryptophan	55-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-163
15456750-7	2004	In Ser-700 constructs, quenching of Trp-698 was incomplete in the Tr2 and Tr3 constructs and complete only in the Tr4 construct.	Tryptophan	36-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-77
15506748-7	2004	Our TR3 data reveal that upon ferrous cyt c photoexcitation, (i) distal Met side chain is instantly released, producing a five-coordinated domed heme structure, (ii) proximal His side chain, coupled to the heme, exhibits distortion due to strain exerted by the protein, and (iii) alteration in heme-cysteine coupling takes place along with the relaxation of the protein-induced deformations of the heme macrocycle.	Cysteine	299-307	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
15601544-0	2004	[Translocation of orphan receptor TR3 from nuclei to mitochondria induced by staurosporine].	Staurosporine	77-90	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-37
15601544-4	2004	This study was to investigate the mechanism by which STS induces apoptosis of gastric cancer cell line BGC-823,and its correlation with translocation of TR3 in BGC-823 cells.	Staurosporine	53-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-156
15319449-9	2004	Moreover, CREB-Nur77 interaction was increased by CREB phosphorylation at Ser-133 and the dominant-negative mutant CREB-M1 efficiently inhibited the synergistic LIF-CRH response.	Serine	74-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-20
15319449-11	2004	We conclude that both CREB phosphorylation at Ser-133 and level of CREB expression are crucial in LIF-CRH synergism where CREB, without direct DNA binding, could improve the stability of Nur77 and STAT1-3 binding to POMC promoter and facilitate the recruitment of coactivators.	Serine	46-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	187-192
15506748-5	2004	The Fe-His stretching mode at 216 cm-1 has been observed in photoproduct TR3 spectra for the first time for a c-type heme.	fe-his	4-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-76
15506748-5	2004	The Fe-His stretching mode at 216 cm-1 has been observed in photoproduct TR3 spectra for the first time for a c-type heme.	Heme	117-121	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-76
15506748-7	2004	Our TR3 data reveal that upon ferrous cyt c photoexcitation, (i) distal Met side chain is instantly released, producing a five-coordinated domed heme structure, (ii) proximal His side chain, coupled to the heme, exhibits distortion due to strain exerted by the protein, and (iii) alteration in heme-cysteine coupling takes place along with the relaxation of the protein-induced deformations of the heme macrocycle.	Heme	145-149	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
15506748-7	2004	Our TR3 data reveal that upon ferrous cyt c photoexcitation, (i) distal Met side chain is instantly released, producing a five-coordinated domed heme structure, (ii) proximal His side chain, coupled to the heme, exhibits distortion due to strain exerted by the protein, and (iii) alteration in heme-cysteine coupling takes place along with the relaxation of the protein-induced deformations of the heme macrocycle.	Heme	206-210	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
15506748-7	2004	Our TR3 data reveal that upon ferrous cyt c photoexcitation, (i) distal Met side chain is instantly released, producing a five-coordinated domed heme structure, (ii) proximal His side chain, coupled to the heme, exhibits distortion due to strain exerted by the protein, and (iii) alteration in heme-cysteine coupling takes place along with the relaxation of the protein-induced deformations of the heme macrocycle.	Heme	206-210	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-7
15666798-0	2004	NGFI-B is important for induction of SF-1 dependent transcription in response to cAMP.	Cyclic AMP	81-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-6
15317822-5	2004	The MLN944 molecule adopts a significantly unexpected conformation and side chain orientation in the DNA complex, with the N10 on the phenazine ring protonated at pH 7.	phenazine	134-143	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-126
15378476-10	2004	CONCLUSIONS: Current data support anastrozole as first-line adjuvant hormonal therapy, or a change to AIs after 2-3 years of tamoxifen, or the use of letrozole at the end of a 5-year course of tamoxifen as first-choice treatment options for the management of hormone receptor-positive breast carcinoma in postmenopausal women.	Anastrozole	34-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	259-275
15476902-11	2004	RESULTS: Anastrozole, letrozole, and exemestane are the 3 commercially available aromatase inhibitors approved by the US Food and Drug Administration for the treatment of hormone receptor-positive breast cancer in postmenopausal women.	Anastrozole	9-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-187
15387586-1	2004	Pico- and nanosecond time-resolved resonance Raman (TR3) spectroscopy have been utilized to study the dynamics and structure of p-hydroxyacetophenone (HA) and the p-hydroxyphenacyl-caged phototrigger compound p-hydroxyphenacyl diethyl phosphate (HPDP) in acetonitrile solution.	4-hydroxyacetophenone	128-149	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-55
15208301-11	2004	Infection of cultured human adrenal cells with adenovirus-containing NGFIB increased cortisol production by 8-fold and increased expression of HSD3B2 mRNA 26-fold over that observed in mock-infected cells.	Hydrocortisone	85-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
15347434-1	2004	Tamoxifen is currently a standard of care for postmenopausal patients with breast cancer with hormone receptor-positive tumors who are candidates for adjuvant endocrine therapy.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-110
15347435-6	2004	The results of 2 large adjuvant trials using AIs sequentially with tamoxifen in postmenopausal women with early-stage, HR-positive breast cancer have been reported.	Tamoxifen	67-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-121
15387586-1	2004	Pico- and nanosecond time-resolved resonance Raman (TR3) spectroscopy have been utilized to study the dynamics and structure of p-hydroxyacetophenone (HA) and the p-hydroxyphenacyl-caged phototrigger compound p-hydroxyphenacyl diethyl phosphate (HPDP) in acetonitrile solution.	4-hydroxyacetophenone	151-153	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-55
15387586-1	2004	Pico- and nanosecond time-resolved resonance Raman (TR3) spectroscopy have been utilized to study the dynamics and structure of p-hydroxyacetophenone (HA) and the p-hydroxyphenacyl-caged phototrigger compound p-hydroxyphenacyl diethyl phosphate (HPDP) in acetonitrile solution.	p-hydroxyphenacyl	163-180	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-55
15342804-7	2004	CONCLUSIONS: As compared with tamoxifen alone, radiotherapy plus tamoxifen significantly reduces the risk of breast and axillary recurrence after lumpectomy in women with small, node-negative, hormone-receptor-positive breast cancers.	Tamoxifen	65-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	193-209
15016657-0	2004	Induction of orphan nuclear receptor Nur77 gene expression and its role in cadmium-induced apoptosis in lung.	Cadmium	75-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-42
15016657-4	2004	In the present study, we characterized the induction of the Nur77 family genes in the lungs after cadmium exposure.	Cadmium	98-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-65
15016657-5	2004	Nur77, Nor-1 and Nurr1 were all induced after cadmium treatment in a dose- and time-dependent manner in WI-38 and A549 lung cell lines.	Cadmium	46-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
15016657-6	2004	Treatment with inhibitors of signaling pathways, such as PD98059 and H89, almost completely blocked the expression of Nur77, indicating that the extracellular signal-regulated kinase and protein kinase A signaling pathways are important in cadmium-induced Nur77 expression.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	57-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
15016657-6	2004	Treatment with inhibitors of signaling pathways, such as PD98059 and H89, almost completely blocked the expression of Nur77, indicating that the extracellular signal-regulated kinase and protein kinase A signaling pathways are important in cadmium-induced Nur77 expression.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	57-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	256-261
15016657-6	2004	Treatment with inhibitors of signaling pathways, such as PD98059 and H89, almost completely blocked the expression of Nur77, indicating that the extracellular signal-regulated kinase and protein kinase A signaling pathways are important in cadmium-induced Nur77 expression.	Cadmium	240-247	nuclear receptor subfamily 4 group A member 1	Homo sapiens	118-123
15016657-6	2004	Treatment with inhibitors of signaling pathways, such as PD98059 and H89, almost completely blocked the expression of Nur77, indicating that the extracellular signal-regulated kinase and protein kinase A signaling pathways are important in cadmium-induced Nur77 expression.	Cadmium	240-247	nuclear receptor subfamily 4 group A member 1	Homo sapiens	256-261
15016657-7	2004	When a plasmid encoding dominant-negative Nur77 was transfected into A549 cells, cadmium-induced apoptotic changes, such as chromosomal condensation and Bax expression, were significantly reduced, suggesting that the expression of Nur77 plays an important role in cadmium-induced apoptosis.	Cadmium	81-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-47
15016657-7	2004	When a plasmid encoding dominant-negative Nur77 was transfected into A549 cells, cadmium-induced apoptotic changes, such as chromosomal condensation and Bax expression, were significantly reduced, suggesting that the expression of Nur77 plays an important role in cadmium-induced apoptosis.	Cadmium	81-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	231-236
15016657-7	2004	When a plasmid encoding dominant-negative Nur77 was transfected into A549 cells, cadmium-induced apoptotic changes, such as chromosomal condensation and Bax expression, were significantly reduced, suggesting that the expression of Nur77 plays an important role in cadmium-induced apoptosis.	Cadmium	264-271	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-47
15016657-7	2004	When a plasmid encoding dominant-negative Nur77 was transfected into A549 cells, cadmium-induced apoptotic changes, such as chromosomal condensation and Bax expression, were significantly reduced, suggesting that the expression of Nur77 plays an important role in cadmium-induced apoptosis.	Cadmium	264-271	nuclear receptor subfamily 4 group A member 1	Homo sapiens	231-236
15016657-9	2004	Taken together, these results demonstrate that cadmium induces the expression of Nur77 family genes, leading to apoptosis in lung cells, which may cause pulmonary toxicity in response to cadmium exposure.	Cadmium	47-54	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-86
15016657-9	2004	Taken together, these results demonstrate that cadmium induces the expression of Nur77 family genes, leading to apoptosis in lung cells, which may cause pulmonary toxicity in response to cadmium exposure.	Cadmium	187-194	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-86
15476902-11	2004	RESULTS: Anastrozole, letrozole, and exemestane are the 3 commercially available aromatase inhibitors approved by the US Food and Drug Administration for the treatment of hormone receptor-positive breast cancer in postmenopausal women.	Letrozole	22-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-187
15476902-11	2004	RESULTS: Anastrozole, letrozole, and exemestane are the 3 commercially available aromatase inhibitors approved by the US Food and Drug Administration for the treatment of hormone receptor-positive breast cancer in postmenopausal women.	exemestane	37-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-187
15159280-0	2004	Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments.	Prostaglandins F	56-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-45
15159280-0	2004	Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments.	Bimatoprost	69-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-45
15159280-10	2004	We also used Nur77 as a marker gene to compare the effects of PGF(2alpha), Butaprost, and Bimatoprost (a prostamide) on Nur77 expression in human primary trabecular meshwork and ciliary smooth muscle (SM) cells, which are target cells for antiglaucoma drugs.	Prostaglandins F	62-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
15159280-0	2004	Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments.	butaprost	86-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-45
15159280-10	2004	We also used Nur77 as a marker gene to compare the effects of PGF(2alpha), Butaprost, and Bimatoprost (a prostamide) on Nur77 expression in human primary trabecular meshwork and ciliary smooth muscle (SM) cells, which are target cells for antiglaucoma drugs.	butaprost	75-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
15159280-10	2004	We also used Nur77 as a marker gene to compare the effects of PGF(2alpha), Butaprost, and Bimatoprost (a prostamide) on Nur77 expression in human primary trabecular meshwork and ciliary smooth muscle (SM) cells, which are target cells for antiglaucoma drugs.	Bimatoprost	90-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-125
15159280-11	2004	The results showed that PGF(2alpha) and Butaprost, but not Bimatoprost, induced upregulation of Nur77 expression in human TM cells.	Prostaglandins F	24-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-101
15159280-3	2004	Using gene chip technology, we first identified that PGF(2alpha) (FP agonist) and Butaprost (EP(2) agonist) induced about a five-fold upregulation of Nur77 mRNA expression in hFP-HEK 293/EBNA and hEP(2)-HEK293/EBNA cells.	Prostaglandins F	53-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-155
15159280-11	2004	The results showed that PGF(2alpha) and Butaprost, but not Bimatoprost, induced upregulation of Nur77 expression in human TM cells.	butaprost	40-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-101
15159280-3	2004	Using gene chip technology, we first identified that PGF(2alpha) (FP agonist) and Butaprost (EP(2) agonist) induced about a five-fold upregulation of Nur77 mRNA expression in hFP-HEK 293/EBNA and hEP(2)-HEK293/EBNA cells.	butaprost	82-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-155
15159280-12	2004	PGF(2alpha), but not Bimatoprost, dramatically induced upregulation of Nur77 mRNA expression in human ciliary SM cells, whereas Butaprost slightly upregulated Nur77 mRNA expression in SM cells.	Prostaglandins F	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-76
15159280-12	2004	PGF(2alpha), but not Bimatoprost, dramatically induced upregulation of Nur77 mRNA expression in human ciliary SM cells, whereas Butaprost slightly upregulated Nur77 mRNA expression in SM cells.	butaprost	128-137	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-164
15159280-4	2004	Northern Blot analysis revealed that PGF(2alpha)- and Butaprost-induced upregulation of Nur77 expression are dose- and time-dependent.	Prostaglandins F	37-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-93
15159280-14	2004	Nur77 promoter deletion analysis indicated that PGF(2alpha), but not Bimatoprost, activated Nur77 promoter-luciferase reporter in hFP-HEK 293/EBNA cells.	Prostaglandins F	48-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
15159280-4	2004	Northern Blot analysis revealed that PGF(2alpha)- and Butaprost-induced upregulation of Nur77 expression are dose- and time-dependent.	butaprost	54-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-93
15159280-14	2004	Nur77 promoter deletion analysis indicated that PGF(2alpha), but not Bimatoprost, activated Nur77 promoter-luciferase reporter in hFP-HEK 293/EBNA cells.	Prostaglandins F	48-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-97
15159280-15	2004	Butaprost was less efficacious in inducing Nur77 promoter-luciferase reporter activity in hEP(2)-HEK293/EBNA cells relative to PGF(2alpha) in the comparable assay.	butaprost	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-48
15159280-6	2004	Both PGF(2alpha) and Butaprost upregulated Nur77 gene expression through the protein kinase C (PKC) pathway.	Prostaglandins F	5-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-48
15159280-18	2004	It appears that PGF(2alpha) and Butaprost activate Nur77 transcription mechanisms through the activation of FP and EP(2) receptor-coupled signaling pathways, whereas Bimatoprost stimulates neither FP nor EP(2) receptors.	Prostaglandins F	16-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
15159280-6	2004	Both PGF(2alpha) and Butaprost upregulated Nur77 gene expression through the protein kinase C (PKC) pathway.	butaprost	21-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-48
15159280-18	2004	It appears that PGF(2alpha) and Butaprost activate Nur77 transcription mechanisms through the activation of FP and EP(2) receptor-coupled signaling pathways, whereas Bimatoprost stimulates neither FP nor EP(2) receptors.	butaprost	32-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
15193263-2	2004	Here, we generated gene expression profiles of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen monotherapy.	Tamoxifen	142-151	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-63
15159280-8	2004	Calcineurin was found to be involved downstream of the PKC pathway in PGF(2alpha)-induced Nur77 expression, but not in Butaprost-induced Nur77 expression.	Prostaglandins F	70-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-95
15128284-10	2004	Increased protein expression of nur77 and the greatest binding of nur77 to its response element was seen when cells were stimulated with A-II in combination with forskolin.	Colforsin	162-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-37
15125747-5	2004	A relationship between objective response rate (complete or partial response) or clinical benefit (complete or partial response or stabilization for &gt; or =24 weeks) and hormone receptor status was apparent for anastrozole but not letrozole treatment.	Anastrozole	213-224	nuclear receptor subfamily 4 group A member 1	Homo sapiens	172-188
15128284-10	2004	Increased protein expression of nur77 and the greatest binding of nur77 to its response element was seen when cells were stimulated with A-II in combination with forskolin.	Colforsin	162-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-71
15128284-11	2004	These data indicate that nur77 may preferentially regulate steroid enzyme genes relevant to cortisol production and thereby regulate differential cortisol and adrenal androgen production.	Steroids	59-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	25-30
15134811-1	2004	The human mineralocorticoid receptor (hMR), a ligand-dependent transcription factor (NR3C2) which belongs to the nuclear receptor superfamily, mediates most of the known effects of aldosterone.	Aldosterone	181-192	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-41
14645496-0	2004	The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production.	Aldosterone	62-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
14766275-3	2004	METHODS: Microarray-based expression profiling was performed on a series of tamoxifen-associated (N = 10) and matched sporadic cases (N = 29) of endometrial carcinoma.	Tamoxifen	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	98-104
14729605-8	2004	The treatment of Nur77 antisense oligonucleotide reduces POMC transcription under hypoxic conditions.	Oligonucleotides	33-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-22
14703069-6	2003	In patients with confirmed hormone receptor (HR)-positive tumors, the CB rate was 51.9 and 65.7%, respectively, for anastrozole and 41.6 and 58.7%, respectively, for tamoxifen.	Anastrozole	116-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-43
14592536-0	2004	Distinct role and functional mode of TR3 and RARalpha in mediating ATRA-induced signalling pathway in breast and gastric cancer cells.	Tretinoin	67-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-40
14592536-4	2004	In the present study, we found that formation of TR3/RXRalpha heterodimers in the nucleus and their subsequent translocation into the cytoplasm, in association with regulation of apoptosis-related proteins Bcl-2, Bcl-xl and Bax, was critical for apoptosis induction by ATRA in breast cancer cells MCF-7.	Tretinoin	269-273	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-52
14592536-8	2004	Furthermore, we demonstrated that the effects of ATRA depend on the relative levels of TR3, RARalpha and RXRalpha expression in cancer cells.	Tretinoin	49-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-90
14592536-9	2004	In ATRA-induced MCF-7 cells, highly expressed TR3 favours the formation of TR3/RXRalpha and promotes the TR3/RXRalpha signalling pathway causing apoptosis; while in ATRA-induced MGC80-3 cells, high expression of RARalpha favours the formation of RARalpha/RXRalpha and promotes the RXRalpha/RARalpha signalling pathway in mediating cell cycle regulation.	Tretinoin	3-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-49
14592536-9	2004	In ATRA-induced MCF-7 cells, highly expressed TR3 favours the formation of TR3/RXRalpha and promotes the TR3/RXRalpha signalling pathway causing apoptosis; while in ATRA-induced MGC80-3 cells, high expression of RARalpha favours the formation of RARalpha/RXRalpha and promotes the RXRalpha/RARalpha signalling pathway in mediating cell cycle regulation.	Tretinoin	3-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-78
14592536-9	2004	In ATRA-induced MCF-7 cells, highly expressed TR3 favours the formation of TR3/RXRalpha and promotes the TR3/RXRalpha signalling pathway causing apoptosis; while in ATRA-induced MGC80-3 cells, high expression of RARalpha favours the formation of RARalpha/RXRalpha and promotes the RXRalpha/RARalpha signalling pathway in mediating cell cycle regulation.	Tretinoin	3-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-78
15033715-0	2003	Orphan nuclear receptor Nur77 translocates to mitochondria in the early phase of apoptosis induced by synthetic chenodeoxycholic acid derivatives in human stomach cancer cell line SNU-1.	Chenodeoxycholic Acid	112-133	nuclear receptor subfamily 4 group A member 1	Homo sapiens	24-29
15033715-3	2003	Importantly, the orphan receptor Nur77 (TR3) was shown to translocate from the nucleus to mitochondria at the early time points after CDCA derivatives treatment.	Chenodeoxycholic Acid	134-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	33-38
15033715-3	2003	Importantly, the orphan receptor Nur77 (TR3) was shown to translocate from the nucleus to mitochondria at the early time points after CDCA derivatives treatment.	Chenodeoxycholic Acid	134-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-43
15033715-4	2003	These data support the theory that CDCA derivatives-induced apoptosis of SNU-1 gastric cancer cell lines is mediated by mitochondria and caspase, and, at least in part, by Nur77.	Chenodeoxycholic Acid	35-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	172-177
14734491-9	2004	Anastrozole should, therefore, now be considered a valid alternative option to tamoxifen for adjuvant hormonal treatment in all postmenopausal women with hormone receptor-positive early breast cancer.	Anastrozole	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	154-170
14703069-6	2003	In patients with confirmed hormone receptor (HR)-positive tumors, the CB rate was 51.9 and 65.7%, respectively, for anastrozole and 41.6 and 58.7%, respectively, for tamoxifen.	Anastrozole	116-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-47
14703069-6	2003	In patients with confirmed hormone receptor (HR)-positive tumors, the CB rate was 51.9 and 65.7%, respectively, for anastrozole and 41.6 and 58.7%, respectively, for tamoxifen.	Tamoxifen	166-175	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-43
14703069-6	2003	In patients with confirmed hormone receptor (HR)-positive tumors, the CB rate was 51.9 and 65.7%, respectively, for anastrozole and 41.6 and 58.7%, respectively, for tamoxifen.	Tamoxifen	166-175	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-47
12947120-3	2003	Here we found that 12-O-tetradecanoylphorbol-13-acetate (TPA) could induce cell apoptosis via induction of TR3 and E2F1 expression in LNCaP prostate cancer cells.	Tetradecanoylphorbol Acetate	19-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-110
14525795-8	2003	VEGF increased protein expression of Nurr1 and Nur77 and decreased Nur77 phosphorylation at the negative regulatory site serine 351.	Serine	121-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-72
12947120-5	2003	These data suggest that TPA is able to induce LNCaP cell apoptosis via induction of TR3 resulting in the induction of E2F1.	Tetradecanoylphorbol Acetate	24-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-87
12947120-3	2003	Here we found that 12-O-tetradecanoylphorbol-13-acetate (TPA) could induce cell apoptosis via induction of TR3 and E2F1 expression in LNCaP prostate cancer cells.	Tetradecanoylphorbol Acetate	57-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-110
12947120-8	2003	Taken together, these data suggest that TPA is able to induce cell apoptosis via a TPA --&gt; TR3 --&gt; E2F1 --&gt; apoptosis pathway in LNCaP cells.	Tetradecanoylphorbol Acetate	40-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-97
12947120-8	2003	Taken together, these data suggest that TPA is able to induce cell apoptosis via a TPA --&gt; TR3 --&gt; E2F1 --&gt; apoptosis pathway in LNCaP cells.	Tetradecanoylphorbol Acetate	83-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-97
14535708-1	2003	[reaction: see text] Biotin was conjugated to chemiluminescent N-sulfonylacridinium-9-carboxamides at the N-10 or 9-position carboxamide.	Biotin	21-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-110
14535708-1	2003	[reaction: see text] Biotin was conjugated to chemiluminescent N-sulfonylacridinium-9-carboxamides at the N-10 or 9-position carboxamide.	n-sulfonylacridinium-9-carboxamides	63-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-110
14535708-1	2003	[reaction: see text] Biotin was conjugated to chemiluminescent N-sulfonylacridinium-9-carboxamides at the N-10 or 9-position carboxamide.	carboxamide	86-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-110
14535708-2	2003	Upon binding to avidin, the light output of the N-10 derivative (8) was quenched up to 92% upon triggering with basic peroxide, while the 9-position carboxamide conjugate (9) was quenched only 33%.	Peroxides	118-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-52
14587704-1	2003	Picosecond time-resolved resonance Raman spectroscopy, TR3, reveals an intense acetylenic band in the S1 state of the prototypical molecular wire 1,4-bis(phenylethynyl)benzene.	1,4-Bis(phenylethynyl)benzene	146-175	nuclear receptor subfamily 4 group A member 1	Homo sapiens	55-58
12974624-7	2003	The crystal structure suggests that a buried Lys(267) is transiently protonated during formyl transfer allowing for the stabilization of the oxyanion transition state and subsequent protonation of N10 on the tetrahydrofolate leaving group.	Lysine	45-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	197-200
14578143-8	2003	Alcohol use appears to be more strongly associated with risk of lobular carcinomas and hormone receptor-positive tumors than it is with other types of breast cancer.	Alcohols	0-7	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-103
12974624-7	2003	The crystal structure suggests that a buried Lys(267) is transiently protonated during formyl transfer allowing for the stabilization of the oxyanion transition state and subsequent protonation of N10 on the tetrahydrofolate leaving group.	5,6,7,8-tetrahydrofolic acid	208-224	nuclear receptor subfamily 4 group A member 1	Homo sapiens	197-200
14500374-4	2003	Nucleus-to-cytoplasm translocation of a green fluorescent protein-TR3 construct, but not its direct mitochondrial targeting, was associated with apoptosis induced by the short-chain fatty acid, butyrate.	Fatty Acids, Volatile	170-192	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-69
12842839-5	2003	Adenoviral overexpression of TR3 in cultured endothelial cells resulted in decreased [3H]thymidine incorporation, whereas a dominant-negative TR3 variant that inhibits the activity of endogenous TR3-like factors enhanced DNA synthesis.	Tritium	86-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-32
12842839-5	2003	Adenoviral overexpression of TR3 in cultured endothelial cells resulted in decreased [3H]thymidine incorporation, whereas a dominant-negative TR3 variant that inhibits the activity of endogenous TR3-like factors enhanced DNA synthesis.	Thymidine	89-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-32
14500374-4	2003	Nucleus-to-cytoplasm translocation of a green fluorescent protein-TR3 construct, but not its direct mitochondrial targeting, was associated with apoptosis induced by the short-chain fatty acid, butyrate.	Butyrates	194-202	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-69
12791423-2	2003	The use of tamoxifen in women with hormone receptor-positive tumors is a relatively simple therapeutic option considering the favourable toxicity profile, whereas the administration of adjuvant chemotherapy is more complicated and a variety of aspects need to be considered.	Tamoxifen	11-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-51
14659138-2	2003	Tamoxifen, a selective estrogen receptor modulator, is the standard endocrine treatment for hormone receptor-positive breast cancer, both in the adjuvant and metastatic settings.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
12429630-0	2002	Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen.	Tamoxifen	108-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-27
12770726-2	2003	In the rat ovary, the preovulatory surge of LH induces NGFI-B expression in granulosa cells of preovulatory follicles, reaching a peak within 1 h and declining to control levels at 6 h. The LH-stimulated NGFI-B expression is abolished by alpha-amanitin, but superinduced by cycloheximide.	Luteinizing Hormone	44-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-210
12770726-2	2003	In the rat ovary, the preovulatory surge of LH induces NGFI-B expression in granulosa cells of preovulatory follicles, reaching a peak within 1 h and declining to control levels at 6 h. The LH-stimulated NGFI-B expression is abolished by alpha-amanitin, but superinduced by cycloheximide.	Alpha-Amanitin	238-252	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-210
12770726-2	2003	In the rat ovary, the preovulatory surge of LH induces NGFI-B expression in granulosa cells of preovulatory follicles, reaching a peak within 1 h and declining to control levels at 6 h. The LH-stimulated NGFI-B expression is abolished by alpha-amanitin, but superinduced by cycloheximide.	Cycloheximide	274-287	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-210
12770726-4	2003	Interestingly, the induction of NGFI-B expression in response to LH stimulation in preovulatory granulosa cells requires signaling through protein kinase Czeta.	Luteinizing Hormone	65-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-38
12704790-9	2003	Finally, we were able to determine that CD437 treatment induced the translocation of TR3, a nuclear orphan receptor, whereas, 4-HPR did not.	CD 437	40-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-88
12429630-2	2002	As a result, only limited data are available on the hormone receptor status of CBCs evolving in tamoxifen-treated patients.	Tamoxifen	96-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	52-68
12429630-3	2002	The aim of our investigation was to evaluate the pattern of hormone receptor status of CBCs in patients treated with adjuvant tamoxifen at our institution.	Tamoxifen	126-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-76
12376465-0	2002	Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells.	Tetradecanoylphorbol Acetate	75-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19
12376465-0	2002	Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells.	Tretinoin	83-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19
12376465-5	2002	The tetradecanoylphorbol-1,3-acetate (TPA) treatment not only resulted in up-regulation of the Nur77 mRNA level, but also led to translocation of Nur77 protein from the nucleus to the mitochondria, and caused the release of cytochrome c.	tetradecanoylphorbol-1,3-acetate	4-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	95-100
12376515-0	2002	Interaction of dietary folate intake, alcohol, and risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women.	Folic Acid	23-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-75
12376465-5	2002	The tetradecanoylphorbol-1,3-acetate (TPA) treatment not only resulted in up-regulation of the Nur77 mRNA level, but also led to translocation of Nur77 protein from the nucleus to the mitochondria, and caused the release of cytochrome c.	tetradecanoylphorbol-1,3-acetate	4-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	146-151
12376465-5	2002	The tetradecanoylphorbol-1,3-acetate (TPA) treatment not only resulted in up-regulation of the Nur77 mRNA level, but also led to translocation of Nur77 protein from the nucleus to the mitochondria, and caused the release of cytochrome c.	Tetradecanoylphorbol Acetate	38-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	95-100
12376465-5	2002	The tetradecanoylphorbol-1,3-acetate (TPA) treatment not only resulted in up-regulation of the Nur77 mRNA level, but also led to translocation of Nur77 protein from the nucleus to the mitochondria, and caused the release of cytochrome c.	Tetradecanoylphorbol Acetate	38-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	146-151
12376465-6	2002	This TPA-induced translocation of Nur77 was in association with the initiation of apoptosis in gastric cancer cells.	Tetradecanoylphorbol Acetate	5-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39
12376465-7	2002	Although all-trans retinoic acid (ATRA) could not induce apoptosis in BGC-823 cells due to failure of stimulating Nur77 translocation, expression of Nur77 in the nucleus was required for cell growth inhibition by ATRA.	Tretinoin	213-217	nuclear receptor subfamily 4 group A member 1	Homo sapiens	149-154
12376465-9	2002	Furthermore, the action of Nur77 in TPA-induced apoptosis was mediated through a protein kinase C signaling pathway, while mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways were responsible for the regulation of Nur77 mRNA expression.	Tetradecanoylphorbol Acetate	36-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32
12376465-10	2002	Taken together, the data revealed the dual functioning mechanisms of Nur77 in gastric cancer cells in response to TPA and ATRA.	Tetradecanoylphorbol Acetate	114-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
12376465-10	2002	Taken together, the data revealed the dual functioning mechanisms of Nur77 in gastric cancer cells in response to TPA and ATRA.	Tretinoin	122-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
12401435-3	2002	An alteration in the fatty acid composition of membrane phospholipids could affect critical membrane-dependent enzymes and processes (e.g., ion and solute transport, hormone-receptor interactions, signal transduction pathways).	Fatty Acids	21-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-182
12401435-3	2002	An alteration in the fatty acid composition of membrane phospholipids could affect critical membrane-dependent enzymes and processes (e.g., ion and solute transport, hormone-receptor interactions, signal transduction pathways).	Phospholipids	56-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-182
12149306-10	2002	A 5-year course of adjuvant tamoxifen remains the standard therapy for women with hormone receptor-positive breast cancer.	Tamoxifen	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
12071889-6	2002	This is in contrast to the increased sex hormone receptor expressions in all uterine cell types, observed in spontaneously occurring CEH.	CEH	133-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-57
12089357-0	2002	Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways.	Cyclic AMP	64-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
12089357-2	2002	In this study we show that in AtT-20 corticotrophs CRH and cAMP induce Nur77 and Nurr1 expression and transcription at the NurRE site by protein kinase A (PKA) and calcium-dependent and -independent mechanisms.	Cyclic AMP	59-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-76
12089357-2	2002	In this study we show that in AtT-20 corticotrophs CRH and cAMP induce Nur77 and Nurr1 expression and transcription at the NurRE site by protein kinase A (PKA) and calcium-dependent and -independent mechanisms.	Calcium	164-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-76
12089357-9	2002	In conclusion, in AtT-20 corticotrophs the CRH/cAMP signaling that leads to Nur77/Nurr1 mRNA induction and transcriptional activation, and thus POMC expression, is dependent on protein kinase A and involves calcium/calmodulin kinase II (Nur induction/activation) and MAPK calcium-dependent and -independent (Nur phosphorylation-activation) pathways.	Cyclic AMP	47-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-81
12089357-9	2002	In conclusion, in AtT-20 corticotrophs the CRH/cAMP signaling that leads to Nur77/Nurr1 mRNA induction and transcriptional activation, and thus POMC expression, is dependent on protein kinase A and involves calcium/calmodulin kinase II (Nur induction/activation) and MAPK calcium-dependent and -independent (Nur phosphorylation-activation) pathways.	Calcium	207-214	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-81
11884470-4	2002	Modulation by proinflammatory mediators in primary RA and normal synoviocytes shows that PGE(2), IL-1beta, and TNF-alpha markedly enhance NURR1 mRNA and protein levels in contrast to other subfamily members, NUR77 and NOR-1.	Prostaglandins E	89-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
11954047-0	2002	Acute methamphetamine administration upregulates NGFI-B mRNA expression in the striatum: co-localization with c-Fos immunoreactivity.	Methamphetamine	6-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-55
11954047-1	2002	In this study, the effects of acute methamphetamine administration on expression of the nuclear transcription factor NGFI-B mRNA and its co-localization with c-Fos immunoreactivity in the striatum were evaluated in animals receiving a single dose of methamphetamine (4 mg/kg) given at 2 or 6 h prior to perfusion.	Methamphetamine	36-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	117-123
11954047-1	2002	In this study, the effects of acute methamphetamine administration on expression of the nuclear transcription factor NGFI-B mRNA and its co-localization with c-Fos immunoreactivity in the striatum were evaluated in animals receiving a single dose of methamphetamine (4 mg/kg) given at 2 or 6 h prior to perfusion.	Methamphetamine	250-265	nuclear receptor subfamily 4 group A member 1	Homo sapiens	117-123
11954047-3	2002	We have found that, similar to c-fos activation, NGFI-B mRNA levels were significantly increased 2 h after methamphetamine treatment and returned to basal levels 6 h later.	Methamphetamine	107-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-55
11954047-4	2002	Induction of NGFI-B mRNA levels by methamphetamine was highest in central striatum as compared to the dorsomedial distribution pattern observed in control animals.	Methamphetamine	35-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-19
11954047-5	2002	After acute methamphetamine treatment, the distribution pattern of NGFI-B mRNA upregulation was very similar to that of methamphetamine induced c-Fos immunoreactivity.	Methamphetamine	12-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-73
11954047-8	2002	This study provides a detailed description of the differential spatial and temporal modulation of NGFI-B and c-Fos expression in the striatum by acute methamphetamine treatment over time.	Methamphetamine	151-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	98-104
12095685-4	2002	NGFI-B mRNA and protein expression were promptly (15 min) increased after 8-Br-cAMP treatment and precedes aldolase C mRNA increase (30 min).	8-Bromo Cyclic Adenosine Monophosphate	74-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-6
12095685-5	2002	After 4 h of 8-Br-cAMP treatment, the binding of NGFI-B protein to the distal element D in the distal promoter region was increased twofold and this correlates with the increased expression of the clone that contains distal element D. These results indicate that the distal element D in the promoter region of the human aldolase C gene is the target of a cAMP-dependent regulation pathway.	8-Bromo Cyclic Adenosine Monophosphate	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-55
12095685-5	2002	After 4 h of 8-Br-cAMP treatment, the binding of NGFI-B protein to the distal element D in the distal promoter region was increased twofold and this correlates with the increased expression of the clone that contains distal element D. These results indicate that the distal element D in the promoter region of the human aldolase C gene is the target of a cAMP-dependent regulation pathway.	Cyclic AMP	18-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-55
12011136-9	2002	CONCLUSION: Vietnamese and Chinese women with hormone receptor-positive operable breast cancer benefit from adjuvant treatment with surgical oophorectomy and tamoxifen.	Tamoxifen	158-167	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-62
11979430-5	2002	The inhibitory effect of nicotine was accompanied with induction of orphan receptor TR3.	Nicotine	25-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-87
11979430-6	2002	Inhibition of TR3 expression by overexpression of TR3 anti-sense RNA in H460 lung cancer cells strongly prevented the suppressive effect of nicotine on trans-RA activity.	Nicotine	140-148	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-17
11979430-6	2002	Inhibition of TR3 expression by overexpression of TR3 anti-sense RNA in H460 lung cancer cells strongly prevented the suppressive effect of nicotine on trans-RA activity.	Nicotine	140-148	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-53
11979430-10	2002	Together, our results demonstrate that nicotine suppresses the growth inhibitory effects of trans-RA by inhibiting RAR beta expression through its induction of TR3 expression and suggest that RXR-selective retinoids may be more effective than classical retinoids for preventing and treating tobacco-associated cancers.	Nicotine	39-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-163
11883936-3	2002	EGF stimulation of cells leads to phosphorylation of threonine in NGFI-B.	Threonine	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-72
11883936-4	2002	Thr-142 of NGFI-B is comprised in a consensus MAP kinase site and was identified as a preferred substrate for ERK2 (but not ERK1) in vitro.	Threonine	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-17
11895893-6	2002	In 1998, letrozole was approved by the United States Food and Drug Administration (FDA) for the treatment of advanced breast cancer in postmenopausal women, with hormone receptor positive or unknown breast cancer, who had failed one prior antiestrogen treatment (i.e., for "second-line" treatment).	Letrozole	9-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	162-178
11895893-11	2002	In July 2000, a marketing application for first-line letrozole treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer was submitted to the FDA.	Letrozole	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	131-147
11895893-11	2002	In July 2000, a marketing application for first-line letrozole treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer was submitted to the FDA.	Letrozole	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-118
11895893-18	2002	On the basis of these results, the United States FDA approved letrozole tablets, 2.5 mg/day, for first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer.	Letrozole	62-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-163
11895893-18	2002	On the basis of these results, the United States FDA approved letrozole tablets, 2.5 mg/day, for first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer.	Letrozole	62-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	176-192
11700033-4	2001	When Chang X-34 expressing HBx under the control of a doxycycline-inducible promoter was examined, induction of Nur77 was observed following HBx expression.	Doxycycline	54-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-117
11719525-0	2002	A calcium/calmodulin-dependent activation of ERK1/2 mediates JunD phosphorylation and induction of nur77 and 20alpha-hsd genes by prostaglandin F2alpha in ovarian cells.	Dinoprost	130-151	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-104
11719525-1	2002	We have previously demonstrated that prostaglandin F(2alpha) (PGF(2alpha)) induces a rapid and transient expression of Nur77 in luteal cells.	Prostaglandins F	37-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-124
11719525-1	2002	We have previously demonstrated that prostaglandin F(2alpha) (PGF(2alpha)) induces a rapid and transient expression of Nur77 in luteal cells.	Prostaglandins F	62-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-124
11719525-2	2002	We have shown that Nur77 plays an important role in ovarian physiology by mediating the PGF(2alpha) induction of 20alpha-HSD, a steroidogenic enzyme involved in the catabolism of progesterone.	Prostaglandins F	88-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-24
11719525-2	2002	We have shown that Nur77 plays an important role in ovarian physiology by mediating the PGF(2alpha) induction of 20alpha-HSD, a steroidogenic enzyme involved in the catabolism of progesterone.	Progesterone	179-191	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-24
11719525-3	2002	In this report we established, using luteinized granulosa cells, that PGF(2alpha) stimulates in vitro nur77 expression in a time- and dose-dependent manner.	Prostaglandins F	70-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-107
11719525-4	2002	Serial 5"-deletion of the nur77 promoter revealed that the necessary and sufficient elements for PGF(2alpha) induction of Nur77 promoter activity are located between the nucleotides -86 and -33 upstream of the transcription start site, this region containing two AP1 elements.	Prostaglandins F	97-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-31
11719525-4	2002	Serial 5"-deletion of the nur77 promoter revealed that the necessary and sufficient elements for PGF(2alpha) induction of Nur77 promoter activity are located between the nucleotides -86 and -33 upstream of the transcription start site, this region containing two AP1 elements.	Prostaglandins F	97-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-127
11719525-6	2002	However, mutation of the AP1 sites as well as a dominant-negative JunD abolished nur77 induction by PGF(2alpha).	Prostaglandins F	100-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-86
11719525-7	2002	PGF(2alpha) induces phosphorylation of JunD bound to the nur77 promoter.	Prostaglandins F	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-62
11719525-10	2002	We conclude that activation of JunD through a calmodulim-dependent activation of ERK1/2 mediates nur77 induction by PGF(2alpha).	Prostaglandins F	116-119	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-102
12490735-16	2002	On April 25, 2002, fulvestrant 250 mg by monthly intramuscular injection was approved by the U.S. Food and Drug Administration for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.	Fulvestrant	19-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	148-164
12421108-1	2002	Anastrozole, a nonsteroidal selective aromatase inhibitor, has recently been approved in the US and several other countries for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.	Anastrozole	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	180-196
11559707-0	2001	Silencing mediator of retinoid and thyroid hormone receptors and activating signal cointegrator-2 as transcriptional coregulators of the orphan nuclear receptor Nur77.	Retinoids	22-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	161-166
11559707-5	2001	Surprisingly, histone deacetylase inhibitor trichostatin A was unable to block the repressive effect of SMRT while dramatically stimulating the Nur77 transactivation.	trichostatin A	44-58	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-149
11697120-4	2001	Time-resolved resonance Raman (TR3) spectra of the radical from 4-hydroxycinnamate were measured using a probe laser wavelength of 600 nm, to be in resonance with the long wavelength absorption band of the radical.	Coumaric Acids	64-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-34
11605012-2	2001	The survival benefit differs considerably between hormone receptor-positive and -negative patients, and it is believed that the effectiveness of adjuvant chemotherapy can be increased by hormonal therapy with tamoxifen.	Tamoxifen	209-218	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
11761324-2	2001	Reduced lumiflavin was found to be bent along the N5-N10 axis, 25 degrees from planarity, which is nearly the same as previously reported restricted Hartree-Fock (RHF) calculations, which predict a bending angle of 27 degrees.	lumiflavin	8-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-56
11761324-3	2001	The major difference in the DFT calculation is that the N10 methyl group adopts a more pseudoequatorial disposition and is only bent 13 degrees above the plane of the isoalloxazine ring system as opposed to 59 degrees in the RHF calculations.	isoalloxazine	167-180	nuclear receptor subfamily 4 group A member 1	Homo sapiens	56-59
11761324-3	2001	The major difference in the DFT calculation is that the N10 methyl group adopts a more pseudoequatorial disposition and is only bent 13 degrees above the plane of the isoalloxazine ring system as opposed to 59 degrees in the RHF calculations.	rhf	225-228	nuclear receptor subfamily 4 group A member 1	Homo sapiens	56-59
11761324-6	2001	This indicates that both electronic and steric interactions of the N10 methyl group of reduced lumiflavin contribute to the bent geometry.	lumiflavin	95-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-70
11602619-2	2001	We found that retinoic acid inhibits the transcriptional activity of AP-1 and the orphan receptors Nur77 and Nurr1 in ACTH-secreting tumor cells.	Tretinoin	14-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-104
11579340-7	2001	In those with hormone receptor-rich tumors, adjuvant chemotherapy is beneficial for HER2-positive tumors, and the regimen should contain an anthracycline.	Anthracyclines	140-153	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-30
11385620-0	2001	Thapsigargin-induced apoptosis involves Cabin1-MEF2-mediated induction of Nur77.	Thapsigargin	0-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-79
11385620-4	2001	The expression of Nur77 in response to TG treatment is sensitive to cyclosporin A, implicating that activation of calcineurin is necessary for Nur77 expression.	Thapsigargin	39-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-23
11385620-4	2001	The expression of Nur77 in response to TG treatment is sensitive to cyclosporin A, implicating that activation of calcineurin is necessary for Nur77 expression.	Thapsigargin	39-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	143-148
11385620-4	2001	The expression of Nur77 in response to TG treatment is sensitive to cyclosporin A, implicating that activation of calcineurin is necessary for Nur77 expression.	Cyclosporine	68-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-23
11465095-3	2001	Both processes are dependent on new mRNA and protein synthesis, involve up-regulation of nur77, and can be inhibited by retinoic acids (RA).	Tretinoin	136-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
11465095-8	2001	Our data suggest a complex interaction between the various isoforms of retinoid receptors in regulating T cell death and demonstrate that the target through which retinoids regulate TCR-mediated apoptosis is nur77.	Retinoids	163-172	nuclear receptor subfamily 4 group A member 1	Homo sapiens	208-213
11550093-9	2001	However, inhibition of the ERK1/2 signaling pathway by PD98059 blocked the induction of Egr-1 and Nur77 mRNA while the p38 MAPK inhibitor PD169316 had little effect.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	55-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	98-103
11250200-5	2001	The structure of this 1:1 complex was determined and the hormone-receptor interface shown to be characterized by a number of hydrophilic interactions mediated by several highly ordered water networks.	Water	185-190	nuclear receptor subfamily 4 group A member 1	Homo sapiens	57-73
11274386-3	2001	Because Nur77 has a putative Akt phosphorylation site at Ser-350, and phosphorylation of this residue is critical for the transactivation activity of Nur77, we investigated whether Akt regulates Nur77.	Serine	57-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	8-13
11274386-5	2001	We further show that Akt specifically phosphorylates Ser-350 of the Nur77 protein within its DNA-binding domain in vitro and in vivo in 293 and NIH 3T3 cells.	Serine	53-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-73
11274386-6	2001	Because phosphorylation of Ser-350 of Nur77 is critical for its function as a transcription factor, we examined the effect of Akt on this function.	Serine	27-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
11274386-8	2001	Thus, we show that Akt interacts with Nur77 and inactivates Nur77 by phosphorylation at Ser-350 in a phosphatidylinositol 3-kinase-dependent manner, connecting the phosphatidylinositol 3-kinase-dependent Akt pathway and a nuclear receptor pathway.	Serine	88-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
11274386-8	2001	Thus, we show that Akt interacts with Nur77 and inactivates Nur77 by phosphorylation at Ser-350 in a phosphatidylinositol 3-kinase-dependent manner, connecting the phosphatidylinositol 3-kinase-dependent Akt pathway and a nuclear receptor pathway.	Serine	88-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-65
11134831-4	2001	A novel constant 17beta-oestradiol, intermittent norgestimate regimen has been developed based on theoretical hormone receptor dynamics in an attempt to minimise the hormonal doses needed, thereby potentially reducing the occurrence of adverse effects associated with higher oestrogen and progestogen doses.	Estradiol	17-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-126
11174853-8	2001	Treatment of transfected cells with dexamethasone resulted in suppression of forskolin- or Nak1-stimulated POMC-reporter gene expression in the presence of co-transfected GR but not with GRDelta.	Dexamethasone	36-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-95
11791121-4	2001	(2) Tamoxifen, administered for 5 years, significantly improves long-term survival for women of all age groups with hormone receptor-positive tumors.	Tamoxifen	4-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	116-132
11205023-3	2001	This study shows that flavins, which bear electron-donating groups on the aromatic ring and/or the N-10 position, are less active and are deactivated during the course of the reaction.	Flavins	22-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-103
11205023-4	2001	Moreover, flavins that are alkylated at the N-1 position instead of the N-10 position and having either no substituents or electron-withdrawing groups on the aromatic ring, remain the most active and stable.	Flavins	10-17	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-76
11134831-4	2001	A novel constant 17beta-oestradiol, intermittent norgestimate regimen has been developed based on theoretical hormone receptor dynamics in an attempt to minimise the hormonal doses needed, thereby potentially reducing the occurrence of adverse effects associated with higher oestrogen and progestogen doses.	norgestimate	49-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-126
11128295-12	2000	(2) The nocturnal level of salivary melatonin measured at 03:30 was 115.2 +/- 40.4 pg/mL (mean +/- SEM, N = 10) without and 51.3 +/- 18.4 pg/mL (mean +/- SEM, N = 10) with foundation garments.	Melatonin	36-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-110
11292179-6	2000	Increasing intracellular Ca2+ concentration ([Ca2+]i) by thapsgargin and A23187 induced the expression of both c-fos and nur77 mRNA expression, and synergistic effects were observed when cells were incubated with sodium butyrate plus thapsgargin and A23187.	thapsgargin	57-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-126
11292179-6	2000	Increasing intracellular Ca2+ concentration ([Ca2+]i) by thapsgargin and A23187 induced the expression of both c-fos and nur77 mRNA expression, and synergistic effects were observed when cells were incubated with sodium butyrate plus thapsgargin and A23187.	Calcimycin	73-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-126
11292179-6	2000	Increasing intracellular Ca2+ concentration ([Ca2+]i) by thapsgargin and A23187 induced the expression of both c-fos and nur77 mRNA expression, and synergistic effects were observed when cells were incubated with sodium butyrate plus thapsgargin and A23187.	Butyric Acid	213-228	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-126
11292179-6	2000	Increasing intracellular Ca2+ concentration ([Ca2+]i) by thapsgargin and A23187 induced the expression of both c-fos and nur77 mRNA expression, and synergistic effects were observed when cells were incubated with sodium butyrate plus thapsgargin and A23187.	thapsgargin	234-245	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-126
11292179-6	2000	Increasing intracellular Ca2+ concentration ([Ca2+]i) by thapsgargin and A23187 induced the expression of both c-fos and nur77 mRNA expression, and synergistic effects were observed when cells were incubated with sodium butyrate plus thapsgargin and A23187.	Calcimycin	250-256	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-126
11292179-8	2000	These results suggest that although sodium butyrate altered Ca2+ signaling which is an important regulatory mechanism for c-fos and nur77 expression, nevertheless the sodium butyrate-induced c-fos and nur77 expression may be not in fact mediated through Ca2+ signaling.	Butyric Acid	36-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-137
11292179-8	2000	These results suggest that although sodium butyrate altered Ca2+ signaling which is an important regulatory mechanism for c-fos and nur77 expression, nevertheless the sodium butyrate-induced c-fos and nur77 expression may be not in fact mediated through Ca2+ signaling.	Butyric Acid	167-182	nuclear receptor subfamily 4 group A member 1	Homo sapiens	201-206
11292179-0	2000	Alterations in Ca2+ signaling, and c-fos and nur77 expression are associated with sodium butyrate-induced differentiation of C6 glioma cell.	Butyric Acid	82-97	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
11292179-5	2000	Sodium butyrate per se enhanced the expression of c-fos mRNA, and the enhanced levels were maintained for 24 h, but over the same time period, the initially increased levels of nur77 expression tailed off, while c-myc expression was slightly reduced.	Butyric Acid	0-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	177-182
12057165-10	2000	Adjuvant hormonal therapy with tamoxifen improves DFS and OS in patients with hormone receptor (HR)-positive tumors, and ovarian ablation should be considered in premenopausal patients with HR-positive tumors and multiple involved nodes or stage IIIB disease.	Tamoxifen	31-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-94
10944115-1	2000	T-cell antigen receptor (TCR)-induced thymocyte apoptosis is mediated by calcium-dependent signal transduction pathways leading to the transcriptional activation of members of the Nur77 family.	Calcium	73-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	180-185
10944115-2	2000	The major calcium- and calcineurin-responsive elements in the Nur77 promoter are binding sites for myocyte enhancer factor-2 (MEF2).	Calcium	10-17	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
12057165-10	2000	Adjuvant hormonal therapy with tamoxifen improves DFS and OS in patients with hormone receptor (HR)-positive tumors, and ovarian ablation should be considered in premenopausal patients with HR-positive tumors and multiple involved nodes or stage IIIB disease.	Tamoxifen	31-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-98
10933397-2	2000	MEF2 has been shown to be the major transcription factor responsible for calcium-dependent Nur77 transcription.	Calcium	73-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-96
10945021-2	2000	Recent development in the field of adjuvant chemo/endocrine therapy is an usage of LH-RH analogue with tamoxifen for premenopausal hormone receptor positive women, and also an emerging role of taxans.	Tamoxifen	103-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	131-147
10919358-0	2000	Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells.	Indomethacin	38-50	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-34
10919358-2	2000	Here, we report that indomethacin induced the expression of Nur77 which has been implicated in activation-induced apoptosis of T-lymphocytes, in a colon cancer cell line, HCT-15.	Indomethacin	21-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-65
10919358-3	2000	The transcript- and protein-level, the transcriptional activity of Nur77 promoter, and the DNA binding of Nur77 were significantly induced following indomethacin treatment.	Indomethacin	149-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-72
10919358-3	2000	The transcript- and protein-level, the transcriptional activity of Nur77 promoter, and the DNA binding of Nur77 were significantly induced following indomethacin treatment.	Indomethacin	149-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	106-111
10933397-7	2000	Thus, activation of MEF2 and the consequent transcription of Nur77 are controlled by the association of MEF2 with the histone deacetylases via the calcium-dependent repressor Cabin1.	Calcium	147-154	nuclear receptor subfamily 4 group A member 1	Homo sapiens	61-66
10773199-0	2000	Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine.	Haloperidol	93-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-44
10772826-0	2000	Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: a possible mechanism for the inhibition of apoptosis by retinoic acid.	Tretinoin	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-93
10772826-0	2000	Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: a possible mechanism for the inhibition of apoptosis by retinoic acid.	Tretinoin	151-164	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-93
10772826-3	2000	To illustrate the mechanism of the inhibition, we examined the effects of retinoic acid (RA) on the expression and transactivation functions of Nur77 in the human peripheral blood mononuclear cells and the human T-cell leukemia, Jurkat.	Tretinoin	74-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-149
10772826-3	2000	To illustrate the mechanism of the inhibition, we examined the effects of retinoic acid (RA) on the expression and transactivation functions of Nur77 in the human peripheral blood mononuclear cells and the human T-cell leukemia, Jurkat.	Tretinoin	89-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	144-149
10772826-8	2000	Taken all together, we demonstrated that RA repressed Nur77 function through multiple mechanisms that may provide the basis for RA inhibition on the apoptosis of activated T-lymphocytes.	Tretinoin	41-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-59
10772826-8	2000	Taken all together, we demonstrated that RA repressed Nur77 function through multiple mechanisms that may provide the basis for RA inhibition on the apoptosis of activated T-lymphocytes.	Tretinoin	128-130	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-59
10773199-2	2000	In this study we have compared the regulation of mRNAs for the nuclear orphan receptor NGFI-B, which forms a functional heterodimer with the retinoid x receptor and the related orphan nuclear receptor Nor1 with c-fos mRNA after acute and chronic treatments with haloperidol and clozapine.	Clozapine	278-287	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-93
10773199-5	2000	Acute haloperidol treatment increased NGFI-B, Nor1 and c-fos mRNAs in nucleus accumbens shell and core as well as medial and lateral caudate putamen.	Haloperidol	6-17	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-44
10939640-0	2000	Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells.	Etoposide	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
10773199-0	2000	Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine.	Clozapine	109-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-44
10773199-6	2000	In contrast, clozapine lead to an increase of NGFI-B, Nor1 and c-fos only in the accumbens shell.	Clozapine	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-52
10773199-2	2000	In this study we have compared the regulation of mRNAs for the nuclear orphan receptor NGFI-B, which forms a functional heterodimer with the retinoid x receptor and the related orphan nuclear receptor Nor1 with c-fos mRNA after acute and chronic treatments with haloperidol and clozapine.	Haloperidol	262-273	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-93
10773199-8	2000	Chronic haloperidol lead to an increase of NGFI-B mRNA in the accumbens core.	Haloperidol	8-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-49
11556039-7	2000	However, the response elicited in a case of the ER-/PR- phenotype justified the randomized use of tamoxifen among patients in Iraq where the necessary requirements for hormone receptor assessment are almost unavailable.	Tamoxifen	98-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-184
10773199-10	2000	Also, the increased levels of NGFI-B, which is an important component in retinoid signaling, both after acute and chronic treatments of haloperidol suggests altered sensitivity to retinoids which could be an important component for the beneficial antipsychotic effect.	Retinoids	73-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-36
10773199-10	2000	Also, the increased levels of NGFI-B, which is an important component in retinoid signaling, both after acute and chronic treatments of haloperidol suggests altered sensitivity to retinoids which could be an important component for the beneficial antipsychotic effect.	Haloperidol	136-147	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-36
10773199-10	2000	Also, the increased levels of NGFI-B, which is an important component in retinoid signaling, both after acute and chronic treatments of haloperidol suggests altered sensitivity to retinoids which could be an important component for the beneficial antipsychotic effect.	Retinoids	180-189	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-36
10745271-0	2000	Ceramide-induced cell death is independent of the Fas/Fas ligand pathway and is prevented by Nur77 overexpression in A20 B cells.	Ceramides	0-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	93-98
10745271-6	2000	We also found that overexpression of Nur77, a zinc-finger transcription factor described to upregulate FasL, antagonizes ceramide-induced apoptosis, but not Fas-induced apoptosis.	Ceramides	121-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-42
10745271-8	2000	Ceramide-induced cell death was associated with increased c-myc, p53, Bax and p27kip1 levels; in contrast, cells transfected with Nur77 (A20Nur77), resistant to ceramide-induced apoptosis, showed a marked downregulation of p53 after ceramide treatment, with neither Bax nor p27kip1 induction.	Ceramides	161-169	nuclear receptor subfamily 4 group A member 1	Homo sapiens	130-135
10745271-8	2000	Ceramide-induced cell death was associated with increased c-myc, p53, Bax and p27kip1 levels; in contrast, cells transfected with Nur77 (A20Nur77), resistant to ceramide-induced apoptosis, showed a marked downregulation of p53 after ceramide treatment, with neither Bax nor p27kip1 induction.	Ceramides	233-241	nuclear receptor subfamily 4 group A member 1	Homo sapiens	130-135
10745271-9	2000	In conclusion, our results suggest that, in the A20 B cell line, Fas and ceramide trigger two distinct pathways and that Nur77 overexpression confers protection against ceramide-mediated apoptosis which correlates with inhibition of p53, Bax and p27kip1 induction.	Ceramides	169-177	nuclear receptor subfamily 4 group A member 1	Homo sapiens	121-126
9987007-1	1999	In the present study in situ hybridization was used to study the effect of kainic acid induced seizures on the expression of the zinc finger immediate-early genes (IEGs) NGFI-A, NGFI-B, NGFI-C, egr-2; egr-3 and Nurr1.	Kainic Acid	75-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	178-184
10531067-1	1999	T cell receptor (TCR)-induced apoptosis of thymocytes is mediated by calcium-dependent expression of the steroid receptors Nur77 and Nor1.	Calcium	69-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	123-128
10895028-0	2000	Endometrial response to sexual steroids as assessed by prostaglandin F(2alpha) output in explant culture and hormone receptor expression.	Steroids	31-39	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-125
9818284-0	1998	Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation.	Fluorodeoxyglucose F18	20-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
9885901-6	1998	Both the transgenic Bcl-2 and zVAD-fmk, an inhibitor of caspases, affected all features of Dex-induced apoptosis in a similar fashion, by inhibiting cell death and PARP cleavage, and by stabilizing AP-1, NF-kappaB p50-p50 and NUR-77 levels.	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	30-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	226-232
9885901-6	1998	Both the transgenic Bcl-2 and zVAD-fmk, an inhibitor of caspases, affected all features of Dex-induced apoptosis in a similar fashion, by inhibiting cell death and PARP cleavage, and by stabilizing AP-1, NF-kappaB p50-p50 and NUR-77 levels.	Dexamethasone	91-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	226-232
9885901-4	1998	Dex-induced apoptotic commitment was preceded by the rapid (3 h) cleavage of both a typical caspase substrate, poly(ADP-ribose) polymerase (PARP), and of nuclear transcription factors AP-1, NF-kappaB p50-p50 and NUR-77.	Dexamethasone	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	212-218
9885901-5	1998	By contrast, phorbol myristate acetate (PMA) and/or ionomycin-induced apoptosis had much slower kinetics, were preceded by an early increase of NF-kappaB/RelA-p50, AP-1 and NUR-77 activities, and were insensitive to proteasome inhibition.	Tetradecanoylphorbol Acetate	13-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	173-179
9885901-5	1998	By contrast, phorbol myristate acetate (PMA) and/or ionomycin-induced apoptosis had much slower kinetics, were preceded by an early increase of NF-kappaB/RelA-p50, AP-1 and NUR-77 activities, and were insensitive to proteasome inhibition.	Tetradecanoylphorbol Acetate	40-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	173-179
9885901-5	1998	By contrast, phorbol myristate acetate (PMA) and/or ionomycin-induced apoptosis had much slower kinetics, were preceded by an early increase of NF-kappaB/RelA-p50, AP-1 and NUR-77 activities, and were insensitive to proteasome inhibition.	Ionomycin	52-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	173-179
9564841-0	1998	Antisense TR3 orphan receptor can increase prostate cancer cell viability with etoposide treatment.	Etoposide	79-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-29
9747867-0	1998	erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.	Doxorubicin	23-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-98
9564841-4	1998	Northern blot analysis shows that human TR3 orphan receptor expression can be induced rapidly after treatment of LNCaP and PC-3 prostate cancer cells with calcium ionophore or etoposide.	Calcium	155-162	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-59
9564841-4	1998	Northern blot analysis shows that human TR3 orphan receptor expression can be induced rapidly after treatment of LNCaP and PC-3 prostate cancer cells with calcium ionophore or etoposide.	Etoposide	176-185	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-59
9564841-5	1998	Our data further demonstrate that a much higher concentration of etoposide was needed to kill the same number of cells in LNCaP and PC-3 cells transfected stably with antisense TR3 orphan receptor compared with that in control vector transfectants.	Etoposide	65-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	177-196
9341769-6	1997	The expression of c-myc and nur77, two immediate-early genes implicated in FasL gene activation, was blocked by lactacystin.	lactacystin	112-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
9353409-11	1997	These benzophenone-containing CT analogs should facilitate studies of hormone-receptor interactions and allow the direct identification of a CT binding domain(s) within the receptor by the analysis of photochemically cross-linked conjugates.	benzophenone	6-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-86
9439682-4	1997	In addition, N10 had a 1.65-fold higher GSH level than did KB and became radiosensitive on treatment with buthionine sulfoximine, an inhibitor of GSH.	Glutathione	40-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-16
9439682-4	1997	In addition, N10 had a 1.65-fold higher GSH level than did KB and became radiosensitive on treatment with buthionine sulfoximine, an inhibitor of GSH.	Buthionine Sulfoximine	106-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-16
9439682-4	1997	In addition, N10 had a 1.65-fold higher GSH level than did KB and became radiosensitive on treatment with buthionine sulfoximine, an inhibitor of GSH.	Glutathione	146-149	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-16
9439682-8	1997	X-Irradiation caused a rapid induction of PARP activity within 1 h in both cell lines, but treatment of cells with nicotinamide, a PARP inhibitor, markedly reduced the enzyme induction in N10, but not in KB, and potentiated the radiosensitivity in N10.	Niacinamide	115-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	188-191
9439682-8	1997	X-Irradiation caused a rapid induction of PARP activity within 1 h in both cell lines, but treatment of cells with nicotinamide, a PARP inhibitor, markedly reduced the enzyme induction in N10, but not in KB, and potentiated the radiosensitivity in N10.	Niacinamide	115-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	248-251
9322922-6	1997	Substitutions of Ser354 with negatively charged amino acids, such as Asp or Glu, dramatically decreased Nur77 DNA-binding and trans-activation activities, whereas mutation to the neutral Ala had no effect.	Aspartic Acid	69-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-109
9322922-6	1997	Substitutions of Ser354 with negatively charged amino acids, such as Asp or Glu, dramatically decreased Nur77 DNA-binding and trans-activation activities, whereas mutation to the neutral Ala had no effect.	Glutamic Acid	76-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-109
9130711-0	1997	Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization.	Tretinoin	14-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-110
9130711-4	1997	Here, we present evidence that nur77, another orphan receptor whose expression is highly induced by phorbol esters and growth factors, is involved in modulation of the RA response.	Phorbol Esters	100-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
9130711-5	1997	Expression of nur77 enhances ligand-independent transactivation of RA response elements (RAREs) and desensitizes their RA responsiveness.	Tretinoin	67-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19
9130711-12	1997	These observations demonstrate that a dynamic equilibrium between orphan receptors nur77 and COUP-TF, through their heterodimerization that regulates COUP-TF RARE binding, is critical for RA responsiveness of human lung cancer cells.	Tretinoin	158-160	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-88
11243104-4	1997	Of the 308 cases, tumor specimens in 130 patients were subjected to hormone receptor analysis by a dextran-coated charcoal technique.	Dextrans	99-106	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
8943276-10	1996	Trp-104 in the receptor, a key residue in the hormone-receptor interaction, has an altered conformation in the low affinity site enabling a favorable hydrogen bond to be formed with Asp-116 of the hormone.	Tryptophan	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-62
9070291-5	1997	In the presence of cycloheximide, all-trans retinoic acid superinduced NOR-1 mRNA, whereas all-trans and 9-cis retinoic acids strongly suppressed the NGFI-B mRNA accumulation.	Tretinoin	111-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-156
8943276-10	1996	Trp-104 in the receptor, a key residue in the hormone-receptor interaction, has an altered conformation in the low affinity site enabling a favorable hydrogen bond to be formed with Asp-116 of the hormone.	Hydrogen	150-158	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-62
8943276-10	1996	Trp-104 in the receptor, a key residue in the hormone-receptor interaction, has an altered conformation in the low affinity site enabling a favorable hydrogen bond to be formed with Asp-116 of the hormone.	Aspartic Acid	182-185	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-62
8621434-5	1996	Both TrkC and TrkA mediate qualitatively similar increases in the tyrosine phosphorylation of phospholipase C (PLC)-gamma1, Shc, SNT, and MAPK and the transcription of the c-fos, c-jun, NGFI-A, and NGFI-B immediate early genes.	Tyrosine	66-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	198-204
11666896-6	1996	The D(2)(d)() symmetric bispentazole (21) is the lowest energy N(10) minimum but is 260 kcal/mol higher in energy than five N(2) molecules.	ispentazole 	25-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
8702665-5	1996	Hormone receptor-dependent stimulation of cAMP accumulation in cells expressing alphas-R231H is reduced by approximately 75% in comparison to cAMP accumulation in cells expressing alphas-WT.	Cyclic AMP	42-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
8702665-5	1996	Hormone receptor-dependent stimulation of cAMP accumulation in cells expressing alphas-R231H is reduced by approximately 75% in comparison to cAMP accumulation in cells expressing alphas-WT.	Cyclic AMP	142-146	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
8702665-8	1996	In three-dimensional structures of G protein heterotrimers, Arg-231 is located in a region, switch 2, that is thought to interact with the betagamma subunit rather than with the hormone receptor.	Arginine	60-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	178-194
8640701-3	1996	Additional chemotherapy and tamoxifen, in hormone receptor-positive tumors, was used after mastectomy.	Tamoxifen	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-58
8883941-0	1996	Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system.	Dopamine	167-175	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-81
8883941-1	1996	Nurr1 and NGFI-B are closely related orphan members of the steroid-thyroid hormone receptor family involved in immediate early responses to stimuli such as growth factors.	Steroids	59-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-16
8647183-4	1996	Furthermore, studies with thymocytes demonstrated that the induction of nur77, a gene shown to be involved in thymocyte apoptosis signaled through the TCR or its surrogates, is not inhibited by NAC or dependent upon molecular oxygen.	Oxygen	226-232	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-77
7499374-0	1995	Chemical modification of the N-10 ribityl side chain of flavins.	Flavins	56-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-33
8613792-5	1996	After ether exposure, c-fos and NGFI-B mRNA induction were maximal at 30--60 min, whereas Fos protein peaked at 60--120 min.	Ether	6-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-38
7499374-2	1995	Three flavin derivatives modified at the 2"-position of the flavin N-10 ribityl side chain were synthesized: arabinoflavin, 2"-F-2"-deoxyarabinoflavin, and 2"-deoxyriboflavin.	4,6-dinitro-o-cresol	6-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-71
7499374-2	1995	Three flavin derivatives modified at the 2"-position of the flavin N-10 ribityl side chain were synthesized: arabinoflavin, 2"-F-2"-deoxyarabinoflavin, and 2"-deoxyriboflavin.	4,6-dinitro-o-cresol	60-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	67-71
7579652-3	1995	Some encouraging results have been obtained using designed metal-binding sites in such diverse applications as the stabilization of artificial peptide assembly, regulation of membrane channels, control of enzyme activity and enhancement of hormone-receptor interactions.	Metals	59-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	240-256
7565789-4	1995	We show that the major control of Nur77 induction is mediated by the calcium signaling pathway.	Calcium	69-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39
7565789-7	1995	CsA decreases both Nur77 protein levels and promoter activity, and the kinetics of CsA inhibition of apoptosis correlates with a decrease in Nur77 protein levels.	Cyclosporine	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-24
7565789-7	1995	CsA decreases both Nur77 protein levels and promoter activity, and the kinetics of CsA inhibition of apoptosis correlates with a decrease in Nur77 protein levels.	Cyclosporine	83-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-146
7565789-9	1995	In addition, Nur77 promoter deletion analysis revealed two RSRF (related to serum-responsive factor) binding sites, which can confer calcium and CsA sensitivity on a heterologous promoter.	Calcium	133-140	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
7565789-9	1995	In addition, Nur77 promoter deletion analysis revealed two RSRF (related to serum-responsive factor) binding sites, which can confer calcium and CsA sensitivity on a heterologous promoter.	Cyclosporine	145-148	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
7565789-10	1995	Taken together, our data suggest that the levels of transcriptional induction of Nur77 play an important role during activation-induced apoptosis and that calcium signals regulate a novel CsA-sensitive nuclear factor required for Nur77 transcription in T cells.	Calcium	155-162	nuclear receptor subfamily 4 group A member 1	Homo sapiens	230-235
8544841-5	1995	The normal response to cAMP could probably be attributed to equal activation of both genes by a transcription factor Nur77.	Cyclic AMP	23-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	117-122
7705655-0	1995	A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1.	Vitamin A	20-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-86
7705655-7	1995	Because expression of both NGFI-B and NURR1 is rapidly induced by various growth factors, these findings also suggest a novel mechanism for convergence between vitamin A or retinoid and growth factor signaling pathways.	Vitamin A	160-169	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-33
7705655-7	1995	Because expression of both NGFI-B and NURR1 is rapidly induced by various growth factors, these findings also suggest a novel mechanism for convergence between vitamin A or retinoid and growth factor signaling pathways.	Retinoids	173-181	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-33
7579504-1	1995	In pre-clinical and limited clinical studies, high doses ( &gt; or = 200 mg/day) of the triphenylethylene derivative toremifene showed activity in estrogen receptor (ER) negative and ER-unknown metastatic breast cancer after progression on tamoxifen, and a mechanism of action independent of hormone receptor binding was speculated.	triphenylethylene	88-105	nuclear receptor subfamily 4 group A member 1	Homo sapiens	292-308
7831306-6	1995	We report here that CsA inhibits the TCR-mediated activation of Nur77 protein in T-cell hybridomas by blocking the DNA binding activity of Nur77 protein rather than its de novo synthesis.	Cyclosporine	20-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
7831306-6	1995	We report here that CsA inhibits the TCR-mediated activation of Nur77 protein in T-cell hybridomas by blocking the DNA binding activity of Nur77 protein rather than its de novo synthesis.	Cyclosporine	20-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
7831306-7	1995	We also show that CsA mediates its negative effects on the Nur77 DNA binding activity through the N-terminal region of the protein.	Cyclosporine	18-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
7831306-8	1995	This complete inhibition of Nur77 protein DNA binding activity may explain how CsA interferes with TCR-mediated apoptosis.	Cyclosporine	79-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
7579504-1	1995	In pre-clinical and limited clinical studies, high doses ( &gt; or = 200 mg/day) of the triphenylethylene derivative toremifene showed activity in estrogen receptor (ER) negative and ER-unknown metastatic breast cancer after progression on tamoxifen, and a mechanism of action independent of hormone receptor binding was speculated.	Toremifene	117-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	292-308
7579504-2	1995	The CALGB conducted a Phase II trial (CALGB 8945) to test the efficacy of high dose toremifene in a population of patients who had hormone receptor-negative, metastatic breast cancer with limited prior chemotherapy exposure, good performance status, and measurable disease.	Toremifene	84-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	131-147
7930567-8	1994	Con A-induced activation of NGFI-B gene expression was not overcome by cyclosporin A or by 8Br-cAMP, but was partially prevented by dexamethasone.	Dexamethasone	132-145	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-34
7981602-5	1994	Various inhibitors of TCR-mediated apoptosis, including cyclosporin A down-regulate the Nur77 DNA binding activity.	Cyclosporine	56-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-93
7930567-9	1994	In lymphoblasts, okadaic acid caused the induction of NGFI-B gene expression, indicating a role for the serine/threonine protein phosphatases PP1 and PP2A in the regulation of this gene in resting cells.	Okadaic Acid	17-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-60
7930567-3	1994	After stimulation of T lymphocytes with Con A or phorbol 12,13 dibutyrate (PDBu), NGFI-B gene expression showed an induction of at least sevenfold within 3 h of stimulation.	Phorbol 12,13-Dibutyrate	49-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-88
7930567-3	1994	After stimulation of T lymphocytes with Con A or phorbol 12,13 dibutyrate (PDBu), NGFI-B gene expression showed an induction of at least sevenfold within 3 h of stimulation.	Phorbol 12,13-Dibutyrate	75-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-88
7930567-7	1994	However, the induction of NGFI-B by IL-2 is dependent on the presence of cycloheximide.	Cycloheximide	73-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-32
7930567-8	1994	Con A-induced activation of NGFI-B gene expression was not overcome by cyclosporin A or by 8Br-cAMP, but was partially prevented by dexamethasone.	Cyclosporine	71-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-34
7930567-10	1994	Okadaic acid-induced NGFI-B transcripts were significantly more stable than PDBu-induced NGFI-B mRNA.	Okadaic Acid	0-12	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-27
8405432-0	1993	Solvent oxygen is not incorporated into N10-formyltetrahydrofolate in the reaction catalyzed by N10-formyltetrahydrofolate synthetase.	Oxygen	8-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-99
7706656-5	1994	Positive hormone receptor assays on the surgical specimen favoured ovarian steroid hormone involvement in the aetiopathology of this strange disease.	Steroids	75-90	nuclear receptor subfamily 4 group A member 1	Homo sapiens	9-25
8405432-1	1993	The mechanism of the reaction catalyzed by N10-formyltetrahydrofolate synthetase involves the formation of formyl phosphate as an intermediate which then formylates tetrahydrofolate at the N-10 position.	formyl phosphate	107-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-46
8405432-1	1993	The mechanism of the reaction catalyzed by N10-formyltetrahydrofolate synthetase involves the formation of formyl phosphate as an intermediate which then formylates tetrahydrofolate at the N-10 position.	formyl phosphate	107-123	nuclear receptor subfamily 4 group A member 1	Homo sapiens	189-193
8405432-1	1993	The mechanism of the reaction catalyzed by N10-formyltetrahydrofolate synthetase involves the formation of formyl phosphate as an intermediate which then formylates tetrahydrofolate at the N-10 position.	formylates tetrahydrofolate	154-181	nuclear receptor subfamily 4 group A member 1	Homo sapiens	43-46
8405432-1	1993	The mechanism of the reaction catalyzed by N10-formyltetrahydrofolate synthetase involves the formation of formyl phosphate as an intermediate which then formylates tetrahydrofolate at the N-10 position.	formylates tetrahydrofolate	154-181	nuclear receptor subfamily 4 group A member 1	Homo sapiens	189-193
8405432-4	1993	If this were the case, oxygen from solvent H2O would be incorporated into the formyl group of the N10-derivative.	Oxygen	23-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	98-101
8405432-4	1993	If this were the case, oxygen from solvent H2O would be incorporated into the formyl group of the N10-derivative.	Water	43-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	98-101
8405432-5	1993	By conducting the reaction in a 1:1 mixture of [16O]H2O and [18O]H2O and using 13C NMR spectroscopy we show that no 18O is incorporated into the product and conclude that the reaction proceeds via a direct formylation of the N-10 position by formyl phosphate.	formyl phosphate	242-258	nuclear receptor subfamily 4 group A member 1	Homo sapiens	225-229
8395013-5	1993	The key features that distinguished the NGFI-B and SF-1 interactions were an amino group in the minor groove of the SF-1 binding sequence and an asparagine in the SF-1 A box.	Asparagine	145-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-46
1419299-5	1992	In this series of relapsing patients, [3H]dT LI was unrelated to hormone receptor status in the primary tumour, but it was higher in the metachronous lesions from patients with hormone receptor-negative primary tumours.	Tritium	39-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	177-193
1323288-0	1992	ABA-induced "lipid melting" and its reversal by umbelliferone in the plasmalemma of guard cell protoplasts: a breakthrough in plant hormone-receptor binding and hormone action.	alisol B 23-acetate	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-148
1323288-0	1992	ABA-induced "lipid melting" and its reversal by umbelliferone in the plasmalemma of guard cell protoplasts: a breakthrough in plant hormone-receptor binding and hormone action.	7-hydroxycoumarin	48-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	132-148
1326675-3	1992	The treatment with the ACE inhibitor captopril led to activation of hormone-receptor interactions.	Captopril	37-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
8247024-7	1993	To ascertain that this phenomenon was not unique to insect cells, aldosterone induced MR nuclear translocation in mouse macrophage cells was also demonstrated immunocytochemically, clearly indicating a role for nuclear translocation in MR function.	Aldosterone	66-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-88
8247024-7	1993	To ascertain that this phenomenon was not unique to insect cells, aldosterone induced MR nuclear translocation in mouse macrophage cells was also demonstrated immunocytochemically, clearly indicating a role for nuclear translocation in MR function.	Aldosterone	66-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	236-238
8095544-1	1993	Chlorpromazine N-oxide, fluphenazine N4"-oxide, prochlorperazine N4"-oxide, sulforidazine N-oxide, and trifluoperazine N4"-oxide were synthesized by oxidation of the designated nitrogen atom in the N-10 side chain of the respective parent drug with 3-chloroperoxybenzoic acid.	trifluoperazine N(4')-oxide	103-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	198-202
8095544-1	1993	Chlorpromazine N-oxide, fluphenazine N4"-oxide, prochlorperazine N4"-oxide, sulforidazine N-oxide, and trifluoperazine N4"-oxide were synthesized by oxidation of the designated nitrogen atom in the N-10 side chain of the respective parent drug with 3-chloroperoxybenzoic acid.	Nitrogen	177-185	nuclear receptor subfamily 4 group A member 1	Homo sapiens	198-202
1644831-3	1992	However, the ligand for NGFI-B does not appear to be a component of cell culture medium, as NGFI-B remained active when expressed in cells grown in medium lacking phenol red, serum, essential vitamins, or essential amino acids.	Phenolsulfonphthalein	163-173	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-98
1644831-3	1992	However, the ligand for NGFI-B does not appear to be a component of cell culture medium, as NGFI-B remained active when expressed in cells grown in medium lacking phenol red, serum, essential vitamins, or essential amino acids.	essential vitamins	182-200	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-98
1644831-3	1992	However, the ligand for NGFI-B does not appear to be a component of cell culture medium, as NGFI-B remained active when expressed in cells grown in medium lacking phenol red, serum, essential vitamins, or essential amino acids.	Amino Acids, Essential	205-226	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-98
1644831-5	1992	The mutation of two adjacent serine and threonine residues within TAB-1 significantly decreased transactivation by NGFI-B.	Serine	29-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-121
1644831-5	1992	The mutation of two adjacent serine and threonine residues within TAB-1 significantly decreased transactivation by NGFI-B.	Threonine	40-49	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-121
1314418-3	1992	A domain separate from the NGFI-B zinc fingers, termed the A box, was identified and is required for recognition of the two adenine-thymidine (A-T) base pairs at the 5" end of the NGFI-B DNA binding element.	adenine-thymidine	124-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-33
1314418-3	1992	A domain separate from the NGFI-B zinc fingers, termed the A box, was identified and is required for recognition of the two adenine-thymidine (A-T) base pairs at the 5" end of the NGFI-B DNA binding element.	adenine-thymidine	124-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	180-186
1558805-7	1992	A negative association emerged which was also observed in vitro in the human breast cancer line MCF-7 treated with Sodium Butyrate, a differentiation inducer, which reduced hormone-receptor levels and increased CaMBr8 expression.	Butyric Acid	115-130	nuclear receptor subfamily 4 group A member 1	Homo sapiens	173-189
1651101-0	1991	Phorbol ester, forskolin, and serum induction of a human colon nuclear hormone receptor gene related to the NUR 77/NGFI-B genes.	Phorbol Esters	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-114
1655735-2	1991	The overproduced hMR binds aldosterone with high affinity (Kd = 1.36 nM) and has high affinity for cortisol, cortexolone, and progesterone.	Aldosterone	27-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
1655735-2	1991	The overproduced hMR binds aldosterone with high affinity (Kd = 1.36 nM) and has high affinity for cortisol, cortexolone, and progesterone.	Hydrocortisone	99-107	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
1655735-2	1991	The overproduced hMR binds aldosterone with high affinity (Kd = 1.36 nM) and has high affinity for cortisol, cortexolone, and progesterone.	Cortodoxone	109-120	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
1655735-2	1991	The overproduced hMR binds aldosterone with high affinity (Kd = 1.36 nM) and has high affinity for cortisol, cortexolone, and progesterone.	Progesterone	126-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-20
1655735-10	1991	Unlike the glucocorticoid receptor, the oligomeric hMR complex can bind DNA-cellulose without prior activation.	Cellulose	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-54
1895294-5	1991	The bridge-extended analogues isohomo-PDDF (7) and isohomo-DMPDDF (8) contain an additional methylene group interposed between N10 and the phenyl ring of 1 and 3, respectively.	isohomo-pddf	30-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	127-130
1895294-5	1991	The bridge-extended analogues isohomo-PDDF (7) and isohomo-DMPDDF (8) contain an additional methylene group interposed between N10 and the phenyl ring of 1 and 3, respectively.	isohomo-dmpddf	51-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	127-130
1651101-0	1991	Phorbol ester, forskolin, and serum induction of a human colon nuclear hormone receptor gene related to the NUR 77/NGFI-B genes.	Phorbol Esters	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-121
1651101-0	1991	Phorbol ester, forskolin, and serum induction of a human colon nuclear hormone receptor gene related to the NUR 77/NGFI-B genes.	Colforsin	15-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-114
1651101-0	1991	Phorbol ester, forskolin, and serum induction of a human colon nuclear hormone receptor gene related to the NUR 77/NGFI-B genes.	Colforsin	15-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-121
1651101-5	1991	ST-59 receptor induction by serum was greatly amplified by cycloheximide and could be detected in actively growing LS-180 cells.	Cycloheximide	59-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
2283997-7	1990	The mRNA of NAK1 was induced rapidly and transiently by growth-stimulating agents, such as adenosine diphosphate, in monkey kidney cells (BSC-1), by phytohemagglutinin in human lymphocytes, and by serum stimulation of arrested fibroblasts.	Adenosine Diphosphate	91-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	12-16
1809075-4	1991	The standardized DCC method is the most common and recognized (Food and Drug Administration) procedure for quantifying hormone receptor in human cancer.	DICYCLOHEXYLCARBODIIMIDE	17-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
1874033-6	1991	However, since modification of either the hormone or the carbohydrate moiety of the receptor can selectively attenuate either the insulin-like or the lipolytic response, more than one hormone receptor interaction is likely.	Carbohydrates	57-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	184-200
33760860-1	2021	Letrozole, an aromatase inhibitor (AI), is the first-line adjuvant drug for treating hormone receptor-positive (HR+) breast cancer in postmenopausal women.	Letrozole	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
2358463-7	1990	The down-regulation of the hormone receptor was also induced with another phorbol diester, phorbol 12,13-didecanoate, but not with the phorbol or phorbol monoesters phorbol 12-myristate and phorbol 13-acetate.	Phorbol Esters	74-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-43
2358463-7	1990	The down-regulation of the hormone receptor was also induced with another phorbol diester, phorbol 12,13-didecanoate, but not with the phorbol or phorbol monoesters phorbol 12-myristate and phorbol 13-acetate.	phorbol-12,13-didecanoate	91-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-43
2358463-7	1990	The down-regulation of the hormone receptor was also induced with another phorbol diester, phorbol 12,13-didecanoate, but not with the phorbol or phorbol monoesters phorbol 12-myristate and phorbol 13-acetate.	phorbol	74-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-43
2358463-7	1990	The down-regulation of the hormone receptor was also induced with another phorbol diester, phorbol 12,13-didecanoate, but not with the phorbol or phorbol monoesters phorbol 12-myristate and phorbol 13-acetate.	phorbol	91-98	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-43
33818022-1	2021	PURPOSE: In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer.	Letrozole	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-106
33818022-1	2021	PURPOSE: In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer.	Letrozole	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-110
1696136-0	1990	[Interaction of hormone-receptor complexes of triiodothyronine with DNA and RNA].	Triiodothyronine	46-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	16-32
33971386-1	2021	BACKGROUND: Neratinib is approved in the European Union for extended adjuvant treatment of human epidermal growth factor receptor 2-positive/hormone receptor-positive (copositive) early breast cancer <=1 year of completion of prior trastuzumab-based therapy.	neratinib	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-157
33822619-7	2021	The dominant initiation paths for N4, N8, and N10 occur in the heterocycle and in the bond between the heterocycle and azo group, while that for N11 is ring elimination.	anthrone	119-122	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-49
33237560-5	2021	In the research, PTE accumulation was determined in the samples of N1 (Pb, As, and Hg), N9 (Cd, As), and N10 (Cd and As) and N8 (Pb) in wheat.	pte	17-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-108
33805613-1	2021	Tamoxifen is an endocrine treatment for hormone receptor positive breast cancer.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-56
33796150-1	2021	Background: The CDK4/6 inhibitor palbociclib combined with endocrine therapy (ET) has proven to prolong progression-free survival (PFS) in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC).	palbociclib	33-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-166
33237560-5	2021	In the research, PTE accumulation was determined in the samples of N1 (Pb, As, and Hg), N9 (Cd, As), and N10 (Cd and As) and N8 (Pb) in wheat.	Cadmium	110-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	105-108
33034801-8	2021	RESULTS: Equol showed bi-phasic protumor and antitumor effects; at a low concentration, it promoted the tumor growth in hormone receptor-positive cell lines, whereas antitumor effects were generally observed when an excessive amount of dose unexpected in the blood and the tissue was administered.	Equol	9-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	120-136
33235235-9	2020	Dexamethasone upregulated TGFBR1, and TGFBR2 in the presence of TGF-beta1 and increased active NR4A1.	Dexamethasone	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	95-100
33235235-12	2020	Dexamethasone exhibited diverse regulation of gene expression including NR4A1 upregulation consistent with the anti-fibrotic potential of GCs.	Dexamethasone	0-13	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-77
34558047-3	2022	In this work, the interaction quantitative model between resonance light scattering intensity and the concentration of binary surfactant mixtures NP-10+SDBS and NP-10+CTAB was established, and the mechanism of binary surfactant interaction was explored through the model by the resonance light scattering method.	Cetrimonium	167-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	146-151
34558047-3	2022	In this work, the interaction quantitative model between resonance light scattering intensity and the concentration of binary surfactant mixtures NP-10+SDBS and NP-10+CTAB was established, and the mechanism of binary surfactant interaction was explored through the model by the resonance light scattering method.	Cetrimonium	167-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	161-166
34868362-13	2022	ALC is a strong and easy-to-use dosage with prognostic factor for patients with HR+/HER2- mBC treated with palbociclib and endocrine therapy.	palbociclib	107-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-82
34463889-0	2022	Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen.	Tamoxifen	103-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-50
34699643-3	2022	Similar results were observed in these same cell lines after treatment with bisindole-derived (CDIMs) NR4A1 antagonists.	bisindole	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-107
34773204-6	2022	Through decidualization induction of the human endometrial stromal cells (hESCs) cultured in vitro and additional P treatment, the results of chromatin immunoprecipitation and other experiments show that the P treatment could upregulate the expression of NR4A1 in hESCs, and this process was mediated under the direct effect of progesterone receptor (PR) and NR4A1.	Progesterone	114-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	255-260
34773204-6	2022	Through decidualization induction of the human endometrial stromal cells (hESCs) cultured in vitro and additional P treatment, the results of chromatin immunoprecipitation and other experiments show that the P treatment could upregulate the expression of NR4A1 in hESCs, and this process was mediated under the direct effect of progesterone receptor (PR) and NR4A1.	Progesterone	114-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	359-364
34773204-6	2022	Through decidualization induction of the human endometrial stromal cells (hESCs) cultured in vitro and additional P treatment, the results of chromatin immunoprecipitation and other experiments show that the P treatment could upregulate the expression of NR4A1 in hESCs, and this process was mediated under the direct effect of progesterone receptor (PR) and NR4A1.	Progesterone	208-209	nuclear receptor subfamily 4 group A member 1	Homo sapiens	255-260
34773204-6	2022	Through decidualization induction of the human endometrial stromal cells (hESCs) cultured in vitro and additional P treatment, the results of chromatin immunoprecipitation and other experiments show that the P treatment could upregulate the expression of NR4A1 in hESCs, and this process was mediated under the direct effect of progesterone receptor (PR) and NR4A1.	Progesterone	208-209	nuclear receptor subfamily 4 group A member 1	Homo sapiens	359-364
34773204-7	2022	When the NR4A1 in hESCs was silenced, the promotion of hESC proliferation by P was inhibited.	Progesterone	77-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	9-14
34773204-9	2022	The results of spheroid adhesion assay show that the silent NR4A1 had reduced the adhesion of decidual hESCs induced in vitro to embryo.	hescs	103-108	nuclear receptor subfamily 4 group A member 1	Homo sapiens	60-65
34931843-1	2021	The dynamics of exciton and free-carrier relaxation of low-dimensional tin iodide perovskites, BA2FAn-1SnnI3n+1, where n = 1 (N1), 2 (N2), 5 (N5), and 10 (N10), were investigated with femtosecond transient absorption spectra (TAS).	tin iodide perovskites	71-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	155-158
34965945-1	2022	PURPOSE: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in the phase 3 MONALEESA-7 trial of pre-/perimenopausal patients with hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC).	ribociclib	9-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	219-235
34965945-1	2022	PURPOSE: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in the phase 3 MONALEESA-7 trial of pre-/perimenopausal patients with hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC).	ribociclib	9-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	237-239
34953442-0	2022	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.	ribociclib	15-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
34906197-2	2021	Based on some of their functional and gene modifying activities as anticancer agents, we hypothesized that kaempferol and quercetin were nuclear receptor 4A1 (NR4A1, Nur77) ligands and confirmed that both compounds directly bound NR4A1 with KD values of 3.1 and 0.93 muM, respectively.	kaempferol	107-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-171
34906197-2	2021	Based on some of their functional and gene modifying activities as anticancer agents, we hypothesized that kaempferol and quercetin were nuclear receptor 4A1 (NR4A1, Nur77) ligands and confirmed that both compounds directly bound NR4A1 with KD values of 3.1 and 0.93 muM, respectively.	kaempferol	107-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	230-235
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	Flavonoids	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-60
34906197-2	2021	Based on some of their functional and gene modifying activities as anticancer agents, we hypothesized that kaempferol and quercetin were nuclear receptor 4A1 (NR4A1, Nur77) ligands and confirmed that both compounds directly bound NR4A1 with KD values of 3.1 and 0.93 muM, respectively.	Quercetin	122-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-157
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	Flavonoids	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	Flavonoids	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
34906197-2	2021	Based on some of their functional and gene modifying activities as anticancer agents, we hypothesized that kaempferol and quercetin were nuclear receptor 4A1 (NR4A1, Nur77) ligands and confirmed that both compounds directly bound NR4A1 with KD values of 3.1 and 0.93 muM, respectively.	Quercetin	122-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-164
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	kaempferol	11-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-60
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	kaempferol	11-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
34906197-2	2021	Based on some of their functional and gene modifying activities as anticancer agents, we hypothesized that kaempferol and quercetin were nuclear receptor 4A1 (NR4A1, Nur77) ligands and confirmed that both compounds directly bound NR4A1 with KD values of 3.1 and 0.93 muM, respectively.	Quercetin	122-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-171
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	kaempferol	11-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
34906197-2	2021	Based on some of their functional and gene modifying activities as anticancer agents, we hypothesized that kaempferol and quercetin were nuclear receptor 4A1 (NR4A1, Nur77) ligands and confirmed that both compounds directly bound NR4A1 with KD values of 3.1 and 0.93 muM, respectively.	Quercetin	122-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	230-235
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	Quercetin	26-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-60
34906197-3	2021	METHODS: The activities of kaempferol and quercetin were determined in direct binding to NR4A1 protein and in NR4A1-dependent transactivation assays in Rh30 and Rh41 rhabdomyosarcoma (RMS) cells.	kaempferol	27-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	Quercetin	26-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-67
34906197-0	2021	Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.	Quercetin	26-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
34906197-3	2021	METHODS: The activities of kaempferol and quercetin were determined in direct binding to NR4A1 protein and in NR4A1-dependent transactivation assays in Rh30 and Rh41 rhabdomyosarcoma (RMS) cells.	kaempferol	27-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-115
34906197-2	2021	Based on some of their functional and gene modifying activities as anticancer agents, we hypothesized that kaempferol and quercetin were nuclear receptor 4A1 (NR4A1, Nur77) ligands and confirmed that both compounds directly bound NR4A1 with KD values of 3.1 and 0.93 muM, respectively.	kaempferol	107-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-157
34906197-3	2021	METHODS: The activities of kaempferol and quercetin were determined in direct binding to NR4A1 protein and in NR4A1-dependent transactivation assays in Rh30 and Rh41 rhabdomyosarcoma (RMS) cells.	Quercetin	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
34906197-2	2021	Based on some of their functional and gene modifying activities as anticancer agents, we hypothesized that kaempferol and quercetin were nuclear receptor 4A1 (NR4A1, Nur77) ligands and confirmed that both compounds directly bound NR4A1 with KD values of 3.1 and 0.93 muM, respectively.	kaempferol	107-117	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-164
34906197-3	2021	METHODS: The activities of kaempferol and quercetin were determined in direct binding to NR4A1 protein and in NR4A1-dependent transactivation assays in Rh30 and Rh41 rhabdomyosarcoma (RMS) cells.	Quercetin	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-115
34906197-6	2021	RESULTS: Kaempferol and quercetin bind NR4A1 protein and inhibit NR4A1-dependent transactivation in RMS cells.	kaempferol	9-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
34906197-6	2021	RESULTS: Kaempferol and quercetin bind NR4A1 protein and inhibit NR4A1-dependent transactivation in RMS cells.	kaempferol	9-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	65-70
34906197-6	2021	RESULTS: Kaempferol and quercetin bind NR4A1 protein and inhibit NR4A1-dependent transactivation in RMS cells.	Quercetin	24-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
34906197-6	2021	RESULTS: Kaempferol and quercetin bind NR4A1 protein and inhibit NR4A1-dependent transactivation in RMS cells.	Quercetin	24-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	65-70
34906197-8	2021	The pro-oncogenic PAX3-FOXO1 and G9a genes are also regulated by NR4A1 and, these pathways and genes are all inhibited by kaempferol and quercetin.	kaempferol	122-132	nuclear receptor subfamily 4 group A member 1	Homo sapiens	65-70
34906197-8	2021	The pro-oncogenic PAX3-FOXO1 and G9a genes are also regulated by NR4A1 and, these pathways and genes are all inhibited by kaempferol and quercetin.	Quercetin	137-146	nuclear receptor subfamily 4 group A member 1	Homo sapiens	65-70
34906197-10	2021	CONCLUSION: These results demonstrate the clinical potential for repurposing kaempferol and quercetin for clinical applications as precision medicine for treating RMS patients that express NR4A1 in order to increase the efficacy and decrease dosages of currently used cytotoxic drugs.	kaempferol	77-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	189-194
34906197-10	2021	CONCLUSION: These results demonstrate the clinical potential for repurposing kaempferol and quercetin for clinical applications as precision medicine for treating RMS patients that express NR4A1 in order to increase the efficacy and decrease dosages of currently used cytotoxic drugs.	Quercetin	92-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	189-194
34324367-1	2021	PURPOSE: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline.	asco	42-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-84
34324367-1	2021	PURPOSE: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline.	asco	42-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-88
34324367-4	2021	RECOMMENDATIONS: Alpelisib in combination with endocrine therapy (ET) should be offered to postmenopausal patients, and to male patients, with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, ABC, or MBC following prior endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor.	Alpelisib	17-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	143-145
34880407-5	2021	Hormone receptor negative breast cancers are highly aggressive, and are thought to originate from a subtype of epithelial cells called the luminal progenitor.	Phenobarbital	139-146	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
34803903-0	2021	The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.	ki67	12-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-80
34480554-4	2021	In phase I/II clinical studies, the efficacy of Z-endoxifen, the active isomer of endoxifen, was evaluated in patients with endocrine-refractory metastatic breast cancer as well as in patients with gynecologic, desmoid and hormone-receptor positive solid tumors, and demonstrated substantial oral bioavailability and promising antitumor activity.	4-hydroxy-N-desmethyltamoxifen	48-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	223-239
34480554-4	2021	In phase I/II clinical studies, the efficacy of Z-endoxifen, the active isomer of endoxifen, was evaluated in patients with endocrine-refractory metastatic breast cancer as well as in patients with gynecologic, desmoid and hormone-receptor positive solid tumors, and demonstrated substantial oral bioavailability and promising antitumor activity.	4-hydroxy-N-desmethyltamoxifen	82-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	223-239
34617955-1	2021	Importance: The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer.	palbociclib	58-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	182-198
34617955-1	2021	Importance: The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer.	Letrozole	90-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	182-198
34819039-1	2021	BACKGROUND: Entinostat is an oral inhibitor of class I histone deacetylases intended for endocrine therapy-resistant patients with hormone receptor-positive (HR+) advanced or metastatic breast cancer (BC).	entinostat	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	131-147
34844978-0	2022	A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.	Anastrozole	50-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	117-133
34868931-1	2021	Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients.	Tamoxifen	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-86
34868931-1	2021	Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients.	Tamoxifen	11-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-86
34830790-4	2021	We report that PGRMC1 overexpression resulted in increased proliferation of hormone receptor positive breast cancer cell lines upon treatment with a subgroup of progestins including norethisterone and dydrogesterone that promote PGRMC1-phosphorylation on S181.	Norethindrone	182-196	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-92
34830790-4	2021	We report that PGRMC1 overexpression resulted in increased proliferation of hormone receptor positive breast cancer cell lines upon treatment with a subgroup of progestins including norethisterone and dydrogesterone that promote PGRMC1-phosphorylation on S181.	Dydrogesterone	201-215	nuclear receptor subfamily 4 group A member 1	Homo sapiens	76-92
34830800-3	2021	RECENT FINDINGS: Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that have been used for decades in the therapy of hormone-receptor-positive breast cancer patients.	Tamoxifen	17-26	nuclear receptor subfamily 4 group A member 1	Homo sapiens	135-151
34754095-1	2022	BACKGROUND: The benefit of alpelisib in hormone-receptor-positive (HR+) metastatic breast cancer patients provided clinical evidence for the increasing importance of PIK3CA testing.	Alpelisib	27-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-56
34402131-15	2021	IMPLICATIONS FOR PRACTICE: The hormone receptor (HRc) subtype was an independent prognostic factor and the estrogen receptor (ER)+/progesterone receptor (PR)+ subtype showed a better survival in ductal carcinoma in situ (DCIS) patients who received tamoxifen therapy.	Tamoxifen	249-258	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-47
34452975-0	2021	Metformin prevents hyperglycaemia-associated, oxidative stress-induced vascular endothelial dysfunction: essential role for the orphan nuclear receptor, Nr4a1 (Nur77).	Metformin	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
34452975-0	2021	Metformin prevents hyperglycaemia-associated, oxidative stress-induced vascular endothelial dysfunction: essential role for the orphan nuclear receptor, Nr4a1 (Nur77).	Metformin	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-165
34452975-5	2021	Using in silico modelling of metformin-NR4A1 interactions, Nr4a1-mutagenesis and a transfected HEK 293T cell functional assay for metformin-activated Nr4a1, we identified two Nr4a1 prolines, P505/P549 (mouse sequences corresponding to human P501/P546), as key residues for enabling metformin to affect mitochondrial function.	Metformin	29-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
34452975-5	2021	Using in silico modelling of metformin-NR4A1 interactions, Nr4a1-mutagenesis and a transfected HEK 293T cell functional assay for metformin-activated Nr4a1, we identified two Nr4a1 prolines, P505/P549 (mouse sequences corresponding to human P501/P546), as key residues for enabling metformin to affect mitochondrial function.	Metformin	130-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-155
34452975-5	2021	Using in silico modelling of metformin-NR4A1 interactions, Nr4a1-mutagenesis and a transfected HEK 293T cell functional assay for metformin-activated Nr4a1, we identified two Nr4a1 prolines, P505/P549 (mouse sequences corresponding to human P501/P546), as key residues for enabling metformin to affect mitochondrial function.	Metformin	130-139	nuclear receptor subfamily 4 group A member 1	Homo sapiens	175-180
34452975-5	2021	Using in silico modelling of metformin-NR4A1 interactions, Nr4a1-mutagenesis and a transfected HEK 293T cell functional assay for metformin-activated Nr4a1, we identified two Nr4a1 prolines, P505/P549 (mouse sequences corresponding to human P501/P546), as key residues for enabling metformin to affect mitochondrial function.	Metformin	282-291	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
34452975-5	2021	Using in silico modelling of metformin-NR4A1 interactions, Nr4a1-mutagenesis and a transfected HEK 293T cell functional assay for metformin-activated Nr4a1, we identified two Nr4a1 prolines, P505/P549 (mouse sequences corresponding to human P501/P546), as key residues for enabling metformin to affect mitochondrial function.	Metformin	282-291	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
34452975-5	2021	Using in silico modelling of metformin-NR4A1 interactions, Nr4a1-mutagenesis and a transfected HEK 293T cell functional assay for metformin-activated Nr4a1, we identified two Nr4a1 prolines, P505/P549 (mouse sequences corresponding to human P501/P546), as key residues for enabling metformin to affect mitochondrial function.	Metformin	282-291	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-155
34452975-5	2021	Using in silico modelling of metformin-NR4A1 interactions, Nr4a1-mutagenesis and a transfected HEK 293T cell functional assay for metformin-activated Nr4a1, we identified two Nr4a1 prolines, P505/P549 (mouse sequences corresponding to human P501/P546), as key residues for enabling metformin to affect mitochondrial function.	Metformin	282-291	nuclear receptor subfamily 4 group A member 1	Homo sapiens	175-180
34452975-6	2021	Our data indicate a critical role for Nr4a1 in metformin"s endothelial-protective effects, observed at micromolar concentrations, which activate AMPKinase but do not affect mitochondrial complex-I or complex-III oxygen consumption rates, as does 0.5 mM metformin.	Metformin	47-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
34452975-7	2021	Thus, therapeutic metformin concentrations, requiring the expression of Nr4a1, protect the vasculature from hyperglycaemia-induced dysfunction in addition to metformin"s action to enhance insulin action in diabetics.	Metformin	18-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	72-77
34452975-10	2021	However, this action of metformin requires the expression of the orphan nuclear receptor, NR4A1/Nur77.	Metformin	24-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-95
34452975-10	2021	However, this action of metformin requires the expression of the orphan nuclear receptor, NR4A1/Nur77.	Metformin	24-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	96-101
34383180-5	2021	Hormone receptor positivity was defined as estrogen receptor-positive, progesterone-positive and HER 2-negative cancer.	Progesterone	71-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
34529000-12	2021	Investigational treatments significantly lowered RCB in HR-negative/ERBB2-negative (graduated and nongraduated treatments) and ERBB2-positive subtypes (graduated treatments), with improved EFS (HZR, 0.61; 95% CI, 0.41-0.93) in the exploratory analysis.	rcb	49-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	56-58
34402131-15	2021	IMPLICATIONS FOR PRACTICE: The hormone receptor (HRc) subtype was an independent prognostic factor and the estrogen receptor (ER)+/progesterone receptor (PR)+ subtype showed a better survival in ductal carcinoma in situ (DCIS) patients who received tamoxifen therapy.	Tamoxifen	249-258	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-52
34745997-0	2021	Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?	palbociclib	65-76	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-155
34745997-0	2021	Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?	Letrozole	97-106	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-155
34745997-1	2021	In this study, we evaluated clinical parameters to predict the primary resistance of palbociclib in combination with endocrine therapy as the first-line treatment in patients with hormone receptor (HR)+, human epidermal growth factor receptor 2 (HER2)- metastatic breast cancer (MBC).	palbociclib	85-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	180-202
34720808-7	2021	However, 15 of the HR+ patients died before tamoxifen became available in 2013.	Tamoxifen	44-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-21
34077833-4	2021	Both PGE2 release and nitric oxide production in macrophage cells were significantly suppressed by the N8 and N10 treatment groups.	Dinoprostone	5-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-113
34077833-4	2021	Both PGE2 release and nitric oxide production in macrophage cells were significantly suppressed by the N8 and N10 treatment groups.	Nitric Oxide	22-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-113
34629883-0	2021	Ethyl 2-(2,3,4-Trimethoxy-6-(1-Octanoyl)Phenyl) Acetate (TMPA) Ameliorates Lipid Accumulation by Disturbing the Combination of LKB1 with Nur77 and Activating the AMPK Pathway in HepG2 Cells and Mice Primary Hepatocytes.	tmpa	57-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-142
34629883-2	2021	Ethyl 2-(2,3,4-trimethoxy-6-(1-octanoyl)phenyl) acetate (TMPA) is a novel AMPK agonist, which influences the stability of Nuclear Receptor Subfamily 4, Group A, Member 1 (Nur77)-serine-threonine kinase 11 (LKB1) in the nucleus.	ethyl 2-(2,3,4-trimethoxy-6-(1-octanoyl)phenyl)acetate	0-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-169
34629883-2	2021	Ethyl 2-(2,3,4-trimethoxy-6-(1-octanoyl)phenyl) acetate (TMPA) is a novel AMPK agonist, which influences the stability of Nuclear Receptor Subfamily 4, Group A, Member 1 (Nur77)-serine-threonine kinase 11 (LKB1) in the nucleus.	ethyl 2-(2,3,4-trimethoxy-6-(1-octanoyl)phenyl)acetate	0-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-176
34629883-2	2021	Ethyl 2-(2,3,4-trimethoxy-6-(1-octanoyl)phenyl) acetate (TMPA) is a novel AMPK agonist, which influences the stability of Nuclear Receptor Subfamily 4, Group A, Member 1 (Nur77)-serine-threonine kinase 11 (LKB1) in the nucleus.	tmpa	57-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-169
34629883-2	2021	Ethyl 2-(2,3,4-trimethoxy-6-(1-octanoyl)phenyl) acetate (TMPA) is a novel AMPK agonist, which influences the stability of Nuclear Receptor Subfamily 4, Group A, Member 1 (Nur77)-serine-threonine kinase 11 (LKB1) in the nucleus.	tmpa	57-61	nuclear receptor subfamily 4 group A member 1	Homo sapiens	171-176
34629883-14	2021	Conclusion: TMPA ameliorated lipid accumulation by influencing the stability of Nur77-LKB1 in vitro.	tmpa	12-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-85
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	sp	42-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-124
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	sp	116-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	sp	116-118	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-124
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	Triterpenes	200-212	nuclear receptor subfamily 4 group A member 1	Homo sapiens	281-286
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	celastrol	213-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	celastrol	213-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-124
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	celastrol	213-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	281-286
34645818-0	2021	Phase separation of Nur77 mediates celastrol-induced mitophagy by promoting the liquidity of p62/SQSTM1 condensates.	celastrol	35-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-25
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-52
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-69
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-77
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-87
34645818-4	2021	Here, we show that the ubiquitinated mitochondrial Nur77 forms membraneless condensates capable of sequestrating damaged mitochondria by interacting with the UBA domain of p62/SQSTM1.	UBP 310	158-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
34740541-0	2022	Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.	Everolimus	23-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
34740541-0	2022	Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.	exemestane	38-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
34740541-1	2022	PURPOSE: Everolimus with exemestane (EVE+EXE) was FDA-approved to treat metastatic hormone receptor-positive breast cancer (mHRBC) based on BOLERO-2.	Everolimus	9-19	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-99
34740541-1	2022	PURPOSE: Everolimus with exemestane (EVE+EXE) was FDA-approved to treat metastatic hormone receptor-positive breast cancer (mHRBC) based on BOLERO-2.	exemestane	25-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	83-99
34692469-5	2021	Herein, we report the clinical history of a young woman with HR-positive HER2-negative metastatic BC and a pancytopenia due to carcinomatosis of the bone marrow receiving letrozole and leuprorelin plus the CDK4/6 inhibitor palbociclib, who significantly derived clinical benefit from treatment.	Letrozole	171-180	nuclear receptor subfamily 4 group A member 1	Homo sapiens	61-63
34692469-5	2021	Herein, we report the clinical history of a young woman with HR-positive HER2-negative metastatic BC and a pancytopenia due to carcinomatosis of the bone marrow receiving letrozole and leuprorelin plus the CDK4/6 inhibitor palbociclib, who significantly derived clinical benefit from treatment.	palbociclib	223-234	nuclear receptor subfamily 4 group A member 1	Homo sapiens	61-63
34629883-0	2021	Ethyl 2-(2,3,4-Trimethoxy-6-(1-Octanoyl)Phenyl) Acetate (TMPA) Ameliorates Lipid Accumulation by Disturbing the Combination of LKB1 with Nur77 and Activating the AMPK Pathway in HepG2 Cells and Mice Primary Hepatocytes.	ethyl 2-(2,3,4-trimethoxy-6-(1-octanoyl)phenyl)acetate	0-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-142
34805355-0	2021	Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.	Everolimus	32-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-107
34805355-1	2021	Background: To analyze the efficacy and safety of everolimus 5 mg/day in combination with endocrine drugs in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer using real-world clinical data.	Everolimus	50-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142
34805355-2	2021	Methods: Clinical data of hormone receptor (HR)-positive and HER2-negative patients with advanced breast cancer treated with everolimus combined with endocrine drugs in our center between August 2012 and May 2017 were retrospectively analyzed.	Everolimus	125-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-48
34805355-11	2021	Conclusions: Our results showed that everolimus (5 mg/day) combined with endocrine therapy was effective and relatively safe for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.	Everolimus	37-47	nuclear receptor subfamily 4 group A member 1	Homo sapiens	143-159
34486957-0	2022	From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data.	Everolimus	54-64	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-116
34657059-0	2021	(A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole).	abemaciclib	105-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
34657059-0	2021	(A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole).	Anastrozole	121-132	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
34357781-0	2021	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer.	e2112	0-5	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-101
34436536-2	2021	Objective: To compare the effectiveness of everolimus plus letrozole vs letrozole alone in premenopausal women with HR-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving SERMs.	Everolimus	43-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	116-118
34436536-2	2021	Objective: To compare the effectiveness of everolimus plus letrozole vs letrozole alone in premenopausal women with HR-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving SERMs.	Letrozole	59-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	116-118
34436536-2	2021	Objective: To compare the effectiveness of everolimus plus letrozole vs letrozole alone in premenopausal women with HR-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving SERMs.	Letrozole	72-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	116-118
34436536-14	2021	Conclusions and Relevance: In this randomized clinical trial, PFS was significantly longer among premenopausal patients with HR-positive/ERBB2-negative advanced breast cancer who received everolimus plus letrozole than among those who received letrozole alone.	Everolimus	188-198	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-127
34436536-14	2021	Conclusions and Relevance: In this randomized clinical trial, PFS was significantly longer among premenopausal patients with HR-positive/ERBB2-negative advanced breast cancer who received everolimus plus letrozole than among those who received letrozole alone.	Letrozole	204-213	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-127
34543613-18	2021	Sequential endocrine therapy with tamoxifen for 2-3 years followed by letrozole for 5 years should be considered as one of the optimal standard endocrine treatments for postmenopausal patients with hormone receptor-positive breast cancer.	Tamoxifen	34-43	nuclear receptor subfamily 4 group A member 1	Homo sapiens	198-214
34543613-18	2021	Sequential endocrine therapy with tamoxifen for 2-3 years followed by letrozole for 5 years should be considered as one of the optimal standard endocrine treatments for postmenopausal patients with hormone receptor-positive breast cancer.	Letrozole	70-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	198-214
34753632-0	2022	A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer.	Cyclophosphamide	115-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	175-191
34753632-0	2022	A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer.	Technetium	133-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	175-191
34514415-0	2021	CPT1A and fatty acid beta-oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer.	Fatty Acids	10-20	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104
34486957-0	2022	From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data.	exemestane	69-79	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-116
34217908-2	2021	This phase I/II trial was designed to test the safety and efficacy of palbociclib, pembrolizumab and letrozole in women with hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC).	Letrozole	101-110	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
34628933-0	2021	Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.	pyrotinib	43-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-130
34628933-0	2021	Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.	Letrozole	57-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	114-130
34416161-0	2021	A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1.	Bile Acids and Salts	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
34414958-1	2021	BACKGROUND: Ovarian function suppressor (OFS) plus either tamoxifen (TAM) or aromatase inhibitor (AI) could improve the survival outcome for premenopausal hormone receptor-positive (HR+) breast cancer.	Tamoxifen	58-67	nuclear receptor subfamily 4 group A member 1	Homo sapiens	155-171
34196874-0	2021	Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer.	entinostat	45-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-149
34196874-1	2021	BACKGROUND: Previous clinical trials have demonstrated that entinostat in combination with exemestane had good tolerability and significant clinical efficacy in patients with advanced hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC) in the USA.	entinostat	60-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	184-200
34196874-1	2021	BACKGROUND: Previous clinical trials have demonstrated that entinostat in combination with exemestane had good tolerability and significant clinical efficacy in patients with advanced hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC) in the USA.	exemestane	91-101	nuclear receptor subfamily 4 group A member 1	Homo sapiens	184-200
34414958-1	2021	BACKGROUND: Ovarian function suppressor (OFS) plus either tamoxifen (TAM) or aromatase inhibitor (AI) could improve the survival outcome for premenopausal hormone receptor-positive (HR+) breast cancer.	Tamoxifen	69-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	155-171
34146662-9	2021	Atrazine altered genes expression levels of PAX6, TUBB3, NCAM1, GFAP, TH, NR4A1, and GRIA1.	Atrazine	0-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-79
34602942-1	2021	Background: Fulvestrant 500 mg monotherapy is recommended as the first-line endocrine treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer (MBC).	Fulvestrant	12-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
34323462-9	2021	Molecules such as decazapentacene (N10) exhibit multistability of oxidation state, and this is predicted to promote the redox catalytic properties of the compounds.	decazapentacene	18-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	35-38
34532493-6	2021	Here, we present a case of a 50-year-old postmenopausal HER2-positive/HR-positive breast cancer patient who received pyrotinib plus letrozole as a first-line treatment following a diagnosis of left axillary lymph node and double lung metastases after modified radical mastectomy for left breast cancer.	pyrotinib	117-126	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-72
34532493-6	2021	Here, we present a case of a 50-year-old postmenopausal HER2-positive/HR-positive breast cancer patient who received pyrotinib plus letrozole as a first-line treatment following a diagnosis of left axillary lymph node and double lung metastases after modified radical mastectomy for left breast cancer.	Letrozole	132-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-72
34532493-10	2021	Our case indicates that the combined therapy of pyrotinib plus letrozole may/can be a promising treatment option for patients with HER2-positive/HR-positive MBC.	pyrotinib	48-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-147
34143979-3	2021	DOP increased pathologic complete response (pCR) rates in all HER2-negative (20%-37%), hormone receptor (HR)-positive/HER2-negative (14%-28%), and triple-negative breast cancer (TNBC) (27%-47%).	Diethylhexyl Phthalate	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-109
34359587-6	2021	In this review, we will discuss the current state of knowledge on the roles of microRNAs and lncRNAs in the main mechanisms of tamoxifen resistance in hormone receptor positive breast cancer.	Tamoxifen	127-136	nuclear receptor subfamily 4 group A member 1	Homo sapiens	151-167
34109683-15	2021	We propose that the suppression of the calcium-NFATc3-NR4A1 cascade by these three drugs plays a role in the development of DIGO.	digo	124-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-59
34109683-14	2021	We confirmed that CsA, NIF, and PHT reduced cytosolic calcium levels increased by TGF-beta, while CaCl2 enhanced the TGF-beta-up-regulated NR4A1 expression.	Cyclosporine	18-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
34109683-14	2021	We confirmed that CsA, NIF, and PHT reduced cytosolic calcium levels increased by TGF-beta, while CaCl2 enhanced the TGF-beta-up-regulated NR4A1 expression.	Calcium Chloride	98-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
34221179-9	2021	The HER2-specific tyrosine kinase inhibitor tucatinib when added to trastuzumab and capecitabine was shown to improve PFS and overall survival (OS) over trastuzumab and capecitabine alone in pretreated patients in the randomized HER2CLIMB trial; this benefit was apparently independent of hormone-receptor expression.	Irbinitinib	44-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	289-305
34109683-15	2021	We propose that the suppression of the calcium-NFATc3-NR4A1 cascade by these three drugs plays a role in the development of DIGO.	Calcium	39-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-59
34182489-7	2021	RESULTS: A substitution in the NR4A1 gene at codon 293 resulting in an amino acid change from arginine to serine was identified only in the affected sisters.	Arginine	94-102	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
34182489-7	2021	RESULTS: A substitution in the NR4A1 gene at codon 293 resulting in an amino acid change from arginine to serine was identified only in the affected sisters.	Serine	106-112	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
34209871-0	2021	NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer.	Tamoxifen	16-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
34096894-1	2021	OBJECTIVES: Letrozole is a nonsteroidal aromatase inhibitor used to treat hormone-receptor-positive breast cancer.	Letrozole	12-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-90
34096894-4	2021	METHODS: The Exemestane and Letrozole Pharmacogenetics (ELPh) Study randomized postmenopausal patients with hormone-receptor-positive nonmetastatic breast cancer to letrozole or exemestane treatment.	exemestane	13-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-124
34096894-4	2021	METHODS: The Exemestane and Letrozole Pharmacogenetics (ELPh) Study randomized postmenopausal patients with hormone-receptor-positive nonmetastatic breast cancer to letrozole or exemestane treatment.	Letrozole	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	108-124
34209871-6	2021	Here, we propose that NR4A1 is a promising target to overcome tamoxifen resistance.	Tamoxifen	62-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	22-27
34209871-7	2021	NR4A1 gene expression was downregulated in tamoxifen-resistant MCF7 (TamR) cells compared to that in MCF7 cells.	Tamoxifen	43-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
34209871-8	2021	Kaplan-Meier plots were used to identify high NR4A1 expression correlated with increased survival rates in patients with ER-positive breast cancer following tamoxifen treatment.	Tamoxifen	157-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-51
34209871-9	2021	Gain and loss of function experiments showed that NR4A1 restores sensitivity to tamoxifen by regulating cell proliferation, migration, invasion, and apoptosis.	Tamoxifen	80-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-55
34209871-11	2021	In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance.	Tamoxifen	79-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-51
34209871-11	2021	In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance.	Tamoxifen	79-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-173
34209871-11	2021	In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance.	Tamoxifen	203-212	nuclear receptor subfamily 4 group A member 1	Homo sapiens	46-51
34209871-11	2021	In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance.	Tamoxifen	203-212	nuclear receptor subfamily 4 group A member 1	Homo sapiens	168-173
34209871-12	2021	These results indicate that NR4A1 could be a potential therapeutic target to overcome tamoxifen resistance in ER-positive breast cancer.	Tamoxifen	86-95	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
34392523-10	2021	Water-related disasters accounted for nearly three-fourths of the natural disasters (hurricanes 40 percent, N = 12; floods, 33.3 percent, N = 10; total 73.3 percent, N = 22), then snow/ice storms (13.3 percent, N = 4).	Water	0-5	nuclear receptor subfamily 4 group A member 1	Homo sapiens	138-144
34248473-5	2021	Case Presentation: Here, we describe a female patient with metastatic hormone receptor-positive/human epidermal growth factor 2-negative breast cancer who developed lung toxicity while on ribociclib.	ribociclib	188-198	nuclear receptor subfamily 4 group A member 1	Homo sapiens	70-86
34128985-3	2021	Lama5 loss in the keratin 8-expressing cells results in reduced frequency and differentiation of hormone receptor expressing (HR+) luminal cells.	Phenobarbital	131-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
34150608-12	2021	Conclusions: Our data provide evidence that the emergence of CTC-WBC clusters underwent EMT before treatment is associated with significantly poorer PFS in HR-positive/HER2-negative metastatic breast cancer patients receiving docetaxel plus capecitabine, which may be used as a parameter to predict the clinical outcomes and a potential target for individualized therapy.	Docetaxel	226-235	nuclear receptor subfamily 4 group A member 1	Homo sapiens	156-158
34150608-12	2021	Conclusions: Our data provide evidence that the emergence of CTC-WBC clusters underwent EMT before treatment is associated with significantly poorer PFS in HR-positive/HER2-negative metastatic breast cancer patients receiving docetaxel plus capecitabine, which may be used as a parameter to predict the clinical outcomes and a potential target for individualized therapy.	Capecitabine	241-253	nuclear receptor subfamily 4 group A member 1	Homo sapiens	156-158
34102639-0	2021	(18F)-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors.	Fluorodeoxyglucose F18	0-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-129
34259084-1	2021	Alpelisib is a alpha-selective phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC).	Alpelisib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	140-156
35605174-0	2022	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.	Everolimus	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-90
35597619-0	2022	Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center"s experience.	exemestane	15-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	29-45
35636320-0	2022	Hormone receptor binding, selectivity and cytotoxicity of steroid D-homo lactone loaded chitosan nanoparticles for the treatment of breast and prostate cancer cells.	Chitosan	88-96	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
35398754-5	2022	Phase I/II studies demonstrated greater efficacy when capivasertib was co-administered with paclitaxel, fulvestrant in hormone receptor (HR)-positive, HER2-negative breast cancer or olaparib.	capivasertib	54-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-141
35567914-2	2022	The CDK 4/6 inhibitor palbociclib has demonstrated efficacy in clinical studies in patients with hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC).	palbociclib	22-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
35577139-8	2022	The proliferation index of the luminal B group was significantly (p < 0.001) higher in the low HR (hormone receptor) group than in the HR group.	Phenobarbital	31-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-115
35579777-1	2022	Patients with hormone receptor (HR)-positive tumors breast cancer usually experience a relatively low pathological complete response (pCR) to neoadjuvant chemotherapy (NAC).	nac	168-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-30
35579777-1	2022	Patients with hormone receptor (HR)-positive tumors breast cancer usually experience a relatively low pathological complete response (pCR) to neoadjuvant chemotherapy (NAC).	nac	168-171	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-34
35534752-0	2022	Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.	palbociclib	37-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-97
35563670-2	2022	In a previous study, we demonstrated that fangchinoline (FCN), a natural inhibitor of nuclear NR4A1, induces NR4A1-dependent apoptosis in human pancreatic cancer cells.	fangchinoline	42-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
35563670-2	2022	In a previous study, we demonstrated that fangchinoline (FCN), a natural inhibitor of nuclear NR4A1, induces NR4A1-dependent apoptosis in human pancreatic cancer cells.	fangchinoline	42-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-114
35563670-2	2022	In a previous study, we demonstrated that fangchinoline (FCN), a natural inhibitor of nuclear NR4A1, induces NR4A1-dependent apoptosis in human pancreatic cancer cells.	fangchinoline	57-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	94-99
35563670-2	2022	In a previous study, we demonstrated that fangchinoline (FCN), a natural inhibitor of nuclear NR4A1, induces NR4A1-dependent apoptosis in human pancreatic cancer cells.	fangchinoline	57-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-114
35563670-3	2022	In this study, we evaluated FCN and its structural analogs (berbamine, isotetrandrine, tetrandrine, and tubocurarine) for their inhibitory effects on NR4A1 transactivity, and confirmed that tetrandrine (TTD) showed the highest inhibitory effect in pancreatic cancer cells.	fangchinoline	28-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-155
35563670-3	2022	In this study, we evaluated FCN and its structural analogs (berbamine, isotetrandrine, tetrandrine, and tubocurarine) for their inhibitory effects on NR4A1 transactivity, and confirmed that tetrandrine (TTD) showed the highest inhibitory effect in pancreatic cancer cells.	tetrandrine	190-201	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-155
35563670-3	2022	In this study, we evaluated FCN and its structural analogs (berbamine, isotetrandrine, tetrandrine, and tubocurarine) for their inhibitory effects on NR4A1 transactivity, and confirmed that tetrandrine (TTD) showed the highest inhibitory effect in pancreatic cancer cells.	tetrandrine	203-206	nuclear receptor subfamily 4 group A member 1	Homo sapiens	150-155
35563670-4	2022	Moreover, in a tryptophan fluorescence quenching assay, TTD directly bound to the ligand binding domain (LBD) of NR4A1 with a KD value of 10.60 muM.	Tryptophan	15-25	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-118
35563670-5	2022	Treatment with TTD decreased proliferation and induced apoptosis in Panc-1 human pancreatic cancer cells in part through the reduced expression of the Sp1-dependent anti-apoptotic gene survivin and induction of ROS-mediated endoplasmic reticulum stress, which are the well-known NR4A1-dependent proapoptotic pathways.	tetrandrine	15-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	279-284
35563670-5	2022	Treatment with TTD decreased proliferation and induced apoptosis in Panc-1 human pancreatic cancer cells in part through the reduced expression of the Sp1-dependent anti-apoptotic gene survivin and induction of ROS-mediated endoplasmic reticulum stress, which are the well-known NR4A1-dependent proapoptotic pathways.	ros	211-214	nuclear receptor subfamily 4 group A member 1	Homo sapiens	279-284
35530963-13	2022	We also explored the relationship between Celastrol and the nuclear receptor Nur77 and found that it could up-regulate the expression of Nur77.	celastrol	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-82
35478061-3	2022	County-level data from the US national datasets were analyzed for the association between emissions of various metals including arsenic, cadmium, chromium VI, lead, and mercury, and the annual age-adjusted incidence of hormone receptor-dependent breast cancer for 1990-2016 and HER2-dependent breast cancer for 2010-2016 using adjusted linear regression models.	Mercury	169-176	nuclear receptor subfamily 4 group A member 1	Homo sapiens	219-235
35530963-13	2022	We also explored the relationship between Celastrol and the nuclear receptor Nur77 and found that it could up-regulate the expression of Nur77.	celastrol	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-142
35000092-0	2022	Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.	Alpelisib	19-28	nuclear receptor subfamily 4 group A member 1	Homo sapiens	62-78
35182885-0	2022	Discovery of a Nur77-mediated cytoplasmic vacuolation and paraptosis inducer (4-PQBH) for the treatment of hepatocellular carcinoma.	4-PQBH	78-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-20
35182885-3	2022	Our recent work demonstrated that certain quinoline-Schiff-base derivatives were good Nur77 mediators that exerted excellent anti-HCC activities in vitro and in vivo.	quinoline	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-91
35182885-3	2022	Our recent work demonstrated that certain quinoline-Schiff-base derivatives were good Nur77 mediators that exerted excellent anti-HCC activities in vitro and in vivo.	Schiff Bases	52-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-91
35182885-5	2022	As a continuous work, we synthesized a series of 4-(quinoline-4-amino) benzoylhydrazide derivatives and evaluated their anti-HCC activity and binding affinity to Nur77 in vitro.	4-(quinoline-4-amino) benzoylhydrazide	49-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	162-167
35182885-6	2022	Compound 4-PQBH emerged as the best Nur77 binder (KD = 1.17 muM) and has potentially selective cytotoxicity to HCC cells.	4-PQBH	9-15	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-41
35182885-7	2022	Mechanistically, 4-PQBH extensively induced caspase-independent cytoplasmic vacuolization and paraptosis through Nur77-mediated ER stress and autophagy.	4-PQBH	17-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	113-118
35182885-8	2022	Moreover, 4-PQBH exhibited an effective xenograft tumor inhibition by modulating Nur77-dependent cytoplasmic vacuolation and paraptosis.	4-PQBH	10-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	81-86
35000092-1	2022	PURPOSE: Alpelisib is a phosphoinositide-3-kinase inhibitor approved for hormone-receptor-positive, PIK3CA-mutated metastatic breast cancer.	Alpelisib	9-18	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-89
35406370-1	2022	Alpelisib is an alpha-selective phosphatidylinositol 3-kinase inhibitor used for treating hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression on or after endocrine therapy.	Alpelisib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-106
35351974-0	2022	Retraction Note: The nuclear orphan receptor Nur77 alleviates palmitate-induced fat accumulation by down-regulating G0S2 in HepG2 cells.	Palmitates	62-71	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
35268797-3	2022	Our previous studies have found that the introduction of bicyclic aromatic rings, such as naphthalyl and quinoline groups, into the N"-methylene position of indoles" Nur77 modulators can effectively improve the anti-tumor activity of the target compounds.	naphthalyl	90-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-171
35300061-0	2022	Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data.	ribociclib	119-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	54-70
35268797-3	2022	Our previous studies have found that the introduction of bicyclic aromatic rings, such as naphthalyl and quinoline groups, into the N"-methylene position of indoles" Nur77 modulators can effectively improve the anti-tumor activity of the target compounds.	quinoline	105-114	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-171
35268797-3	2022	Our previous studies have found that the introduction of bicyclic aromatic rings, such as naphthalyl and quinoline groups, into the N"-methylene position of indoles" Nur77 modulators can effectively improve the anti-tumor activity of the target compounds.	n"-methylene	132-144	nuclear receptor subfamily 4 group A member 1	Homo sapiens	166-171
35268797-0	2022	Synthesis and Biological Evaluation of 1-(2-(6-Methoxynaphthalen-2-yl)-6-methylnicotinoyl)-4-Substituted Semicarbazides/Thiosemicarbazides as Anti-Tumor Nur77 Modulators.	1-(2-(6-methoxynaphthalen-2-yl)-6-methylnicotinoyl)-4-substituted semicarbazides	39-119	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
35091347-11	2022	Moreover, we observed that the virulent ST59 and ST22 can resist killing by human antimicrobial peptides (AMPs).	Peptides	96-104	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-44
35268797-0	2022	Synthesis and Biological Evaluation of 1-(2-(6-Methoxynaphthalen-2-yl)-6-methylnicotinoyl)-4-Substituted Semicarbazides/Thiosemicarbazides as Anti-Tumor Nur77 Modulators.	thiosemicarbazide	120-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	153-158
35172272-0	2022	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.	palbociclib	131-142	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-65
35172272-0	2022	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.	Fulvestrant	147-158	nuclear receptor subfamily 4 group A member 1	Homo sapiens	49-65
35268797-9	2022	We initially explored the mechanism of 9h-induced apoptosis and found that compound 9h can upregulate Nur77 expression and triggered Nur77 nuclear export, indicating the occurrence of Nur77-mediated apoptosis.	9h	39-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-107
35268797-9	2022	We initially explored the mechanism of 9h-induced apoptosis and found that compound 9h can upregulate Nur77 expression and triggered Nur77 nuclear export, indicating the occurrence of Nur77-mediated apoptosis.	9h	39-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-138
35268797-9	2022	We initially explored the mechanism of 9h-induced apoptosis and found that compound 9h can upregulate Nur77 expression and triggered Nur77 nuclear export, indicating the occurrence of Nur77-mediated apoptosis.	9h	39-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	184-189
35220235-6	2022	RESULTS: The disease-free survival (DFS) period after NAC for the high-FF-TIL group was found to be significantly longer than that for the low-FF-TIL group for all cases (p<0.001) and for all subtypes of triple-negative breast cancer (TNBC) (p=0.001), human epidermal growth factor receptor 2-enriched breast cancer (HER2BC) (p=0.010), and hormone receptor-positive breast cancer (HRBC) (p=0.003).	nac	54-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	340-356
34995105-1	2022	PURPOSE: The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.	palbociclib	63-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	193-209
35091347-11	2022	Moreover, we observed that the virulent ST59 and ST22 can resist killing by human antimicrobial peptides (AMPs).	Adenylyl sulfate	106-110	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-44
35089453-1	2022	BACKGROUND: Everolimus is a mechanistic-target-of-rapamycin (mTOR) inhibitor bearing a potent antitumor effect against hormone receptor-positive breast cancer.	Everolimus	12-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
34983437-0	2022	Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.	Fulvestrant	16-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	99-115